data_5o1q_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5o1q _Structure_validation_residue.Date_analyzed 2017-09-15 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 19.0 108.555 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 20.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.417 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 21.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 22.0 107.943 170.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 23.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 24.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 25.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 26.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.5 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 27.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.519 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 28.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 29.0 106.169 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.456 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 30.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 31.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 32.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 33.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 34.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 35.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 36.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 37.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.46 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 38.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 39.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 40.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 41.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 42.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 43.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 44.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 45.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 46.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 47.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 48.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 49.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 50.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 51.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 52.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 53.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.456 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 54.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 55.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 56.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 57.0 110.475 177.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 58.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 59.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 60.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 61.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 62.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 63.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 64.0 110.856 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.409 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 65.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 66.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 67.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 68.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 69.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.45 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 70.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 71.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 72.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 73.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.45 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 . . . . . 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 74.0 108.98 177.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.494 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 . . . . . 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 81.0 107.254 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 82.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.494 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 83.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 84.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.4 ' O ' HG22 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 85.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 86.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.491 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 87.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 88.0 110.358 179.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 89.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.416 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 90.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 91.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 92.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 93.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 94.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 95.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.607 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 96.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.428 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 97.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 98.0 112.371 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 99.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 100.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.491 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 101.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 102.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 103.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 104.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 105.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.5 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 106.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 62.6 m . . . . . 0 N--CA 1.41 -2.431 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.418 ' CD1' ' HB ' ' A' ' 92' ' ' VAL . 79.1 m95 -93.93 134.41 36.34 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -137.68 162.65 33.28 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.564 0.54 . . . . 0.0 110.742 -177.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 61.2 pttt -155.04 145.25 15.84 Favored Pre-proline 0 C--N 1.298 -1.639 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 170.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -76.64 132.31 13.19 Favored 'Trans proline' 0 N--CA 1.445 -1.336 0 C-N-CA 122.161 1.908 . . . . 0.0 109.956 175.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -151.77 123.85 8.14 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.438 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -105.42 110.61 23.01 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.556 ' HB1' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.66 166.76 32.53 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.701 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 76.9 m -103.54 119.55 39.11 Favored 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.19 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 60.0 t80 -99.09 120.08 38.89 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.409 ' HB ' HG21 ' A' ' 104' ' ' VAL . 92.5 t -107.37 109.81 29.52 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 176.366 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.515 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 55.5 t30 -61.02 148.47 40.09 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 123.804 0.69 . . . . 0.0 110.443 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -85.68 -130.74 2.51 Favored Glycine 0 N--CA 1.432 -1.623 0 CA-C-O 121.321 0.401 . . . . 0.0 113.638 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.24 -7.68 52.88 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -172.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -120.37 141.02 31.14 Favored Pre-proline 0 C--N 1.307 -1.276 0 C-N-CA 120.347 -0.541 . . . . 0.0 111.156 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.73 150.85 68.91 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.069 1.846 . . . . 0.0 110.955 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.559 HG21 ' SG ' ' A' ' 84' ' ' CYS . 7.5 mm -116.24 141.34 34.31 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.186 -174.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.79 117.2 35.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 176.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.2 p -97.4 158.79 15.29 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 116.862 -0.153 . . . . 0.0 111.382 -174.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mmt180 -130.06 156.51 44.39 Favored 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.407 ' C ' ' H ' ' A' ' 41' ' ' SER . 51.0 mt -115.96 137.64 49.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.55 -36.83 2.61 Favored Glycine 0 CA--C 1.493 -1.333 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.802 174.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.407 ' H ' ' C ' ' A' ' 39' ' ' ILE . 6.8 m -138.08 151.12 69.31 Favored Pre-proline 0 C--N 1.28 -2.425 0 CA-C-N 114.944 -0.628 . . . . 0.0 111.46 -171.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -94.01 49.69 0.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.369 2.713 . . . . 0.0 111.328 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 99.9 m-85 -121.3 153.04 38.22 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -77.27 -8.78 58.18 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.808 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -103.7 4.63 35.57 Favored 'General case' 0 C--O 1.245 0.842 0 CA-C-O 121.618 0.723 . . . . 0.0 110.647 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.5 158.73 70.96 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.78 140.32 93.27 Favored 'Trans proline' 0 C--O 1.247 0.93 0 C-N-CA 122.491 2.127 . . . . 0.0 111.834 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.0 t -74.13 126.63 35.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.75 -14.27 65.54 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 129.9 -176.57 18.61 Favored Glycine 0 N--CA 1.414 -2.814 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -108.56 130.26 55.3 Favored 'General case' 0 C--N 1.273 -2.729 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -80.99 124.71 81.13 Favored Pre-proline 0 C--N 1.281 -2.402 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -61.97 149.98 88.15 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.288 1.992 . . . . 0.0 112.59 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.515 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -68.7 117.82 10.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.572 177.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 30' ' ' ASN . . . 101.78 4.67 51.7 Favored Glycine 0 C--N 1.304 -1.204 0 C-N-CA 121.121 -0.562 . . . . 0.0 112.96 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.05 146.39 53.55 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.5 0.556 . . . . 0.0 112.5 -178.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.6 p -101.57 105.42 16.37 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.778 0.831 . . . . 0.0 110.791 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.9 mm -107.74 134.79 48.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 123.339 0.656 . . . . 0.0 111.296 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.78 116.17 48.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 170.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.556 ' CZ ' ' HB1' ' A' ' 26' ' ' ALA . 54.8 p90 -111.05 162.15 15.17 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.053 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -129.28 6.0 5.3 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 123.791 0.682 . . . . 0.0 111.376 -177.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -158.74 154.89 27.02 Favored 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.8 t -133.51 133.75 57.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 172.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 54.5 m -126.25 154.26 43.61 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 123.419 0.688 . . . . 0.0 110.576 178.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 66.0 mt -123.21 123.12 67.04 Favored 'Isoleucine or valine' 0 C--O 1.255 1.377 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.7 tp-100 -171.9 152.72 3.06 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.76 26.42 15.6 Favored 'General case' 0 C--O 1.243 0.757 0 C-N-CA 123.682 0.793 . . . . 0.0 111.045 177.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.33 5.8 82.45 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.202 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -120.6 153.86 36.22 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 121.053 0.454 . . . . 0.0 111.34 -177.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 24.0 mt -100.74 131.91 47.44 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.424 ' CZ3' ' HD3' ' A' ' 85' ' ' PRO . 55.3 m95 -123.62 140.47 52.96 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -172.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.3 pt -97.37 134.44 35.3 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 172.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.13 124.45 8.06 Favored Glycine 0 N--CA 1.425 -2.08 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.483 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.6 p90 . . . . . 0 C--N 1.299 -1.626 0 CA-C-O 120.734 0.302 . . . . 0.0 110.625 179.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 . . . . . 0 C--O 1.202 -1.412 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 26.6 t -104.91 132.91 50.51 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.948 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.05 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -111.12 125.94 54.31 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.216 177.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . 0.559 ' SG ' HG21 ' A' ' 35' ' ' ILE . 41.0 t -116.49 120.46 34.63 Favored Pre-proline 0 C--N 1.286 -2.159 0 CA-C-N 115.373 -0.831 . . . . 0.0 108.883 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.424 ' HD3' ' CZ3' ' A' ' 71' ' ' TRP . 37.9 Cg_endo -72.31 119.26 6.03 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 121.708 1.605 . . . . 0.0 109.134 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 29.0 m -105.85 -14.15 9.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.469 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.1 ptt180 -176.23 176.31 1.71 Allowed 'General case' 0 CA--C 1.503 -0.834 0 O-C-N 123.732 0.645 . . . . 0.0 109.581 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.6 p -95.6 167.15 11.48 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 123.357 0.411 . . . . 0.0 110.862 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.587 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.1 t -150.71 127.91 11.25 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 174.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.495 HE21 HD12 ' A' ' 97' ' ' ILE . 6.2 tt0 -87.24 110.52 20.24 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.5 -155.45 32.36 Favored Glycine 0 N--CA 1.423 -2.219 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.735 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.418 ' HB ' ' CD1' ' A' ' 20' ' ' TRP . 8.3 m -134.39 155.52 79.7 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.44 ' HA ' ' N ' ' A' ' 95' ' ' ASN . 19.6 Cg_endo -63.19 167.68 12.21 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.198 1.932 . . . . 0.0 111.515 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.81 -4.76 5.97 Favored 'Cis proline' 0 C--N 1.352 0.752 0 N-CA-C 115.513 1.313 . . . . 0.0 115.513 4.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . 0.44 ' N ' ' HA ' ' A' ' 93' ' ' PRO . 39.1 m-80 -108.79 80.45 1.33 Allowed 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.471 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.0 pt20 -96.57 146.08 25.15 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.587 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 83.7 mt -122.0 87.77 47.43 Favored Pre-proline 0 C--N 1.273 -2.734 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.7 128.52 11.0 Favored 'Trans proline' 0 N--CA 1.442 -1.534 0 C-N-CA 122.647 2.232 . . . . 0.0 112.987 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.53 -175.79 49.56 Favored Glycine 0 N--CA 1.433 -1.558 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.793 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.1 p -67.31 133.98 30.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 120.947 0.403 . . . . 0.0 110.009 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.469 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -67.13 143.18 56.78 Favored 'General case' 0 N--CA 1.434 -1.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.777 -179.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 39.4 m0 -92.48 17.41 10.06 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.907 176.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.85 -173.39 42.38 Favored Glycine 0 N--CA 1.427 -1.959 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.796 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.8 OUTLIER -96.6 156.49 3.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -177.605 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -129.02 102.97 6.74 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 175.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.473 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 65.4 mttm . . . . . 0 C--N 1.301 -1.524 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.384 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.6 m . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.426 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 95.4 m95 -88.41 140.06 29.86 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 175.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.405 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 39.7 p90 -146.51 154.6 41.74 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 120.568 0.223 . . . . 0.0 110.954 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -144.83 145.69 28.73 Favored Pre-proline 0 C--N 1.305 -1.332 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -80.88 119.74 3.67 Favored 'Trans proline' 0 C--O 1.249 1.056 0 C-N-CA 122.64 2.227 . . . . 0.0 110.784 178.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -145.86 123.56 11.87 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -99.12 109.33 22.05 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.549 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.81 162.85 40.41 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.59 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.453 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.4 m -100.54 119.7 38.91 Favored 'General case' 0 N--CA 1.419 -2.024 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.059 177.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.531 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 67.2 t80 -98.97 113.98 26.41 Favored 'General case' 0 N--CA 1.416 -2.163 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.4 t -101.67 109.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 N-CA-C 106.001 -1.852 . . . . 0.0 106.001 176.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.494 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 53.6 t30 -61.56 149.43 39.1 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 123.567 0.542 . . . . 0.0 110.252 -177.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -88.71 -126.46 2.69 Favored Glycine 0 N--CA 1.423 -2.215 0 N-CA-C 114.259 0.464 . . . . 0.0 114.259 -174.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -89.92 -21.93 22.23 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -172.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -105.24 137.41 19.24 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.842 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.95 147.97 50.43 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.191 1.928 . . . . 0.0 109.319 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.6 mt -120.67 136.49 57.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.059 -174.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 69.8 t -79.16 116.82 23.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.48 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 72.2 p -91.49 157.12 17.22 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.686 -0.233 . . . . 0.0 110.617 -176.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -124.31 152.13 43.46 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.445 HG12 HG22 ' A' ' 82' ' ' VAL . 21.0 mt -116.2 136.38 53.34 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -176.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.62 -45.83 3.5 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.868 174.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 40.8 m -138.17 144.33 42.87 Favored Pre-proline 0 C--N 1.274 -2.709 0 CA-C-N 113.972 -1.114 . . . . 0.0 110.324 -173.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -89.34 79.84 0.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.083 0 C-N-CA 122.411 2.074 . . . . 0.0 112.43 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -143.14 154.12 43.58 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 89.9 mt -76.6 -13.5 60.06 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.079 0.942 . . . . 0.0 108.773 174.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -91.24 -8.41 48.47 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.766 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -83.32 156.04 66.26 Favored Pre-proline 0 C--O 1.256 1.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.024 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.62 143.89 93.88 Favored 'Trans proline' 0 C--N 1.359 1.103 0 C-N-CA 123.145 2.563 . . . . 0.0 112.396 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.8 t -82.36 131.57 33.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.05 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.52 -27.9 28.61 Favored Glycine 0 C--N 1.3 -1.438 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 177.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 147.36 -176.33 26.27 Favored Glycine 0 N--CA 1.426 -2.012 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.24 117.5 34.67 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 20.4 tp -69.36 123.86 89.26 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -55.94 141.21 86.31 Favored 'Trans proline' 0 N--CA 1.432 -2.105 0 C-N-CA 122.487 2.125 . . . . 0.0 113.266 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.494 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -67.26 116.58 8.2 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.73 0.11 42.48 Favored Glycine 0 C--N 1.304 -1.2 0 C-N-CA 120.728 -0.749 . . . . 0.0 113.1 -177.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -71.86 149.73 44.92 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.899 0.35 . . . . 0.0 111.554 -179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.9 p -104.79 108.83 20.52 Favored 'General case' 0 N--CA 1.439 -1.006 0 CA-C-O 121.55 0.691 . . . . 0.0 111.76 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.5 mm -105.48 132.64 51.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 C-N-CA 123.841 0.857 . . . . 0.0 110.954 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.19 116.89 48.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.549 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 52.0 p90 -112.84 164.71 13.07 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.395 -0.522 . . . . 0.0 110.241 -177.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -123.52 -3.01 8.37 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.436 0.46 . . . . 0.0 111.666 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -154.92 154.43 32.62 Favored 'General case' 0 N--CA 1.434 -1.229 0 C-N-CA 119.445 -0.902 . . . . 0.0 109.85 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 21.6 t -127.04 135.58 63.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 175.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . 0.426 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 61.6 m -125.35 157.03 37.76 Favored 'General case' 0 C--N 1.293 -1.853 0 O-C-N 123.199 0.312 . . . . 0.0 110.98 -178.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.4 HG12 HG12 ' A' ' 70' ' ' ILE . 73.0 mt -127.51 109.91 21.27 Favored 'Isoleucine or valine' 0 C--O 1.253 1.259 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 175.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -156.36 151.61 26.55 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.26 24.99 15.03 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 123.699 0.799 . . . . 0.0 110.361 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.56 13.27 68.11 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.398 -178.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -120.18 154.72 34.4 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 122.3 -0.53 . . . . 0.0 109.781 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.411 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 20.4 mt -101.29 133.89 43.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 174.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 53.9 m95 -126.02 150.82 47.82 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -172.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 29.0 pt -106.39 130.71 57.7 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.707 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 170.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -100.05 119.02 6.36 Favored Glycine 0 N--CA 1.417 -2.572 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 51.9 p90 . . . . . 0 N--CA 1.414 -2.257 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.977 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.403 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 25.2 tpt180 . . . . . 0 CA--C 1.487 -1.453 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.48 ' CG1' ' HB ' ' A' ' 37' ' ' THR . 38.3 t -116.93 134.95 58.87 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.681 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.533 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.8 m-85 -117.4 123.2 45.85 Favored 'General case' 0 C--N 1.281 -2.408 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.2 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -112.39 126.01 29.11 Favored Pre-proline 0 C--N 1.279 -2.467 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -71.79 129.78 15.96 Favored 'Trans proline' 0 N--CA 1.439 -1.678 0 C-N-CA 121.374 1.382 . . . . 0.0 108.778 176.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.51 -13.11 11.48 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -174.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.423 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.6 ptm180 -178.31 167.0 1.91 Allowed 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 16.2 p -92.33 162.68 14.17 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.8 t -141.39 120.69 13.06 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.465 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 28.1 tt0 -83.63 111.32 19.01 Favored 'General case' 0 N--CA 1.424 -1.768 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 177.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.17 -166.13 51.24 Favored Glycine 0 N--CA 1.426 -1.994 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.427 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 13.9 m -121.22 160.49 45.28 Favored Pre-proline 0 C--N 1.297 -1.707 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.427 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 31.4 Cg_endo -65.67 167.41 17.33 Favored 'Trans proline' 0 CA--C 1.547 1.155 0 C-N-CA 121.987 1.792 . . . . 0.0 112.48 179.337 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -65.37 -28.46 4.36 Favored 'Cis proline' 0 C--N 1.363 1.307 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.985 4.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -90.86 79.31 5.96 Favored 'General case' 0 CA--C 1.485 -1.549 0 CA-C-O 122.17 0.986 . . . . 0.0 110.169 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 0.9 OUTLIER -94.26 143.82 26.06 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 176.409 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.465 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.0 mt -122.15 92.46 48.88 Favored Pre-proline 0 C--N 1.27 -2.873 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 177.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 88' ' ' THR . 58.7 Cg_endo -79.66 135.69 11.72 Favored 'Trans proline' 0 N--CA 1.434 -2.029 0 C-N-CA 122.263 1.976 . . . . 0.0 112.226 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.71 -159.07 23.38 Favored Glycine 0 C--N 1.311 -0.816 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -63.83 139.19 21.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.423 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.75 135.1 36.42 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 42.3 m0 -83.77 9.41 11.94 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.786 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -174.02 -172.08 38.97 Favored Glycine 0 N--CA 1.428 -1.891 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 178.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.5 t -97.36 149.35 5.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 -178.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -122.2 108.67 13.56 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 175.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.453 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 82.3 mttt . . . . . 0 C--N 1.285 -2.229 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.2 m . . . . . 0 N--CA 1.412 -2.327 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.413 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 89.6 m95 -86.38 125.37 33.61 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.135 -1.432 . . . . 0.0 107.135 175.106 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -134.64 151.57 51.14 Favored 'General case' 0 C--N 1.281 -2.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.562 -177.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -135.59 143.53 45.34 Favored Pre-proline 0 C--N 1.292 -1.926 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 173.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -76.8 113.03 3.56 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.216 1.944 . . . . 0.0 109.542 176.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -147.82 124.13 10.91 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.434 -178.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -100.06 106.59 18.35 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -178.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.538 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . . . -147.11 160.4 42.46 Favored 'General case' 0 C--N 1.288 -2.067 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.616 -178.429 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.548 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 55.6 m -102.81 121.57 42.75 Favored 'General case' 0 C--N 1.288 -2.1 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.835 178.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.549 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.5 t80 -99.25 112.09 24.33 Favored 'General case' 0 C--N 1.284 -2.269 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 99.3 t -97.17 108.28 21.28 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.407 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 54.2 t30 -63.84 143.76 57.59 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 123.502 0.501 . . . . 0.0 110.069 -178.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -83.12 -128.05 1.27 Allowed Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 116.112 -0.494 . . . . 0.0 113.319 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -90.67 -14.61 31.93 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -172.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -108.26 136.86 19.8 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.947 -0.471 . . . . 0.0 111.575 -177.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -71.44 142.24 40.32 Favored 'Trans proline' 0 C--O 1.247 0.949 0 C-N-CA 121.974 1.783 . . . . 0.0 109.711 172.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.416 HG22 ' O ' ' A' ' 85' ' ' PRO . 1.4 mt -117.26 133.24 64.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.085 -174.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -77.56 113.08 16.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.7 p -89.04 156.57 18.77 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.679 -175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -126.95 156.28 41.79 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -177.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.419 HG12 HG22 ' A' ' 82' ' ' VAL . 50.7 mt -122.09 135.83 60.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -177.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.54 -35.17 3.04 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.301 -0.863 . . . . 0.0 113.511 173.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 56.1 m -139.43 139.48 22.75 Favored Pre-proline 0 C--N 1.261 -3.253 0 C-N-CA 123.16 0.584 . . . . 0.0 111.343 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -87.13 55.06 2.99 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.714 2.276 . . . . 0.0 111.179 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -123.81 157.76 33.34 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.044 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.87 -14.03 59.93 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.551 0.691 . . . . 0.0 110.232 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -97.58 4.28 50.29 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.414 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.11 155.08 64.0 Favored Pre-proline 0 C--N 1.314 -0.935 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.64 136.75 77.61 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 122.991 2.46 . . . . 0.0 112.33 -178.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -78.27 124.48 36.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 115.355 -0.838 . . . . 0.0 109.701 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.36 -25.97 53.0 Favored Glycine 0 C--N 1.302 -1.331 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.56 -176.73 21.26 Favored Glycine 0 N--CA 1.421 -2.345 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -95.66 130.62 42.48 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.4 tp -77.01 126.31 85.69 Favored Pre-proline 0 C--N 1.285 -2.196 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 173.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -60.78 148.41 92.06 Favored 'Trans proline' 0 N--CA 1.44 -1.673 0 C-N-CA 121.913 1.742 . . . . 0.0 112.3 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.407 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.26 132.81 47.06 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 91.23 2.66 70.64 Favored Glycine 0 C--N 1.302 -1.333 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.069 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -75.24 144.67 42.46 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.37 0.605 . . . . 0.0 110.974 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -104.8 107.92 19.13 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.12 -176.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.4 mm -106.95 130.09 59.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 C-N-CA 123.38 0.672 . . . . 0.0 111.323 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.0 t -100.03 117.54 45.36 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 170.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.538 ' CZ ' ' HB2' ' A' ' 26' ' ' ALA . 55.1 p90 -116.09 163.57 15.74 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.906 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -121.74 -0.59 9.61 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 123.409 0.443 . . . . 0.0 111.689 -178.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -153.27 148.54 26.93 Favored 'General case' 0 N--CA 1.433 -1.322 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.11 -176.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.4 t -120.98 133.48 67.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 105.681 -1.97 . . . . 0.0 105.681 173.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 3.9 m -125.66 150.1 47.9 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -175.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 64.3 mt -123.01 118.19 54.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 173.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -160.31 145.5 14.85 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -178.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.87 29.59 17.94 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 124.191 0.996 . . . . 0.0 110.759 177.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.06 10.47 73.4 Favored Glycine 0 CA--C 1.519 0.29 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.414 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -119.58 153.13 35.92 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 122.402 -0.469 . . . . 0.0 110.114 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 23.5 mt -103.37 133.94 45.88 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 174.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -127.73 153.61 46.32 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -171.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -109.96 130.25 63.47 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.774 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 171.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.47 122.52 7.55 Favored Glycine 0 N--CA 1.42 -2.424 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.456 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.2 p90 . . . . . 0 C--N 1.292 -1.928 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.7 tpt180 . . . . . 0 CA--C 1.492 -1.267 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.419 HG22 HG12 ' A' ' 39' ' ' ILE . 35.9 t -97.39 130.48 45.99 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.494 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.483 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.6 m-85 -112.4 125.17 53.92 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.309 178.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -114.14 125.06 29.83 Favored Pre-proline 0 C--N 1.278 -2.501 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 176.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.416 ' O ' HG22 ' A' ' 35' ' ' ILE . 42.8 Cg_endo -72.59 129.07 14.17 Favored 'Trans proline' 0 N--CA 1.439 -1.731 0 C-N-CA 121.271 1.314 . . . . 0.0 108.724 177.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.7 m -112.39 -15.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.448 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptt180 -177.48 173.12 1.73 Allowed 'General case' 0 CA--C 1.503 -0.853 0 C-N-CA 123.629 0.772 . . . . 0.0 109.457 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.6 p -99.93 168.3 9.96 Favored 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.593 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 45.1 t -147.55 123.86 10.91 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.3 tt0 -82.91 96.31 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.56 174.83 44.58 Favored Glycine 0 N--CA 1.429 -1.809 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.759 178.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.63 154.91 39.73 Favored Pre-proline 0 C--N 1.295 -1.797 0 C-N-CA 122.081 0.152 . . . . 0.0 111.011 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.47 167.01 13.9 Favored 'Trans proline' 0 CA--C 1.556 1.617 0 C-N-CA 122.677 2.252 . . . . 0.0 112.8 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.13 -24.58 6.17 Favored 'Cis proline' 0 C--N 1.372 1.794 0 C-N-CA 124.156 -1.185 . . . . 0.0 113.278 5.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -89.21 79.04 7.2 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 121.727 0.775 . . . . 0.0 109.26 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.593 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 12.8 pt20 -101.84 152.06 21.34 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 68.0 mt -130.28 88.02 49.03 Favored Pre-proline 0 C--N 1.284 -2.277 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -73.46 133.81 19.65 Favored 'Trans proline' 0 N--CA 1.443 -1.453 0 C-N-CA 122.433 2.089 . . . . 0.0 112.536 -178.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -85.42 -163.38 37.32 Favored Glycine 0 N--CA 1.441 -1.002 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.748 178.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -69.54 131.85 33.65 Favored 'Isoleucine or valine' 0 C--O 1.251 1.145 0 CA-C-O 120.88 0.371 . . . . 0.0 110.695 -178.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.448 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -71.6 140.55 49.82 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.445 177.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.4 m0 -90.2 10.86 22.95 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.799 179.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -167.54 -159.95 14.08 Favored Glycine 0 N--CA 1.43 -1.712 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.22 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.7 OUTLIER -113.03 154.64 14.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.045 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -123.76 103.61 8.48 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.548 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 87.5 mttt . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 173.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 87.3 m . . . . . 0 N--CA 1.421 -1.91 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -84.91 135.9 33.86 Favored 'General case' 0 CA--C 1.485 -1.536 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 175.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -149.5 162.51 40.01 Favored 'General case' 0 C--N 1.281 -2.388 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -177.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -150.36 144.7 17.71 Favored Pre-proline 0 N--CA 1.422 -1.852 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.17 126.84 11.46 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.621 2.214 . . . . 0.0 109.73 176.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -152.76 123.7 7.45 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.7 108.88 20.85 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.571 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.21 164.77 38.35 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.642 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 65.1 m -105.72 120.85 42.74 Favored 'General case' 0 N--CA 1.416 -2.154 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.43 177.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.515 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.7 t80 -98.98 125.25 44.4 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.1 109.72 29.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.419 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 51.8 t30 -65.33 145.28 56.39 Favored 'General case' 0 C--N 1.308 -1.205 0 O-C-N 123.778 0.674 . . . . 0.0 110.699 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -84.54 -108.49 0.62 Allowed Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 114.863 0.705 . . . . 0.0 114.863 -174.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.26 -25.04 13.82 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 122.599 0.36 . . . . 0.0 111.717 -170.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -110.84 133.63 21.18 Favored Pre-proline 0 C--N 1.295 -1.769 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.802 -176.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.05 140.72 55.25 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.211 1.941 . . . . 0.0 110.568 175.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.85 136.25 52.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.746 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 52.6 t -77.36 121.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.8 p -94.19 157.84 15.87 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.034 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.424 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 27.0 mmt180 -130.72 155.01 47.35 Favored 'General case' 0 C--O 1.21 -0.985 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 -174.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.422 HG12 HG21 ' A' ' 82' ' ' VAL . 18.6 mt -112.46 138.95 39.67 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.45 -48.74 4.11 Favored Glycine 0 CA--C 1.502 -0.719 0 C-N-CA 124.921 1.248 . . . . 0.0 113.752 174.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 14.8 m -137.35 154.2 75.26 Favored Pre-proline 0 C--N 1.279 -2.499 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.991 -170.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -91.03 67.22 1.31 Allowed 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 123.006 2.47 . . . . 0.0 111.77 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -131.17 156.45 45.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.7 mt -76.46 -19.98 57.49 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.959 0.409 . . . . 0.0 111.024 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -100.39 18.16 19.68 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 121.556 0.694 . . . . 0.0 111.208 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.424 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -85.22 152.62 58.6 Favored Pre-proline 0 C--N 1.308 -1.239 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.4 143.24 94.61 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.462 HG11 ' H ' ' A' ' 50' ' ' GLY . 51.7 t -79.57 126.19 39.05 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.01 7.69 67.36 Favored Glycine 0 C--N 1.308 -0.976 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.462 ' H ' HG11 ' A' ' 48' ' ' VAL . . . 122.28 170.51 13.71 Favored Glycine 0 N--CA 1.423 -2.21 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -113.19 117.17 31.17 Favored 'General case' 0 C--N 1.28 -2.418 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.42 HD13 ' HD2' ' A' ' 53' ' ' PRO . 19.6 tp -68.78 125.7 92.08 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.212 -176.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' HD13 ' A' ' 52' ' ' LEU . 1.3 Cg_endo -63.14 156.8 52.99 Favored 'Trans proline' 0 N--CA 1.439 -1.735 0 C-N-CA 122.28 1.986 . . . . 0.0 112.768 178.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -76.99 128.19 34.06 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 176.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.76 21.36 50.95 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.828 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 146.1 24.43 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-O 120.706 0.289 . . . . 0.0 110.799 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.8 p -98.18 120.8 39.22 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.453 -179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mm -118.69 134.91 60.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 123.894 0.877 . . . . 0.0 109.834 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.0 t -108.94 117.49 54.44 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 172.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.571 ' CZ ' ' HB2' ' A' ' 26' ' ' ALA . 53.4 p90 -111.38 172.96 6.57 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 120.494 -0.483 . . . . 0.0 110.95 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -131.47 2.61 4.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.364 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -158.08 152.96 25.16 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.218 -175.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.4 t -126.37 134.63 65.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 172.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 76.1 m -127.64 155.63 43.61 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 122.509 0.323 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 60.4 mt -124.86 114.41 40.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 175.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -164.59 150.77 10.6 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.2 29.69 17.5 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 123.781 0.832 . . . . 0.0 110.021 178.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.04 8.76 65.31 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.125 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -120.67 157.34 29.8 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 122.346 -0.502 . . . . 0.0 110.795 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 20.1 mt -104.96 133.45 49.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -127.13 154.17 45.09 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -170.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 32.5 pt -109.24 136.04 46.34 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 171.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -108.15 130.38 10.06 Favored Glycine 0 N--CA 1.42 -2.425 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.524 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 39.0 p90 . . . . . 0 C--N 1.293 -1.853 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.1 tpt180 . . . . . 0 N--CA 1.428 -1.55 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.422 HG21 HG12 ' A' ' 39' ' ' ILE . 46.6 t -126.16 135.47 63.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.277 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.485 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.7 m-85 -118.06 151.94 36.54 Favored 'General case' 0 C--N 1.281 -2.38 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.273 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 45.2 t -141.9 128.73 11.29 Favored Pre-proline 0 C--N 1.275 -2.647 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -74.12 134.94 20.14 Favored 'Trans proline' 0 N--CA 1.436 -1.858 0 C-N-CA 121.483 1.455 . . . . 0.0 109.395 177.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.8 m -116.52 -13.12 11.25 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.477 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.6 ptm180 -176.34 168.94 2.76 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.9 p -97.07 165.43 12.07 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 53.2 t -145.53 121.45 10.65 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 177.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.525 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 0.5 OUTLIER -86.56 115.18 23.88 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.898 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 -167.49 45.88 Favored Glycine 0 N--CA 1.428 -1.897 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.212 -179.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 8.3 m -132.07 155.27 81.54 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 123.869 0.868 . . . . 0.0 108.838 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.421 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 19.3 Cg_endo -59.51 163.04 13.55 Favored 'Trans proline' 0 CA--C 1.555 1.562 0 C-N-CA 122.232 1.955 . . . . 0.0 113.2 -178.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.421 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 55.3 Cg_endo -68.38 -26.32 6.77 Favored 'Cis proline' 0 C--N 1.364 1.346 0 C-N-CA 123.822 -1.324 . . . . 0.0 112.824 7.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -91.93 78.75 5.32 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.862 0.839 . . . . 0.0 109.288 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.423 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.7 pt20 -95.25 147.17 23.76 Favored 'General case' 0 N--CA 1.426 -1.634 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 175.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.525 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 85.7 mt -123.37 87.99 51.61 Favored Pre-proline 0 C--N 1.265 -3.076 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -78.6 132.43 10.99 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.285 1.99 . . . . 0.0 112.71 -177.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -83.32 -171.5 47.61 Favored Glycine 0 N--CA 1.437 -1.251 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.31 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.3 p -64.21 136.67 26.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-O 120.751 0.31 . . . . 0.0 110.417 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -73.46 145.09 45.97 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.069 0.461 . . . . 0.0 110.602 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.6 m0 -94.27 11.31 30.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.538 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.03 -174.32 40.05 Favored Glycine 0 N--CA 1.419 -2.489 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.94 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 2.9 t -96.63 151.11 4.16 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -177.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -122.53 102.98 8.4 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 176.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 57.7 mttm . . . . . 0 C--N 1.298 -1.643 0 CA-C-O 118.276 -0.869 . . . . 0.0 108.682 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.403 HG22 ' HB2' ' A' ' 66' ' ' GLN . 86.9 m . . . . . 0 N--CA 1.424 -1.727 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 74.4 m95 -90.86 134.38 34.5 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -138.85 153.51 48.33 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -137.29 145.38 49.52 Favored Pre-proline 0 C--N 1.291 -1.973 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 173.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -75.56 124.75 8.49 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.342 2.028 . . . . 0.0 109.122 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.86 123.05 4.44 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -103.73 108.52 19.85 Favored 'General case' 0 C--N 1.29 -1.983 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.577 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.78 165.99 29.78 Favored 'General case' 0 C--N 1.284 -2.252 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.952 -178.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 82.7 m -102.5 118.69 37.4 Favored 'General case' 0 N--CA 1.41 -2.433 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.845 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -99.03 111.92 24.19 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.62 110.09 25.33 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.465 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 50.1 t30 -63.03 145.71 54.82 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.637 0.586 . . . . 0.0 110.705 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.78 -118.75 0.4 Allowed Glycine 0 N--CA 1.426 -1.984 0 CA-C-N 115.889 -0.596 . . . . 0.0 114.016 -176.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -100.44 -11.38 20.24 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 112.748 0.648 . . . . 0.0 112.748 -170.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -121.96 137.44 27.35 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.435 -174.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -67.92 142.58 57.53 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 121.98 1.787 . . . . 0.0 110.364 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mt -116.22 141.83 32.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 C-N-CA 120.287 -0.565 . . . . 0.0 110.66 -174.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.9 t -84.92 117.55 30.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.427 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 82.4 p -93.77 153.8 18.11 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.513 -0.312 . . . . 0.0 111.083 -176.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.479 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 35.5 mmt180 -121.74 160.88 23.63 Favored 'General case' 0 C--O 1.208 -1.1 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -177.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 56.2 mt -126.21 135.99 62.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.415 0.626 . . . . 0.0 112.566 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.52 -48.09 3.08 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.414 173.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 25.3 m -138.15 146.15 50.6 Favored Pre-proline 0 C--N 1.271 -2.833 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.793 -174.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -87.17 81.12 1.34 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.363 2.042 . . . . 0.0 112.235 177.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -144.46 157.26 44.33 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 86.0 mt -76.29 -16.9 59.68 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.995 0.902 . . . . 0.0 108.661 175.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -91.15 3.14 55.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 114.249 -1.341 . . . . 0.0 110.695 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.45 50.42 Favored Pre-proline 0 C--O 1.256 1.437 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.835 -176.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -57.51 147.07 80.71 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 123.167 2.578 . . . . 0.0 111.616 176.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 50' ' ' GLY . 32.8 t -90.42 135.71 25.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.8 -175.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.15 -14.56 54.17 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 177.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.431 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 127.91 -176.77 17.92 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.9 128.89 51.38 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.959 0.88 . . . . 0.0 109.802 176.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 16.4 tp -77.16 127.79 82.5 Favored Pre-proline 0 C--N 1.294 -1.831 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -63.81 154.47 69.42 Favored 'Trans proline' 0 N--CA 1.443 -1.487 0 C-N-CA 122.03 1.82 . . . . 0.0 112.452 178.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -73.06 136.85 45.03 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.534 -0.914 . . . . 0.0 108.534 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.41 5.04 85.43 Favored Glycine 0 C--N 1.312 -0.785 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.314 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.27 145.7 37.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 117.029 0.415 . . . . 0.0 111.649 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.6 p -100.75 107.03 18.52 Favored 'General case' 0 N--CA 1.438 -1.028 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.366 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.98 141.56 18.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.6 p -116.11 116.43 52.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 171.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.577 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.6 p90 -111.03 167.22 10.42 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.846 -176.369 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -124.56 -3.95 7.78 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.57 -179.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -153.37 154.13 33.9 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.592 -175.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.2 t -128.53 135.83 61.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 74.0 m -126.77 156.27 41.48 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.458 0.303 . . . . 0.0 110.766 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.429 HG12 HG12 ' A' ' 70' ' ' ILE . 66.4 mt -124.88 117.74 51.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 176.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . 0.403 ' HB2' HG22 ' A' ' 19' ' ' THR . 6.8 tp-100 -164.73 149.81 9.73 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.41 28.35 16.8 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.089 0.956 . . . . 0.0 110.376 178.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.25 8.04 69.16 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.537 -178.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -119.76 155.22 32.93 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 122.093 -0.651 . . . . 0.0 110.486 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.457 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 16.9 mt -104.21 134.27 45.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 174.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -125.78 148.72 49.02 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -171.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -106.71 137.28 38.15 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 172.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.72 125.98 8.15 Favored Glycine 0 N--CA 1.419 -2.456 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.629 -178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.475 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.1 p90 . . . . . 0 C--N 1.294 -1.824 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 176.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.434 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 26.0 tpt180 . . . . . 0 C--O 1.207 -1.182 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 27.1 t -93.45 128.36 44.92 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.835 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.324 -173.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.506 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 58.2 m-85 -113.48 120.27 40.43 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.853 177.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.9 t -110.33 127.1 27.59 Favored Pre-proline 0 C--N 1.28 -2.428 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.45 131.54 17.72 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 121.454 1.436 . . . . 0.0 108.711 176.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.12 -12.58 11.35 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.507 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.6 ptm180 -178.78 174.21 1.17 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.0 p -98.49 167.77 10.61 Favored 'General case' 0 C--N 1.288 -2.066 0 C-N-CA 122.631 0.372 . . . . 0.0 110.414 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.496 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.2 t -149.96 118.73 6.6 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.459 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 16.1 tt0 -81.31 90.38 6.13 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 96.94 -174.56 30.31 Favored Glycine 0 N--CA 1.433 -1.515 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.134 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.455 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 25.7 m -111.81 158.76 35.73 Favored Pre-proline 0 C--N 1.302 -1.49 0 C-N-CA 122.184 0.194 . . . . 0.0 110.917 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.477 ' HB3' HE21 ' A' ' 96' ' ' GLN . 14.1 Cg_endo -63.4 171.5 6.57 Favored 'Trans proline' 0 CA--C 1.555 1.54 0 C-N-CA 122.728 2.286 . . . . 0.0 112.516 177.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.13 -25.01 5.99 Favored 'Cis proline' 0 C--N 1.371 1.751 0 CA-C-N 119.674 0.919 . . . . 0.0 113.4 3.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -91.99 79.34 5.23 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 122.278 1.037 . . . . 0.0 110.013 177.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.477 HE21 ' HB3' ' A' ' 93' ' ' PRO . 1.7 pt20 -96.17 151.29 19.62 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.205 -1.361 . . . . 0.0 107.488 177.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.496 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 71.1 mt -129.59 86.93 54.32 Favored Pre-proline 0 C--N 1.282 -2.349 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -75.21 128.21 11.15 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 122.286 1.991 . . . . 0.0 112.195 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.17 -161.73 29.44 Favored Glycine 0 C--N 1.315 -0.62 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.93 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.1 p -63.81 135.16 28.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 117.099 0.449 . . . . 0.0 110.872 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -81.63 147.91 29.32 Favored 'General case' 0 N--CA 1.436 -1.152 0 CA-C-O 121.294 0.569 . . . . 0.0 111.071 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.3 m0 -96.2 13.46 27.33 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.846 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -178.89 -164.47 31.71 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -105.76 153.52 7.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.4 104.55 8.23 Favored 'General case' 0 N--CA 1.419 -2.02 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 85.4 mttt . . . . . 0 C--N 1.289 -2.059 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 176.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 90.5 m . . . . . 0 N--CA 1.414 -2.226 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 73.7 m95 -86.7 123.96 32.43 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.409 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 47.6 p90 -129.0 164.22 23.68 Favored 'General case' 0 C--N 1.282 -2.359 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -177.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -152.8 142.06 14.54 Favored Pre-proline 0 C--N 1.287 -2.137 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -78.49 113.21 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 C-N-CA 122.407 2.071 . . . . 0.0 109.844 175.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -135.44 124.79 24.75 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -176.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -100.87 107.14 18.58 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -177.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.611 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . . . -154.6 168.83 25.44 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.547 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 52.5 m -106.19 121.32 43.94 Favored 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.848 177.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.58 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 72.5 t80 -99.18 113.23 25.38 Favored 'General case' 0 N--CA 1.406 -2.642 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.3 t -100.81 116.22 43.89 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.526 0 N-CA-C 105.599 -2.001 . . . . 0.0 105.599 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -68.14 149.44 49.59 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.6 -0.44 . . . . 0.0 110.485 -177.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.28 -144.94 3.74 Favored Glycine 0 N--CA 1.433 -1.548 0 CA-C-N 116.368 -0.378 . . . . 0.0 113.174 -176.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.36 -6.06 59.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.25 0.548 . . . . 0.0 111.388 -175.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.4 pt20 -117.23 137.55 24.09 Favored Pre-proline 0 C--O 1.207 -1.142 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.233 -178.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.78 155.14 63.12 Favored 'Trans proline' 0 C--O 1.255 1.364 0 C-N-CA 122.611 2.207 . . . . 0.0 110.552 175.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.442 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.9 mt -126.48 134.94 65.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.646 -177.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 53.7 t -76.25 121.38 28.18 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 77.0 p -97.57 156.7 16.39 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 122.322 -0.236 . . . . 0.0 111.428 -175.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.0 mmt180 -124.0 155.12 38.81 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -178.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.9 mt -116.55 137.83 49.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -175.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.56 -45.15 3.33 Favored Glycine 0 CA--C 1.502 -0.773 0 CA-C-N 114.726 -1.124 . . . . 0.0 113.299 175.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 16.1 p -138.39 155.48 73.89 Favored Pre-proline 0 C--N 1.275 -2.647 0 CA-C-N 114.483 -0.858 . . . . 0.0 111.233 -171.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -95.37 58.55 0.2 Allowed 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.483 2.789 . . . . 0.0 112.043 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -121.23 155.8 33.82 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.3 mt -76.65 -23.63 53.29 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.481 0.657 . . . . 0.0 109.419 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -82.22 -13.77 56.57 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.237 177.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.53 152.68 96.01 Favored Pre-proline 0 C--O 1.249 1.072 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.365 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.3 136.72 74.09 Favored 'Trans proline' 0 C--O 1.241 0.655 0 C-N-CA 122.867 2.378 . . . . 0.0 112.728 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.01 132.84 32.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.59 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.11 -18.39 43.32 Favored Glycine 0 C--O 1.241 0.539 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 135.42 -177.31 19.5 Favored Glycine 0 N--CA 1.428 -1.871 0 N-CA-C 109.219 -1.553 . . . . 0.0 109.219 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.35 131.97 43.52 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 118.043 0.922 . . . . 0.0 109.744 175.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.7 tp -78.2 126.82 82.86 Favored Pre-proline 0 C--N 1.291 -1.964 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 173.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -62.48 151.56 82.36 Favored 'Trans proline' 0 N--CA 1.437 -1.805 0 C-N-CA 122.086 1.857 . . . . 0.0 112.507 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -68.52 137.42 54.36 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 175.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.31 22.43 77.58 Favored Glycine 0 N--CA 1.438 -1.181 0 C-N-CA 121.002 -0.618 . . . . 0.0 113.534 -178.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -89.33 152.05 21.75 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 117.8 0.8 . . . . 0.0 110.081 177.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.13 119.44 38.81 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-O 121.163 0.506 . . . . 0.0 109.987 -177.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.4 mm -117.09 130.02 72.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.77 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.7 p -101.63 116.8 45.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 169.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.611 ' CZ ' ' HB2' ' A' ' 26' ' ' ALA . 53.7 p90 -112.73 160.62 17.76 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.869 -178.288 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -123.32 1.16 9.03 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 123.609 0.568 . . . . 0.0 110.75 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -155.24 152.25 29.07 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.044 -173.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 10.8 t -131.4 133.32 62.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 56.7 m -124.56 148.5 47.77 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 123.014 0.526 . . . . 0.0 110.747 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.405 HG12 HG12 ' A' ' 70' ' ' ILE . 59.4 mt -117.95 116.6 52.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -163.19 147.4 11.03 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 123.572 0.545 . . . . 0.0 109.585 -178.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 60.23 30.99 20.33 Favored 'General case' 0 C--O 1.242 0.71 0 C-N-CA 124.052 0.941 . . . . 0.0 111.446 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 6.62 81.24 Favored Glycine 0 CA--C 1.508 -0.351 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.682 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -120.2 154.2 35.17 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 122.608 -0.348 . . . . 0.0 110.338 -178.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.405 HG12 HG12 ' A' ' 65' ' ' ILE . 19.5 mt -105.81 133.82 49.09 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 172.116 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -125.69 149.96 48.06 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.07 0.548 . . . . 0.0 109.753 -171.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 28.7 pt -106.47 137.01 39.01 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 171.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.08 121.33 6.98 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 41.5 p90 . . . . . 0 C--N 1.302 -1.489 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.419 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 . . . . . 0 CA--C 1.498 -1.031 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 45.2 t -123.56 135.88 61.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.1 m-85 -115.65 123.5 48.53 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.627 -1.17 . . . . 0.0 109.942 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.2 t -111.31 125.85 29.74 Favored Pre-proline 0 C--N 1.281 -2.375 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 177.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.442 ' O ' HG21 ' A' ' 35' ' ' ILE . 33.7 Cg_endo -71.88 129.9 16.03 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 121.54 1.493 . . . . 0.0 108.638 176.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.45 -10.39 12.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.438 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 6.5 ptm180 178.81 173.54 0.72 Allowed 'General case' 0 C--O 1.246 0.899 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.2 p -98.96 167.37 10.78 Favored 'General case' 0 C--N 1.289 -2.033 0 C-N-CA 122.238 0.215 . . . . 0.0 110.737 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.463 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 48.6 t -145.2 128.03 16.35 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 177.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.521 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 60.8 tt0 -90.1 96.31 10.61 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 97.64 -157.94 20.84 Favored Glycine 0 N--CA 1.418 -2.505 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.688 177.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.3 m -130.26 150.86 77.31 Favored Pre-proline 0 C--N 1.297 -1.712 0 C-N-CA 123.353 0.661 . . . . 0.0 109.619 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.427 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 42.2 Cg_endo -66.57 165.63 24.62 Favored 'Trans proline' 0 CA--C 1.555 1.534 0 C-N-CA 122.363 2.042 . . . . 0.0 111.175 -178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.42 -5.89 20.15 Favored 'Cis proline' 0 C--N 1.356 0.973 0 C-N-CA 124.301 -1.125 . . . . 0.0 113.329 4.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -101.43 77.48 1.78 Allowed 'General case' 0 N--CA 1.427 -1.597 0 C-N-CA 118.315 -1.354 . . . . 0.0 108.355 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.463 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.5 pm0 -103.08 153.03 20.7 Favored 'General case' 0 N--CA 1.427 -1.584 0 CA-C-N 114.756 -1.111 . . . . 0.0 108.034 178.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 58.1 mt -131.27 87.56 47.17 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' A' ' 88' ' ' THR . 67.7 Cg_endo -73.53 135.6 22.32 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.544 2.163 . . . . 0.0 112.841 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.45 -170.85 44.52 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.4 p -69.01 138.26 22.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 116.994 0.397 . . . . 0.0 110.25 -178.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.438 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -72.01 141.36 49.34 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.163 -178.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 43.6 m0 -87.54 2.49 50.61 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.329 -179.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -159.39 -160.03 10.15 Favored Glycine 0 N--CA 1.43 -1.748 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 178.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -115.15 149.37 17.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -117.56 106.73 13.44 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 175.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.49 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 63.4 mttm . . . . . 0 C--N 1.288 -2.092 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 176.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.452 ' CG2' ' HB3' ' A' ' 64' ' ' CYS . 84.5 m . . . . . 0 N--CA 1.403 -2.783 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.0 m95 -88.97 127.05 35.65 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -133.82 158.85 42.34 Favored 'General case' 0 C--N 1.292 -1.91 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.382 -178.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -149.03 150.71 32.89 Favored Pre-proline 0 N--CA 1.426 -1.672 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 170.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.37 131.79 18.22 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 121.742 1.628 . . . . 0.0 110.064 176.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -151.81 123.62 8.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -108.72 106.18 16.09 Favored 'General case' 0 C--N 1.292 -1.903 0 C-N-CA 118.776 -1.17 . . . . 0.0 108.563 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.44 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -150.1 167.74 25.93 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.8 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.439 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.1 m -111.06 122.58 48.25 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-O 121.534 0.683 . . . . 0.0 111.134 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.503 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 55.2 t80 -98.62 122.4 41.78 Favored 'General case' 0 N--CA 1.415 -2.18 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.413 HG23 ' HE3' ' A' ' 106' ' ' LYS . 48.2 t -105.32 114.96 46.16 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 176.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.44 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 52.5 t30 -67.66 148.22 51.65 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 123.429 0.456 . . . . 0.0 110.003 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -90.47 -119.98 2.15 Favored Glycine 0 N--CA 1.419 -2.437 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.8 -176.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -85.94 -28.61 24.17 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 -172.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 10.9 pt20 -110.21 136.18 20.52 Favored Pre-proline 0 C--N 1.286 -2.188 0 O-C-N 122.046 -0.409 . . . . 0.0 111.652 -174.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -68.46 140.05 46.85 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.969 1.78 . . . . 0.0 109.809 175.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -112.4 131.1 64.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.913 -172.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.1 t -72.19 116.18 13.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 80.4 p -95.54 162.84 13.47 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.251 -178.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 47' ' ' PRO . 33.4 mmt180 -129.8 155.38 46.06 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -176.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.443 HG12 HG22 ' A' ' 82' ' ' VAL . 26.5 mt -116.37 137.29 50.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -175.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.55 -48.67 3.93 Favored Glycine 0 CA--C 1.494 -1.277 0 CA-C-N 114.218 -1.355 . . . . 0.0 112.623 174.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 43.7 m -139.05 146.9 51.5 Favored Pre-proline 0 C--N 1.264 -3.148 0 CA-C-N 114.353 -0.924 . . . . 0.0 110.264 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -85.9 84.88 1.14 Allowed 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.075 1.85 . . . . 0.0 112.239 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -142.25 156.91 45.32 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.3 mt -76.85 -22.44 53.52 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -90.32 8.0 35.61 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.916 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.95 156.68 42.19 Favored Pre-proline 0 C--O 1.253 1.274 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.428 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 15.6 Cg_endo -57.99 150.79 61.98 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.972 2.448 . . . . 0.0 112.007 179.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.3 t -86.04 125.08 40.64 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.59 -177.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.41 -8.05 78.33 Favored Glycine 0 CA--C 1.496 -1.15 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 128.08 179.38 15.83 Favored Glycine 0 N--CA 1.411 -2.983 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -109.66 110.84 22.01 Favored 'General case' 0 C--N 1.269 -2.921 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . 0.418 HD12 ' HD2' ' A' ' 53' ' ' PRO . 29.6 tp -63.14 126.84 89.98 Favored Pre-proline 0 C--N 1.303 -1.415 0 CA-C-N 114.288 -1.324 . . . . 0.0 109.466 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.418 ' HD2' HD12 ' A' ' 52' ' ' LEU . 11.9 Cg_exo -60.6 146.72 96.56 Favored 'Trans proline' 0 N--CA 1.431 -2.2 0 C-N-CA 122.402 2.068 . . . . 0.0 112.551 -178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.44 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -70.94 116.26 11.03 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.86 -0.66 45.07 Favored Glycine 0 C--N 1.306 -1.09 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.337 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -74.83 143.79 43.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.237 0.541 . . . . 0.0 111.608 -178.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -98.42 117.13 32.15 Favored 'General case' 0 N--CA 1.421 -1.885 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.819 -176.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.5 mm -115.23 127.41 72.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 123.707 0.803 . . . . 0.0 111.389 -179.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 79.2 t -98.95 116.76 42.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 171.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 55.0 p90 -114.53 164.59 13.78 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.441 -178.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -124.11 3.5 8.62 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.769 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -155.37 147.9 24.06 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.638 -0.825 . . . . 0.0 109.888 -175.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.5 t -122.46 135.41 62.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 173.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . 0.452 ' HB3' ' CG2' ' A' ' 19' ' ' THR . 82.7 m -130.4 150.91 51.41 Favored 'General case' 0 C--N 1.286 -2.17 0 O-C-N 123.306 0.379 . . . . 0.0 110.748 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -119.68 121.37 66.04 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 176.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -167.86 150.08 5.6 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 123.723 0.639 . . . . 0.0 109.51 -178.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 59.49 31.28 20.91 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 123.93 0.892 . . . . 0.0 111.301 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.21 6.77 70.06 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.57 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -120.1 156.68 30.52 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 122.537 -0.39 . . . . 0.0 110.69 -177.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.427 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 23.2 mt -104.87 134.35 46.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.6 m95 -125.72 153.82 43.36 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -170.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.511 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.5 pt -113.44 136.61 49.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 173.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.28 123.59 7.48 Favored Glycine 0 N--CA 1.423 -2.178 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.947 -178.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.41 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 37.7 p90 . . . . . 0 C--N 1.296 -1.76 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 . . . . . 0 C--O 1.209 -1.056 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.443 HG22 HG12 ' A' ' 39' ' ' ILE . 39.4 t -118.14 131.79 69.87 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 C-N-CA 119.399 -0.92 . . . . 0.0 109.774 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.511 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 66.6 m-85 -114.06 128.2 56.28 Favored 'General case' 0 C--N 1.286 -2.191 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.31 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.6 t -115.96 128.43 25.98 Favored Pre-proline 0 C--N 1.285 -2.2 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -74.01 130.52 14.46 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.427 1.418 . . . . 0.0 108.74 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.8 m -114.32 -13.5 11.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -175.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.481 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.5 ptm180 -176.51 174.31 1.92 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -178.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.1 p -98.25 165.23 11.97 Favored 'General case' 0 C--N 1.286 -2.175 0 C-N-CA 122.781 0.432 . . . . 0.0 110.832 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.699 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.0 t -149.98 116.29 5.74 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 122.901 0.48 . . . . 0.0 110.202 177.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.419 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.2 tt0 -83.86 103.23 12.96 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.86 -176.04 40.65 Favored Glycine 0 N--CA 1.432 -1.626 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.437 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.403 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 16.1 m -112.69 155.12 44.4 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.403 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 36.3 Cg_endo -63.67 164.9 19.68 Favored 'Trans proline' 0 CA--C 1.552 1.4 0 C-N-CA 122.432 2.088 . . . . 0.0 110.861 -178.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.49 -5.05 30.82 Favored 'Cis proline' 0 C--N 1.359 1.094 0 C-N-CA 124.573 -1.011 . . . . 0.0 113.363 7.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -104.49 78.82 1.5 Allowed 'General case' 0 CA--C 1.475 -1.916 0 C-N-CA 119.548 -0.861 . . . . 0.0 109.088 171.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.699 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -98.93 151.42 20.9 Favored 'General case' 0 N--CA 1.418 -2.071 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 60.1 mt -125.86 86.06 58.24 Favored Pre-proline 0 C--N 1.291 -1.962 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 88' ' ' THR . 54.7 Cg_endo -68.92 129.03 17.72 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.355 2.036 . . . . 0.0 112.666 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.33 -166.83 41.64 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 177.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.7 p -63.34 135.91 26.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.158 0.504 . . . . 0.0 110.596 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.481 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -76.86 144.63 38.88 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.569 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 44.4 m0 -90.35 8.79 31.68 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.334 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -170.51 -156.48 11.37 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.569 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 6.7 t -111.61 154.47 13.15 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -125.97 102.84 7.44 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 176.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.439 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 93.3 mttt . . . . . 0 C--N 1.288 -2.087 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 56.6 m . . . . . 0 N--CA 1.434 -1.271 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.426 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 81.9 m95 -82.94 130.77 35.18 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.2 p90 -141.39 159.33 42.45 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -176.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -150.28 147.47 21.96 Favored Pre-proline 0 N--CA 1.419 -2.015 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -76.37 121.95 6.31 Favored 'Trans proline' 0 N--CA 1.449 -1.109 0 C-N-CA 122.575 2.184 . . . . 0.0 110.121 174.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.28 123.15 8.71 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.508 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 23.9 t-20 -107.26 106.46 16.93 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.614 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.5 166.09 29.23 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.794 -175.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 98.0 m -103.9 119.78 39.63 Favored 'General case' 0 N--CA 1.414 -2.271 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.239 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.541 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -98.99 118.89 36.79 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.25 106.1 19.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.917 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 177.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -62.87 142.68 58.17 Favored 'General case' 0 C--N 1.316 -0.854 0 O-C-N 124.024 0.827 . . . . 0.0 111.325 -176.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.75 -140.72 0.91 Allowed Glycine 0 N--CA 1.428 -1.87 0 CA-C-N 115.696 -0.683 . . . . 0.0 113.688 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.67 -13.53 56.26 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 -173.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -110.67 138.71 21.11 Favored Pre-proline 0 C--N 1.31 -1.151 0 O-C-N 121.415 -0.803 . . . . 0.0 111.389 -177.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -69.29 145.85 61.19 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 122.334 2.023 . . . . 0.0 110.422 174.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.37 136.26 56.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.784 -175.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.7 t -75.8 121.89 28.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.5 p -104.59 158.24 16.63 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 110.375 -0.231 . . . . 0.0 110.375 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.493 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 26.5 mmt180 -127.6 160.97 29.95 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -174.19 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.435 HG12 HG21 ' A' ' 82' ' ' VAL . 50.3 mt -122.79 138.1 54.04 Favored 'Isoleucine or valine' 0 C--O 1.243 0.75 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.62 -47.1 2.54 Favored Glycine 0 CA--C 1.497 -1.081 0 CA-C-N 114.517 -1.219 . . . . 0.0 112.561 174.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 45.2 m -139.24 151.83 68.24 Favored Pre-proline 0 C--N 1.273 -2.742 0 C-N-CA 123.794 0.838 . . . . 0.0 111.052 -174.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -90.78 80.85 0.46 Allowed 'Trans proline' 0 N--CA 1.446 -1.293 0 C-N-CA 122.712 2.275 . . . . 0.0 111.761 175.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -141.69 157.76 44.66 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -76.72 -20.72 56.23 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.717 0.77 . . . . 0.0 109.189 178.21 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -98.48 13.09 32.99 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.994 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.493 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -87.56 152.14 51.53 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -58.11 138.79 87.78 Favored 'Trans proline' 0 C--O 1.249 1.054 0 C-N-CA 122.641 2.227 . . . . 0.0 112.568 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 69.4 t -68.61 118.03 11.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -80.65 -19.52 68.12 Favored Glycine 0 C--N 1.292 -1.907 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 144.11 -177.11 22.98 Favored Glycine 0 N--CA 1.401 -3.67 0 N-CA-C 107.97 -2.052 . . . . 0.0 107.97 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -112.5 140.06 47.56 Favored 'General case' 0 C--N 1.263 -3.191 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 21.8 tp -85.25 126.11 68.19 Favored Pre-proline 0 C--N 1.281 -2.393 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.335 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -62.46 154.07 66.76 Favored 'Trans proline' 0 N--CA 1.438 -1.756 0 C-N-CA 122.101 1.867 . . . . 0.0 112.511 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -71.66 135.37 46.86 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 175.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.68 12.96 79.19 Favored Glycine 0 C--N 1.312 -0.799 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.57 146.71 32.44 Favored 'General case' 0 CA--C 1.495 -1.152 0 CA-C-O 121.224 0.535 . . . . 0.0 110.773 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.9 m -108.77 110.62 22.06 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.896 -1.047 . . . . 0.0 109.001 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -110.41 133.9 54.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 123.201 0.6 . . . . 0.0 110.841 -177.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.72 117.0 50.65 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 171.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.614 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.0 p90 -111.86 163.4 14.24 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.128 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.39 2.45 8.41 Favored 'General case' 0 C--N 1.309 -1.195 0 O-C-N 123.613 0.571 . . . . 0.0 111.309 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -157.22 152.81 26.63 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.545 -175.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.2 t -130.54 137.3 56.5 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . 0.426 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 99.3 m -126.73 152.95 46.14 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.89 0.476 . . . . 0.0 110.998 178.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -123.34 110.35 25.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 173.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -159.52 147.34 17.25 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.42 30.21 18.82 Favored 'General case' 0 C--O 1.246 0.916 0 C-N-CA 123.952 0.901 . . . . 0.0 110.209 178.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.58 11.01 64.66 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.051 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.8 m80 -120.48 154.0 35.86 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 122.186 -0.597 . . . . 0.0 110.152 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.431 HG13 ' HB2' ' A' ' 89' ' ' CYS . 18.0 mt -101.5 133.16 45.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 171.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 57.8 m95 -125.31 148.13 48.84 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -172.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.6 pt -106.99 136.89 40.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 171.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.96 123.67 7.4 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.43 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 33.5 p90 . . . . . 0 C--N 1.297 -1.701 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.402 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 23.0 tpt180 . . . . . 0 CA--C 1.494 -1.209 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.435 HG21 HG12 ' A' ' 39' ' ' ILE . 23.1 t -102.75 129.15 54.82 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.025 -176.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.505 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 64.5 m-85 -111.63 134.88 52.89 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.583 177.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -123.13 127.0 25.81 Favored Pre-proline 0 C--N 1.287 -2.117 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 178.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -72.95 128.7 13.43 Favored 'Trans proline' 0 N--CA 1.437 -1.808 0 N-CA-C 108.334 -1.449 . . . . 0.0 108.334 175.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -112.9 -9.35 12.14 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -176.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.521 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.4 ptm180 179.75 167.29 1.2 Allowed 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.2 p -90.45 171.19 9.61 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.624 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 46.1 t -153.62 127.81 9.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.575 0.703 . . . . 0.0 109.863 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.479 ' HB2' ' HB ' ' A' ' 97' ' ' ILE . 11.6 mt-30 -93.15 112.16 24.02 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.228 173.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.09 167.11 32.72 Favored Glycine 0 N--CA 1.422 -2.292 0 CA-C-N 115.081 -0.963 . . . . 0.0 113.17 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.417 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 17.3 m -97.73 156.19 36.33 Favored Pre-proline 0 C--N 1.289 -2.054 0 CA-C-N 114.749 -0.725 . . . . 0.0 109.144 176.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.497 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 19.3 Cg_endo -62.65 168.86 9.35 Favored 'Trans proline' 0 CA--C 1.559 1.759 0 C-N-CA 122.536 2.158 . . . . 0.0 111.672 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -68.34 -18.14 9.96 Favored 'Cis proline' 0 C--N 1.366 1.49 0 CA-C-N 119.715 0.934 . . . . 0.0 114.024 4.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -99.55 79.7 2.3 Favored 'General case' 0 CA--C 1.484 -1.585 0 CA-C-O 121.435 0.636 . . . . 0.0 110.086 175.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.624 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -99.59 146.26 26.64 Favored 'General case' 0 N--CA 1.421 -1.889 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 174.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.479 ' HB ' ' HB2' ' A' ' 90' ' ' GLN . 63.8 mt -122.02 88.51 47.97 Favored Pre-proline 0 C--N 1.29 -1.993 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.638 177.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -65.73 140.75 63.08 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.347 2.032 . . . . 0.0 112.095 177.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.32 -158.4 33.47 Favored Glycine 0 C--N 1.306 -1.088 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.3 p -66.73 132.68 32.02 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-N 116.996 0.398 . . . . 0.0 110.182 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.521 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.02 139.32 38.2 Favored 'General case' 0 CA--C 1.49 -1.335 0 CA-C-O 120.89 0.376 . . . . 0.0 110.28 178.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 33.6 m0 -92.58 15.29 14.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.016 -177.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.71 -177.46 46.54 Favored Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.975 178.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.7 t -92.7 153.7 3.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -127.0 103.15 7.31 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 176.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.498 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 84.9 mttt . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 177.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.417 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 170.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 0.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.5 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.519 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.456 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 0.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 0.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 0.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 0.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 0.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 0.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.46 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 0.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 0.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 0.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 0.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 0.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 0.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 0.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 0.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 0.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.456 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 0.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 0.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 0.0 110.475 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 0.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 0.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 0.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 0.0 110.856 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.409 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 0.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 0.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 0.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.45 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.489 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' TYR . . . . . 0.45 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 . . . . . 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . 0.494 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 . . . . . 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.494 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.4 ' O ' HG22 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 0.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ARG . . . . . 0.491 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 0.0 110.358 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . 0.416 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 0.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 0.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 0.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 0.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.607 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 0.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.428 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 0.0 112.371 -178.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.491 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 0.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . 0.5 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 0.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.223 -0.31 0 N-CA-C 109.006 -0.738 . . . . 1.0 109.006 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.3 m 65.42 77.54 0.28 Allowed Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 124.722 1.209 . . . . 2.0 112.998 179.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -110.75 -153.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 124.229 3.286 . . . . 3.0 108.683 170.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.06 120.66 27.69 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.344 -1.354 . . . . 4.0 107.344 172.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.3 m -70.57 -45.97 64.38 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 112.04 0.385 . . . . 5.0 112.04 -174.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -79.48 152.27 75.49 Favored Pre-proline 0 C--N 1.315 -0.917 0 CA-C-N 116.535 -0.302 . . . . 6.0 110.872 -178.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.3 106.47 0.84 Allowed 'Trans proline' 0 C--O 1.247 0.945 0 C-N-CA 122.142 1.895 . . . . 7.0 108.997 173.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.03 142.63 35.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 116.07 -0.514 . . . . 8.0 109.971 -173.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.314 5.1 p 59.16 -6.98 0.05 Allowed 'General case' 0 CA--C 1.56 1.341 0 N-CA-C 117.582 2.438 . . . . 9.0 117.582 175.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.27 -97.64 0.86 Allowed Glycine 0 C--O 1.25 1.123 0 CA-C-O 120.929 0.183 . . . . 10.0 113.236 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.8 m -63.54 -57.64 9.54 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 123.129 0.571 . . . . 11.0 109.926 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.414 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 88.9 m95 -83.38 146.52 28.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.6 -0.727 . . . . 12.0 109.207 -179.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.6 mtmm -146.37 153.59 40.67 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.948 -1.501 . . . . 13.0 106.948 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -104.51 137.48 42.3 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.005 -0.678 . . . . 14.0 110.699 -177.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.0 p30 -91.74 -177.48 4.77 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 116.16 -0.473 . . . . 15.0 111.044 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -56.77 -30.49 63.68 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.287 1.035 . . . . 16.0 113.373 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -82.6 -8.01 59.62 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.862 0.363 . . . . 17.0 111.425 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.24 18.45 59.1 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.734 -0.946 . . . . 18.0 110.734 -176.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m -95.84 131.95 41.62 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 19.0 108.555 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 20.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.417 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 21.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.414 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 22.0 107.943 170.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 23.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 24.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 25.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 26.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.5 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 27.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.519 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 28.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 29.0 106.169 177.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.456 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 30.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 31.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 32.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 33.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 34.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 35.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 36.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 37.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.46 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 38.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 39.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 40.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 41.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 42.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 43.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 44.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 45.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 46.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 47.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 48.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 49.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 50.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 51.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 52.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 53.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.456 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 54.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 55.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 56.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 57.0 110.475 177.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 58.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 59.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 60.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 61.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 62.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 63.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 64.0 110.856 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.409 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 65.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 66.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 67.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 68.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 69.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.45 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 70.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 71.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 72.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 73.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.45 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 -142.19 171.97 13.34 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 74.0 108.98 177.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -111.45 145.22 39.38 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.785 -0.366 . . . . 75.0 110.416 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -92.35 171.48 9.03 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.981 -1.118 . . . . 76.0 107.981 173.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -62.75 -20.58 65.09 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 123.331 0.652 . . . . 77.0 111.876 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.669 ' HB2' ' OD1' ' A' ' 80' ' ' ASN . 61.3 m-20 -91.23 1.99 56.69 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.888 -0.507 . . . . 78.0 110.099 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.13 8.65 68.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 119.996 -1.097 . . . . 79.0 112.094 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.669 ' OD1' ' HB2' ' A' ' 78' ' ' ASN . 6.9 m120 -71.91 139.19 48.65 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 109.462 -0.57 . . . . 80.0 109.462 -178.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.494 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 -86.41 97.56 10.52 Favored 'General case' 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 81.0 107.254 175.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 82.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.494 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 83.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 84.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.4 ' O ' HG22 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 85.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 86.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.491 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 87.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 88.0 110.358 179.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 89.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.416 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 90.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 91.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 92.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 93.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 94.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 95.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.607 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 96.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.428 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 97.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 98.0 112.371 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 99.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 100.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.491 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 101.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 102.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 103.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 104.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 105.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.5 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 106.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 . . . . . 0 N--CA 1.452 -0.35 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.6 m -79.78 114.98 50.51 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.112 0.965 . . . . 0.0 108.924 177.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -69.05 -31.44 23.66 Favored 'Trans proline' 0 C--O 1.233 0.268 0 C-N-CA 122.647 2.231 . . . . 0.0 111.26 179.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -65.03 140.43 58.85 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.362 177.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p -67.87 114.79 6.74 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.858 177.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -67.53 140.8 94.98 Favored Pre-proline 0 C--O 1.244 0.802 0 C-N-CA 121.065 -0.254 . . . . 0.0 110.718 -179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -80.02 87.38 1.53 Allowed 'Trans proline' 0 N--CA 1.433 -2.076 0 C-N-CA 121.948 1.765 . . . . 0.0 110.797 179.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.1 p -79.04 -43.34 24.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.323 -178.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.9 p -126.85 109.11 11.63 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.14 -87.33 1.02 Allowed Glycine 0 CA--C 1.498 -1.012 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.2 m -65.15 -48.65 72.79 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -85.19 122.88 30.01 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.41 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 31.0 mtmm -125.75 144.48 50.61 Favored 'General case' 0 C--N 1.293 -1.851 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.549 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 51.7 tttm -95.21 132.53 40.08 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.212 0.53 . . . . 0.0 110.123 -175.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.404 HD22 ' HB ' ' A' ' 19' ' ' THR . 37.6 p30 -93.24 -177.33 4.42 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.936 -178.553 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -60.18 -25.71 65.77 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.531 0.732 . . . . 0.0 112.638 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -87.48 -6.47 58.37 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.485 0.659 . . . . 0.0 110.135 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.99 16.2 68.08 Favored Glycine 0 CA--C 1.498 -1.009 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.416 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.404 ' HB ' HD22 ' A' ' 15' ' ' ASN . 62.6 m -92.21 138.8 31.23 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.418 ' CD1' ' HB ' ' A' ' 92' ' ' VAL . 79.1 m95 -93.93 134.41 36.34 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -137.68 162.65 33.28 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.564 0.54 . . . . 0.0 110.742 -177.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 61.2 pttt -155.04 145.25 15.84 Favored Pre-proline 0 C--N 1.298 -1.639 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 170.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -76.64 132.31 13.19 Favored 'Trans proline' 0 N--CA 1.445 -1.336 0 C-N-CA 122.161 1.908 . . . . 0.0 109.956 175.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -151.77 123.85 8.14 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.438 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -105.42 110.61 23.01 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.556 ' HB1' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.66 166.76 32.53 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.701 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 76.9 m -103.54 119.55 39.11 Favored 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.19 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 60.0 t80 -99.09 120.08 38.89 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.409 ' HB ' HG21 ' A' ' 104' ' ' VAL . 92.5 t -107.37 109.81 29.52 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 176.366 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.515 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 55.5 t30 -61.02 148.47 40.09 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 123.804 0.69 . . . . 0.0 110.443 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -85.68 -130.74 2.51 Favored Glycine 0 N--CA 1.432 -1.623 0 CA-C-O 121.321 0.401 . . . . 0.0 113.638 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.24 -7.68 52.88 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -172.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -120.37 141.02 31.14 Favored Pre-proline 0 C--N 1.307 -1.276 0 C-N-CA 120.347 -0.541 . . . . 0.0 111.156 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.73 150.85 68.91 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.069 1.846 . . . . 0.0 110.955 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.559 HG21 ' SG ' ' A' ' 84' ' ' CYS . 7.5 mm -116.24 141.34 34.31 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.186 -174.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.79 117.2 35.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 176.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.2 p -97.4 158.79 15.29 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 116.862 -0.153 . . . . 0.0 111.382 -174.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mmt180 -130.06 156.51 44.39 Favored 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.407 ' C ' ' H ' ' A' ' 41' ' ' SER . 51.0 mt -115.96 137.64 49.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.55 -36.83 2.61 Favored Glycine 0 CA--C 1.493 -1.333 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.802 174.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.407 ' H ' ' C ' ' A' ' 39' ' ' ILE . 6.8 m -138.08 151.12 69.31 Favored Pre-proline 0 C--N 1.28 -2.425 0 CA-C-N 114.944 -0.628 . . . . 0.0 111.46 -171.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -94.01 49.69 0.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.369 2.713 . . . . 0.0 111.328 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 99.9 m-85 -121.3 153.04 38.22 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -77.27 -8.78 58.18 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.808 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -103.7 4.63 35.57 Favored 'General case' 0 C--O 1.245 0.842 0 CA-C-O 121.618 0.723 . . . . 0.0 110.647 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.5 158.73 70.96 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.78 140.32 93.27 Favored 'Trans proline' 0 C--O 1.247 0.93 0 C-N-CA 122.491 2.127 . . . . 0.0 111.834 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.0 t -74.13 126.63 35.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.75 -14.27 65.54 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 129.9 -176.57 18.61 Favored Glycine 0 N--CA 1.414 -2.814 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -108.56 130.26 55.3 Favored 'General case' 0 C--N 1.273 -2.729 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -80.99 124.71 81.13 Favored Pre-proline 0 C--N 1.281 -2.402 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -61.97 149.98 88.15 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.288 1.992 . . . . 0.0 112.59 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.515 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -68.7 117.82 10.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.572 177.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 30' ' ' ASN . . . 101.78 4.67 51.7 Favored Glycine 0 C--N 1.304 -1.204 0 C-N-CA 121.121 -0.562 . . . . 0.0 112.96 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.05 146.39 53.55 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.5 0.556 . . . . 0.0 112.5 -178.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.6 p -101.57 105.42 16.37 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.778 0.831 . . . . 0.0 110.791 -179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.9 mm -107.74 134.79 48.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 123.339 0.656 . . . . 0.0 111.296 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.78 116.17 48.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 170.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.556 ' CZ ' ' HB1' ' A' ' 26' ' ' ALA . 54.8 p90 -111.05 162.15 15.17 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.053 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -129.28 6.0 5.3 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 123.791 0.682 . . . . 0.0 111.376 -177.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -158.74 154.89 27.02 Favored 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 8.8 t -133.51 133.75 57.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 172.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 54.5 m -126.25 154.26 43.61 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 123.419 0.688 . . . . 0.0 110.576 178.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 66.0 mt -123.21 123.12 67.04 Favored 'Isoleucine or valine' 0 C--O 1.255 1.377 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.7 tp-100 -171.9 152.72 3.06 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.76 26.42 15.6 Favored 'General case' 0 C--O 1.243 0.757 0 C-N-CA 123.682 0.793 . . . . 0.0 111.045 177.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.33 5.8 82.45 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.202 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -120.6 153.86 36.22 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 121.053 0.454 . . . . 0.0 111.34 -177.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 24.0 mt -100.74 131.91 47.44 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.424 ' CZ3' ' HD3' ' A' ' 85' ' ' PRO . 55.3 m95 -123.62 140.47 52.96 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -172.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 30.3 pt -97.37 134.44 35.3 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 172.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.13 124.45 8.06 Favored Glycine 0 N--CA 1.425 -2.08 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.483 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.6 p90 -141.62 165.89 26.26 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 120.734 0.302 . . . . 0.0 110.625 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -105.7 122.97 47.15 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -74.9 175.96 7.58 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 70.3 t80 -56.35 -35.49 67.7 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.403 0.62 . . . . 0.0 110.444 178.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -77.81 0.31 24.3 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.557 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.39 -20.65 29.31 Favored Glycine 0 C--O 1.24 0.473 0 O-C-N 121.985 -0.447 . . . . 0.0 112.294 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -53.78 135.58 41.31 Favored 'General case' 0 C--O 1.247 0.942 0 C-N-CA 124.636 1.174 . . . . 0.0 111.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -76.9 107.73 9.44 Favored 'General case' 0 C--O 1.202 -1.412 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 26.6 t -104.91 132.91 50.51 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.948 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.05 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.1 m-85 -111.12 125.94 54.31 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.216 177.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.559 ' SG ' HG21 ' A' ' 35' ' ' ILE . 41.0 t -116.49 120.46 34.63 Favored Pre-proline 0 C--N 1.286 -2.159 0 CA-C-N 115.373 -0.831 . . . . 0.0 108.883 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.424 ' HD3' ' CZ3' ' A' ' 71' ' ' TRP . 37.9 Cg_endo -72.31 119.26 6.03 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 121.708 1.605 . . . . 0.0 109.134 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 29.0 m -105.85 -14.15 9.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.469 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.1 ptt180 -176.23 176.31 1.71 Allowed 'General case' 0 CA--C 1.503 -0.834 0 O-C-N 123.732 0.645 . . . . 0.0 109.581 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.6 p -95.6 167.15 11.48 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 123.357 0.411 . . . . 0.0 110.862 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.587 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.1 t -150.71 127.91 11.25 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 174.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.495 HE21 HD12 ' A' ' 97' ' ' ILE . 6.2 tt0 -87.24 110.52 20.24 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.5 -155.45 32.36 Favored Glycine 0 N--CA 1.423 -2.219 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.735 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.418 ' HB ' ' CD1' ' A' ' 20' ' ' TRP . 8.3 m -134.39 155.52 79.7 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.44 ' HA ' ' N ' ' A' ' 95' ' ' ASN . 19.6 Cg_endo -63.19 167.68 12.21 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.198 1.932 . . . . 0.0 111.515 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.81 -4.76 5.97 Favored 'Cis proline' 0 C--N 1.352 0.752 0 N-CA-C 115.513 1.313 . . . . 0.0 115.513 4.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . 0.44 ' N ' ' HA ' ' A' ' 93' ' ' PRO . 39.1 m-80 -108.79 80.45 1.33 Allowed 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.471 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.0 pt20 -96.57 146.08 25.15 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.587 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 83.7 mt -122.0 87.77 47.43 Favored Pre-proline 0 C--N 1.273 -2.734 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.7 128.52 11.0 Favored 'Trans proline' 0 N--CA 1.442 -1.534 0 C-N-CA 122.647 2.232 . . . . 0.0 112.987 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.53 -175.79 49.56 Favored Glycine 0 N--CA 1.433 -1.558 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.793 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.1 p -67.31 133.98 30.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 120.947 0.403 . . . . 0.0 110.009 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.469 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -67.13 143.18 56.78 Favored 'General case' 0 N--CA 1.434 -1.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.777 -179.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 39.4 m0 -92.48 17.41 10.06 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.907 176.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.85 -173.39 42.38 Favored Glycine 0 N--CA 1.427 -1.959 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.796 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.8 OUTLIER -96.6 156.49 3.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -177.605 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -129.02 102.97 6.74 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 175.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.473 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 65.4 mttm . . . . . 0 C--N 1.301 -1.524 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.384 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 120.364 0.126 . . . . 0.0 110.803 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 2.9 m -58.86 114.3 8.7 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.429 1.092 . . . . 0.0 112.092 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.9 141.26 64.14 Favored 'Trans proline' 0 C--O 1.25 1.077 0 C-N-CA 122.617 2.212 . . . . 0.0 111.19 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.98 84.41 7.46 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-O 121.005 0.431 . . . . 0.0 110.034 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.7 p -103.14 -17.43 15.38 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.714 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -83.69 136.08 42.5 Favored Pre-proline 0 C--N 1.323 -0.553 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.766 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.429 ' HB3' ' O ' ' A' ' 10' ' ' GLY . 47.5 Cg_exo -59.25 123.29 13.1 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 123.081 2.521 . . . . 0.0 111.948 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -91.28 -64.67 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.0 p -114.48 35.77 4.07 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 122.137 0.97 . . . . 0.0 108.897 178.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.429 ' O ' ' HB3' ' A' ' 7' ' ' PRO . . . 104.01 -119.47 6.32 Favored Glycine 0 N--CA 1.424 -2.136 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.7 m -73.47 -25.57 60.53 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.7 0.762 . . . . 0.0 110.038 178.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 77.3 m95 -84.71 130.43 34.7 Favored 'General case' 0 N--CA 1.423 -1.783 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.115 -175.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 mtmm -129.63 151.97 49.65 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.416 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 26.4 ttpp -114.05 146.09 40.69 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 120.191 -0.604 . . . . 0.0 110.423 -176.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.2 p30 -98.33 -177.92 3.86 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.655 175.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -58.61 -23.46 58.9 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.637 1.175 . . . . 0.0 113.485 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -90.31 -6.07 55.53 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.024 0.44 . . . . 0.0 111.0 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.416 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 88.0 15.66 60.7 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.981 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.6 m -89.19 125.84 35.23 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.426 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 95.4 m95 -88.41 140.06 29.86 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 175.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.405 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 39.7 p90 -146.51 154.6 41.74 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 120.568 0.223 . . . . 0.0 110.954 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -144.83 145.69 28.73 Favored Pre-proline 0 C--N 1.305 -1.332 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -80.88 119.74 3.67 Favored 'Trans proline' 0 C--O 1.249 1.056 0 C-N-CA 122.64 2.227 . . . . 0.0 110.784 178.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -145.86 123.56 11.87 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -99.12 109.33 22.05 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.549 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.81 162.85 40.41 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.59 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.453 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.4 m -100.54 119.7 38.91 Favored 'General case' 0 N--CA 1.419 -2.024 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.059 177.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.531 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 67.2 t80 -98.97 113.98 26.41 Favored 'General case' 0 N--CA 1.416 -2.163 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.4 t -101.67 109.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 N-CA-C 106.001 -1.852 . . . . 0.0 106.001 176.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.494 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 53.6 t30 -61.56 149.43 39.1 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 123.567 0.542 . . . . 0.0 110.252 -177.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -88.71 -126.46 2.69 Favored Glycine 0 N--CA 1.423 -2.215 0 N-CA-C 114.259 0.464 . . . . 0.0 114.259 -174.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -89.92 -21.93 22.23 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -172.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -105.24 137.41 19.24 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.842 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.95 147.97 50.43 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.191 1.928 . . . . 0.0 109.319 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.6 mt -120.67 136.49 57.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.059 -174.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 69.8 t -79.16 116.82 23.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.48 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 72.2 p -91.49 157.12 17.22 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.686 -0.233 . . . . 0.0 110.617 -176.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -124.31 152.13 43.46 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.445 HG12 HG22 ' A' ' 82' ' ' VAL . 21.0 mt -116.2 136.38 53.34 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -176.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.62 -45.83 3.5 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.868 174.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 40.8 m -138.17 144.33 42.87 Favored Pre-proline 0 C--N 1.274 -2.709 0 CA-C-N 113.972 -1.114 . . . . 0.0 110.324 -173.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -89.34 79.84 0.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.083 0 C-N-CA 122.411 2.074 . . . . 0.0 112.43 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -143.14 154.12 43.58 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 89.9 mt -76.6 -13.5 60.06 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.079 0.942 . . . . 0.0 108.773 174.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -91.24 -8.41 48.47 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.766 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -83.32 156.04 66.26 Favored Pre-proline 0 C--O 1.256 1.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.024 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.62 143.89 93.88 Favored 'Trans proline' 0 C--N 1.359 1.103 0 C-N-CA 123.145 2.563 . . . . 0.0 112.396 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.8 t -82.36 131.57 33.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.05 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.52 -27.9 28.61 Favored Glycine 0 C--N 1.3 -1.438 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 177.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 147.36 -176.33 26.27 Favored Glycine 0 N--CA 1.426 -2.012 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.24 117.5 34.67 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 20.4 tp -69.36 123.86 89.26 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -55.94 141.21 86.31 Favored 'Trans proline' 0 N--CA 1.432 -2.105 0 C-N-CA 122.487 2.125 . . . . 0.0 113.266 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.494 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -67.26 116.58 8.2 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.73 0.11 42.48 Favored Glycine 0 C--N 1.304 -1.2 0 C-N-CA 120.728 -0.749 . . . . 0.0 113.1 -177.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -71.86 149.73 44.92 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.899 0.35 . . . . 0.0 111.554 -179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.9 p -104.79 108.83 20.52 Favored 'General case' 0 N--CA 1.439 -1.006 0 CA-C-O 121.55 0.691 . . . . 0.0 111.76 -178.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.5 mm -105.48 132.64 51.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 C-N-CA 123.841 0.857 . . . . 0.0 110.954 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.19 116.89 48.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.549 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 52.0 p90 -112.84 164.71 13.07 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.395 -0.522 . . . . 0.0 110.241 -177.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -123.52 -3.01 8.37 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.436 0.46 . . . . 0.0 111.666 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -154.92 154.43 32.62 Favored 'General case' 0 N--CA 1.434 -1.229 0 C-N-CA 119.445 -0.902 . . . . 0.0 109.85 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 21.6 t -127.04 135.58 63.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 175.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . 0.426 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 61.6 m -125.35 157.03 37.76 Favored 'General case' 0 C--N 1.293 -1.853 0 O-C-N 123.199 0.312 . . . . 0.0 110.98 -178.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.4 HG12 HG12 ' A' ' 70' ' ' ILE . 73.0 mt -127.51 109.91 21.27 Favored 'Isoleucine or valine' 0 C--O 1.253 1.259 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 175.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -156.36 151.61 26.55 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.26 24.99 15.03 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 123.699 0.799 . . . . 0.0 110.361 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.56 13.27 68.11 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.398 -178.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -120.18 154.72 34.4 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 122.3 -0.53 . . . . 0.0 109.781 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.411 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 20.4 mt -101.29 133.89 43.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 174.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 53.9 m95 -126.02 150.82 47.82 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -172.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 29.0 pt -106.39 130.71 57.7 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.707 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 170.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -100.05 119.02 6.36 Favored Glycine 0 N--CA 1.417 -2.572 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -142.34 168.15 20.41 Favored 'General case' 0 N--CA 1.414 -2.257 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -104.41 127.67 52.13 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 174.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -78.54 172.06 14.22 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.708 -177.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.64 -21.6 66.76 Favored 'General case' 0 C--O 1.22 -0.495 0 CA-C-O 121.994 0.902 . . . . 0.0 108.754 175.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -79.08 -7.49 58.19 Favored 'General case' 0 CA--C 1.555 1.146 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.922 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.64 7.51 87.33 Favored Glycine 0 C--O 1.227 -0.327 0 O-C-N 121.537 -0.727 . . . . 0.0 113.338 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -99.05 157.61 16.23 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 122.348 -0.501 . . . . 0.0 111.826 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.403 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 25.2 tpt180 -79.43 114.34 18.28 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.48 ' CG1' ' HB ' ' A' ' 37' ' ' THR . 38.3 t -116.93 134.95 58.87 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.681 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.533 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.8 m-85 -117.4 123.2 45.85 Favored 'General case' 0 C--N 1.281 -2.408 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.2 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -112.39 126.01 29.11 Favored Pre-proline 0 C--N 1.279 -2.467 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -71.79 129.78 15.96 Favored 'Trans proline' 0 N--CA 1.439 -1.678 0 C-N-CA 121.374 1.382 . . . . 0.0 108.778 176.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.51 -13.11 11.48 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -174.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.423 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.6 ptm180 -178.31 167.0 1.91 Allowed 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.493 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 16.2 p -92.33 162.68 14.17 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.8 t -141.39 120.69 13.06 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.465 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 28.1 tt0 -83.63 111.32 19.01 Favored 'General case' 0 N--CA 1.424 -1.768 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 177.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.17 -166.13 51.24 Favored Glycine 0 N--CA 1.426 -1.994 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.427 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 13.9 m -121.22 160.49 45.28 Favored Pre-proline 0 C--N 1.297 -1.707 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.427 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 31.4 Cg_endo -65.67 167.41 17.33 Favored 'Trans proline' 0 CA--C 1.547 1.155 0 C-N-CA 121.987 1.792 . . . . 0.0 112.48 179.337 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -65.37 -28.46 4.36 Favored 'Cis proline' 0 C--N 1.363 1.307 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.985 4.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -90.86 79.31 5.96 Favored 'General case' 0 CA--C 1.485 -1.549 0 CA-C-O 122.17 0.986 . . . . 0.0 110.169 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 0.9 OUTLIER -94.26 143.82 26.06 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 176.409 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.465 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.0 mt -122.15 92.46 48.88 Favored Pre-proline 0 C--N 1.27 -2.873 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 177.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 88' ' ' THR . 58.7 Cg_endo -79.66 135.69 11.72 Favored 'Trans proline' 0 N--CA 1.434 -2.029 0 C-N-CA 122.263 1.976 . . . . 0.0 112.226 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.71 -159.07 23.38 Favored Glycine 0 C--N 1.311 -0.816 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -63.83 139.19 21.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.423 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.75 135.1 36.42 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 42.3 m0 -83.77 9.41 11.94 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.786 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -174.02 -172.08 38.97 Favored Glycine 0 N--CA 1.428 -1.891 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 178.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.5 t -97.36 149.35 5.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 -178.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -122.2 108.67 13.56 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 175.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.453 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 82.3 mttt . . . . . 0 C--N 1.285 -2.229 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 121.192 0.52 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.5 m -95.73 130.35 31.97 Favored Pre-proline 0 N--CA 1.428 -1.572 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 177.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.22 34.94 0.3 Allowed 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.419 2.746 . . . . 0.0 112.874 178.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.7 158.58 43.94 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -178.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.3 p -72.97 159.95 32.87 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-O 121.109 0.48 . . . . 0.0 111.262 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 81.2 mtt180 -74.3 134.66 76.7 Favored Pre-proline 0 C--N 1.308 -1.212 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.799 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.54 112.88 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.616 2.21 . . . . 0.0 111.515 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.39 -41.32 86.14 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 175.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.634 ' HB ' ' O ' ' A' ' 12' ' ' TRP . 0.2 OUTLIER -146.03 108.26 4.41 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.156 -1.383 . . . . 0.0 110.625 179.519 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.69 -26.01 7.0 Favored Glycine 0 C--N 1.31 -0.876 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 p -73.38 -54.79 7.47 Favored 'General case' 0 N--CA 1.433 -1.277 0 C-N-CA 124.322 1.049 . . . . 0.0 110.077 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.634 ' O ' ' HB ' ' A' ' 9' ' ' THR . 72.7 m95 -103.87 143.5 32.75 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -125.65 140.23 52.89 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -103.98 139.44 39.1 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 120.051 -0.66 . . . . 0.0 109.784 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.8 p30 -95.27 -177.8 4.23 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.105 176.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -63.18 -23.91 67.64 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -75.58 -17.52 60.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.533 0.682 . . . . 0.0 109.597 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.79 8.7 60.45 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.2 m -86.08 125.4 33.43 Favored 'General case' 0 N--CA 1.412 -2.327 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.413 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 89.6 m95 -86.38 125.37 33.61 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.135 -1.432 . . . . 0.0 107.135 175.106 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -134.64 151.57 51.14 Favored 'General case' 0 C--N 1.281 -2.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.562 -177.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -135.59 143.53 45.34 Favored Pre-proline 0 C--N 1.292 -1.926 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 173.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -76.8 113.03 3.56 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.216 1.944 . . . . 0.0 109.542 176.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -147.82 124.13 10.91 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.434 -178.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -100.06 106.59 18.35 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -178.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.538 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . . . -147.11 160.4 42.46 Favored 'General case' 0 C--N 1.288 -2.067 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.616 -178.429 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.548 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 55.6 m -102.81 121.57 42.75 Favored 'General case' 0 C--N 1.288 -2.1 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.835 178.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.549 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.5 t80 -99.25 112.09 24.33 Favored 'General case' 0 C--N 1.284 -2.269 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 99.3 t -97.17 108.28 21.28 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.407 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 54.2 t30 -63.84 143.76 57.59 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 123.502 0.501 . . . . 0.0 110.069 -178.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -83.12 -128.05 1.27 Allowed Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 116.112 -0.494 . . . . 0.0 113.319 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -90.67 -14.61 31.93 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -172.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -108.26 136.86 19.8 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.947 -0.471 . . . . 0.0 111.575 -177.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -71.44 142.24 40.32 Favored 'Trans proline' 0 C--O 1.247 0.949 0 C-N-CA 121.974 1.783 . . . . 0.0 109.711 172.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.416 HG22 ' O ' ' A' ' 85' ' ' PRO . 1.4 mt -117.26 133.24 64.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.085 -174.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -77.56 113.08 16.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 70.7 p -89.04 156.57 18.77 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.679 -175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -126.95 156.28 41.79 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -177.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.419 HG12 HG22 ' A' ' 82' ' ' VAL . 50.7 mt -122.09 135.83 60.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -177.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.54 -35.17 3.04 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.301 -0.863 . . . . 0.0 113.511 173.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 56.1 m -139.43 139.48 22.75 Favored Pre-proline 0 C--N 1.261 -3.253 0 C-N-CA 123.16 0.584 . . . . 0.0 111.343 -176.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_endo -87.13 55.06 2.99 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.714 2.276 . . . . 0.0 111.179 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -123.81 157.76 33.34 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.044 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.87 -14.03 59.93 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.551 0.691 . . . . 0.0 110.232 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -97.58 4.28 50.29 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.414 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.11 155.08 64.0 Favored Pre-proline 0 C--N 1.314 -0.935 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.64 136.75 77.61 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 122.991 2.46 . . . . 0.0 112.33 -178.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -78.27 124.48 36.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 115.355 -0.838 . . . . 0.0 109.701 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.36 -25.97 53.0 Favored Glycine 0 C--N 1.302 -1.331 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.56 -176.73 21.26 Favored Glycine 0 N--CA 1.421 -2.345 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -95.66 130.62 42.48 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.4 tp -77.01 126.31 85.69 Favored Pre-proline 0 C--N 1.285 -2.196 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 173.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -60.78 148.41 92.06 Favored 'Trans proline' 0 N--CA 1.44 -1.673 0 C-N-CA 121.913 1.742 . . . . 0.0 112.3 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.407 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.26 132.81 47.06 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 91.23 2.66 70.64 Favored Glycine 0 C--N 1.302 -1.333 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.069 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -75.24 144.67 42.46 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.37 0.605 . . . . 0.0 110.974 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.1 m -104.8 107.92 19.13 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.12 -176.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.4 mm -106.95 130.09 59.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 C-N-CA 123.38 0.672 . . . . 0.0 111.323 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.0 t -100.03 117.54 45.36 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 170.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.538 ' CZ ' ' HB2' ' A' ' 26' ' ' ALA . 55.1 p90 -116.09 163.57 15.74 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.906 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -121.74 -0.59 9.61 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 123.409 0.443 . . . . 0.0 111.689 -178.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -153.27 148.54 26.93 Favored 'General case' 0 N--CA 1.433 -1.322 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.11 -176.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.4 t -120.98 133.48 67.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 105.681 -1.97 . . . . 0.0 105.681 173.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . 0.413 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 3.9 m -125.66 150.1 47.9 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -175.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 64.3 mt -123.01 118.19 54.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 173.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -160.31 145.5 14.85 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -178.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.87 29.59 17.94 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 124.191 0.996 . . . . 0.0 110.759 177.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.06 10.47 73.4 Favored Glycine 0 CA--C 1.519 0.29 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.414 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -119.58 153.13 35.92 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 122.402 -0.469 . . . . 0.0 110.114 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 23.5 mt -103.37 133.94 45.88 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 174.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -127.73 153.61 46.32 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -171.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.483 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -109.96 130.25 63.47 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.774 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 171.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.47 122.52 7.55 Favored Glycine 0 N--CA 1.42 -2.424 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.456 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.2 p90 -142.38 149.56 39.54 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -86.98 122.74 31.25 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -67.89 175.58 2.99 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 123.656 0.597 . . . . 0.0 109.617 178.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -57.36 -34.51 68.89 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 123.122 0.569 . . . . 0.0 111.175 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -83.51 -10.05 58.57 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-O 121.482 0.658 . . . . 0.0 110.97 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.83 -9.81 55.43 Favored Glycine 0 C--N 1.312 -0.794 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.035 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -58.43 139.92 54.68 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.918 0.487 . . . . 0.0 110.875 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.7 tpt180 -82.74 99.04 9.41 Favored 'General case' 0 CA--C 1.492 -1.267 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.419 HG22 HG12 ' A' ' 39' ' ' ILE . 35.9 t -97.39 130.48 45.99 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.494 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.483 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.6 m-85 -112.4 125.17 53.92 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.309 178.04 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -114.14 125.06 29.83 Favored Pre-proline 0 C--N 1.278 -2.501 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 176.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.416 ' O ' HG22 ' A' ' 35' ' ' ILE . 42.8 Cg_endo -72.59 129.07 14.17 Favored 'Trans proline' 0 N--CA 1.439 -1.731 0 C-N-CA 121.271 1.314 . . . . 0.0 108.724 177.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.7 m -112.39 -15.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.448 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptt180 -177.48 173.12 1.73 Allowed 'General case' 0 CA--C 1.503 -0.853 0 C-N-CA 123.629 0.772 . . . . 0.0 109.457 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.6 p -99.93 168.3 9.96 Favored 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.593 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 45.1 t -147.55 123.86 10.91 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.3 tt0 -82.91 96.31 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.56 174.83 44.58 Favored Glycine 0 N--CA 1.429 -1.809 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.759 178.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.63 154.91 39.73 Favored Pre-proline 0 C--N 1.295 -1.797 0 C-N-CA 122.081 0.152 . . . . 0.0 111.011 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.47 167.01 13.9 Favored 'Trans proline' 0 CA--C 1.556 1.617 0 C-N-CA 122.677 2.252 . . . . 0.0 112.8 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -66.13 -24.58 6.17 Favored 'Cis proline' 0 C--N 1.372 1.794 0 C-N-CA 124.156 -1.185 . . . . 0.0 113.278 5.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -89.21 79.04 7.2 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 121.727 0.775 . . . . 0.0 109.26 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.593 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 12.8 pt20 -101.84 152.06 21.34 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 68.0 mt -130.28 88.02 49.03 Favored Pre-proline 0 C--N 1.284 -2.277 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -73.46 133.81 19.65 Favored 'Trans proline' 0 N--CA 1.443 -1.453 0 C-N-CA 122.433 2.089 . . . . 0.0 112.536 -178.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -85.42 -163.38 37.32 Favored Glycine 0 N--CA 1.441 -1.002 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.748 178.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -69.54 131.85 33.65 Favored 'Isoleucine or valine' 0 C--O 1.251 1.145 0 CA-C-O 120.88 0.371 . . . . 0.0 110.695 -178.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.448 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -71.6 140.55 49.82 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.445 177.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.4 m0 -90.2 10.86 22.95 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.799 179.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -167.54 -159.95 14.08 Favored Glycine 0 N--CA 1.43 -1.712 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.22 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.7 OUTLIER -113.03 154.64 14.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.045 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -123.76 103.61 8.48 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.548 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 87.5 mttt . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 173.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 . . . . . 0 C--O 1.234 0.264 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 78.1 m -103.26 121.37 48.97 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.58 93.5 0.37 Allowed 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.006 1.804 . . . . 0.0 110.474 175.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.8 9.69 17.68 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.469 0.652 . . . . 0.0 110.108 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.1 m -94.67 26.95 3.24 Favored 'General case' 0 CA--C 1.558 1.268 0 CA-C-O 122.3 1.048 . . . . 0.0 108.974 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 58.3 ttt180 -63.41 134.12 95.73 Favored Pre-proline 0 C--O 1.246 0.91 0 CA-C-N 114.253 -1.34 . . . . 0.0 111.966 -177.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.31 140.16 57.44 Favored 'Trans proline' 0 C--O 1.239 0.57 0 C-N-CA 123.182 2.588 . . . . 0.0 110.705 177.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.47 -33.5 7.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -175.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 36.2 p -96.83 -28.92 14.03 Favored 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.964 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.63 -68.78 0.53 Allowed Glycine 0 N--CA 1.43 -1.714 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.207 179.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.7 t -92.97 -20.23 20.81 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 120.635 0.255 . . . . 0.0 110.603 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -115.92 151.73 34.8 Favored 'General case' 0 C--O 1.254 1.317 0 CA-C-O 121.659 0.743 . . . . 0.0 111.68 -177.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -126.75 149.82 49.42 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -117.94 134.02 55.35 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.985 -0.686 . . . . 0.0 109.391 176.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.1 p30 -92.72 -175.37 3.92 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.86 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -64.04 -19.01 64.9 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -92.99 -3.24 54.79 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.947 0.403 . . . . 0.0 110.766 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.53 17.04 67.12 Favored Glycine 0 CA--C 1.507 -0.43 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 87.3 m -89.68 127.6 35.95 Favored 'General case' 0 N--CA 1.421 -1.91 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -84.91 135.9 33.86 Favored 'General case' 0 CA--C 1.485 -1.536 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 175.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -149.5 162.51 40.01 Favored 'General case' 0 C--N 1.281 -2.388 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -177.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -150.36 144.7 17.71 Favored Pre-proline 0 N--CA 1.422 -1.852 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.17 126.84 11.46 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.621 2.214 . . . . 0.0 109.73 176.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -152.76 123.7 7.45 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.7 108.88 20.85 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.571 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.21 164.77 38.35 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.642 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 65.1 m -105.72 120.85 42.74 Favored 'General case' 0 N--CA 1.416 -2.154 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.43 177.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.515 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.7 t80 -98.98 125.25 44.4 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.1 109.72 29.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.419 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 51.8 t30 -65.33 145.28 56.39 Favored 'General case' 0 C--N 1.308 -1.205 0 O-C-N 123.778 0.674 . . . . 0.0 110.699 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -84.54 -108.49 0.62 Allowed Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 114.863 0.705 . . . . 0.0 114.863 -174.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.26 -25.04 13.82 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 122.599 0.36 . . . . 0.0 111.717 -170.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -110.84 133.63 21.18 Favored Pre-proline 0 C--N 1.295 -1.769 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.802 -176.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.05 140.72 55.25 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.211 1.941 . . . . 0.0 110.568 175.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.85 136.25 52.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.746 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 52.6 t -77.36 121.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.8 p -94.19 157.84 15.87 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.034 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.424 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 27.0 mmt180 -130.72 155.01 47.35 Favored 'General case' 0 C--O 1.21 -0.985 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 -174.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.422 HG12 HG21 ' A' ' 82' ' ' VAL . 18.6 mt -112.46 138.95 39.67 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.45 -48.74 4.11 Favored Glycine 0 CA--C 1.502 -0.719 0 C-N-CA 124.921 1.248 . . . . 0.0 113.752 174.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 14.8 m -137.35 154.2 75.26 Favored Pre-proline 0 C--N 1.279 -2.499 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.991 -170.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -91.03 67.22 1.31 Allowed 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 123.006 2.47 . . . . 0.0 111.77 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -131.17 156.45 45.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.7 mt -76.46 -19.98 57.49 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.959 0.409 . . . . 0.0 111.024 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -100.39 18.16 19.68 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 121.556 0.694 . . . . 0.0 111.208 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.424 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -85.22 152.62 58.6 Favored Pre-proline 0 C--N 1.308 -1.239 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.4 143.24 94.61 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.462 HG11 ' H ' ' A' ' 50' ' ' GLY . 51.7 t -79.57 126.19 39.05 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.01 7.69 67.36 Favored Glycine 0 C--N 1.308 -0.976 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.462 ' H ' HG11 ' A' ' 48' ' ' VAL . . . 122.28 170.51 13.71 Favored Glycine 0 N--CA 1.423 -2.21 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -113.19 117.17 31.17 Favored 'General case' 0 C--N 1.28 -2.418 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.42 HD13 ' HD2' ' A' ' 53' ' ' PRO . 19.6 tp -68.78 125.7 92.08 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.212 -176.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' HD13 ' A' ' 52' ' ' LEU . 1.3 Cg_endo -63.14 156.8 52.99 Favored 'Trans proline' 0 N--CA 1.439 -1.735 0 C-N-CA 122.28 1.986 . . . . 0.0 112.768 178.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.419 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -76.99 128.19 34.06 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 176.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.76 21.36 50.95 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.828 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 146.1 24.43 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-O 120.706 0.289 . . . . 0.0 110.799 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.8 p -98.18 120.8 39.22 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.453 -179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mm -118.69 134.91 60.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 123.894 0.877 . . . . 0.0 109.834 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.0 t -108.94 117.49 54.44 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 172.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.571 ' CZ ' ' HB2' ' A' ' 26' ' ' ALA . 53.4 p90 -111.38 172.96 6.57 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 120.494 -0.483 . . . . 0.0 110.95 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -131.47 2.61 4.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.364 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -158.08 152.96 25.16 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.218 -175.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.4 t -126.37 134.63 65.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 172.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 76.1 m -127.64 155.63 43.61 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 122.509 0.323 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 60.4 mt -124.86 114.41 40.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 175.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -164.59 150.77 10.6 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.2 29.69 17.5 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 123.781 0.832 . . . . 0.0 110.021 178.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.04 8.76 65.31 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.125 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -120.67 157.34 29.8 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 122.346 -0.502 . . . . 0.0 110.795 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 20.1 mt -104.96 133.45 49.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -127.13 154.17 45.09 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -170.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 32.5 pt -109.24 136.04 46.34 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 171.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -108.15 130.38 10.06 Favored Glycine 0 N--CA 1.42 -2.425 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.524 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 39.0 p90 -146.85 172.31 13.86 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -107.92 142.94 37.25 Favored 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.323 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -81.58 178.22 8.47 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 175.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -61.99 -28.12 69.34 Favored 'General case' 0 C--N 1.313 -1.004 0 C-N-CA 122.459 0.304 . . . . 0.0 110.802 179.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -70.74 -19.35 62.74 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 121.469 0.652 . . . . 0.0 110.884 174.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.9 0.96 68.06 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 -173.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 -70.13 154.04 42.41 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.1 tpt180 -83.67 128.23 34.37 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.422 HG21 HG12 ' A' ' 39' ' ' ILE . 46.6 t -126.16 135.47 63.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.277 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.485 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.7 m-85 -118.06 151.94 36.54 Favored 'General case' 0 C--N 1.281 -2.38 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.273 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 45.2 t -141.9 128.73 11.29 Favored Pre-proline 0 C--N 1.275 -2.647 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -74.12 134.94 20.14 Favored 'Trans proline' 0 N--CA 1.436 -1.858 0 C-N-CA 121.483 1.455 . . . . 0.0 109.395 177.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.8 m -116.52 -13.12 11.25 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.477 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.6 ptm180 -176.34 168.94 2.76 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.9 p -97.07 165.43 12.07 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 53.2 t -145.53 121.45 10.65 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 177.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.525 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 0.5 OUTLIER -86.56 115.18 23.88 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.898 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 -167.49 45.88 Favored Glycine 0 N--CA 1.428 -1.897 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.212 -179.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 8.3 m -132.07 155.27 81.54 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 123.869 0.868 . . . . 0.0 108.838 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.421 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 19.3 Cg_endo -59.51 163.04 13.55 Favored 'Trans proline' 0 CA--C 1.555 1.562 0 C-N-CA 122.232 1.955 . . . . 0.0 113.2 -178.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.421 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 55.3 Cg_endo -68.38 -26.32 6.77 Favored 'Cis proline' 0 C--N 1.364 1.346 0 C-N-CA 123.822 -1.324 . . . . 0.0 112.824 7.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -91.93 78.75 5.32 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.862 0.839 . . . . 0.0 109.288 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.423 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.7 pt20 -95.25 147.17 23.76 Favored 'General case' 0 N--CA 1.426 -1.634 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 175.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.525 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 85.7 mt -123.37 87.99 51.61 Favored Pre-proline 0 C--N 1.265 -3.076 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -78.6 132.43 10.99 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.285 1.99 . . . . 0.0 112.71 -177.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -83.32 -171.5 47.61 Favored Glycine 0 N--CA 1.437 -1.251 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.31 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.3 p -64.21 136.67 26.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-O 120.751 0.31 . . . . 0.0 110.417 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -73.46 145.09 45.97 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.069 0.461 . . . . 0.0 110.602 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.6 m0 -94.27 11.31 30.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.538 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.03 -174.32 40.05 Favored Glycine 0 N--CA 1.419 -2.489 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.94 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 2.9 t -96.63 151.11 4.16 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -177.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -122.53 102.98 8.4 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 176.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 57.7 mttm . . . . . 0 C--N 1.298 -1.643 0 CA-C-O 118.276 -0.869 . . . . 0.0 108.682 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 . . . . . 0 N--CA 1.469 0.483 0 N-CA-C 110.77 -0.085 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.3 m -75.46 113.63 28.0 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.06 129.68 10.71 Favored 'Trans proline' 0 N--CA 1.448 -1.164 0 C-N-CA 122.122 1.881 . . . . 0.0 112.001 -177.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.96 45.78 1.3 Allowed 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.809 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -68.75 101.75 1.39 Allowed 'General case' 0 N--CA 1.425 -1.703 0 CA-C-O 121.93 0.871 . . . . 0.0 111.306 -178.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 46.8 mtm-85 -95.14 156.02 38.28 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.561 -176.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -68.51 102.6 0.86 Allowed 'Trans proline' 0 N--CA 1.452 -0.94 0 C-N-CA 122.327 2.018 . . . . 0.0 110.962 176.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 48.7 t -100.07 138.11 25.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.272 6.4 p 57.34 -82.66 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.583 1.553 . . . . 0.0 114.77 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.16 -57.36 0.48 Allowed Glycine 0 CA--C 1.493 -1.293 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.728 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.2 p -74.22 -65.41 0.85 Allowed 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 176.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.432 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 85.5 m95 -79.4 143.13 35.35 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-N 114.748 -1.115 . . . . 0.0 108.682 175.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -133.94 153.63 51.63 Favored 'General case' 0 C--N 1.283 -2.302 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 174.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 27.1 ttpp -102.82 135.08 45.15 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.065 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.3 p30 -95.26 -178.89 4.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.577 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -62.34 -16.04 51.94 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 124.119 0.967 . . . . 0.0 113.505 -177.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -87.54 -2.04 58.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.38 29.94 69.64 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 -174.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.403 HG22 ' HB2' ' A' ' 66' ' ' GLN . 86.9 m -105.26 134.89 47.62 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 74.4 m95 -90.86 134.38 34.5 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -138.85 153.51 48.33 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.432 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 59.6 pttt -137.29 145.38 49.52 Favored Pre-proline 0 C--N 1.291 -1.973 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 173.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -75.56 124.75 8.49 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.342 2.028 . . . . 0.0 109.122 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.86 123.05 4.44 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -103.73 108.52 19.85 Favored 'General case' 0 C--N 1.29 -1.983 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.577 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.78 165.99 29.78 Favored 'General case' 0 C--N 1.284 -2.252 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.952 -178.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 82.7 m -102.5 118.69 37.4 Favored 'General case' 0 N--CA 1.41 -2.433 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.845 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -99.03 111.92 24.19 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.62 110.09 25.33 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.465 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 50.1 t30 -63.03 145.71 54.82 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.637 0.586 . . . . 0.0 110.705 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.78 -118.75 0.4 Allowed Glycine 0 N--CA 1.426 -1.984 0 CA-C-N 115.889 -0.596 . . . . 0.0 114.016 -176.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -100.44 -11.38 20.24 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 112.748 0.648 . . . . 0.0 112.748 -170.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -121.96 137.44 27.35 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.435 -174.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -67.92 142.58 57.53 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 121.98 1.787 . . . . 0.0 110.364 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mt -116.22 141.83 32.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 C-N-CA 120.287 -0.565 . . . . 0.0 110.66 -174.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.9 t -84.92 117.55 30.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.427 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 82.4 p -93.77 153.8 18.11 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.513 -0.312 . . . . 0.0 111.083 -176.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.479 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 35.5 mmt180 -121.74 160.88 23.63 Favored 'General case' 0 C--O 1.208 -1.1 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -177.599 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 56.2 mt -126.21 135.99 62.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.415 0.626 . . . . 0.0 112.566 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.52 -48.09 3.08 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.414 173.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 25.3 m -138.15 146.15 50.6 Favored Pre-proline 0 C--N 1.271 -2.833 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.793 -174.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -87.17 81.12 1.34 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.363 2.042 . . . . 0.0 112.235 177.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -144.46 157.26 44.33 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 86.0 mt -76.29 -16.9 59.68 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.995 0.902 . . . . 0.0 108.661 175.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -91.15 3.14 55.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 114.249 -1.341 . . . . 0.0 110.695 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.45 50.42 Favored Pre-proline 0 C--O 1.256 1.437 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.835 -176.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -57.51 147.07 80.71 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 123.167 2.578 . . . . 0.0 111.616 176.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.431 HG12 ' H ' ' A' ' 50' ' ' GLY . 32.8 t -90.42 135.71 25.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.8 -175.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.15 -14.56 54.17 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 177.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.431 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 127.91 -176.77 17.92 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.9 128.89 51.38 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.959 0.88 . . . . 0.0 109.802 176.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 16.4 tp -77.16 127.79 82.5 Favored Pre-proline 0 C--N 1.294 -1.831 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -63.81 154.47 69.42 Favored 'Trans proline' 0 N--CA 1.443 -1.487 0 C-N-CA 122.03 1.82 . . . . 0.0 112.452 178.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -73.06 136.85 45.03 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.534 -0.914 . . . . 0.0 108.534 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.41 5.04 85.43 Favored Glycine 0 C--N 1.312 -0.785 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.314 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.27 145.7 37.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 117.029 0.415 . . . . 0.0 111.649 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.6 p -100.75 107.03 18.52 Favored 'General case' 0 N--CA 1.438 -1.028 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.366 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.98 141.56 18.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.6 p -116.11 116.43 52.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 171.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.577 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.6 p90 -111.03 167.22 10.42 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.846 -176.369 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -124.56 -3.95 7.78 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.57 -179.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -153.37 154.13 33.9 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.592 -175.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.2 t -128.53 135.83 61.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 74.0 m -126.77 156.27 41.48 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.458 0.303 . . . . 0.0 110.766 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.429 HG12 HG12 ' A' ' 70' ' ' ILE . 66.4 mt -124.88 117.74 51.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 176.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.403 ' HB2' HG22 ' A' ' 19' ' ' THR . 6.8 tp-100 -164.73 149.81 9.73 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.41 28.35 16.8 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.089 0.956 . . . . 0.0 110.376 178.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.25 8.04 69.16 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.537 -178.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -119.76 155.22 32.93 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 122.093 -0.651 . . . . 0.0 110.486 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.457 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 16.9 mt -104.21 134.27 45.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 174.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -125.78 148.72 49.02 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -171.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -106.71 137.28 38.15 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 172.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.72 125.98 8.15 Favored Glycine 0 N--CA 1.419 -2.456 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.629 -178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.475 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.1 p90 -147.76 174.17 12.08 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 80' ' ' ASN . 16.3 m120 -120.36 134.44 55.27 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -82.24 178.59 8.18 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -53.3 -42.7 66.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -72.64 -7.67 51.47 Favored 'General case' 0 CA--C 1.551 1.012 0 CA-C-O 121.544 0.688 . . . . 0.0 110.916 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 95.91 5.25 59.85 Favored Glycine 0 CA--C 1.498 -1.017 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -178.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 75' ' ' ASN . 74.3 m-20 -59.0 127.83 34.17 Favored 'General case' 0 CA--C 1.498 -1.02 0 C-N-CA 123.519 0.728 . . . . 0.0 109.558 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.434 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 26.0 tpt180 -79.44 93.85 5.45 Favored 'General case' 0 C--O 1.207 -1.182 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 27.1 t -93.45 128.36 44.92 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.835 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.324 -173.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.506 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 58.2 m-85 -113.48 120.27 40.43 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.853 177.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.9 t -110.33 127.1 27.59 Favored Pre-proline 0 C--N 1.28 -2.428 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.45 131.54 17.72 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 121.454 1.436 . . . . 0.0 108.711 176.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.12 -12.58 11.35 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.507 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.6 ptm180 -178.78 174.21 1.17 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.0 p -98.49 167.77 10.61 Favored 'General case' 0 C--N 1.288 -2.066 0 C-N-CA 122.631 0.372 . . . . 0.0 110.414 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.496 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.2 t -149.96 118.73 6.6 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.459 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 16.1 tt0 -81.31 90.38 6.13 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 96.94 -174.56 30.31 Favored Glycine 0 N--CA 1.433 -1.515 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.134 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.455 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 25.7 m -111.81 158.76 35.73 Favored Pre-proline 0 C--N 1.302 -1.49 0 C-N-CA 122.184 0.194 . . . . 0.0 110.917 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.477 ' HB3' HE21 ' A' ' 96' ' ' GLN . 14.1 Cg_endo -63.4 171.5 6.57 Favored 'Trans proline' 0 CA--C 1.555 1.54 0 C-N-CA 122.728 2.286 . . . . 0.0 112.516 177.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.13 -25.01 5.99 Favored 'Cis proline' 0 C--N 1.371 1.751 0 CA-C-N 119.674 0.919 . . . . 0.0 113.4 3.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -91.99 79.34 5.23 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 122.278 1.037 . . . . 0.0 110.013 177.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.477 HE21 ' HB3' ' A' ' 93' ' ' PRO . 1.7 pt20 -96.17 151.29 19.62 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.205 -1.361 . . . . 0.0 107.488 177.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.496 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 71.1 mt -129.59 86.93 54.32 Favored Pre-proline 0 C--N 1.282 -2.349 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo -75.21 128.21 11.15 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 122.286 1.991 . . . . 0.0 112.195 -179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.17 -161.73 29.44 Favored Glycine 0 C--N 1.315 -0.62 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.93 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.1 p -63.81 135.16 28.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 117.099 0.449 . . . . 0.0 110.872 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -81.63 147.91 29.32 Favored 'General case' 0 N--CA 1.436 -1.152 0 CA-C-O 121.294 0.569 . . . . 0.0 111.071 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.3 m0 -96.2 13.46 27.33 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.846 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -178.89 -164.47 31.71 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -105.76 153.52 7.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.4 104.55 8.23 Favored 'General case' 0 N--CA 1.419 -2.02 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 85.4 mttt . . . . . 0 C--N 1.289 -2.059 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 176.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.242 0.677 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.2 m -94.26 119.29 66.75 Favored Pre-proline 0 N--CA 1.424 -1.764 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 177.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.33 99.26 1.0 Allowed 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.286 1.99 . . . . 0.0 114.152 -174.018 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.04 -54.43 6.02 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 85.9 m -86.89 111.94 21.28 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -163.64 141.55 5.94 Favored Pre-proline 0 C--N 1.311 -1.105 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 -177.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.78 91.52 1.08 Allowed 'Trans proline' 0 N--CA 1.445 -1.329 0 C-N-CA 122.038 1.825 . . . . 0.0 109.296 174.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -125.36 142.28 42.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.606 -176.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.7 t -102.31 134.57 45.38 Favored 'General case' 0 N--CA 1.418 -2.047 0 CA-C-O 121.193 0.521 . . . . 0.0 110.278 -178.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.49 179.95 23.75 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -178.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.3 m -91.59 -4.78 54.93 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.615 0.721 . . . . 0.0 110.699 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 58.2 m95 -94.82 158.46 15.49 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.182 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -125.11 138.36 54.17 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.432 ' HE2' ' HA2' ' A' ' 18' ' ' GLY . 45.2 tttm -101.87 134.51 44.95 Favored 'General case' 0 C--N 1.286 -2.181 0 CA-C-O 120.834 0.349 . . . . 0.0 110.146 -178.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.406 ' ND2' ' HB ' ' A' ' 19' ' ' THR . 36.0 p30 -94.69 -177.79 4.32 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.861 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -65.92 -16.68 64.08 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.857 0.863 . . . . 0.0 113.121 -177.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -92.42 -7.86 46.4 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.229 0.538 . . . . 0.0 110.02 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.432 ' HA2' ' HE2' ' A' ' 14' ' ' LYS . . . 83.97 22.49 55.06 Favored Glycine 0 N--CA 1.439 -1.121 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.523 -178.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.406 ' HB ' ' ND2' ' A' ' 15' ' ' ASN . 90.5 m -95.3 127.41 41.32 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.205 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 73.7 m95 -86.7 123.96 32.43 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.409 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 47.6 p90 -129.0 164.22 23.68 Favored 'General case' 0 C--N 1.282 -2.359 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -177.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -152.8 142.06 14.54 Favored Pre-proline 0 C--N 1.287 -2.137 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -78.49 113.21 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 C-N-CA 122.407 2.071 . . . . 0.0 109.844 175.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -135.44 124.79 24.75 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -176.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -100.87 107.14 18.58 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -177.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.611 ' HB2' ' CZ ' ' A' ' 60' ' ' TYR . . . -154.6 168.83 25.44 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.547 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 52.5 m -106.19 121.32 43.94 Favored 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.848 177.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.58 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 72.5 t80 -99.18 113.23 25.38 Favored 'General case' 0 N--CA 1.406 -2.642 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.3 t -100.81 116.22 43.89 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.526 0 N-CA-C 105.599 -2.001 . . . . 0.0 105.599 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -68.14 149.44 49.59 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.6 -0.44 . . . . 0.0 110.485 -177.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.28 -144.94 3.74 Favored Glycine 0 N--CA 1.433 -1.548 0 CA-C-N 116.368 -0.378 . . . . 0.0 113.174 -176.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.36 -6.06 59.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.25 0.548 . . . . 0.0 111.388 -175.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.4 pt20 -117.23 137.55 24.09 Favored Pre-proline 0 C--O 1.207 -1.142 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.233 -178.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.78 155.14 63.12 Favored 'Trans proline' 0 C--O 1.255 1.364 0 C-N-CA 122.611 2.207 . . . . 0.0 110.552 175.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.442 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.9 mt -126.48 134.94 65.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.646 -177.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 53.7 t -76.25 121.38 28.18 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 77.0 p -97.57 156.7 16.39 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 122.322 -0.236 . . . . 0.0 111.428 -175.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.0 mmt180 -124.0 155.12 38.81 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -178.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.9 mt -116.55 137.83 49.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -175.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.56 -45.15 3.33 Favored Glycine 0 CA--C 1.502 -0.773 0 CA-C-N 114.726 -1.124 . . . . 0.0 113.299 175.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 16.1 p -138.39 155.48 73.89 Favored Pre-proline 0 C--N 1.275 -2.647 0 CA-C-N 114.483 -0.858 . . . . 0.0 111.233 -171.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -95.37 58.55 0.2 Allowed 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.483 2.789 . . . . 0.0 112.043 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -121.23 155.8 33.82 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.3 mt -76.65 -23.63 53.29 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.481 0.657 . . . . 0.0 109.419 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -82.22 -13.77 56.57 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.237 177.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.53 152.68 96.01 Favored Pre-proline 0 C--O 1.249 1.072 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.365 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.3 136.72 74.09 Favored 'Trans proline' 0 C--O 1.241 0.655 0 C-N-CA 122.867 2.378 . . . . 0.0 112.728 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.01 132.84 32.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.59 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.11 -18.39 43.32 Favored Glycine 0 C--O 1.241 0.539 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 135.42 -177.31 19.5 Favored Glycine 0 N--CA 1.428 -1.871 0 N-CA-C 109.219 -1.553 . . . . 0.0 109.219 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.35 131.97 43.52 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 118.043 0.922 . . . . 0.0 109.744 175.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.7 tp -78.2 126.82 82.86 Favored Pre-proline 0 C--N 1.291 -1.964 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 173.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -62.48 151.56 82.36 Favored 'Trans proline' 0 N--CA 1.437 -1.805 0 C-N-CA 122.086 1.857 . . . . 0.0 112.507 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -68.52 137.42 54.36 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 175.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.31 22.43 77.58 Favored Glycine 0 N--CA 1.438 -1.181 0 C-N-CA 121.002 -0.618 . . . . 0.0 113.534 -178.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -89.33 152.05 21.75 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 117.8 0.8 . . . . 0.0 110.081 177.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.13 119.44 38.81 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-O 121.163 0.506 . . . . 0.0 109.987 -177.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.4 mm -117.09 130.02 72.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.77 179.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.7 p -101.63 116.8 45.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 169.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.611 ' CZ ' ' HB2' ' A' ' 26' ' ' ALA . 53.7 p90 -112.73 160.62 17.76 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.869 -178.288 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -123.32 1.16 9.03 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 123.609 0.568 . . . . 0.0 110.75 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -155.24 152.25 29.07 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.044 -173.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 10.8 t -131.4 133.32 62.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 56.7 m -124.56 148.5 47.77 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 123.014 0.526 . . . . 0.0 110.747 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.405 HG12 HG12 ' A' ' 70' ' ' ILE . 59.4 mt -117.95 116.6 52.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -163.19 147.4 11.03 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 123.572 0.545 . . . . 0.0 109.585 -178.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 60.23 30.99 20.33 Favored 'General case' 0 C--O 1.242 0.71 0 C-N-CA 124.052 0.941 . . . . 0.0 111.446 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 6.62 81.24 Favored Glycine 0 CA--C 1.508 -0.351 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.682 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -120.2 154.2 35.17 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 122.608 -0.348 . . . . 0.0 110.338 -178.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.405 HG12 HG12 ' A' ' 65' ' ' ILE . 19.5 mt -105.81 133.82 49.09 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 172.116 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -125.69 149.96 48.06 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.07 0.548 . . . . 0.0 109.753 -171.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 28.7 pt -106.47 137.01 39.01 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 171.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.08 121.33 6.98 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -141.72 173.97 11.01 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -107.68 141.47 39.15 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -84.29 166.69 17.26 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 79.3 t80 -62.56 -18.24 61.65 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.85 0.833 . . . . 0.0 109.924 175.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -77.4 -6.15 52.34 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.754 177.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 83.77 7.89 85.22 Favored Glycine 0 C--N 1.34 0.765 0 C-N-CA 121.066 -0.588 . . . . 0.0 111.979 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -101.23 160.66 14.22 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 122.691 -0.299 . . . . 0.0 110.403 -174.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 -83.73 126.76 33.23 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 45.2 t -123.56 135.88 61.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.1 m-85 -115.65 123.5 48.53 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.627 -1.17 . . . . 0.0 109.942 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.2 t -111.31 125.85 29.74 Favored Pre-proline 0 C--N 1.281 -2.375 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 177.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.442 ' O ' HG21 ' A' ' 35' ' ' ILE . 33.7 Cg_endo -71.88 129.9 16.03 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 121.54 1.493 . . . . 0.0 108.638 176.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.45 -10.39 12.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.438 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 6.5 ptm180 178.81 173.54 0.72 Allowed 'General case' 0 C--O 1.246 0.899 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.429 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.2 p -98.96 167.37 10.78 Favored 'General case' 0 C--N 1.289 -2.033 0 C-N-CA 122.238 0.215 . . . . 0.0 110.737 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.463 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 48.6 t -145.2 128.03 16.35 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 177.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.521 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 60.8 tt0 -90.1 96.31 10.61 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 97.64 -157.94 20.84 Favored Glycine 0 N--CA 1.418 -2.505 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.688 177.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.3 m -130.26 150.86 77.31 Favored Pre-proline 0 C--N 1.297 -1.712 0 C-N-CA 123.353 0.661 . . . . 0.0 109.619 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.427 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 42.2 Cg_endo -66.57 165.63 24.62 Favored 'Trans proline' 0 CA--C 1.555 1.534 0 C-N-CA 122.363 2.042 . . . . 0.0 111.175 -178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.42 -5.89 20.15 Favored 'Cis proline' 0 C--N 1.356 0.973 0 C-N-CA 124.301 -1.125 . . . . 0.0 113.329 4.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -101.43 77.48 1.78 Allowed 'General case' 0 N--CA 1.427 -1.597 0 C-N-CA 118.315 -1.354 . . . . 0.0 108.355 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.463 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.5 pm0 -103.08 153.03 20.7 Favored 'General case' 0 N--CA 1.427 -1.584 0 CA-C-N 114.756 -1.111 . . . . 0.0 108.034 178.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 58.1 mt -131.27 87.56 47.17 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' A' ' 88' ' ' THR . 67.7 Cg_endo -73.53 135.6 22.32 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.544 2.163 . . . . 0.0 112.841 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.45 -170.85 44.52 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.4 p -69.01 138.26 22.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 116.994 0.397 . . . . 0.0 110.25 -178.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.438 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -72.01 141.36 49.34 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.163 -178.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 43.6 m0 -87.54 2.49 50.61 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.329 -179.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -159.39 -160.03 10.15 Favored Glycine 0 N--CA 1.43 -1.748 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 178.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.58 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -115.15 149.37 17.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -117.56 106.73 13.44 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 175.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.49 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 63.4 mttm . . . . . 0 C--N 1.288 -2.092 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 176.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.511 -0.528 0 N-CA-C 110.827 -0.064 . . . . 0.0 110.827 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 44.8 m 64.73 97.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.756 0 C-N-CA 123.716 0.806 . . . . 0.0 109.669 -173.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -65.08 91.5 0.2 Allowed 'Trans proline' 0 N--CA 1.458 -0.61 0 C-N-CA 122.407 2.071 . . . . 0.0 112.8 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.15 -31.26 30.6 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 p -78.62 81.39 4.94 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.456 174.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 63.5 mtp180 -79.0 137.92 57.12 Favored Pre-proline 0 N--CA 1.429 -1.494 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.745 -175.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_exo -46.51 112.9 0.53 Allowed 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 123.937 3.091 . . . . 0.0 113.102 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.94 153.57 10.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.594 ' OG1' ' HD3' ' A' ' 94' ' ' PRO . 26.4 m -80.07 116.36 20.15 Favored 'General case' 0 C--N 1.286 -2.155 0 C-N-CA 122.66 0.384 . . . . 0.0 110.833 -178.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -118.43 -9.8 9.15 Favored Glycine 0 N--CA 1.443 -0.85 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.369 177.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.0 p -63.13 -42.06 99.42 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 175.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 61.4 m95 -110.02 139.74 44.81 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 104.371 -2.455 . . . . 0.0 104.371 168.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 37.1 mtmm -117.01 135.74 53.47 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.863 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.46 ' HD3' ' NE1' ' A' ' 20' ' ' TRP . 38.8 ttpt -96.4 134.4 39.6 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 120.851 0.358 . . . . 0.0 110.302 -178.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -98.02 -173.86 2.71 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.471 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -63.16 -17.54 62.49 Favored 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 123.301 0.64 . . . . 0.0 112.334 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 -85.93 -10.31 55.44 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.37 0.605 . . . . 0.0 109.461 -176.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.97 18.9 68.64 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -177.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.452 ' CG2' ' HB3' ' A' ' 64' ' ' CYS . 84.5 m -98.33 130.3 45.0 Favored 'General case' 0 N--CA 1.403 -2.783 0 CA-C-N 114.201 -1.0 . . . . 0.0 108.707 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.476 ' CH2' ' HB ' ' A' ' 9' ' ' THR . 86.0 m95 -88.97 127.05 35.65 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -133.82 158.85 42.34 Favored 'General case' 0 C--N 1.292 -1.91 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.382 -178.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -149.03 150.71 32.89 Favored Pre-proline 0 N--CA 1.426 -1.672 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 170.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.37 131.79 18.22 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 121.742 1.628 . . . . 0.0 110.064 176.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -151.81 123.62 8.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -108.72 106.18 16.09 Favored 'General case' 0 C--N 1.292 -1.903 0 C-N-CA 118.776 -1.17 . . . . 0.0 108.563 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.44 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -150.1 167.74 25.93 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.8 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.439 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.1 m -111.06 122.58 48.25 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-O 121.534 0.683 . . . . 0.0 111.134 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.503 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 55.2 t80 -98.62 122.4 41.78 Favored 'General case' 0 N--CA 1.415 -2.18 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.413 HG23 ' HE3' ' A' ' 106' ' ' LYS . 48.2 t -105.32 114.96 46.16 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 176.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.44 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 52.5 t30 -67.66 148.22 51.65 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 123.429 0.456 . . . . 0.0 110.003 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -90.47 -119.98 2.15 Favored Glycine 0 N--CA 1.419 -2.437 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.8 -176.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -85.94 -28.61 24.17 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 -172.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 10.9 pt20 -110.21 136.18 20.52 Favored Pre-proline 0 C--N 1.286 -2.188 0 O-C-N 122.046 -0.409 . . . . 0.0 111.652 -174.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -68.46 140.05 46.85 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.969 1.78 . . . . 0.0 109.809 175.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -112.4 131.1 64.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.913 -172.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.1 t -72.19 116.18 13.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 80.4 p -95.54 162.84 13.47 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.251 -178.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 47' ' ' PRO . 33.4 mmt180 -129.8 155.38 46.06 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -176.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.443 HG12 HG22 ' A' ' 82' ' ' VAL . 26.5 mt -116.37 137.29 50.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -175.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.55 -48.67 3.93 Favored Glycine 0 CA--C 1.494 -1.277 0 CA-C-N 114.218 -1.355 . . . . 0.0 112.623 174.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 43.7 m -139.05 146.9 51.5 Favored Pre-proline 0 C--N 1.264 -3.148 0 CA-C-N 114.353 -0.924 . . . . 0.0 110.264 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -85.9 84.88 1.14 Allowed 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.075 1.85 . . . . 0.0 112.239 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -142.25 156.91 45.32 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.3 mt -76.85 -22.44 53.52 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -90.32 8.0 35.61 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.916 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.95 156.68 42.19 Favored Pre-proline 0 C--O 1.253 1.274 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.428 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 15.6 Cg_endo -57.99 150.79 61.98 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.972 2.448 . . . . 0.0 112.007 179.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.3 t -86.04 125.08 40.64 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.59 -177.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.41 -8.05 78.33 Favored Glycine 0 CA--C 1.496 -1.15 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 128.08 179.38 15.83 Favored Glycine 0 N--CA 1.411 -2.983 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -109.66 110.84 22.01 Favored 'General case' 0 C--N 1.269 -2.921 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . 0.418 HD12 ' HD2' ' A' ' 53' ' ' PRO . 29.6 tp -63.14 126.84 89.98 Favored Pre-proline 0 C--N 1.303 -1.415 0 CA-C-N 114.288 -1.324 . . . . 0.0 109.466 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.418 ' HD2' HD12 ' A' ' 52' ' ' LEU . 11.9 Cg_exo -60.6 146.72 96.56 Favored 'Trans proline' 0 N--CA 1.431 -2.2 0 C-N-CA 122.402 2.068 . . . . 0.0 112.551 -178.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.44 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -70.94 116.26 11.03 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.86 -0.66 45.07 Favored Glycine 0 C--N 1.306 -1.09 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.337 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -74.83 143.79 43.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.237 0.541 . . . . 0.0 111.608 -178.04 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -98.42 117.13 32.15 Favored 'General case' 0 N--CA 1.421 -1.885 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.819 -176.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.5 mm -115.23 127.41 72.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 123.707 0.803 . . . . 0.0 111.389 -179.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 79.2 t -98.95 116.76 42.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 171.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 55.0 p90 -114.53 164.59 13.78 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.441 -178.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -124.11 3.5 8.62 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.769 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -155.37 147.9 24.06 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.638 -0.825 . . . . 0.0 109.888 -175.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.5 t -122.46 135.41 62.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 173.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . 0.452 ' HB3' ' CG2' ' A' ' 19' ' ' THR . 82.7 m -130.4 150.91 51.41 Favored 'General case' 0 C--N 1.286 -2.17 0 O-C-N 123.306 0.379 . . . . 0.0 110.748 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -119.68 121.37 66.04 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 176.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -167.86 150.08 5.6 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 123.723 0.639 . . . . 0.0 109.51 -178.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 59.49 31.28 20.91 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 123.93 0.892 . . . . 0.0 111.301 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.21 6.77 70.06 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.57 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -120.1 156.68 30.52 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 122.537 -0.39 . . . . 0.0 110.69 -177.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.427 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 23.2 mt -104.87 134.35 46.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.6 m95 -125.72 153.82 43.36 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -170.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.511 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.5 pt -113.44 136.61 49.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 173.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.28 123.59 7.48 Favored Glycine 0 N--CA 1.423 -2.178 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.947 -178.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.41 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 37.7 p90 -141.42 172.36 12.79 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 -109.62 143.61 39.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.762 -177.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -95.37 165.45 12.37 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.653 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -55.67 -35.28 65.83 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 124.987 1.315 . . . . 0.0 111.487 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -83.93 8.6 14.57 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.404 0.52 . . . . 0.0 112.404 -177.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.82 82.92 Favored Glycine 0 C--O 1.228 -0.26 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.187 176.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.429 ' HB3' HG23 ' A' ' 39' ' ' ILE . 57.3 m-80 -92.25 155.99 17.59 Favored 'General case' 0 C--N 1.31 -1.14 0 O-C-N 122.821 -0.223 . . . . 0.0 111.139 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -87.83 125.9 34.72 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 177.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.443 HG22 HG12 ' A' ' 39' ' ' ILE . 39.4 t -118.14 131.79 69.87 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 C-N-CA 119.399 -0.92 . . . . 0.0 109.774 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.511 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 66.6 m-85 -114.06 128.2 56.28 Favored 'General case' 0 C--N 1.286 -2.191 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.31 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.6 t -115.96 128.43 25.98 Favored Pre-proline 0 C--N 1.285 -2.2 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -74.01 130.52 14.46 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.427 1.418 . . . . 0.0 108.74 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.8 m -114.32 -13.5 11.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -175.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.481 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.5 ptm180 -176.51 174.31 1.92 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -178.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.425 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.1 p -98.25 165.23 11.97 Favored 'General case' 0 C--N 1.286 -2.175 0 C-N-CA 122.781 0.432 . . . . 0.0 110.832 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.699 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.0 t -149.98 116.29 5.74 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 122.901 0.48 . . . . 0.0 110.202 177.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.419 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.2 tt0 -83.86 103.23 12.96 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.86 -176.04 40.65 Favored Glycine 0 N--CA 1.432 -1.626 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.437 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.403 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 16.1 m -112.69 155.12 44.4 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.403 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 36.3 Cg_endo -63.67 164.9 19.68 Favored 'Trans proline' 0 CA--C 1.552 1.4 0 C-N-CA 122.432 2.088 . . . . 0.0 110.861 -178.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.594 ' HD3' ' OG1' ' A' ' 9' ' ' THR . 91.9 Cg_endo -77.49 -5.05 30.82 Favored 'Cis proline' 0 C--N 1.359 1.094 0 C-N-CA 124.573 -1.011 . . . . 0.0 113.363 7.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -104.49 78.82 1.5 Allowed 'General case' 0 CA--C 1.475 -1.916 0 C-N-CA 119.548 -0.861 . . . . 0.0 109.088 171.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.699 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -98.93 151.42 20.9 Favored 'General case' 0 N--CA 1.418 -2.071 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 60.1 mt -125.86 86.06 58.24 Favored Pre-proline 0 C--N 1.291 -1.962 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 88' ' ' THR . 54.7 Cg_endo -68.92 129.03 17.72 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.355 2.036 . . . . 0.0 112.666 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.33 -166.83 41.64 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 177.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.7 p -63.34 135.91 26.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.158 0.504 . . . . 0.0 110.596 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.481 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -76.86 144.63 38.88 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.569 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 44.4 m0 -90.35 8.79 31.68 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.334 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -170.51 -156.48 11.37 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.569 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 6.7 t -111.61 154.47 13.15 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -125.97 102.84 7.44 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 176.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.439 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 93.3 mttt . . . . . 0 C--N 1.288 -2.087 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 . . . . . 0 CA--C 1.515 -0.39 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.3 m -108.65 121.0 44.58 Favored Pre-proline 0 N--CA 1.422 -1.845 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.64 -39.28 92.46 Favored 'Trans proline' 0 C--N 1.355 0.894 0 C-N-CA 122.816 2.344 . . . . 0.0 112.855 -178.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.47 18.37 6.29 Favored 'General case' 0 C--O 1.246 0.878 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.454 -178.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 m 73.76 -63.22 0.44 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.585 1.154 . . . . 0.0 111.546 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -92.78 124.59 58.22 Favored Pre-proline 0 N--CA 1.429 -1.497 0 CA-C-O 120.69 0.281 . . . . 0.0 110.679 -176.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.24 110.99 1.91 Allowed 'Trans proline' 0 C--O 1.247 0.939 0 C-N-CA 122.967 2.444 . . . . 0.0 111.49 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.25 126.25 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.411 ' HB ' ' O ' ' A' ' 12' ' ' TRP . 7.9 m 74.62 1.5 3.83 Favored 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 123.905 0.882 . . . . 0.0 111.21 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 77.54 -100.2 1.53 Allowed Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.829 175.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.4 m -77.05 -33.33 57.29 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 122.625 0.37 . . . . 0.0 111.738 -176.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.411 ' O ' ' HB ' ' A' ' 9' ' ' THR . 91.6 m95 -96.85 129.76 44.24 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.754 -175.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -121.99 155.61 35.19 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 176.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.54 ' HD3' ' CE2' ' A' ' 20' ' ' TRP . 35.4 ttpt -106.58 130.89 54.26 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.003 -174.492 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.404 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 41.0 t-20 -78.27 151.04 33.24 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 176.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -54.48 -19.18 5.26 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -87.13 2.8 48.71 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.046 -0.409 . . . . 0.0 112.014 178.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.0 12.81 67.57 Favored Glycine 0 C--N 1.319 -0.412 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 179.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.404 ' HB ' ' HB3' ' A' ' 15' ' ' ASN . 56.6 m -90.37 119.3 30.55 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.54 ' CE2' ' HD3' ' A' ' 14' ' ' LYS . 81.9 m95 -82.94 130.77 35.18 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.423 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.2 p90 -141.39 159.33 42.45 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -176.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -150.28 147.47 21.96 Favored Pre-proline 0 N--CA 1.419 -2.015 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -76.37 121.95 6.31 Favored 'Trans proline' 0 N--CA 1.449 -1.109 0 C-N-CA 122.575 2.184 . . . . 0.0 110.121 174.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.28 123.15 8.71 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.508 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 23.9 t-20 -107.26 106.46 16.93 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.614 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.5 166.09 29.23 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.794 -175.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 98.0 m -103.9 119.78 39.63 Favored 'General case' 0 N--CA 1.414 -2.271 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.239 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.541 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -98.99 118.89 36.79 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.25 106.1 19.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.917 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 177.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -62.87 142.68 58.17 Favored 'General case' 0 C--N 1.316 -0.854 0 O-C-N 124.024 0.827 . . . . 0.0 111.325 -176.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.75 -140.72 0.91 Allowed Glycine 0 N--CA 1.428 -1.87 0 CA-C-N 115.696 -0.683 . . . . 0.0 113.688 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.67 -13.53 56.26 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 -173.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -110.67 138.71 21.11 Favored Pre-proline 0 C--N 1.31 -1.151 0 O-C-N 121.415 -0.803 . . . . 0.0 111.389 -177.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -69.29 145.85 61.19 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 122.334 2.023 . . . . 0.0 110.422 174.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.37 136.26 56.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.784 -175.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.7 t -75.8 121.89 28.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.5 p -104.59 158.24 16.63 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 110.375 -0.231 . . . . 0.0 110.375 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.493 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 26.5 mmt180 -127.6 160.97 29.95 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -174.19 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.435 HG12 HG21 ' A' ' 82' ' ' VAL . 50.3 mt -122.79 138.1 54.04 Favored 'Isoleucine or valine' 0 C--O 1.243 0.75 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.62 -47.1 2.54 Favored Glycine 0 CA--C 1.497 -1.081 0 CA-C-N 114.517 -1.219 . . . . 0.0 112.561 174.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 45.2 m -139.24 151.83 68.24 Favored Pre-proline 0 C--N 1.273 -2.742 0 C-N-CA 123.794 0.838 . . . . 0.0 111.052 -174.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -90.78 80.85 0.46 Allowed 'Trans proline' 0 N--CA 1.446 -1.293 0 C-N-CA 122.712 2.275 . . . . 0.0 111.761 175.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -141.69 157.76 44.66 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -76.72 -20.72 56.23 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.717 0.77 . . . . 0.0 109.189 178.21 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -98.48 13.09 32.99 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.994 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.493 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -87.56 152.14 51.53 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -58.11 138.79 87.78 Favored 'Trans proline' 0 C--O 1.249 1.054 0 C-N-CA 122.641 2.227 . . . . 0.0 112.568 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 69.4 t -68.61 118.03 11.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -80.65 -19.52 68.12 Favored Glycine 0 C--N 1.292 -1.907 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 144.11 -177.11 22.98 Favored Glycine 0 N--CA 1.401 -3.67 0 N-CA-C 107.97 -2.052 . . . . 0.0 107.97 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -112.5 140.06 47.56 Favored 'General case' 0 C--N 1.263 -3.191 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 21.8 tp -85.25 126.11 68.19 Favored Pre-proline 0 C--N 1.281 -2.393 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.335 178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -62.46 154.07 66.76 Favored 'Trans proline' 0 N--CA 1.438 -1.756 0 C-N-CA 122.101 1.867 . . . . 0.0 112.511 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -71.66 135.37 46.86 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 175.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.68 12.96 79.19 Favored Glycine 0 C--N 1.312 -0.799 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.57 146.71 32.44 Favored 'General case' 0 CA--C 1.495 -1.152 0 CA-C-O 121.224 0.535 . . . . 0.0 110.773 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.9 m -108.77 110.62 22.06 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.896 -1.047 . . . . 0.0 109.001 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -110.41 133.9 54.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 123.201 0.6 . . . . 0.0 110.841 -177.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.72 117.0 50.65 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 171.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.614 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.0 p90 -111.86 163.4 14.24 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.128 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.39 2.45 8.41 Favored 'General case' 0 C--N 1.309 -1.195 0 O-C-N 123.613 0.571 . . . . 0.0 111.309 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -157.22 152.81 26.63 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.545 -175.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.2 t -130.54 137.3 56.5 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . 0.426 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 99.3 m -126.73 152.95 46.14 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.89 0.476 . . . . 0.0 110.998 178.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -123.34 110.35 25.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 173.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -159.52 147.34 17.25 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.42 30.21 18.82 Favored 'General case' 0 C--O 1.246 0.916 0 C-N-CA 123.952 0.901 . . . . 0.0 110.209 178.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.58 11.01 64.66 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.051 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.8 m80 -120.48 154.0 35.86 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 122.186 -0.597 . . . . 0.0 110.152 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.431 HG13 ' HB2' ' A' ' 89' ' ' CYS . 18.0 mt -101.5 133.16 45.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 171.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 57.8 m95 -125.31 148.13 48.84 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -172.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.505 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.6 pt -106.99 136.89 40.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 171.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.96 123.67 7.4 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.43 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 33.5 p90 -138.86 152.9 48.2 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -95.12 122.51 37.87 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.11 174.77 5.88 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.795 -175.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -64.62 -32.16 73.69 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.593 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -91.35 4.13 53.17 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-O 121.706 0.765 . . . . 0.0 110.703 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.21 8.28 75.33 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 119.788 -1.196 . . . . 0.0 113.858 177.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -75.66 144.64 41.54 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 178.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.402 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 23.0 tpt180 -85.53 101.25 12.51 Favored 'General case' 0 CA--C 1.494 -1.209 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.435 HG21 HG12 ' A' ' 39' ' ' ILE . 23.1 t -102.75 129.15 54.82 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.025 -176.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.505 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 64.5 m-85 -111.63 134.88 52.89 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.583 177.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -123.13 127.0 25.81 Favored Pre-proline 0 C--N 1.287 -2.117 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 178.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -72.95 128.7 13.43 Favored 'Trans proline' 0 N--CA 1.437 -1.808 0 N-CA-C 108.334 -1.449 . . . . 0.0 108.334 175.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -112.9 -9.35 12.14 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -176.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.521 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.4 ptm180 179.75 167.29 1.2 Allowed 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.2 p -90.45 171.19 9.61 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.624 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 46.1 t -153.62 127.81 9.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.575 0.703 . . . . 0.0 109.863 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.479 ' HB2' ' HB ' ' A' ' 97' ' ' ILE . 11.6 mt-30 -93.15 112.16 24.02 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.228 173.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.09 167.11 32.72 Favored Glycine 0 N--CA 1.422 -2.292 0 CA-C-N 115.081 -0.963 . . . . 0.0 113.17 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.417 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 17.3 m -97.73 156.19 36.33 Favored Pre-proline 0 C--N 1.289 -2.054 0 CA-C-N 114.749 -0.725 . . . . 0.0 109.144 176.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.497 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 19.3 Cg_endo -62.65 168.86 9.35 Favored 'Trans proline' 0 CA--C 1.559 1.759 0 C-N-CA 122.536 2.158 . . . . 0.0 111.672 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -68.34 -18.14 9.96 Favored 'Cis proline' 0 C--N 1.366 1.49 0 CA-C-N 119.715 0.934 . . . . 0.0 114.024 4.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -99.55 79.7 2.3 Favored 'General case' 0 CA--C 1.484 -1.585 0 CA-C-O 121.435 0.636 . . . . 0.0 110.086 175.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.624 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -99.59 146.26 26.64 Favored 'General case' 0 N--CA 1.421 -1.889 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 174.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.479 ' HB ' ' HB2' ' A' ' 90' ' ' GLN . 63.8 mt -122.02 88.51 47.97 Favored Pre-proline 0 C--N 1.29 -1.993 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.638 177.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -65.73 140.75 63.08 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.347 2.032 . . . . 0.0 112.095 177.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.32 -158.4 33.47 Favored Glycine 0 C--N 1.306 -1.088 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.3 p -66.73 132.68 32.02 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-N 116.996 0.398 . . . . 0.0 110.182 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.521 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.02 139.32 38.2 Favored 'General case' 0 CA--C 1.49 -1.335 0 CA-C-O 120.89 0.376 . . . . 0.0 110.28 178.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 33.6 m0 -92.58 15.29 14.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.016 -177.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.71 -177.46 46.54 Favored Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.975 178.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.7 t -92.7 153.7 3.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -127.0 103.15 7.31 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 176.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.498 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 84.9 mttt . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 177.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.223 -0.31 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.3 m 65.42 77.54 0.28 Allowed Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 124.722 1.209 . . . . 0.0 112.998 179.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -110.75 -153.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 124.229 3.286 . . . . 0.0 108.683 170.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.06 120.66 27.69 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 172.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.3 m -70.57 -45.97 64.38 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -174.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -79.48 152.27 75.49 Favored Pre-proline 0 C--N 1.315 -0.917 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.872 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.3 106.47 0.84 Allowed 'Trans proline' 0 C--O 1.247 0.945 0 C-N-CA 122.142 1.895 . . . . 0.0 108.997 173.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.03 142.63 35.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.971 -173.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.314 5.1 p 59.16 -6.98 0.05 Allowed 'General case' 0 CA--C 1.56 1.341 0 N-CA-C 117.582 2.438 . . . . 0.0 117.582 175.208 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.27 -97.64 0.86 Allowed Glycine 0 C--O 1.25 1.123 0 CA-C-O 120.929 0.183 . . . . 0.0 113.236 175.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.8 m -63.54 -57.64 9.54 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 123.129 0.571 . . . . 0.0 109.926 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' TRP . . . . . 0.414 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 88.9 m95 -83.38 146.52 28.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.207 -179.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.6 mtmm -146.37 153.59 40.67 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 177.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -104.51 137.48 42.3 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.699 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.0 p30 -91.74 -177.48 4.77 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -56.77 -30.49 63.68 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.287 1.035 . . . . 0.0 113.373 -178.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -82.6 -8.01 59.62 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.862 0.363 . . . . 0.0 111.425 -176.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.24 18.45 59.1 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m -95.84 131.95 41.62 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.417 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.414 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 170.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 0.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . 0.506 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.5 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.519 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.456 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 0.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 0.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 0.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 0.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.4 HG22 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 0.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 0.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.46 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 0.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 0.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 0.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 0.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 0.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 0.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 0.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 0.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 0.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.456 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 0.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 0.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 0.0 110.475 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 0.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 0.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 0.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 0.0 110.856 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.409 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 0.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 0.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 0.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.45 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.489 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' TYR . . . . . 0.45 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 -142.19 171.97 13.34 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -111.45 145.22 39.38 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.416 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -92.35 171.48 9.03 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 173.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -62.75 -20.58 65.09 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 123.331 0.652 . . . . 0.0 111.876 -177.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.669 ' HB2' ' OD1' ' A' ' 80' ' ' ASN . 61.3 m-20 -91.23 1.99 56.69 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.888 -0.507 . . . . 0.0 110.099 179.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.13 8.65 68.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 119.996 -1.097 . . . . 0.0 112.094 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . 0.669 ' OD1' ' HB2' ' A' ' 78' ' ' ASN . 6.9 m120 -71.91 139.19 48.65 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.494 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 -86.41 97.56 10.52 Favored 'General case' 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 175.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.494 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.4 ' O ' HG22 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 0.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . 0.491 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 0.0 110.358 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.607 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . 0.416 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 0.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 0.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 0.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 0.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.607 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 0.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.428 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 0.0 112.371 -178.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.491 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 0.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' VAL . . . . . 0.519 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . 0.5 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 0.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 19.0 108.555 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 20.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 21.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 22.0 107.943 170.106 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 23.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 24.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 25.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 26.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 27.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 28.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 29.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 30.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 31.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 32.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 33.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 34.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 35.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 36.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 37.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 38.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 39.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 40.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 41.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 42.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 43.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 44.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 45.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 46.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 47.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 48.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 49.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 50.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 51.0 109.389 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 52.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 53.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 54.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 55.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 56.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 57.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 58.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 59.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 60.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 61.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 62.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 63.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 64.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 65.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 66.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 67.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 68.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 69.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 70.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 71.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 72.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 73.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 . . . . . 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 74.0 108.98 177.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 . . . . . 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 81.0 107.254 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 82.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 83.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 84.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 85.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 86.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 87.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 88.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 89.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 90.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 91.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 92.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 93.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 94.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 95.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 96.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 97.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 98.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 99.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 100.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 101.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 102.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 103.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 104.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 105.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 106.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 62.6 m . . . . . 0 N--CA 1.41 -2.431 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.413 ' CD1' ' HB ' ' A' ' 92' ' ' VAL . 79.1 m95 -93.93 134.41 36.34 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -137.68 162.65 33.28 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.564 0.54 . . . . 0.0 110.742 -177.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 61.2 pttt -155.04 145.25 15.84 Favored Pre-proline 0 C--N 1.298 -1.639 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 170.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -76.64 132.31 13.19 Favored 'Trans proline' 0 N--CA 1.445 -1.336 0 C-N-CA 122.161 1.908 . . . . 0.0 109.956 175.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.4 ' HB3' HG23 ' A' ' 63' ' ' VAL . 34.5 tt0 -151.77 123.85 8.14 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.438 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.401 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 17.8 t-20 -105.42 110.61 23.01 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.19 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.66 166.76 32.53 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.701 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 76.9 m -103.54 119.55 39.11 Favored 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.19 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.569 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 60.0 t80 -99.09 120.08 38.89 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.379 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.543 ' HB ' HG22 ' A' ' 104' ' ' VAL . 92.5 t -107.37 109.81 29.52 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 176.366 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.516 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 55.5 t30 -61.02 148.47 40.09 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 123.804 0.69 . . . . 0.0 110.443 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -85.68 -130.74 2.51 Favored Glycine 0 N--CA 1.432 -1.623 0 CA-C-O 121.321 0.401 . . . . 0.0 113.638 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -90.24 -7.68 52.88 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -172.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -120.37 141.02 31.14 Favored Pre-proline 0 C--N 1.307 -1.276 0 C-N-CA 120.347 -0.541 . . . . 0.0 111.156 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.73 150.85 68.91 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.069 1.846 . . . . 0.0 110.955 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.528 HG21 ' SG ' ' A' ' 84' ' ' CYS . 7.5 mm -116.24 141.34 34.31 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.186 -174.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.79 117.2 35.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 176.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.2 p -97.4 158.79 15.29 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 116.862 -0.153 . . . . 0.0 111.382 -174.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mmt180 -130.06 156.51 44.39 Favored 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 51.0 mt -115.96 137.64 49.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.55 -36.83 2.61 Favored Glycine 0 CA--C 1.493 -1.333 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.802 174.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.421 ' HB3' ' HD2' ' A' ' 43' ' ' PHE . 6.8 m -138.08 151.12 69.31 Favored Pre-proline 0 C--N 1.28 -2.425 0 CA-C-N 114.944 -0.628 . . . . 0.0 111.46 -171.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 19.6 Cg_endo -94.01 49.69 0.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.369 2.713 . . . . 0.0 111.328 177.175 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.421 ' HD2' ' HB3' ' A' ' 41' ' ' SER . 99.9 m-85 -121.3 153.04 38.22 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -77.27 -8.78 58.18 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.808 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -103.7 4.63 35.57 Favored 'General case' 0 C--O 1.245 0.842 0 CA-C-O 121.618 0.723 . . . . 0.0 110.647 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.5 158.73 70.96 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.78 140.32 93.27 Favored 'Trans proline' 0 C--O 1.247 0.93 0 C-N-CA 122.491 2.127 . . . . 0.0 111.834 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.488 HG12 ' H ' ' A' ' 50' ' ' GLY . 44.0 t -74.13 126.63 35.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.75 -14.27 65.54 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.488 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 129.9 -176.57 18.61 Favored Glycine 0 N--CA 1.414 -2.814 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -108.56 130.26 55.3 Favored 'General case' 0 C--N 1.273 -2.729 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.467 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -80.99 124.71 81.13 Favored Pre-proline 0 C--N 1.281 -2.402 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.07 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 9.4 Cg_endo -61.97 149.98 88.15 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.288 1.992 . . . . 0.0 112.59 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.516 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -68.7 117.82 10.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.572 177.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 30' ' ' ASN . . . 101.78 4.67 51.7 Favored Glycine 0 C--N 1.304 -1.204 0 C-N-CA 121.121 -0.562 . . . . 0.0 112.96 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB2' ' HG2' ' A' ' 53' ' ' PRO . . . -68.05 146.39 53.55 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.5 0.556 . . . . 0.0 112.5 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.409 HG22 HG22 ' A' ' 29' ' ' VAL . 7.6 p -101.57 105.42 16.37 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.778 0.831 . . . . 0.0 110.791 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 27' ' ' THR . 19.9 mm -107.74 134.79 48.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 123.339 0.656 . . . . 0.0 111.296 -178.082 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.78 116.17 48.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 170.11 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -111.05 162.15 15.17 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.053 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -129.28 6.0 5.3 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 123.791 0.682 . . . . 0.0 111.376 -177.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -158.74 154.89 27.02 Favored 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.4 HG23 ' HB3' ' A' ' 24' ' ' GLU . 8.8 t -133.51 133.75 57.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 172.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 54.5 m -126.25 154.26 43.61 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 123.419 0.688 . . . . 0.0 110.576 178.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 70' ' ' ILE . 66.0 mt -123.21 123.12 67.04 Favored 'Isoleucine or valine' 0 C--O 1.255 1.377 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.151 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 44.7 tp60 -171.9 152.72 3.06 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.76 26.42 15.6 Favored 'General case' 0 C--O 1.243 0.757 0 C-N-CA 123.682 0.793 . . . . 0.0 111.045 177.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.33 5.8 82.45 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.202 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -120.6 153.86 36.22 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 121.053 0.454 . . . . 0.0 111.34 -177.063 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 65' ' ' ILE . 24.0 mt -100.74 131.91 47.44 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 172.348 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.414 ' CZ3' ' HD3' ' A' ' 85' ' ' PRO . 55.3 m95 -123.62 140.47 52.96 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -172.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.3 pt -97.37 134.44 35.3 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 172.202 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.13 124.45 8.06 Favored Glycine 0 N--CA 1.425 -2.08 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.56 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.6 p90 . . . . . 0 C--N 1.299 -1.626 0 CA-C-O 120.734 0.302 . . . . 0.0 110.625 179.231 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 . . . . . 0 C--O 1.202 -1.412 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 26.6 t -104.91 132.91 50.51 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.948 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.05 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.4 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 61.1 m-85 -111.12 125.94 54.31 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.216 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.528 ' SG ' HG21 ' A' ' 35' ' ' ILE . 41.0 t -116.49 120.46 34.63 Favored Pre-proline 0 C--N 1.286 -2.159 0 CA-C-N 115.373 -0.831 . . . . 0.0 108.883 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.414 ' HD3' ' CZ3' ' A' ' 71' ' ' TRP . 37.9 Cg_endo -72.31 119.26 6.03 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 121.708 1.605 . . . . 0.0 109.134 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 29.0 m -105.85 -14.15 9.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.507 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.1 ptt180 -176.23 176.31 1.71 Allowed 'General case' 0 CA--C 1.503 -0.834 0 O-C-N 123.732 0.645 . . . . 0.0 109.581 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.6 p -95.6 167.15 11.48 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 123.357 0.411 . . . . 0.0 110.862 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.1 t -150.71 127.91 11.25 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 174.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -87.24 110.52 20.24 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.169 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.5 -155.45 32.36 Favored Glycine 0 N--CA 1.423 -2.219 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.735 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.413 ' HB ' ' CD1' ' A' ' 20' ' ' TRP . 8.3 m -134.39 155.52 79.7 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.493 ' HA ' ' N ' ' A' ' 95' ' ' ASN . 19.6 Cg_endo -63.19 167.68 12.21 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.198 1.932 . . . . 0.0 111.515 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.81 -4.76 5.97 Favored 'Cis proline' 0 C--N 1.352 0.752 0 N-CA-C 115.513 1.313 . . . . 0.0 115.513 4.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASN . . . . . 0.493 ' N ' ' HA ' ' A' ' 93' ' ' PRO . 39.1 m-80 -108.79 80.45 1.33 Allowed 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.482 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.0 pt20 -96.57 146.08 25.15 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.585 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 83.7 mt -122.0 87.77 47.43 Favored Pre-proline 0 C--N 1.273 -2.734 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.7 128.52 11.0 Favored 'Trans proline' 0 N--CA 1.442 -1.534 0 C-N-CA 122.647 2.232 . . . . 0.0 112.987 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.53 -175.79 49.56 Favored Glycine 0 N--CA 1.433 -1.558 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.793 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.1 p -67.31 133.98 30.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 120.947 0.403 . . . . 0.0 110.009 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -67.13 143.18 56.78 Favored 'General case' 0 N--CA 1.434 -1.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.777 -179.773 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 39.4 m0 -92.48 17.41 10.06 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.907 176.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.85 -173.39 42.38 Favored Glycine 0 N--CA 1.427 -1.959 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.796 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.569 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.8 OUTLIER -96.6 156.49 3.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -177.605 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -129.02 102.97 6.74 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 175.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.495 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 65.4 mttm . . . . . 0 C--N 1.301 -1.524 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.384 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.6 m . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.434 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 95.4 m95 -88.41 140.06 29.86 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 175.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 39.7 p90 -146.51 154.6 41.74 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 120.568 0.223 . . . . 0.0 110.954 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -144.83 145.69 28.73 Favored Pre-proline 0 C--N 1.305 -1.332 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -80.88 119.74 3.67 Favored 'Trans proline' 0 C--O 1.249 1.056 0 C-N-CA 122.64 2.227 . . . . 0.0 110.784 178.028 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -145.86 123.56 11.87 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -99.12 109.33 22.05 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.564 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.81 162.85 40.41 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.59 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.475 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.4 m -100.54 119.7 38.91 Favored 'General case' 0 N--CA 1.419 -2.024 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.059 177.239 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.534 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 67.2 t80 -98.97 113.98 26.41 Favored 'General case' 0 N--CA 1.416 -2.163 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 57' ' ' THR . 41.4 t -101.67 109.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 N-CA-C 106.001 -1.852 . . . . 0.0 106.001 176.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.49 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 53.6 t30 -61.56 149.43 39.1 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 123.567 0.542 . . . . 0.0 110.252 -177.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -88.71 -126.46 2.69 Favored Glycine 0 N--CA 1.423 -2.215 0 N-CA-C 114.259 0.464 . . . . 0.0 114.259 -174.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -89.92 -21.93 22.23 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -172.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -105.24 137.41 19.24 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.842 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.95 147.97 50.43 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.191 1.928 . . . . 0.0 109.319 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.417 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.6 mt -120.67 136.49 57.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.059 -174.359 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 69.8 t -79.16 116.82 23.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.484 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 72.2 p -91.49 157.12 17.22 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.686 -0.233 . . . . 0.0 110.617 -176.459 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -124.31 152.13 43.46 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 82' ' ' VAL . 21.0 mt -116.2 136.38 53.34 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -176.215 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.62 -45.83 3.5 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.868 174.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 40.8 m -138.17 144.33 42.87 Favored Pre-proline 0 C--N 1.274 -2.709 0 CA-C-N 113.972 -1.114 . . . . 0.0 110.324 -173.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -89.34 79.84 0.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.083 0 C-N-CA 122.411 2.074 . . . . 0.0 112.43 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -143.14 154.12 43.58 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 89.9 mt -76.6 -13.5 60.06 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.079 0.942 . . . . 0.0 108.773 174.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -91.24 -8.41 48.47 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.766 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -83.32 156.04 66.26 Favored Pre-proline 0 C--O 1.256 1.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.024 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.62 143.89 93.88 Favored 'Trans proline' 0 C--N 1.359 1.103 0 C-N-CA 123.145 2.563 . . . . 0.0 112.396 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.8 t -82.36 131.57 33.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.05 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.52 -27.9 28.61 Favored Glycine 0 C--N 1.3 -1.438 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 177.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 147.36 -176.33 26.27 Favored Glycine 0 N--CA 1.426 -2.012 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -103.24 117.5 34.67 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 173.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.411 HD12 ' HD2' ' A' ' 53' ' ' PRO . 20.4 tp -69.36 123.86 89.26 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.274 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.411 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.4 Cg_endo -55.94 141.21 86.31 Favored 'Trans proline' 0 N--CA 1.432 -2.105 0 C-N-CA 122.487 2.125 . . . . 0.0 113.266 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -67.26 116.58 8.2 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.167 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.73 0.11 42.48 Favored Glycine 0 C--N 1.304 -1.2 0 C-N-CA 120.728 -0.749 . . . . 0.0 113.1 -177.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -71.86 149.73 44.92 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.899 0.35 . . . . 0.0 111.554 -179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.428 HG22 HG22 ' A' ' 29' ' ' VAL . 20.9 p -104.79 108.83 20.52 Favored 'General case' 0 N--CA 1.439 -1.006 0 CA-C-O 121.55 0.691 . . . . 0.0 111.76 -178.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.5 mm -105.48 132.64 51.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 C-N-CA 123.841 0.857 . . . . 0.0 110.954 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.19 116.89 48.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.564 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 52.0 p90 -112.84 164.71 13.07 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.395 -0.522 . . . . 0.0 110.241 -177.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -123.52 -3.01 8.37 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.436 0.46 . . . . 0.0 111.666 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -154.92 154.43 32.62 Favored 'General case' 0 N--CA 1.434 -1.229 0 C-N-CA 119.445 -0.902 . . . . 0.0 109.85 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 21.6 t -127.04 135.58 63.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 175.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 61.6 m -125.35 157.03 37.76 Favored 'General case' 0 C--N 1.293 -1.853 0 O-C-N 123.199 0.312 . . . . 0.0 110.98 -178.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.426 HG12 HG12 ' A' ' 70' ' ' ILE . 73.0 mt -127.51 109.91 21.27 Favored 'Isoleucine or valine' 0 C--O 1.253 1.259 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 175.341 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -156.36 151.61 26.55 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.26 24.99 15.03 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 123.699 0.799 . . . . 0.0 110.361 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.56 13.27 68.11 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.398 -178.307 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -120.18 154.72 34.4 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 122.3 -0.53 . . . . 0.0 109.781 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.448 HG13 ' HB2' ' A' ' 89' ' ' CYS . 20.4 mt -101.29 133.89 43.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 174.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 53.9 m95 -126.02 150.82 47.82 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -172.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 29.0 pt -106.39 130.71 57.7 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.707 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 170.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -100.05 119.02 6.36 Favored Glycine 0 N--CA 1.417 -2.572 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 51.9 p90 . . . . . 0 N--CA 1.414 -2.257 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 25.2 tpt180 . . . . . 0 CA--C 1.487 -1.453 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.484 ' CG1' ' HB ' ' A' ' 37' ' ' THR . 38.3 t -116.93 134.95 58.87 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.681 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.54 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.8 m-85 -117.4 123.2 45.85 Favored 'General case' 0 C--N 1.281 -2.408 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.2 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -112.39 126.01 29.11 Favored Pre-proline 0 C--N 1.279 -2.467 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 35' ' ' ILE . 36.8 Cg_endo -71.79 129.78 15.96 Favored 'Trans proline' 0 N--CA 1.439 -1.678 0 C-N-CA 121.374 1.382 . . . . 0.0 108.778 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.51 -13.11 11.48 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -174.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.456 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.6 ptm180 -178.31 167.0 1.91 Allowed 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 16.2 p -92.33 162.68 14.17 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.501 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.8 t -141.39 120.69 13.06 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.554 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 28.1 tt0 -83.63 111.32 19.01 Favored 'General case' 0 N--CA 1.424 -1.768 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 177.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.17 -166.13 51.24 Favored Glycine 0 N--CA 1.426 -1.994 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.455 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 13.9 m -121.22 160.49 45.28 Favored Pre-proline 0 C--N 1.297 -1.707 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 31.4 Cg_endo -65.67 167.41 17.33 Favored 'Trans proline' 0 CA--C 1.547 1.155 0 C-N-CA 121.987 1.792 . . . . 0.0 112.48 179.337 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.407 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.4 Cg_endo -65.37 -28.46 4.36 Favored 'Cis proline' 0 C--N 1.363 1.307 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.985 4.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -90.86 79.31 5.96 Favored 'General case' 0 CA--C 1.485 -1.549 0 CA-C-O 122.17 0.986 . . . . 0.0 110.169 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.501 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 4.2 pt20 -94.26 143.82 26.06 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 176.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.554 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.0 mt -122.15 92.46 48.88 Favored Pre-proline 0 C--N 1.27 -2.873 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 177.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.529 ' HA ' ' O ' ' A' ' 88' ' ' THR . 58.7 Cg_endo -79.66 135.69 11.72 Favored 'Trans proline' 0 N--CA 1.434 -2.029 0 C-N-CA 122.263 1.976 . . . . 0.0 112.226 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.71 -159.07 23.38 Favored Glycine 0 C--N 1.311 -0.816 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -63.83 139.19 21.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.456 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.75 135.1 36.42 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 42.3 m0 -83.77 9.41 11.94 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.786 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -174.02 -172.08 38.97 Favored Glycine 0 N--CA 1.428 -1.891 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 178.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.5 t -97.36 149.35 5.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 -178.113 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -122.2 108.67 13.56 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 175.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.475 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 82.3 mttt . . . . . 0 C--N 1.285 -2.229 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.2 m . . . . . 0 N--CA 1.412 -2.327 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 89.6 m95 -86.38 125.37 33.61 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.135 -1.432 . . . . 0.0 107.135 175.106 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -134.64 151.57 51.14 Favored 'General case' 0 C--N 1.281 -2.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.562 -177.053 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -135.59 143.53 45.34 Favored Pre-proline 0 C--N 1.292 -1.926 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 173.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -76.8 113.03 3.56 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.216 1.944 . . . . 0.0 109.542 176.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -147.82 124.13 10.91 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.434 -178.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -100.06 106.59 18.35 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -178.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -147.11 160.4 42.46 Favored 'General case' 0 C--N 1.288 -2.067 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.616 -178.429 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.6 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 55.6 m -102.81 121.57 42.75 Favored 'General case' 0 C--N 1.288 -2.1 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.835 178.181 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.554 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.5 t80 -99.25 112.09 24.33 Favored 'General case' 0 C--N 1.284 -2.269 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.501 ' HB ' HG22 ' A' ' 104' ' ' VAL . 99.3 t -97.17 108.28 21.28 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -63.84 143.76 57.59 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 123.502 0.501 . . . . 0.0 110.069 -178.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -83.12 -128.05 1.27 Allowed Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 116.112 -0.494 . . . . 0.0 113.319 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -90.67 -14.61 31.93 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -172.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -108.26 136.86 19.8 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.947 -0.471 . . . . 0.0 111.575 -177.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -71.44 142.24 40.32 Favored 'Trans proline' 0 C--O 1.247 0.949 0 C-N-CA 121.974 1.783 . . . . 0.0 109.711 172.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.424 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.4 mt -117.26 133.24 64.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.085 -174.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -77.56 113.08 16.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.403 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 70.7 p -89.04 156.57 18.77 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.679 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -126.95 156.28 41.79 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -177.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.436 HG12 HG22 ' A' ' 82' ' ' VAL . 50.7 mt -122.09 135.83 60.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -177.181 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.54 -35.17 3.04 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.301 -0.863 . . . . 0.0 113.511 173.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 56.1 m -139.43 139.48 22.75 Favored Pre-proline 0 C--N 1.261 -3.253 0 C-N-CA 123.16 0.584 . . . . 0.0 111.343 -176.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 21.1 Cg_endo -87.13 55.06 2.99 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.714 2.276 . . . . 0.0 111.179 177.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -123.81 157.76 33.34 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.044 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.87 -14.03 59.93 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.551 0.691 . . . . 0.0 110.232 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -97.58 4.28 50.29 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.414 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.11 155.08 64.0 Favored Pre-proline 0 C--N 1.314 -0.935 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.64 136.75 77.61 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 122.991 2.46 . . . . 0.0 112.33 -178.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -78.27 124.48 36.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 115.355 -0.838 . . . . 0.0 109.701 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.36 -25.97 53.0 Favored Glycine 0 C--N 1.302 -1.331 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.56 -176.73 21.26 Favored Glycine 0 N--CA 1.421 -2.345 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -95.66 130.62 42.48 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.231 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.427 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.4 tp -77.01 126.31 85.69 Favored Pre-proline 0 C--N 1.285 -2.196 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 173.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HD2' HD12 ' A' ' 52' ' ' LEU . 6.2 Cg_endo -60.78 148.41 92.06 Favored 'Trans proline' 0 N--CA 1.44 -1.673 0 C-N-CA 121.913 1.742 . . . . 0.0 112.3 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.26 132.81 47.06 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 175.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 91.23 2.66 70.64 Favored Glycine 0 C--N 1.302 -1.333 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.069 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -75.24 144.67 42.46 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.37 0.605 . . . . 0.0 110.974 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.423 HG23 HG22 ' A' ' 29' ' ' VAL . 3.1 m -104.8 107.92 19.13 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.12 -176.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.4 mm -106.95 130.09 59.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 C-N-CA 123.38 0.672 . . . . 0.0 111.323 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.0 t -100.03 117.54 45.36 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 170.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 55.1 p90 -116.09 163.57 15.74 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.906 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -121.74 -0.59 9.61 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 123.409 0.443 . . . . 0.0 111.689 -178.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -153.27 148.54 26.93 Favored 'General case' 0 N--CA 1.433 -1.322 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.11 -176.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.4 t -120.98 133.48 67.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 105.681 -1.97 . . . . 0.0 105.681 173.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 3.9 m -125.66 150.1 47.9 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -175.186 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.41 HG12 HG12 ' A' ' 70' ' ' ILE . 64.3 mt -123.01 118.19 54.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 173.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -160.31 145.5 14.85 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -178.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.87 29.59 17.94 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 124.191 0.996 . . . . 0.0 110.759 177.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.06 10.47 73.4 Favored Glycine 0 CA--C 1.519 0.29 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.414 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -119.58 153.13 35.92 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 122.402 -0.469 . . . . 0.0 110.114 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' A' ' 87' ' ' ARG . 23.5 mt -103.37 133.94 45.88 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 174.184 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -127.73 153.61 46.32 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -171.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.49 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -109.96 130.25 63.47 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.774 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 171.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.47 122.52 7.55 Favored Glycine 0 N--CA 1.42 -2.424 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.536 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.2 p90 . . . . . 0 C--N 1.292 -1.928 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.7 tpt180 . . . . . 0 CA--C 1.492 -1.267 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.436 HG22 HG12 ' A' ' 39' ' ' ILE . 35.9 t -97.39 130.48 45.99 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.494 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.6 m-85 -112.4 125.17 53.92 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.309 178.04 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -114.14 125.06 29.83 Favored Pre-proline 0 C--N 1.278 -2.501 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 176.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.424 ' O ' HG21 ' A' ' 35' ' ' ILE . 42.8 Cg_endo -72.59 129.07 14.17 Favored 'Trans proline' 0 N--CA 1.439 -1.731 0 C-N-CA 121.271 1.314 . . . . 0.0 108.724 177.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.7 m -112.39 -15.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptt180 -177.48 173.12 1.73 Allowed 'General case' 0 CA--C 1.503 -0.853 0 C-N-CA 123.629 0.772 . . . . 0.0 109.457 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.6 p -99.93 168.3 9.96 Favored 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.598 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 45.1 t -147.55 123.86 10.91 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.108 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.568 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 44.0 tt0 -82.91 96.31 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.56 174.83 44.58 Favored Glycine 0 N--CA 1.429 -1.809 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.759 178.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.63 154.91 39.73 Favored Pre-proline 0 C--N 1.295 -1.797 0 C-N-CA 122.081 0.152 . . . . 0.0 111.011 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.431 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 38.4 Cg_endo -63.47 167.01 13.9 Favored 'Trans proline' 0 CA--C 1.556 1.617 0 C-N-CA 122.677 2.252 . . . . 0.0 112.8 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.431 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.1 Cg_endo -66.13 -24.58 6.17 Favored 'Cis proline' 0 C--N 1.372 1.794 0 C-N-CA 124.156 -1.185 . . . . 0.0 113.278 5.577 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -89.21 79.04 7.2 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 121.727 0.775 . . . . 0.0 109.26 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.598 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 12.8 pt20 -101.84 152.06 21.34 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.568 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 68.0 mt -130.28 88.02 49.03 Favored Pre-proline 0 C--N 1.284 -2.277 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -73.46 133.81 19.65 Favored 'Trans proline' 0 N--CA 1.443 -1.453 0 C-N-CA 122.433 2.089 . . . . 0.0 112.536 -178.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -85.42 -163.38 37.32 Favored Glycine 0 N--CA 1.441 -1.002 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.748 178.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -69.54 131.85 33.65 Favored 'Isoleucine or valine' 0 C--O 1.251 1.145 0 CA-C-O 120.88 0.371 . . . . 0.0 110.695 -178.156 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.482 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -71.6 140.55 49.82 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.445 177.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.4 m0 -90.2 10.86 22.95 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.799 179.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -167.54 -159.95 14.08 Favored Glycine 0 N--CA 1.43 -1.712 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.22 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.7 OUTLIER -113.03 154.64 14.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.045 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -123.76 103.61 8.48 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.6 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 87.5 mttt . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 173.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 87.3 m . . . . . 0 N--CA 1.421 -1.91 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -84.91 135.9 33.86 Favored 'General case' 0 CA--C 1.485 -1.536 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 175.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -149.5 162.51 40.01 Favored 'General case' 0 C--N 1.281 -2.388 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -177.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -150.36 144.7 17.71 Favored Pre-proline 0 N--CA 1.422 -1.852 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.17 126.84 11.46 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.621 2.214 . . . . 0.0 109.73 176.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -152.76 123.7 7.45 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.7 108.88 20.85 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.21 164.77 38.35 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.642 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.542 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 65.1 m -105.72 120.85 42.74 Favored 'General case' 0 N--CA 1.416 -2.154 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.43 177.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.7 t80 -98.98 125.25 44.4 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.1 109.72 29.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.416 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 51.8 t30 -65.33 145.28 56.39 Favored 'General case' 0 C--N 1.308 -1.205 0 O-C-N 123.778 0.674 . . . . 0.0 110.699 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -84.54 -108.49 0.62 Allowed Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 114.863 0.705 . . . . 0.0 114.863 -174.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.26 -25.04 13.82 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 122.599 0.36 . . . . 0.0 111.717 -170.241 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -110.84 133.63 21.18 Favored Pre-proline 0 C--N 1.295 -1.769 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.802 -176.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.05 140.72 55.25 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.211 1.941 . . . . 0.0 110.568 175.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.85 136.25 52.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.746 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.402 HG22 ' ND2' ' A' ' 51' ' ' ASN . 52.6 t -77.36 121.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.8 p -94.19 157.84 15.87 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.034 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.44 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 27.0 mmt180 -130.72 155.01 47.35 Favored 'General case' 0 C--O 1.21 -0.985 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 -174.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.441 HG12 HG22 ' A' ' 82' ' ' VAL . 18.6 mt -112.46 138.95 39.67 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.45 -48.74 4.11 Favored Glycine 0 CA--C 1.502 -0.719 0 C-N-CA 124.921 1.248 . . . . 0.0 113.752 174.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 14.8 m -137.35 154.2 75.26 Favored Pre-proline 0 C--N 1.279 -2.499 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.991 -170.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -91.03 67.22 1.31 Allowed 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 123.006 2.47 . . . . 0.0 111.77 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -131.17 156.45 45.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.7 mt -76.46 -19.98 57.49 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.959 0.409 . . . . 0.0 111.024 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -100.39 18.16 19.68 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 121.556 0.694 . . . . 0.0 111.208 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -85.22 152.62 58.6 Favored Pre-proline 0 C--N 1.308 -1.239 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.4 143.24 94.61 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 50' ' ' GLY . 51.7 t -79.57 126.19 39.05 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.01 7.69 67.36 Favored Glycine 0 C--N 1.308 -0.976 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.637 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 122.28 170.51 13.71 Favored Glycine 0 N--CA 1.423 -2.21 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.402 ' ND2' HG22 ' A' ' 36' ' ' VAL . 2.3 m-20 -113.19 117.17 31.17 Favored 'General case' 0 C--N 1.28 -2.418 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.494 HD12 ' HD2' ' A' ' 53' ' ' PRO . 19.6 tp -68.78 125.7 92.08 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.212 -176.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.3 Cg_endo -63.14 156.8 52.99 Favored 'Trans proline' 0 N--CA 1.439 -1.735 0 C-N-CA 122.28 1.986 . . . . 0.0 112.768 178.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.416 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -76.99 128.19 34.06 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 176.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.76 21.36 50.95 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.828 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 146.1 24.43 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-O 120.706 0.289 . . . . 0.0 110.799 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.8 p -98.18 120.8 39.22 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.453 -179.295 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mm -118.69 134.91 60.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 123.894 0.877 . . . . 0.0 109.834 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.0 t -108.94 117.49 54.44 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 172.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.59 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 53.4 p90 -111.38 172.96 6.57 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 120.494 -0.483 . . . . 0.0 110.95 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -131.47 2.61 4.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.364 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -158.08 152.96 25.16 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.218 -175.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.4 t -126.37 134.63 65.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 172.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.406 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 76.1 m -127.64 155.63 43.61 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 122.509 0.323 . . . . 0.0 110.987 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 70' ' ' ILE . 60.4 mt -124.86 114.41 40.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 175.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -164.59 150.77 10.6 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.2 29.69 17.5 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 123.781 0.832 . . . . 0.0 110.021 178.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.04 8.76 65.31 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.125 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -120.67 157.34 29.8 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 122.346 -0.502 . . . . 0.0 110.795 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 65' ' ' ILE . 20.1 mt -104.96 133.45 49.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 173.226 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -127.13 154.17 45.09 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -170.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 32.5 pt -109.24 136.04 46.34 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 171.561 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -108.15 130.38 10.06 Favored Glycine 0 N--CA 1.42 -2.425 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.59 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 39.0 p90 . . . . . 0 C--N 1.293 -1.853 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.417 ' HD2' ' HA ' ' A' ' 81' ' ' ARG . 18.1 tpt180 . . . . . 0 N--CA 1.428 -1.55 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.441 HG22 HG12 ' A' ' 39' ' ' ILE . 46.6 t -126.16 135.47 63.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.277 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.7 m-85 -118.06 151.94 36.54 Favored 'General case' 0 C--N 1.281 -2.38 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.273 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 45.2 t -141.9 128.73 11.29 Favored Pre-proline 0 C--N 1.275 -2.647 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -74.12 134.94 20.14 Favored 'Trans proline' 0 N--CA 1.436 -1.858 0 C-N-CA 121.483 1.455 . . . . 0.0 109.395 177.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.8 m -116.52 -13.12 11.25 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.523 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.6 ptm180 -176.34 168.94 2.76 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.9 p -97.07 165.43 12.07 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 53.2 t -145.53 121.45 10.65 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 177.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.607 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 0.5 OUTLIER -86.56 115.18 23.88 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.898 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 -167.49 45.88 Favored Glycine 0 N--CA 1.428 -1.897 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.212 -179.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 8.3 m -132.07 155.27 81.54 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 123.869 0.868 . . . . 0.0 108.838 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.463 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 19.3 Cg_endo -59.51 163.04 13.55 Favored 'Trans proline' 0 CA--C 1.555 1.562 0 C-N-CA 122.232 1.955 . . . . 0.0 113.2 -178.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.463 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 55.3 Cg_endo -68.38 -26.32 6.77 Favored 'Cis proline' 0 C--N 1.364 1.346 0 C-N-CA 123.822 -1.324 . . . . 0.0 112.824 7.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -91.93 78.75 5.32 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.862 0.839 . . . . 0.0 109.288 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.435 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.7 pt20 -95.25 147.17 23.76 Favored 'General case' 0 N--CA 1.426 -1.634 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 175.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.607 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 85.7 mt -123.37 87.99 51.61 Favored Pre-proline 0 C--N 1.265 -3.076 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -78.6 132.43 10.99 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.285 1.99 . . . . 0.0 112.71 -177.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -83.32 -171.5 47.61 Favored Glycine 0 N--CA 1.437 -1.251 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.31 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.3 p -64.21 136.67 26.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-O 120.751 0.31 . . . . 0.0 110.417 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.523 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -73.46 145.09 45.97 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.069 0.461 . . . . 0.0 110.602 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.6 m0 -94.27 11.31 30.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.538 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.03 -174.32 40.05 Favored Glycine 0 N--CA 1.419 -2.489 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.94 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 2.9 t -96.63 151.11 4.16 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -177.364 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -122.53 102.98 8.4 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 176.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.542 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 57.7 mttm . . . . . 0 C--N 1.298 -1.643 0 CA-C-O 118.276 -0.869 . . . . 0.0 108.682 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.497 HG23 ' HB2' ' A' ' 66' ' ' GLN . 86.9 m . . . . . 0 N--CA 1.424 -1.727 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 74.4 m95 -90.86 134.38 34.5 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -138.85 153.51 48.33 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -137.29 145.38 49.52 Favored Pre-proline 0 C--N 1.291 -1.973 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 173.497 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -75.56 124.75 8.49 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.342 2.028 . . . . 0.0 109.122 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.86 123.05 4.44 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -103.73 108.52 19.85 Favored 'General case' 0 C--N 1.29 -1.983 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.78 165.99 29.78 Favored 'General case' 0 C--N 1.284 -2.252 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.952 -178.568 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.535 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 82.7 m -102.5 118.69 37.4 Favored 'General case' 0 N--CA 1.41 -2.433 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.845 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.523 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -99.03 111.92 24.19 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.62 110.09 25.33 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.458 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 50.1 t30 -63.03 145.71 54.82 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.637 0.586 . . . . 0.0 110.705 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.78 -118.75 0.4 Allowed Glycine 0 N--CA 1.426 -1.984 0 CA-C-N 115.889 -0.596 . . . . 0.0 114.016 -176.241 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -100.44 -11.38 20.24 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 112.748 0.648 . . . . 0.0 112.748 -170.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -121.96 137.44 27.35 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.435 -174.599 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -67.92 142.58 57.53 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 121.98 1.787 . . . . 0.0 110.364 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mt -116.22 141.83 32.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 C-N-CA 120.287 -0.565 . . . . 0.0 110.66 -174.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.9 t -84.92 117.55 30.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.431 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 82.4 p -93.77 153.8 18.11 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.513 -0.312 . . . . 0.0 111.083 -176.079 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.479 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 35.5 mmt180 -121.74 160.88 23.63 Favored 'General case' 0 C--O 1.208 -1.1 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -177.599 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 56.2 mt -126.21 135.99 62.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.415 0.626 . . . . 0.0 112.566 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.52 -48.09 3.08 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.414 173.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 25.3 m -138.15 146.15 50.6 Favored Pre-proline 0 C--N 1.271 -2.833 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.793 -174.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -87.17 81.12 1.34 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.363 2.042 . . . . 0.0 112.235 177.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -144.46 157.26 44.33 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 86.0 mt -76.29 -16.9 59.68 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.995 0.902 . . . . 0.0 108.661 175.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -91.15 3.14 55.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 114.249 -1.341 . . . . 0.0 110.695 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.45 50.42 Favored Pre-proline 0 C--O 1.256 1.437 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.835 -176.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -57.51 147.07 80.71 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 123.167 2.578 . . . . 0.0 111.616 176.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.593 HG12 ' H ' ' A' ' 50' ' ' GLY . 32.8 t -90.42 135.71 25.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.8 -175.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.15 -14.56 54.17 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 177.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.593 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 127.91 -176.77 17.92 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -103.9 128.89 51.38 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.959 0.88 . . . . 0.0 109.802 176.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.42 HD12 ' HD2' ' A' ' 53' ' ' PRO . 16.4 tp -77.16 127.79 82.5 Favored Pre-proline 0 C--N 1.294 -1.831 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 175.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' HD12 ' A' ' 52' ' ' LEU . 10.0 Cg_endo -63.81 154.47 69.42 Favored 'Trans proline' 0 N--CA 1.443 -1.487 0 C-N-CA 122.03 1.82 . . . . 0.0 112.452 178.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.458 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -73.06 136.85 45.03 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.534 -0.914 . . . . 0.0 108.534 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.41 5.04 85.43 Favored Glycine 0 C--N 1.312 -0.785 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.314 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.27 145.7 37.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 117.029 0.415 . . . . 0.0 111.649 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.6 p -100.75 107.03 18.52 Favored 'General case' 0 N--CA 1.438 -1.028 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.366 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.98 141.56 18.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.6 p -116.11 116.43 52.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 171.211 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.6 p90 -111.03 167.22 10.42 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.846 -176.369 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -124.56 -3.95 7.78 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.57 -179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -153.37 154.13 33.9 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.592 -175.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.2 t -128.53 135.83 61.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.432 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 74.0 m -126.77 156.27 41.48 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.458 0.303 . . . . 0.0 110.766 179.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.46 HG12 HG12 ' A' ' 70' ' ' ILE . 66.4 mt -124.88 117.74 51.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 176.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLN . . . . . 0.497 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.8 tp-100 -164.73 149.81 9.73 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.41 28.35 16.8 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.089 0.956 . . . . 0.0 110.376 178.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.25 8.04 69.16 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.537 -178.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -119.76 155.22 32.93 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 122.093 -0.651 . . . . 0.0 110.486 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.48 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 16.9 mt -104.21 134.27 45.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 174.403 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -125.78 148.72 49.02 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -171.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -106.71 137.28 38.15 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 172.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.72 125.98 8.15 Favored Glycine 0 N--CA 1.419 -2.456 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.629 -178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.511 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.1 p90 . . . . . 0 C--N 1.294 -1.824 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 176.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.458 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 26.0 tpt180 . . . . . 0 C--O 1.207 -1.182 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 27.1 t -93.45 128.36 44.92 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.835 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.324 -173.298 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.516 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 58.2 m-85 -113.48 120.27 40.43 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.853 177.364 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.9 t -110.33 127.1 27.59 Favored Pre-proline 0 C--N 1.28 -2.428 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.45 131.54 17.72 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 121.454 1.436 . . . . 0.0 108.711 176.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.12 -12.58 11.35 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.573 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.6 ptm180 -178.78 174.21 1.17 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 7.0 p -98.49 167.77 10.61 Favored 'General case' 0 C--N 1.288 -2.066 0 C-N-CA 122.631 0.372 . . . . 0.0 110.414 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.2 t -149.96 118.73 6.6 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.154 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.546 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 16.1 tt0 -81.31 90.38 6.13 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 96.94 -174.56 30.31 Favored Glycine 0 N--CA 1.433 -1.515 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.134 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 25.7 m -111.81 158.76 35.73 Favored Pre-proline 0 C--N 1.302 -1.49 0 C-N-CA 122.184 0.194 . . . . 0.0 110.917 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 14.1 Cg_endo -63.4 171.5 6.57 Favored 'Trans proline' 0 CA--C 1.555 1.54 0 C-N-CA 122.728 2.286 . . . . 0.0 112.516 177.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.13 -25.01 5.99 Favored 'Cis proline' 0 C--N 1.371 1.751 0 CA-C-N 119.674 0.919 . . . . 0.0 113.4 3.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -91.99 79.34 5.23 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 122.278 1.037 . . . . 0.0 110.013 177.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.453 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 9.0 pt20 -96.17 151.29 19.62 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.205 -1.361 . . . . 0.0 107.488 177.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.546 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.1 mt -129.59 86.93 54.32 Favored Pre-proline 0 C--N 1.282 -2.349 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 88' ' ' THR . 20.3 Cg_endo -75.21 128.21 11.15 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 122.286 1.991 . . . . 0.0 112.195 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.17 -161.73 29.44 Favored Glycine 0 C--N 1.315 -0.62 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.93 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.1 p -63.81 135.16 28.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 117.099 0.449 . . . . 0.0 110.872 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.573 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -81.63 147.91 29.32 Favored 'General case' 0 N--CA 1.436 -1.152 0 CA-C-O 121.294 0.569 . . . . 0.0 111.071 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.3 m0 -96.2 13.46 27.33 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.846 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -178.89 -164.47 31.71 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -105.76 153.52 7.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.4 104.55 8.23 Favored 'General case' 0 N--CA 1.419 -2.02 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.535 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 85.4 mttt . . . . . 0 C--N 1.289 -2.059 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 176.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.415 HG23 ' HB2' ' A' ' 66' ' ' GLN . 90.5 m . . . . . 0 N--CA 1.414 -2.226 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 73.7 m95 -86.7 123.96 32.43 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 47.6 p90 -129.0 164.22 23.68 Favored 'General case' 0 C--N 1.282 -2.359 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -177.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -152.8 142.06 14.54 Favored Pre-proline 0 C--N 1.287 -2.137 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -78.49 113.21 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 C-N-CA 122.407 2.071 . . . . 0.0 109.844 175.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -135.44 124.79 24.75 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -176.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -100.87 107.14 18.58 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -177.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.624 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -154.6 168.83 25.44 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.547 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 52.5 m -106.19 121.32 43.94 Favored 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.848 177.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.591 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 72.5 t80 -99.18 113.23 25.38 Favored 'General case' 0 N--CA 1.406 -2.642 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.3 t -100.81 116.22 43.89 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.526 0 N-CA-C 105.599 -2.001 . . . . 0.0 105.599 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -68.14 149.44 49.59 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.6 -0.44 . . . . 0.0 110.485 -177.126 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.28 -144.94 3.74 Favored Glycine 0 N--CA 1.433 -1.548 0 CA-C-N 116.368 -0.378 . . . . 0.0 113.174 -176.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.36 -6.06 59.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.25 0.548 . . . . 0.0 111.388 -175.392 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.4 pt20 -117.23 137.55 24.09 Favored Pre-proline 0 C--O 1.207 -1.142 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.233 -178.141 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.78 155.14 63.12 Favored 'Trans proline' 0 C--O 1.255 1.364 0 C-N-CA 122.611 2.207 . . . . 0.0 110.552 175.334 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.453 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.9 mt -126.48 134.94 65.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.646 -177.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 53.7 t -76.25 121.38 28.18 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 77.0 p -97.57 156.7 16.39 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 122.322 -0.236 . . . . 0.0 111.428 -175.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.0 mmt180 -124.0 155.12 38.81 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -178.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 82' ' ' VAL . 24.9 mt -116.55 137.83 49.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -175.264 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.56 -45.15 3.33 Favored Glycine 0 CA--C 1.502 -0.773 0 CA-C-N 114.726 -1.124 . . . . 0.0 113.299 175.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 16.1 p -138.39 155.48 73.89 Favored Pre-proline 0 C--N 1.275 -2.647 0 CA-C-N 114.483 -0.858 . . . . 0.0 111.233 -171.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 30.5 Cg_endo -95.37 58.55 0.2 Allowed 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.483 2.789 . . . . 0.0 112.043 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -121.23 155.8 33.82 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.3 mt -76.65 -23.63 53.29 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.481 0.657 . . . . 0.0 109.419 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -82.22 -13.77 56.57 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.237 177.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.53 152.68 96.01 Favored Pre-proline 0 C--O 1.249 1.072 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.365 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.3 136.72 74.09 Favored 'Trans proline' 0 C--O 1.241 0.655 0 C-N-CA 122.867 2.378 . . . . 0.0 112.728 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.01 132.84 32.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.59 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.11 -18.39 43.32 Favored Glycine 0 C--O 1.241 0.539 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 135.42 -177.31 19.5 Favored Glycine 0 N--CA 1.428 -1.871 0 N-CA-C 109.219 -1.553 . . . . 0.0 109.219 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -97.35 131.97 43.52 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 118.043 0.922 . . . . 0.0 109.744 175.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.465 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.7 tp -78.2 126.82 82.86 Favored Pre-proline 0 C--N 1.291 -1.964 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 173.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.465 ' HD2' HD12 ' A' ' 52' ' ' LEU . 4.0 Cg_endo -62.48 151.56 82.36 Favored 'Trans proline' 0 N--CA 1.437 -1.805 0 C-N-CA 122.086 1.857 . . . . 0.0 112.507 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -68.52 137.42 54.36 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 175.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.31 22.43 77.58 Favored Glycine 0 N--CA 1.438 -1.181 0 C-N-CA 121.002 -0.618 . . . . 0.0 113.534 -178.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -89.33 152.05 21.75 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 117.8 0.8 . . . . 0.0 110.081 177.328 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.13 119.44 38.81 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-O 121.163 0.506 . . . . 0.0 109.987 -177.642 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.413 HG21 HD12 ' A' ' 72' ' ' ILE . 21.4 mm -117.09 130.02 72.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.77 179.069 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.7 p -101.63 116.8 45.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 169.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.624 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 53.7 p90 -112.73 160.62 17.76 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.869 -178.288 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -123.32 1.16 9.03 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 123.609 0.568 . . . . 0.0 110.75 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -155.24 152.25 29.07 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.044 -173.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 10.8 t -131.4 133.32 62.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 56.7 m -124.56 148.5 47.77 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 123.014 0.526 . . . . 0.0 110.747 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 70' ' ' ILE . 59.4 mt -117.95 116.6 52.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLN . . . . . 0.415 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.7 tp-100 -163.19 147.4 11.03 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 123.572 0.545 . . . . 0.0 109.585 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 60.23 30.99 20.33 Favored 'General case' 0 C--O 1.242 0.71 0 C-N-CA 124.052 0.941 . . . . 0.0 111.446 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 6.62 81.24 Favored Glycine 0 CA--C 1.508 -0.351 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.682 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -120.2 154.2 35.17 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 122.608 -0.348 . . . . 0.0 110.338 -178.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 65' ' ' ILE . 19.5 mt -105.81 133.82 49.09 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 172.116 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -125.69 149.96 48.06 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.07 0.548 . . . . 0.0 109.753 -171.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 28.7 pt -106.47 137.01 39.01 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 171.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.08 121.33 6.98 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 41.5 p90 . . . . . 0 C--N 1.302 -1.489 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.419 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 . . . . . 0 CA--C 1.498 -1.031 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.407 HG22 HG12 ' A' ' 39' ' ' ILE . 45.2 t -123.56 135.88 61.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.323 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.499 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.1 m-85 -115.65 123.5 48.53 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.627 -1.17 . . . . 0.0 109.942 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.2 t -111.31 125.85 29.74 Favored Pre-proline 0 C--N 1.281 -2.375 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 177.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.453 ' O ' HG21 ' A' ' 35' ' ' ILE . 33.7 Cg_endo -71.88 129.9 16.03 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 121.54 1.493 . . . . 0.0 108.638 176.195 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.45 -10.39 12.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.47 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 6.5 ptm180 178.81 173.54 0.72 Allowed 'General case' 0 C--O 1.246 0.899 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.2 p -98.96 167.37 10.78 Favored 'General case' 0 C--N 1.289 -2.033 0 C-N-CA 122.238 0.215 . . . . 0.0 110.737 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.476 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 48.6 t -145.2 128.03 16.35 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 177.046 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 60.8 tt0 -90.1 96.31 10.61 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 97.64 -157.94 20.84 Favored Glycine 0 N--CA 1.418 -2.505 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.688 177.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.3 m -130.26 150.86 77.31 Favored Pre-proline 0 C--N 1.297 -1.712 0 C-N-CA 123.353 0.661 . . . . 0.0 109.619 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.443 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 42.2 Cg_endo -66.57 165.63 24.62 Favored 'Trans proline' 0 CA--C 1.555 1.534 0 C-N-CA 122.363 2.042 . . . . 0.0 111.175 -178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.42 -5.89 20.15 Favored 'Cis proline' 0 C--N 1.356 0.973 0 C-N-CA 124.301 -1.125 . . . . 0.0 113.329 4.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -101.43 77.48 1.78 Allowed 'General case' 0 N--CA 1.427 -1.597 0 C-N-CA 118.315 -1.354 . . . . 0.0 108.355 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.476 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.5 pm0 -103.08 153.03 20.7 Favored 'General case' 0 N--CA 1.427 -1.584 0 CA-C-N 114.756 -1.111 . . . . 0.0 108.034 178.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 58.1 mt -131.27 87.56 47.17 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 88' ' ' THR . 67.7 Cg_endo -73.53 135.6 22.32 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.544 2.163 . . . . 0.0 112.841 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.45 -170.85 44.52 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.4 p -69.01 138.26 22.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 116.994 0.397 . . . . 0.0 110.25 -178.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -72.01 141.36 49.34 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.163 -178.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 43.6 m0 -87.54 2.49 50.61 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.329 -179.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -159.39 -160.03 10.15 Favored Glycine 0 N--CA 1.43 -1.748 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 178.373 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -115.15 149.37 17.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -117.56 106.73 13.44 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 175.411 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 63.4 mttm . . . . . 0 C--N 1.288 -2.092 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 176.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 64' ' ' CYS . 84.5 m . . . . . 0 N--CA 1.403 -2.783 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.404 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 86.0 m95 -88.97 127.05 35.65 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -133.82 158.85 42.34 Favored 'General case' 0 C--N 1.292 -1.91 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.382 -178.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -149.03 150.71 32.89 Favored Pre-proline 0 N--CA 1.426 -1.672 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 170.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.37 131.79 18.22 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 121.742 1.628 . . . . 0.0 110.064 176.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.41 ' HB3' HG23 ' A' ' 63' ' ' VAL . 8.0 tp10 -151.81 123.62 8.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -108.72 106.18 16.09 Favored 'General case' 0 C--N 1.292 -1.903 0 C-N-CA 118.776 -1.17 . . . . 0.0 108.563 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -150.1 167.74 25.93 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.8 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.472 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.1 m -111.06 122.58 48.25 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-O 121.534 0.683 . . . . 0.0 111.134 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.51 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 55.2 t80 -98.62 122.4 41.78 Favored 'General case' 0 N--CA 1.415 -2.18 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.463 HG21 ' HE3' ' A' ' 106' ' ' LYS . 48.2 t -105.32 114.96 46.16 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 176.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.438 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 52.5 t30 -67.66 148.22 51.65 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 123.429 0.456 . . . . 0.0 110.003 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -90.47 -119.98 2.15 Favored Glycine 0 N--CA 1.419 -2.437 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.8 -176.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -85.94 -28.61 24.17 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 -172.42 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 10.9 pt20 -110.21 136.18 20.52 Favored Pre-proline 0 C--N 1.286 -2.188 0 O-C-N 122.046 -0.409 . . . . 0.0 111.652 -174.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -68.46 140.05 46.85 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.969 1.78 . . . . 0.0 109.809 175.166 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -112.4 131.1 64.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.913 -172.329 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.1 t -72.19 116.18 13.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 80.4 p -95.54 162.84 13.47 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.251 -178.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 47' ' ' PRO . 33.4 mmt180 -129.8 155.38 46.06 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -176.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.46 HG12 HG22 ' A' ' 82' ' ' VAL . 26.5 mt -116.37 137.29 50.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -175.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.55 -48.67 3.93 Favored Glycine 0 CA--C 1.494 -1.277 0 CA-C-N 114.218 -1.355 . . . . 0.0 112.623 174.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 43.7 m -139.05 146.9 51.5 Favored Pre-proline 0 C--N 1.264 -3.148 0 CA-C-N 114.353 -0.924 . . . . 0.0 110.264 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -85.9 84.88 1.14 Allowed 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.075 1.85 . . . . 0.0 112.239 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -142.25 156.91 45.32 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.3 mt -76.85 -22.44 53.52 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -90.32 8.0 35.61 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.916 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.95 156.68 42.19 Favored Pre-proline 0 C--O 1.253 1.274 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.436 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 15.6 Cg_endo -57.99 150.79 61.98 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.972 2.448 . . . . 0.0 112.007 179.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.547 HG12 ' H ' ' A' ' 50' ' ' GLY . 59.3 t -86.04 125.08 40.64 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.59 -177.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.41 -8.05 78.33 Favored Glycine 0 CA--C 1.496 -1.15 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.547 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 128.08 179.38 15.83 Favored Glycine 0 N--CA 1.411 -2.983 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -109.66 110.84 22.01 Favored 'General case' 0 C--N 1.269 -2.921 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.579 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 53' ' ' PRO . 29.6 tp -63.14 126.84 89.98 Favored Pre-proline 0 C--N 1.303 -1.415 0 CA-C-N 114.288 -1.324 . . . . 0.0 109.466 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.515 ' HD2' HD12 ' A' ' 52' ' ' LEU . 11.9 Cg_exo -60.6 146.72 96.56 Favored 'Trans proline' 0 N--CA 1.431 -2.2 0 C-N-CA 122.402 2.068 . . . . 0.0 112.551 -178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -70.94 116.26 11.03 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.86 -0.66 45.07 Favored Glycine 0 C--N 1.306 -1.09 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.337 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -74.83 143.79 43.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.237 0.541 . . . . 0.0 111.608 -178.04 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -98.42 117.13 32.15 Favored 'General case' 0 N--CA 1.421 -1.885 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.819 -176.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.5 mm -115.23 127.41 72.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 123.707 0.803 . . . . 0.0 111.389 -179.003 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 79.2 t -98.95 116.76 42.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 171.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.456 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 55.0 p90 -114.53 164.59 13.78 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.441 -178.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -124.11 3.5 8.62 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.769 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -155.37 147.9 24.06 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.638 -0.825 . . . . 0.0 109.888 -175.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 24' ' ' GLU . 12.5 t -122.46 135.41 62.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.459 ' HB3' ' CG2' ' A' ' 19' ' ' THR . 82.7 m -130.4 150.91 51.41 Favored 'General case' 0 C--N 1.286 -2.17 0 O-C-N 123.306 0.379 . . . . 0.0 110.748 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -119.68 121.37 66.04 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 176.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLN . . . . . 0.403 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.5 tp-100 -167.86 150.08 5.6 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 123.723 0.639 . . . . 0.0 109.51 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 59.49 31.28 20.91 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 123.93 0.892 . . . . 0.0 111.301 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.21 6.77 70.06 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.57 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' HIS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 77.0 m80 -120.1 156.68 30.52 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 122.537 -0.39 . . . . 0.0 110.69 -177.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.467 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 23.2 mt -104.87 134.35 46.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.6 m95 -125.72 153.82 43.36 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -170.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.523 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.5 pt -113.44 136.61 49.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 173.373 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.28 123.59 7.48 Favored Glycine 0 N--CA 1.423 -2.178 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.947 -178.208 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.456 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 37.7 p90 . . . . . 0 C--N 1.296 -1.76 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 . . . . . 0 C--O 1.209 -1.056 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.46 HG22 HG12 ' A' ' 39' ' ' ILE . 39.4 t -118.14 131.79 69.87 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 C-N-CA 119.399 -0.92 . . . . 0.0 109.774 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.523 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 66.6 m-85 -114.06 128.2 56.28 Favored 'General case' 0 C--N 1.286 -2.191 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.31 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.6 t -115.96 128.43 25.98 Favored Pre-proline 0 C--N 1.285 -2.2 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.655 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -74.01 130.52 14.46 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.427 1.418 . . . . 0.0 108.74 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.8 m -114.32 -13.5 11.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -175.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.531 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.5 ptm180 -176.51 174.31 1.92 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -178.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.473 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.1 p -98.25 165.23 11.97 Favored 'General case' 0 C--N 1.286 -2.175 0 C-N-CA 122.781 0.432 . . . . 0.0 110.832 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.713 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.0 t -149.98 116.29 5.74 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 122.901 0.48 . . . . 0.0 110.202 177.582 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 46.8 tt0 -83.86 103.23 12.96 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.86 -176.04 40.65 Favored Glycine 0 N--CA 1.432 -1.626 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.437 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.415 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 16.1 m -112.69 155.12 44.4 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.116 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 36.3 Cg_endo -63.67 164.9 19.68 Favored 'Trans proline' 0 CA--C 1.552 1.4 0 C-N-CA 122.432 2.088 . . . . 0.0 110.861 -178.648 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.49 -5.05 30.82 Favored 'Cis proline' 0 C--N 1.359 1.094 0 C-N-CA 124.573 -1.011 . . . . 0.0 113.363 7.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -104.49 78.82 1.5 Allowed 'General case' 0 CA--C 1.475 -1.916 0 C-N-CA 119.548 -0.861 . . . . 0.0 109.088 171.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.713 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -98.93 151.42 20.9 Favored 'General case' 0 N--CA 1.418 -2.071 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 60.1 mt -125.86 86.06 58.24 Favored Pre-proline 0 C--N 1.291 -1.962 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.473 ' HA ' ' O ' ' A' ' 88' ' ' THR . 54.7 Cg_endo -68.92 129.03 17.72 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.355 2.036 . . . . 0.0 112.666 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.33 -166.83 41.64 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 177.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.7 p -63.34 135.91 26.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.158 0.504 . . . . 0.0 110.596 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.531 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -76.86 144.63 38.88 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.569 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 44.4 m0 -90.35 8.79 31.68 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.334 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -170.51 -156.48 11.37 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.569 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 6.7 t -111.61 154.47 13.15 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -125.97 102.84 7.44 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 176.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 93.3 mttt . . . . . 0 C--N 1.288 -2.087 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.454 HG23 ' HB2' ' A' ' 66' ' ' GLN . 56.6 m . . . . . 0 N--CA 1.434 -1.271 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.422 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 81.9 m95 -82.94 130.77 35.18 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.413 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.2 p90 -141.39 159.33 42.45 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -176.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -150.28 147.47 21.96 Favored Pre-proline 0 N--CA 1.419 -2.015 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.641 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -76.37 121.95 6.31 Favored 'Trans proline' 0 N--CA 1.449 -1.109 0 C-N-CA 122.575 2.184 . . . . 0.0 110.121 174.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.28 123.15 8.71 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.518 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 23.9 t-20 -107.26 106.46 16.93 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.613 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.5 166.09 29.23 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.794 -175.487 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 98.0 m -103.9 119.78 39.63 Favored 'General case' 0 N--CA 1.414 -2.271 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.239 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -98.99 118.89 36.79 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.25 106.1 19.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.917 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 177.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -62.87 142.68 58.17 Favored 'General case' 0 C--N 1.316 -0.854 0 O-C-N 124.024 0.827 . . . . 0.0 111.325 -176.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.75 -140.72 0.91 Allowed Glycine 0 N--CA 1.428 -1.87 0 CA-C-N 115.696 -0.683 . . . . 0.0 113.688 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.67 -13.53 56.26 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 -173.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -110.67 138.71 21.11 Favored Pre-proline 0 C--N 1.31 -1.151 0 O-C-N 121.415 -0.803 . . . . 0.0 111.389 -177.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -69.29 145.85 61.19 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 122.334 2.023 . . . . 0.0 110.422 174.133 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.37 136.26 56.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.784 -175.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.7 t -75.8 121.89 28.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.519 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.5 p -104.59 158.24 16.63 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 110.375 -0.231 . . . . 0.0 110.375 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 26.5 mmt180 -127.6 160.97 29.95 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -174.19 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.465 HG12 HG22 ' A' ' 82' ' ' VAL . 50.3 mt -122.79 138.1 54.04 Favored 'Isoleucine or valine' 0 C--O 1.243 0.75 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.62 -47.1 2.54 Favored Glycine 0 CA--C 1.497 -1.081 0 CA-C-N 114.517 -1.219 . . . . 0.0 112.561 174.101 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 45.2 m -139.24 151.83 68.24 Favored Pre-proline 0 C--N 1.273 -2.742 0 C-N-CA 123.794 0.838 . . . . 0.0 111.052 -174.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -90.78 80.85 0.46 Allowed 'Trans proline' 0 N--CA 1.446 -1.293 0 C-N-CA 122.712 2.275 . . . . 0.0 111.761 175.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -141.69 157.76 44.66 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -76.72 -20.72 56.23 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.717 0.77 . . . . 0.0 109.189 178.21 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -98.48 13.09 32.99 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.994 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -87.56 152.14 51.53 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -58.11 138.79 87.78 Favored 'Trans proline' 0 C--O 1.249 1.054 0 C-N-CA 122.641 2.227 . . . . 0.0 112.568 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 69.4 t -68.61 118.03 11.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -80.65 -19.52 68.12 Favored Glycine 0 C--N 1.292 -1.907 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 144.11 -177.11 22.98 Favored Glycine 0 N--CA 1.401 -3.67 0 N-CA-C 107.97 -2.052 . . . . 0.0 107.97 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -112.5 140.06 47.56 Favored 'General case' 0 C--N 1.263 -3.191 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.466 HD12 ' HD2' ' A' ' 53' ' ' PRO . 21.8 tp -85.25 126.11 68.19 Favored Pre-proline 0 C--N 1.281 -2.393 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.335 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.466 ' HD2' HD12 ' A' ' 52' ' ' LEU . 5.2 Cg_endo -62.46 154.07 66.76 Favored 'Trans proline' 0 N--CA 1.438 -1.756 0 C-N-CA 122.101 1.867 . . . . 0.0 112.511 178.189 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -71.66 135.37 46.86 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 175.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.68 12.96 79.19 Favored Glycine 0 C--N 1.312 -0.799 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.57 146.71 32.44 Favored 'General case' 0 CA--C 1.495 -1.152 0 CA-C-O 121.224 0.535 . . . . 0.0 110.773 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.9 m -108.77 110.62 22.06 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.896 -1.047 . . . . 0.0 109.001 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 27' ' ' THR . 16.8 mm -110.41 133.9 54.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 123.201 0.6 . . . . 0.0 110.841 -177.697 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.72 117.0 50.65 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 171.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.613 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.0 p90 -111.86 163.4 14.24 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.128 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.39 2.45 8.41 Favored 'General case' 0 C--N 1.309 -1.195 0 O-C-N 123.613 0.571 . . . . 0.0 111.309 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -157.22 152.81 26.63 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.545 -175.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.2 t -130.54 137.3 56.5 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.455 ' HG ' ' HE2' ' A' ' 83' ' ' TYR . 99.3 m -126.73 152.95 46.14 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.89 0.476 . . . . 0.0 110.998 178.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -123.34 110.35 25.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 173.223 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLN . . . . . 0.454 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.3 tp-100 -159.52 147.34 17.25 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.534 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.42 30.21 18.82 Favored 'General case' 0 C--O 1.246 0.916 0 C-N-CA 123.952 0.901 . . . . 0.0 110.209 178.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.58 11.01 64.66 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.051 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.8 m80 -120.48 154.0 35.86 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 122.186 -0.597 . . . . 0.0 110.152 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.523 HG13 ' HB2' ' A' ' 89' ' ' CYS . 18.0 mt -101.5 133.16 45.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 171.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 57.8 m95 -125.31 148.13 48.84 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -172.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.6 pt -106.99 136.89 40.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 171.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.96 123.67 7.4 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.496 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 33.5 p90 . . . . . 0 C--N 1.297 -1.701 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.41 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 23.0 tpt180 . . . . . 0 CA--C 1.494 -1.209 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.465 HG22 HG12 ' A' ' 39' ' ' ILE . 23.1 t -102.75 129.15 54.82 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.025 -176.078 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.513 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 64.5 m-85 -111.63 134.88 52.89 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.583 177.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -123.13 127.0 25.81 Favored Pre-proline 0 C--N 1.287 -2.117 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 178.179 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -72.95 128.7 13.43 Favored 'Trans proline' 0 N--CA 1.437 -1.808 0 N-CA-C 108.334 -1.449 . . . . 0.0 108.334 175.105 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -112.9 -9.35 12.14 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -176.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.4 ptm180 179.75 167.29 1.2 Allowed 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.2 p -90.45 171.19 9.61 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.043 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 46.1 t -153.62 127.81 9.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.575 0.703 . . . . 0.0 109.863 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB2' ' HB ' ' A' ' 97' ' ' ILE . 37.6 mt-30 -93.15 112.16 24.02 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.228 173.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.09 167.11 32.72 Favored Glycine 0 N--CA 1.422 -2.292 0 CA-C-N 115.081 -0.963 . . . . 0.0 113.17 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.417 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 17.3 m -97.73 156.19 36.33 Favored Pre-proline 0 C--N 1.289 -2.054 0 CA-C-N 114.749 -0.725 . . . . 0.0 109.144 176.1 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.509 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 19.3 Cg_endo -62.65 168.86 9.35 Favored 'Trans proline' 0 CA--C 1.559 1.759 0 C-N-CA 122.536 2.158 . . . . 0.0 111.672 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -68.34 -18.14 9.96 Favored 'Cis proline' 0 C--N 1.366 1.49 0 CA-C-N 119.715 0.934 . . . . 0.0 114.024 4.15 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -99.55 79.7 2.3 Favored 'General case' 0 CA--C 1.484 -1.585 0 CA-C-O 121.435 0.636 . . . . 0.0 110.086 175.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.634 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -99.59 146.26 26.64 Favored 'General case' 0 N--CA 1.421 -1.889 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 174.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB2' ' A' ' 90' ' ' GLN . 63.8 mt -122.02 88.51 47.97 Favored Pre-proline 0 C--N 1.29 -1.993 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.638 177.48 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 87' ' ' ARG . 29.1 Cg_endo -65.73 140.75 63.08 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.347 2.032 . . . . 0.0 112.095 177.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.32 -158.4 33.47 Favored Glycine 0 C--N 1.306 -1.088 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.3 p -66.73 132.68 32.02 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-N 116.996 0.398 . . . . 0.0 110.182 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.577 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.02 139.32 38.2 Favored 'General case' 0 CA--C 1.49 -1.335 0 CA-C-O 120.89 0.376 . . . . 0.0 110.28 178.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 33.6 m0 -92.58 15.29 14.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.016 -177.536 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.71 -177.46 46.54 Favored Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.975 178.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.7 t -92.7 153.7 3.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -127.0 103.15 7.31 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 176.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.522 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 84.9 mttt . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 177.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 170.106 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 0.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 0.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 0.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 0.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 0.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 0.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 0.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 0.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 0.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 0.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 0.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 0.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 0.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 0.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 0.0 109.389 175.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 0.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 0.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 0.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 0.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 0.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 0.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 0.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 0.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 0.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 0.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 . . . . . 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 . . . . . 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 0.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 0.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 0.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 0.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 0.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 0.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 0.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 0.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 0.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 0.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.223 -0.31 0 N-CA-C 109.006 -0.738 . . . . 1.0 109.006 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.3 m 65.42 77.54 0.28 Allowed Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 124.722 1.209 . . . . 2.0 112.998 179.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -110.75 -153.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 124.229 3.286 . . . . 3.0 108.683 170.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.06 120.66 27.69 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.344 -1.354 . . . . 4.0 107.344 172.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.3 m -70.57 -45.97 64.38 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 112.04 0.385 . . . . 5.0 112.04 -174.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -79.48 152.27 75.49 Favored Pre-proline 0 C--N 1.315 -0.917 0 CA-C-N 116.535 -0.302 . . . . 6.0 110.872 -178.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.3 106.47 0.84 Allowed 'Trans proline' 0 C--O 1.247 0.945 0 C-N-CA 122.142 1.895 . . . . 7.0 108.997 173.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.03 142.63 35.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 116.07 -0.514 . . . . 8.0 109.971 -173.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.314 5.1 p 59.16 -6.98 0.05 Allowed 'General case' 0 CA--C 1.56 1.341 0 N-CA-C 117.582 2.438 . . . . 9.0 117.582 175.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.27 -97.64 0.86 Allowed Glycine 0 C--O 1.25 1.123 0 CA-C-O 120.929 0.183 . . . . 10.0 113.236 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.8 m -63.54 -57.64 9.54 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 123.129 0.571 . . . . 11.0 109.926 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.412 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 88.9 m95 -83.38 146.52 28.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.6 -0.727 . . . . 12.0 109.207 -179.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.6 mtmm -146.37 153.59 40.67 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.948 -1.501 . . . . 13.0 106.948 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -104.51 137.48 42.3 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.005 -0.678 . . . . 14.0 110.699 -177.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.0 p30 -91.74 -177.48 4.77 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 116.16 -0.473 . . . . 15.0 111.044 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -56.77 -30.49 63.68 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.287 1.035 . . . . 16.0 113.373 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -82.6 -8.01 59.62 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.862 0.363 . . . . 17.0 111.425 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.24 18.45 59.1 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.734 -0.946 . . . . 18.0 110.734 -176.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m -95.84 131.95 41.62 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 19.0 108.555 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 20.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 21.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.412 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 22.0 107.943 170.106 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 23.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 24.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 25.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 26.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 27.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 28.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 29.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 30.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 31.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 32.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 33.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 34.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 35.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 36.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 37.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 38.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 39.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 40.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 41.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 42.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 43.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 44.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 45.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 46.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 47.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 48.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 49.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 50.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 51.0 109.389 175.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 52.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 53.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 54.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 55.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 56.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 57.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 58.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 59.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 60.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 61.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 62.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 63.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 64.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 65.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 66.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 67.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 68.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 69.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 70.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 71.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 72.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 73.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 -142.19 171.97 13.34 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 74.0 108.98 177.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -111.45 145.22 39.38 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.785 -0.366 . . . . 75.0 110.416 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -92.35 171.48 9.03 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.981 -1.118 . . . . 76.0 107.981 173.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -62.75 -20.58 65.09 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 123.331 0.652 . . . . 77.0 111.876 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.671 ' HB2' ' OD1' ' A' ' 80' ' ' ASN . 61.3 m-20 -91.23 1.99 56.69 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.888 -0.507 . . . . 78.0 110.099 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.13 8.65 68.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 119.996 -1.097 . . . . 79.0 112.094 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.671 ' OD1' ' HB2' ' A' ' 78' ' ' ASN . 6.9 m120 -71.91 139.19 48.65 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 109.462 -0.57 . . . . 80.0 109.462 -178.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 -86.41 97.56 10.52 Favored 'General case' 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 81.0 107.254 175.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 82.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 83.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 84.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 85.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 86.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 87.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 88.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 89.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 90.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 91.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 92.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 93.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 94.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 95.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 96.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 97.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 98.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 99.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 100.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 101.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 102.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 103.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 104.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 105.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 106.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 . . . . . 0 N--CA 1.452 -0.35 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.6 m -79.78 114.98 50.51 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.112 0.965 . . . . 0.0 108.924 177.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -69.05 -31.44 23.66 Favored 'Trans proline' 0 C--O 1.233 0.268 0 C-N-CA 122.647 2.231 . . . . 0.0 111.26 179.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -65.03 140.43 58.85 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.362 177.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p -67.87 114.79 6.74 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.858 177.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -67.53 140.8 94.98 Favored Pre-proline 0 C--O 1.244 0.802 0 C-N-CA 121.065 -0.254 . . . . 0.0 110.718 -179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -80.02 87.38 1.53 Allowed 'Trans proline' 0 N--CA 1.433 -2.076 0 C-N-CA 121.948 1.765 . . . . 0.0 110.797 179.038 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.1 p -79.04 -43.34 24.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.323 -178.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.9 p -126.85 109.11 11.63 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.14 -87.33 1.02 Allowed Glycine 0 CA--C 1.498 -1.012 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.2 m -65.15 -48.65 72.79 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.01 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -85.19 122.88 30.01 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.41 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 31.0 mtmm -125.75 144.48 50.61 Favored 'General case' 0 C--N 1.293 -1.851 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.549 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.449 ' HE2' ' HA2' ' A' ' 18' ' ' GLY . 51.7 tttm -95.21 132.53 40.08 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.212 0.53 . . . . 0.0 110.123 -175.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.433 HD21 ' HB ' ' A' ' 19' ' ' THR . 37.6 p30 -93.24 -177.33 4.42 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.936 -178.553 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -60.18 -25.71 65.77 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.531 0.732 . . . . 0.0 112.638 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -87.48 -6.47 58.37 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.485 0.659 . . . . 0.0 110.135 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.449 ' HA2' ' HE2' ' A' ' 14' ' ' LYS . . . 83.99 16.2 68.08 Favored Glycine 0 CA--C 1.498 -1.009 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.416 -178.403 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.433 ' HB ' HD21 ' A' ' 15' ' ' ASN . 62.6 m -92.21 138.8 31.23 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.413 ' CD1' ' HB ' ' A' ' 92' ' ' VAL . 79.1 m95 -93.93 134.41 36.34 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -137.68 162.65 33.28 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.564 0.54 . . . . 0.0 110.742 -177.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 61.2 pttt -155.04 145.25 15.84 Favored Pre-proline 0 C--N 1.298 -1.639 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 170.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -76.64 132.31 13.19 Favored 'Trans proline' 0 N--CA 1.445 -1.336 0 C-N-CA 122.161 1.908 . . . . 0.0 109.956 175.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.4 ' HB3' HG23 ' A' ' 63' ' ' VAL . 34.5 tt0 -151.77 123.85 8.14 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.438 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.401 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 17.8 t-20 -105.42 110.61 23.01 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.19 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.66 166.76 32.53 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.701 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 76.9 m -103.54 119.55 39.11 Favored 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.19 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.569 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 60.0 t80 -99.09 120.08 38.89 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.379 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.543 ' HB ' HG22 ' A' ' 104' ' ' VAL . 92.5 t -107.37 109.81 29.52 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 176.366 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.516 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 55.5 t30 -61.02 148.47 40.09 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 123.804 0.69 . . . . 0.0 110.443 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -85.68 -130.74 2.51 Favored Glycine 0 N--CA 1.432 -1.623 0 CA-C-O 121.321 0.401 . . . . 0.0 113.638 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -90.24 -7.68 52.88 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -172.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -120.37 141.02 31.14 Favored Pre-proline 0 C--N 1.307 -1.276 0 C-N-CA 120.347 -0.541 . . . . 0.0 111.156 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.73 150.85 68.91 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.069 1.846 . . . . 0.0 110.955 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.528 HG21 ' SG ' ' A' ' 84' ' ' CYS . 7.5 mm -116.24 141.34 34.31 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.186 -174.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.8 t -92.79 117.2 35.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 176.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.2 p -97.4 158.79 15.29 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 116.862 -0.153 . . . . 0.0 111.382 -174.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mmt180 -130.06 156.51 44.39 Favored 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 51.0 mt -115.96 137.64 49.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.55 -36.83 2.61 Favored Glycine 0 CA--C 1.493 -1.333 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.802 174.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.421 ' HB3' ' HD2' ' A' ' 43' ' ' PHE . 6.8 m -138.08 151.12 69.31 Favored Pre-proline 0 C--N 1.28 -2.425 0 CA-C-N 114.944 -0.628 . . . . 0.0 111.46 -171.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 19.6 Cg_endo -94.01 49.69 0.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.369 2.713 . . . . 0.0 111.328 177.175 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.421 ' HD2' ' HB3' ' A' ' 41' ' ' SER . 99.9 m-85 -121.3 153.04 38.22 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -77.27 -8.78 58.18 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.808 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -103.7 4.63 35.57 Favored 'General case' 0 C--O 1.245 0.842 0 CA-C-O 121.618 0.723 . . . . 0.0 110.647 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.5 158.73 70.96 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.78 140.32 93.27 Favored 'Trans proline' 0 C--O 1.247 0.93 0 C-N-CA 122.491 2.127 . . . . 0.0 111.834 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.488 HG12 ' H ' ' A' ' 50' ' ' GLY . 44.0 t -74.13 126.63 35.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.75 -14.27 65.54 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.488 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 129.9 -176.57 18.61 Favored Glycine 0 N--CA 1.414 -2.814 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -108.56 130.26 55.3 Favored 'General case' 0 C--N 1.273 -2.729 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.467 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -80.99 124.71 81.13 Favored Pre-proline 0 C--N 1.281 -2.402 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 9.4 Cg_endo -61.97 149.98 88.15 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.288 1.992 . . . . 0.0 112.59 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.516 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -68.7 117.82 10.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.572 177.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 30' ' ' ASN . . . 101.78 4.67 51.7 Favored Glycine 0 C--N 1.304 -1.204 0 C-N-CA 121.121 -0.562 . . . . 0.0 112.96 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB2' ' HG2' ' A' ' 53' ' ' PRO . . . -68.05 146.39 53.55 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.5 0.556 . . . . 0.0 112.5 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.409 HG22 HG22 ' A' ' 29' ' ' VAL . 7.6 p -101.57 105.42 16.37 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.778 0.831 . . . . 0.0 110.791 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 27' ' ' THR . 19.9 mm -107.74 134.79 48.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 123.339 0.656 . . . . 0.0 111.296 -178.082 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.78 116.17 48.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 170.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -111.05 162.15 15.17 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.053 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -129.28 6.0 5.3 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 123.791 0.682 . . . . 0.0 111.376 -177.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -158.74 154.89 27.02 Favored 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.4 HG23 ' HB3' ' A' ' 24' ' ' GLU . 8.8 t -133.51 133.75 57.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 172.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 54.5 m -126.25 154.26 43.61 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 123.419 0.688 . . . . 0.0 110.576 178.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 70' ' ' ILE . 66.0 mt -123.21 123.12 67.04 Favored 'Isoleucine or valine' 0 C--O 1.255 1.377 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.151 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 44.7 tp60 -171.9 152.72 3.06 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.76 26.42 15.6 Favored 'General case' 0 C--O 1.243 0.757 0 C-N-CA 123.682 0.793 . . . . 0.0 111.045 177.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.33 5.8 82.45 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.202 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -120.6 153.86 36.22 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 121.053 0.454 . . . . 0.0 111.34 -177.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 65' ' ' ILE . 24.0 mt -100.74 131.91 47.44 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 172.348 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.414 ' CZ3' ' HD3' ' A' ' 85' ' ' PRO . 55.3 m95 -123.62 140.47 52.96 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -172.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.3 pt -97.37 134.44 35.3 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 172.202 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.13 124.45 8.06 Favored Glycine 0 N--CA 1.425 -2.08 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.56 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.6 p90 -141.62 165.89 26.26 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 120.734 0.302 . . . . 0.0 110.625 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -105.7 122.97 47.15 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -74.9 175.96 7.58 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 70.3 t80 -56.35 -35.49 67.7 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.403 0.62 . . . . 0.0 110.444 178.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -77.81 0.31 24.3 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.557 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.39 -20.65 29.31 Favored Glycine 0 C--O 1.24 0.473 0 O-C-N 121.985 -0.447 . . . . 0.0 112.294 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -53.78 135.58 41.31 Favored 'General case' 0 C--O 1.247 0.942 0 C-N-CA 124.636 1.174 . . . . 0.0 111.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -76.9 107.73 9.44 Favored 'General case' 0 C--O 1.202 -1.412 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 26.6 t -104.91 132.91 50.51 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.948 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.05 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.4 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 61.1 m-85 -111.12 125.94 54.31 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.216 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.528 ' SG ' HG21 ' A' ' 35' ' ' ILE . 41.0 t -116.49 120.46 34.63 Favored Pre-proline 0 C--N 1.286 -2.159 0 CA-C-N 115.373 -0.831 . . . . 0.0 108.883 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.414 ' HD3' ' CZ3' ' A' ' 71' ' ' TRP . 37.9 Cg_endo -72.31 119.26 6.03 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 121.708 1.605 . . . . 0.0 109.134 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 29.0 m -105.85 -14.15 9.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.507 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.1 ptt180 -176.23 176.31 1.71 Allowed 'General case' 0 CA--C 1.503 -0.834 0 O-C-N 123.732 0.645 . . . . 0.0 109.581 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.6 p -95.6 167.15 11.48 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 123.357 0.411 . . . . 0.0 110.862 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.1 t -150.71 127.91 11.25 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 174.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -87.24 110.52 20.24 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.5 -155.45 32.36 Favored Glycine 0 N--CA 1.423 -2.219 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.735 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.413 ' HB ' ' CD1' ' A' ' 20' ' ' TRP . 8.3 m -134.39 155.52 79.7 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.493 ' HA ' ' N ' ' A' ' 95' ' ' ASN . 19.6 Cg_endo -63.19 167.68 12.21 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.198 1.932 . . . . 0.0 111.515 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.81 -4.76 5.97 Favored 'Cis proline' 0 C--N 1.352 0.752 0 N-CA-C 115.513 1.313 . . . . 0.0 115.513 4.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASN . . . . . 0.493 ' N ' ' HA ' ' A' ' 93' ' ' PRO . 39.1 m-80 -108.79 80.45 1.33 Allowed 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.482 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 5.1 pt20 -96.57 146.08 25.15 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.585 ' O ' ' HA ' ' A' ' 89' ' ' CYS . 83.7 mt -122.0 87.77 47.43 Favored Pre-proline 0 C--N 1.273 -2.734 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.7 128.52 11.0 Favored 'Trans proline' 0 N--CA 1.442 -1.534 0 C-N-CA 122.647 2.232 . . . . 0.0 112.987 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.53 -175.79 49.56 Favored Glycine 0 N--CA 1.433 -1.558 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.793 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.1 p -67.31 133.98 30.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 120.947 0.403 . . . . 0.0 110.009 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -67.13 143.18 56.78 Favored 'General case' 0 N--CA 1.434 -1.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.777 -179.773 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 39.4 m0 -92.48 17.41 10.06 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.907 176.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.85 -173.39 42.38 Favored Glycine 0 N--CA 1.427 -1.959 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.796 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.569 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.8 OUTLIER -96.6 156.49 3.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -177.605 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -129.02 102.97 6.74 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 175.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.495 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 65.4 mttm . . . . . 0 C--N 1.301 -1.524 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.384 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 120.364 0.126 . . . . 0.0 110.803 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.4 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 2.9 m -58.86 114.3 8.7 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.429 1.092 . . . . 0.0 112.092 -176.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 2' ' ' THR . 21.2 Cg_exo -65.9 141.26 64.14 Favored 'Trans proline' 0 C--O 1.25 1.077 0 C-N-CA 122.617 2.212 . . . . 0.0 111.19 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.98 84.41 7.46 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-O 121.005 0.431 . . . . 0.0 110.034 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.7 p -103.14 -17.43 15.38 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.714 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.403 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -83.69 136.08 42.5 Favored Pre-proline 0 C--N 1.323 -0.553 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.766 -179.821 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.421 ' HB3' ' O ' ' A' ' 10' ' ' GLY . 47.5 Cg_exo -59.25 123.29 13.1 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 123.081 2.521 . . . . 0.0 111.948 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -91.28 -64.67 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.0 p -114.48 35.77 4.07 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 122.137 0.97 . . . . 0.0 108.897 178.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 7' ' ' PRO . . . 104.01 -119.47 6.32 Favored Glycine 0 N--CA 1.424 -2.136 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.7 m -73.47 -25.57 60.53 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.7 0.762 . . . . 0.0 110.038 178.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 77.3 m95 -84.71 130.43 34.7 Favored 'General case' 0 N--CA 1.423 -1.783 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.115 -175.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 mtmm -129.63 151.97 49.65 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.488 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 26.4 ttpp -114.05 146.09 40.69 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 120.191 -0.604 . . . . 0.0 110.423 -176.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.2 p30 -98.33 -177.92 3.86 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.655 175.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -58.61 -23.46 58.9 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.637 1.175 . . . . 0.0 113.485 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -90.31 -6.07 55.53 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.024 0.44 . . . . 0.0 111.0 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.488 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 88.0 15.66 60.7 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.981 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.6 m -89.19 125.84 35.23 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.434 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 95.4 m95 -88.41 140.06 29.86 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 175.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 39.7 p90 -146.51 154.6 41.74 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 120.568 0.223 . . . . 0.0 110.954 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -144.83 145.69 28.73 Favored Pre-proline 0 C--N 1.305 -1.332 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -80.88 119.74 3.67 Favored 'Trans proline' 0 C--O 1.249 1.056 0 C-N-CA 122.64 2.227 . . . . 0.0 110.784 178.028 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -145.86 123.56 11.87 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -99.12 109.33 22.05 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.564 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.81 162.85 40.41 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.59 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.475 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.4 m -100.54 119.7 38.91 Favored 'General case' 0 N--CA 1.419 -2.024 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.059 177.239 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.534 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 67.2 t80 -98.97 113.98 26.41 Favored 'General case' 0 N--CA 1.416 -2.163 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 57' ' ' THR . 41.4 t -101.67 109.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 N-CA-C 106.001 -1.852 . . . . 0.0 106.001 176.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.49 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 53.6 t30 -61.56 149.43 39.1 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 123.567 0.542 . . . . 0.0 110.252 -177.484 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -88.71 -126.46 2.69 Favored Glycine 0 N--CA 1.423 -2.215 0 N-CA-C 114.259 0.464 . . . . 0.0 114.259 -174.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -89.92 -21.93 22.23 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -172.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -105.24 137.41 19.24 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.842 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.95 147.97 50.43 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.191 1.928 . . . . 0.0 109.319 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.417 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.6 mt -120.67 136.49 57.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.059 -174.359 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 69.8 t -79.16 116.82 23.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.484 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 72.2 p -91.49 157.12 17.22 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.686 -0.233 . . . . 0.0 110.617 -176.459 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -124.31 152.13 43.46 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 82' ' ' VAL . 21.0 mt -116.2 136.38 53.34 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -176.215 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.62 -45.83 3.5 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.868 174.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 40.8 m -138.17 144.33 42.87 Favored Pre-proline 0 C--N 1.274 -2.709 0 CA-C-N 113.972 -1.114 . . . . 0.0 110.324 -173.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -89.34 79.84 0.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.083 0 C-N-CA 122.411 2.074 . . . . 0.0 112.43 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -143.14 154.12 43.58 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 89.9 mt -76.6 -13.5 60.06 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.079 0.942 . . . . 0.0 108.773 174.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -91.24 -8.41 48.47 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.766 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -83.32 156.04 66.26 Favored Pre-proline 0 C--O 1.256 1.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.024 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.62 143.89 93.88 Favored 'Trans proline' 0 C--N 1.359 1.103 0 C-N-CA 123.145 2.563 . . . . 0.0 112.396 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.8 t -82.36 131.57 33.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.05 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.52 -27.9 28.61 Favored Glycine 0 C--N 1.3 -1.438 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 177.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 147.36 -176.33 26.27 Favored Glycine 0 N--CA 1.426 -2.012 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m-20 -103.24 117.5 34.67 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 173.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.411 HD12 ' HD2' ' A' ' 53' ' ' PRO . 20.4 tp -69.36 123.86 89.26 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.274 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.411 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.4 Cg_endo -55.94 141.21 86.31 Favored 'Trans proline' 0 N--CA 1.432 -2.105 0 C-N-CA 122.487 2.125 . . . . 0.0 113.266 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -67.26 116.58 8.2 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.167 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.73 0.11 42.48 Favored Glycine 0 C--N 1.304 -1.2 0 C-N-CA 120.728 -0.749 . . . . 0.0 113.1 -177.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -71.86 149.73 44.92 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.899 0.35 . . . . 0.0 111.554 -179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.428 HG22 HG22 ' A' ' 29' ' ' VAL . 20.9 p -104.79 108.83 20.52 Favored 'General case' 0 N--CA 1.439 -1.006 0 CA-C-O 121.55 0.691 . . . . 0.0 111.76 -178.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.5 mm -105.48 132.64 51.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 C-N-CA 123.841 0.857 . . . . 0.0 110.954 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.19 116.89 48.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.564 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 52.0 p90 -112.84 164.71 13.07 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.395 -0.522 . . . . 0.0 110.241 -177.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -123.52 -3.01 8.37 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.436 0.46 . . . . 0.0 111.666 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -154.92 154.43 32.62 Favored 'General case' 0 N--CA 1.434 -1.229 0 C-N-CA 119.445 -0.902 . . . . 0.0 109.85 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 21.6 t -127.04 135.58 63.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 175.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 61.6 m -125.35 157.03 37.76 Favored 'General case' 0 C--N 1.293 -1.853 0 O-C-N 123.199 0.312 . . . . 0.0 110.98 -178.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.426 HG12 HG12 ' A' ' 70' ' ' ILE . 73.0 mt -127.51 109.91 21.27 Favored 'Isoleucine or valine' 0 C--O 1.253 1.259 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 175.341 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -156.36 151.61 26.55 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.26 24.99 15.03 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 123.699 0.799 . . . . 0.0 110.361 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.56 13.27 68.11 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.398 -178.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -120.18 154.72 34.4 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 122.3 -0.53 . . . . 0.0 109.781 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.448 HG13 ' HB2' ' A' ' 89' ' ' CYS . 20.4 mt -101.29 133.89 43.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 174.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 53.9 m95 -126.02 150.82 47.82 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -172.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 29.0 pt -106.39 130.71 57.7 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.707 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 170.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -100.05 119.02 6.36 Favored Glycine 0 N--CA 1.417 -2.572 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 51.9 p90 -142.34 168.15 20.41 Favored 'General case' 0 N--CA 1.414 -2.257 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -104.41 127.67 52.13 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 174.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.483 ' HB2' HG21 ' A' ' 82' ' ' VAL . . . -78.54 172.06 14.22 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.708 -177.467 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.64 -21.6 66.76 Favored 'General case' 0 C--O 1.22 -0.495 0 CA-C-O 121.994 0.902 . . . . 0.0 108.754 175.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -79.08 -7.49 58.19 Favored 'General case' 0 CA--C 1.555 1.146 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.922 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.64 7.51 87.33 Favored Glycine 0 C--O 1.227 -0.327 0 O-C-N 121.537 -0.727 . . . . 0.0 113.338 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -99.05 157.61 16.23 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 122.348 -0.501 . . . . 0.0 111.826 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 25.2 tpt180 -79.43 114.34 18.28 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.484 ' CG1' ' HB ' ' A' ' 37' ' ' THR . 38.3 t -116.93 134.95 58.87 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.681 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.54 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.8 m-85 -117.4 123.2 45.85 Favored 'General case' 0 C--N 1.281 -2.408 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.2 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -112.39 126.01 29.11 Favored Pre-proline 0 C--N 1.279 -2.467 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 35' ' ' ILE . 36.8 Cg_endo -71.79 129.78 15.96 Favored 'Trans proline' 0 N--CA 1.439 -1.678 0 C-N-CA 121.374 1.382 . . . . 0.0 108.778 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.51 -13.11 11.48 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -174.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.456 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.6 ptm180 -178.31 167.0 1.91 Allowed 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 16.2 p -92.33 162.68 14.17 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.501 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.8 t -141.39 120.69 13.06 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.554 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 28.1 tt0 -83.63 111.32 19.01 Favored 'General case' 0 N--CA 1.424 -1.768 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 177.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.17 -166.13 51.24 Favored Glycine 0 N--CA 1.426 -1.994 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.455 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 13.9 m -121.22 160.49 45.28 Favored Pre-proline 0 C--N 1.297 -1.707 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 31.4 Cg_endo -65.67 167.41 17.33 Favored 'Trans proline' 0 CA--C 1.547 1.155 0 C-N-CA 121.987 1.792 . . . . 0.0 112.48 179.337 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.407 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.4 Cg_endo -65.37 -28.46 4.36 Favored 'Cis proline' 0 C--N 1.363 1.307 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.985 4.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -90.86 79.31 5.96 Favored 'General case' 0 CA--C 1.485 -1.549 0 CA-C-O 122.17 0.986 . . . . 0.0 110.169 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.501 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 4.2 pt20 -94.26 143.82 26.06 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 176.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.554 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.0 mt -122.15 92.46 48.88 Favored Pre-proline 0 C--N 1.27 -2.873 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 177.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.529 ' HA ' ' O ' ' A' ' 88' ' ' THR . 58.7 Cg_endo -79.66 135.69 11.72 Favored 'Trans proline' 0 N--CA 1.434 -2.029 0 C-N-CA 122.263 1.976 . . . . 0.0 112.226 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.71 -159.07 23.38 Favored Glycine 0 C--N 1.311 -0.816 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -63.83 139.19 21.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.456 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.75 135.1 36.42 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 42.3 m0 -83.77 9.41 11.94 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.786 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -174.02 -172.08 38.97 Favored Glycine 0 N--CA 1.428 -1.891 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 178.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.5 t -97.36 149.35 5.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 -178.113 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -122.2 108.67 13.56 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 175.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.475 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 82.3 mttt . . . . . 0 C--N 1.285 -2.229 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 121.192 0.52 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.5 m -95.73 130.35 31.97 Favored Pre-proline 0 N--CA 1.428 -1.572 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 177.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.22 34.94 0.3 Allowed 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.419 2.746 . . . . 0.0 112.874 178.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.7 158.58 43.94 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -178.447 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.3 p -72.97 159.95 32.87 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-O 121.109 0.48 . . . . 0.0 111.262 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 81.2 mtt180 -74.3 134.66 76.7 Favored Pre-proline 0 C--N 1.308 -1.212 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.799 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.54 112.88 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.616 2.21 . . . . 0.0 111.515 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.39 -41.32 86.14 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 175.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.648 ' HB ' ' O ' ' A' ' 12' ' ' TRP . 0.2 OUTLIER -146.03 108.26 4.41 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.156 -1.383 . . . . 0.0 110.625 179.519 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.69 -26.01 7.0 Favored Glycine 0 C--N 1.31 -0.876 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 p -73.38 -54.79 7.47 Favored 'General case' 0 N--CA 1.433 -1.277 0 C-N-CA 124.322 1.049 . . . . 0.0 110.077 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.648 ' O ' ' HB ' ' A' ' 9' ' ' THR . 72.7 m95 -103.87 143.5 32.75 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.023 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -125.65 140.23 52.89 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.418 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 25.9 ttpp -103.98 139.44 39.1 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 120.051 -0.66 . . . . 0.0 109.784 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.8 p30 -95.27 -177.8 4.23 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.105 176.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -63.18 -23.91 67.64 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -75.58 -17.52 60.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.533 0.682 . . . . 0.0 109.597 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.418 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 93.79 8.7 60.45 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -178.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.2 m -86.08 125.4 33.43 Favored 'General case' 0 N--CA 1.412 -2.327 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 89.6 m95 -86.38 125.37 33.61 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.135 -1.432 . . . . 0.0 107.135 175.106 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -134.64 151.57 51.14 Favored 'General case' 0 C--N 1.281 -2.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.562 -177.053 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -135.59 143.53 45.34 Favored Pre-proline 0 C--N 1.292 -1.926 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 173.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -76.8 113.03 3.56 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.216 1.944 . . . . 0.0 109.542 176.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -147.82 124.13 10.91 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.434 -178.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -100.06 106.59 18.35 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -178.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -147.11 160.4 42.46 Favored 'General case' 0 C--N 1.288 -2.067 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.616 -178.429 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.6 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 55.6 m -102.81 121.57 42.75 Favored 'General case' 0 C--N 1.288 -2.1 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.835 178.181 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.554 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.5 t80 -99.25 112.09 24.33 Favored 'General case' 0 C--N 1.284 -2.269 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.501 ' HB ' HG22 ' A' ' 104' ' ' VAL . 99.3 t -97.17 108.28 21.28 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -63.84 143.76 57.59 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 123.502 0.501 . . . . 0.0 110.069 -178.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -83.12 -128.05 1.27 Allowed Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 116.112 -0.494 . . . . 0.0 113.319 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -90.67 -14.61 31.93 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -172.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -108.26 136.86 19.8 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.947 -0.471 . . . . 0.0 111.575 -177.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -71.44 142.24 40.32 Favored 'Trans proline' 0 C--O 1.247 0.949 0 C-N-CA 121.974 1.783 . . . . 0.0 109.711 172.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.424 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.4 mt -117.26 133.24 64.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.085 -174.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -77.56 113.08 16.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.403 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 70.7 p -89.04 156.57 18.77 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.679 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -126.95 156.28 41.79 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -177.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.436 HG12 HG22 ' A' ' 82' ' ' VAL . 50.7 mt -122.09 135.83 60.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -177.181 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.54 -35.17 3.04 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.301 -0.863 . . . . 0.0 113.511 173.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 56.1 m -139.43 139.48 22.75 Favored Pre-proline 0 C--N 1.261 -3.253 0 C-N-CA 123.16 0.584 . . . . 0.0 111.343 -176.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 21.1 Cg_endo -87.13 55.06 2.99 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.714 2.276 . . . . 0.0 111.179 177.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -123.81 157.76 33.34 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.044 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.87 -14.03 59.93 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.551 0.691 . . . . 0.0 110.232 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -97.58 4.28 50.29 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.414 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.11 155.08 64.0 Favored Pre-proline 0 C--N 1.314 -0.935 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.64 136.75 77.61 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 122.991 2.46 . . . . 0.0 112.33 -178.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -78.27 124.48 36.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 115.355 -0.838 . . . . 0.0 109.701 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.36 -25.97 53.0 Favored Glycine 0 C--N 1.302 -1.331 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.56 -176.73 21.26 Favored Glycine 0 N--CA 1.421 -2.345 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -95.66 130.62 42.48 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.427 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.4 tp -77.01 126.31 85.69 Favored Pre-proline 0 C--N 1.285 -2.196 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 173.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HD2' HD12 ' A' ' 52' ' ' LEU . 6.2 Cg_endo -60.78 148.41 92.06 Favored 'Trans proline' 0 N--CA 1.44 -1.673 0 C-N-CA 121.913 1.742 . . . . 0.0 112.3 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.26 132.81 47.06 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 175.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 91.23 2.66 70.64 Favored Glycine 0 C--N 1.302 -1.333 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.069 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -75.24 144.67 42.46 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.37 0.605 . . . . 0.0 110.974 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.423 HG23 HG22 ' A' ' 29' ' ' VAL . 3.1 m -104.8 107.92 19.13 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.12 -176.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.4 mm -106.95 130.09 59.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 C-N-CA 123.38 0.672 . . . . 0.0 111.323 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.0 t -100.03 117.54 45.36 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 170.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 55.1 p90 -116.09 163.57 15.74 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.906 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -121.74 -0.59 9.61 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 123.409 0.443 . . . . 0.0 111.689 -178.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -153.27 148.54 26.93 Favored 'General case' 0 N--CA 1.433 -1.322 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.11 -176.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.4 t -120.98 133.48 67.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 105.681 -1.97 . . . . 0.0 105.681 173.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 3.9 m -125.66 150.1 47.9 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -175.186 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.41 HG12 HG12 ' A' ' 70' ' ' ILE . 64.3 mt -123.01 118.19 54.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 173.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -160.31 145.5 14.85 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -178.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.87 29.59 17.94 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 124.191 0.996 . . . . 0.0 110.759 177.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.06 10.47 73.4 Favored Glycine 0 CA--C 1.519 0.29 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.414 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -119.58 153.13 35.92 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 122.402 -0.469 . . . . 0.0 110.114 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' A' ' 87' ' ' ARG . 23.5 mt -103.37 133.94 45.88 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 174.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -127.73 153.61 46.32 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -171.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.49 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -109.96 130.25 63.47 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.774 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 171.54 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.47 122.52 7.55 Favored Glycine 0 N--CA 1.42 -2.424 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.536 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.2 p90 -142.38 149.56 39.54 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -86.98 122.74 31.25 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.073 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -67.89 175.58 2.99 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 123.656 0.597 . . . . 0.0 109.617 178.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -57.36 -34.51 68.89 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 123.122 0.569 . . . . 0.0 111.175 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -83.51 -10.05 58.57 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-O 121.482 0.658 . . . . 0.0 110.97 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.83 -9.81 55.43 Favored Glycine 0 C--N 1.312 -0.794 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.035 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -58.43 139.92 54.68 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.918 0.487 . . . . 0.0 110.875 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.7 tpt180 -82.74 99.04 9.41 Favored 'General case' 0 CA--C 1.492 -1.267 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.436 HG22 HG12 ' A' ' 39' ' ' ILE . 35.9 t -97.39 130.48 45.99 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.494 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.6 m-85 -112.4 125.17 53.92 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.309 178.04 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -114.14 125.06 29.83 Favored Pre-proline 0 C--N 1.278 -2.501 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 176.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.424 ' O ' HG21 ' A' ' 35' ' ' ILE . 42.8 Cg_endo -72.59 129.07 14.17 Favored 'Trans proline' 0 N--CA 1.439 -1.731 0 C-N-CA 121.271 1.314 . . . . 0.0 108.724 177.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.7 m -112.39 -15.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptt180 -177.48 173.12 1.73 Allowed 'General case' 0 CA--C 1.503 -0.853 0 C-N-CA 123.629 0.772 . . . . 0.0 109.457 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.6 p -99.93 168.3 9.96 Favored 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.598 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 45.1 t -147.55 123.86 10.91 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.108 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.568 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 44.0 tt0 -82.91 96.31 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.56 174.83 44.58 Favored Glycine 0 N--CA 1.429 -1.809 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.759 178.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.63 154.91 39.73 Favored Pre-proline 0 C--N 1.295 -1.797 0 C-N-CA 122.081 0.152 . . . . 0.0 111.011 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.431 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 38.4 Cg_endo -63.47 167.01 13.9 Favored 'Trans proline' 0 CA--C 1.556 1.617 0 C-N-CA 122.677 2.252 . . . . 0.0 112.8 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.431 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.1 Cg_endo -66.13 -24.58 6.17 Favored 'Cis proline' 0 C--N 1.372 1.794 0 C-N-CA 124.156 -1.185 . . . . 0.0 113.278 5.577 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -89.21 79.04 7.2 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 121.727 0.775 . . . . 0.0 109.26 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.598 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 12.8 pt20 -101.84 152.06 21.34 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.568 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 68.0 mt -130.28 88.02 49.03 Favored Pre-proline 0 C--N 1.284 -2.277 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -73.46 133.81 19.65 Favored 'Trans proline' 0 N--CA 1.443 -1.453 0 C-N-CA 122.433 2.089 . . . . 0.0 112.536 -178.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -85.42 -163.38 37.32 Favored Glycine 0 N--CA 1.441 -1.002 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.748 178.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -69.54 131.85 33.65 Favored 'Isoleucine or valine' 0 C--O 1.251 1.145 0 CA-C-O 120.88 0.371 . . . . 0.0 110.695 -178.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.482 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -71.6 140.55 49.82 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.445 177.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.4 m0 -90.2 10.86 22.95 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.799 179.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -167.54 -159.95 14.08 Favored Glycine 0 N--CA 1.43 -1.712 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.22 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.7 OUTLIER -113.03 154.64 14.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.045 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -123.76 103.61 8.48 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.6 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 87.5 mttt . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 173.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 . . . . . 0 C--O 1.234 0.264 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 78.1 m -103.26 121.37 48.97 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.58 93.5 0.37 Allowed 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.006 1.804 . . . . 0.0 110.474 175.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.8 9.69 17.68 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.469 0.652 . . . . 0.0 110.108 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.1 m -94.67 26.95 3.24 Favored 'General case' 0 CA--C 1.558 1.268 0 CA-C-O 122.3 1.048 . . . . 0.0 108.974 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 58.3 ttt180 -63.41 134.12 95.73 Favored Pre-proline 0 C--O 1.246 0.91 0 CA-C-N 114.253 -1.34 . . . . 0.0 111.966 -177.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.31 140.16 57.44 Favored 'Trans proline' 0 C--O 1.239 0.57 0 C-N-CA 123.182 2.588 . . . . 0.0 110.705 177.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.47 -33.5 7.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -175.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 36.2 p -96.83 -28.92 14.03 Favored 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.964 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.63 -68.78 0.53 Allowed Glycine 0 N--CA 1.43 -1.714 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.207 179.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.7 t -92.97 -20.23 20.81 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 120.635 0.255 . . . . 0.0 110.603 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -115.92 151.73 34.8 Favored 'General case' 0 C--O 1.254 1.317 0 CA-C-O 121.659 0.743 . . . . 0.0 111.68 -177.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -126.75 149.82 49.42 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -117.94 134.02 55.35 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.985 -0.686 . . . . 0.0 109.391 176.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.1 p30 -92.72 -175.37 3.92 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.86 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -64.04 -19.01 64.9 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -92.99 -3.24 54.79 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.947 0.403 . . . . 0.0 110.766 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.53 17.04 67.12 Favored Glycine 0 CA--C 1.507 -0.43 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 87.3 m -89.68 127.6 35.95 Favored 'General case' 0 N--CA 1.421 -1.91 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -84.91 135.9 33.86 Favored 'General case' 0 CA--C 1.485 -1.536 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 175.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -149.5 162.51 40.01 Favored 'General case' 0 C--N 1.281 -2.388 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -177.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -150.36 144.7 17.71 Favored Pre-proline 0 N--CA 1.422 -1.852 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.17 126.84 11.46 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.621 2.214 . . . . 0.0 109.73 176.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -152.76 123.7 7.45 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.7 108.88 20.85 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.21 164.77 38.35 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.642 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.542 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 65.1 m -105.72 120.85 42.74 Favored 'General case' 0 N--CA 1.416 -2.154 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.43 177.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.7 t80 -98.98 125.25 44.4 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.1 109.72 29.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.416 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 51.8 t30 -65.33 145.28 56.39 Favored 'General case' 0 C--N 1.308 -1.205 0 O-C-N 123.778 0.674 . . . . 0.0 110.699 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -84.54 -108.49 0.62 Allowed Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 114.863 0.705 . . . . 0.0 114.863 -174.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.26 -25.04 13.82 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 122.599 0.36 . . . . 0.0 111.717 -170.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -110.84 133.63 21.18 Favored Pre-proline 0 C--N 1.295 -1.769 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.802 -176.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.05 140.72 55.25 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.211 1.941 . . . . 0.0 110.568 175.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.85 136.25 52.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.746 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.402 HG22 ' ND2' ' A' ' 51' ' ' ASN . 52.6 t -77.36 121.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.8 p -94.19 157.84 15.87 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.034 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.44 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 27.0 mmt180 -130.72 155.01 47.35 Favored 'General case' 0 C--O 1.21 -0.985 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 -174.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.441 HG12 HG22 ' A' ' 82' ' ' VAL . 18.6 mt -112.46 138.95 39.67 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.45 -48.74 4.11 Favored Glycine 0 CA--C 1.502 -0.719 0 C-N-CA 124.921 1.248 . . . . 0.0 113.752 174.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 14.8 m -137.35 154.2 75.26 Favored Pre-proline 0 C--N 1.279 -2.499 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.991 -170.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -91.03 67.22 1.31 Allowed 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 123.006 2.47 . . . . 0.0 111.77 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -131.17 156.45 45.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.7 mt -76.46 -19.98 57.49 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.959 0.409 . . . . 0.0 111.024 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -100.39 18.16 19.68 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 121.556 0.694 . . . . 0.0 111.208 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -85.22 152.62 58.6 Favored Pre-proline 0 C--N 1.308 -1.239 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.4 143.24 94.61 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 50' ' ' GLY . 51.7 t -79.57 126.19 39.05 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.01 7.69 67.36 Favored Glycine 0 C--N 1.308 -0.976 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.637 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 122.28 170.51 13.71 Favored Glycine 0 N--CA 1.423 -2.21 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.402 ' ND2' HG22 ' A' ' 36' ' ' VAL . 2.3 m-20 -113.19 117.17 31.17 Favored 'General case' 0 C--N 1.28 -2.418 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.494 HD12 ' HD2' ' A' ' 53' ' ' PRO . 19.6 tp -68.78 125.7 92.08 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.212 -176.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.3 Cg_endo -63.14 156.8 52.99 Favored 'Trans proline' 0 N--CA 1.439 -1.735 0 C-N-CA 122.28 1.986 . . . . 0.0 112.768 178.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.416 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -76.99 128.19 34.06 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 176.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.76 21.36 50.95 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.828 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 146.1 24.43 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-O 120.706 0.289 . . . . 0.0 110.799 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.8 p -98.18 120.8 39.22 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.453 -179.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mm -118.69 134.91 60.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 123.894 0.877 . . . . 0.0 109.834 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.0 t -108.94 117.49 54.44 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 172.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.59 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 53.4 p90 -111.38 172.96 6.57 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 120.494 -0.483 . . . . 0.0 110.95 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -131.47 2.61 4.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.364 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -158.08 152.96 25.16 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.218 -175.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.4 t -126.37 134.63 65.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 172.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.406 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 76.1 m -127.64 155.63 43.61 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 122.509 0.323 . . . . 0.0 110.987 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 70' ' ' ILE . 60.4 mt -124.86 114.41 40.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 175.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -164.59 150.77 10.6 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.2 29.69 17.5 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 123.781 0.832 . . . . 0.0 110.021 178.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.04 8.76 65.31 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.125 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -120.67 157.34 29.8 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 122.346 -0.502 . . . . 0.0 110.795 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 65' ' ' ILE . 20.1 mt -104.96 133.45 49.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 173.226 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -127.13 154.17 45.09 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -170.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 32.5 pt -109.24 136.04 46.34 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 171.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -108.15 130.38 10.06 Favored Glycine 0 N--CA 1.42 -2.425 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.59 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 39.0 p90 -146.85 172.31 13.86 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -107.92 142.94 37.25 Favored 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.323 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -81.58 178.22 8.47 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 175.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -61.99 -28.12 69.34 Favored 'General case' 0 C--N 1.313 -1.004 0 C-N-CA 122.459 0.304 . . . . 0.0 110.802 179.231 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -70.74 -19.35 62.74 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 121.469 0.652 . . . . 0.0 110.884 174.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.9 0.96 68.06 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 -173.197 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 -70.13 154.04 42.41 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.417 ' HD2' ' HA ' ' A' ' 81' ' ' ARG . 18.1 tpt180 -83.67 128.23 34.37 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.441 HG22 HG12 ' A' ' 39' ' ' ILE . 46.6 t -126.16 135.47 63.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.277 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.7 m-85 -118.06 151.94 36.54 Favored 'General case' 0 C--N 1.281 -2.38 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.273 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 45.2 t -141.9 128.73 11.29 Favored Pre-proline 0 C--N 1.275 -2.647 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -74.12 134.94 20.14 Favored 'Trans proline' 0 N--CA 1.436 -1.858 0 C-N-CA 121.483 1.455 . . . . 0.0 109.395 177.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.8 m -116.52 -13.12 11.25 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.523 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.6 ptm180 -176.34 168.94 2.76 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.9 p -97.07 165.43 12.07 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 53.2 t -145.53 121.45 10.65 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 177.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.607 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 0.5 OUTLIER -86.56 115.18 23.88 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.898 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 -167.49 45.88 Favored Glycine 0 N--CA 1.428 -1.897 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.212 -179.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 8.3 m -132.07 155.27 81.54 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 123.869 0.868 . . . . 0.0 108.838 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.463 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 19.3 Cg_endo -59.51 163.04 13.55 Favored 'Trans proline' 0 CA--C 1.555 1.562 0 C-N-CA 122.232 1.955 . . . . 0.0 113.2 -178.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.463 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 55.3 Cg_endo -68.38 -26.32 6.77 Favored 'Cis proline' 0 C--N 1.364 1.346 0 C-N-CA 123.822 -1.324 . . . . 0.0 112.824 7.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -91.93 78.75 5.32 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.862 0.839 . . . . 0.0 109.288 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.435 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.7 pt20 -95.25 147.17 23.76 Favored 'General case' 0 N--CA 1.426 -1.634 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 175.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.607 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 85.7 mt -123.37 87.99 51.61 Favored Pre-proline 0 C--N 1.265 -3.076 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -78.6 132.43 10.99 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.285 1.99 . . . . 0.0 112.71 -177.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -83.32 -171.5 47.61 Favored Glycine 0 N--CA 1.437 -1.251 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.31 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.3 p -64.21 136.67 26.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-O 120.751 0.31 . . . . 0.0 110.417 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.523 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -73.46 145.09 45.97 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.069 0.461 . . . . 0.0 110.602 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.6 m0 -94.27 11.31 30.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.538 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.03 -174.32 40.05 Favored Glycine 0 N--CA 1.419 -2.489 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.94 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 2.9 t -96.63 151.11 4.16 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -177.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -122.53 102.98 8.4 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 176.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.542 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 57.7 mttm . . . . . 0 C--N 1.298 -1.643 0 CA-C-O 118.276 -0.869 . . . . 0.0 108.682 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 . . . . . 0 N--CA 1.469 0.483 0 N-CA-C 110.77 -0.085 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.3 m -75.46 113.63 28.0 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.06 129.68 10.71 Favored 'Trans proline' 0 N--CA 1.448 -1.164 0 C-N-CA 122.122 1.881 . . . . 0.0 112.001 -177.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.96 45.78 1.3 Allowed 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.809 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -68.75 101.75 1.39 Allowed 'General case' 0 N--CA 1.425 -1.703 0 CA-C-O 121.93 0.871 . . . . 0.0 111.306 -178.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 46.8 mtm-85 -95.14 156.02 38.28 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.561 -176.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -68.51 102.6 0.86 Allowed 'Trans proline' 0 N--CA 1.452 -0.94 0 C-N-CA 122.327 2.018 . . . . 0.0 110.962 176.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 48.7 t -100.07 138.11 25.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.272 6.4 p 57.34 -82.66 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.583 1.553 . . . . 0.0 114.77 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.16 -57.36 0.48 Allowed Glycine 0 CA--C 1.493 -1.293 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.728 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.2 p -74.22 -65.41 0.85 Allowed 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 176.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.431 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 85.5 m95 -79.4 143.13 35.35 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-N 114.748 -1.115 . . . . 0.0 108.682 175.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -133.94 153.63 51.63 Favored 'General case' 0 C--N 1.283 -2.302 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 174.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.437 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 27.1 ttpp -102.82 135.08 45.15 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.065 -179.076 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.3 p30 -95.26 -178.89 4.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.577 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -62.34 -16.04 51.94 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 124.119 0.967 . . . . 0.0 113.505 -177.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -87.54 -2.04 58.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.437 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 70.38 29.94 69.64 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 -174.08 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.497 HG23 ' HB2' ' A' ' 66' ' ' GLN . 86.9 m -105.26 134.89 47.62 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 74.4 m95 -90.86 134.38 34.5 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -138.85 153.51 48.33 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.431 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 59.6 pttt -137.29 145.38 49.52 Favored Pre-proline 0 C--N 1.291 -1.973 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 173.497 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -75.56 124.75 8.49 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.342 2.028 . . . . 0.0 109.122 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.86 123.05 4.44 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -103.73 108.52 19.85 Favored 'General case' 0 C--N 1.29 -1.983 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.78 165.99 29.78 Favored 'General case' 0 C--N 1.284 -2.252 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.952 -178.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.535 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 82.7 m -102.5 118.69 37.4 Favored 'General case' 0 N--CA 1.41 -2.433 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.845 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.523 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -99.03 111.92 24.19 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.62 110.09 25.33 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.458 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 50.1 t30 -63.03 145.71 54.82 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.637 0.586 . . . . 0.0 110.705 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.78 -118.75 0.4 Allowed Glycine 0 N--CA 1.426 -1.984 0 CA-C-N 115.889 -0.596 . . . . 0.0 114.016 -176.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -100.44 -11.38 20.24 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 112.748 0.648 . . . . 0.0 112.748 -170.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -121.96 137.44 27.35 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.435 -174.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -67.92 142.58 57.53 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 121.98 1.787 . . . . 0.0 110.364 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mt -116.22 141.83 32.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 C-N-CA 120.287 -0.565 . . . . 0.0 110.66 -174.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.9 t -84.92 117.55 30.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.431 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 82.4 p -93.77 153.8 18.11 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.513 -0.312 . . . . 0.0 111.083 -176.079 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.479 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 35.5 mmt180 -121.74 160.88 23.63 Favored 'General case' 0 C--O 1.208 -1.1 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -177.599 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 56.2 mt -126.21 135.99 62.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.415 0.626 . . . . 0.0 112.566 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.52 -48.09 3.08 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.414 173.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 25.3 m -138.15 146.15 50.6 Favored Pre-proline 0 C--N 1.271 -2.833 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.793 -174.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -87.17 81.12 1.34 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.363 2.042 . . . . 0.0 112.235 177.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -144.46 157.26 44.33 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 86.0 mt -76.29 -16.9 59.68 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.995 0.902 . . . . 0.0 108.661 175.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -91.15 3.14 55.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 114.249 -1.341 . . . . 0.0 110.695 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.45 50.42 Favored Pre-proline 0 C--O 1.256 1.437 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.835 -176.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -57.51 147.07 80.71 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 123.167 2.578 . . . . 0.0 111.616 176.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.593 HG12 ' H ' ' A' ' 50' ' ' GLY . 32.8 t -90.42 135.71 25.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.8 -175.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.15 -14.56 54.17 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 177.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.593 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 127.91 -176.77 17.92 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -103.9 128.89 51.38 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.959 0.88 . . . . 0.0 109.802 176.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.42 HD12 ' HD2' ' A' ' 53' ' ' PRO . 16.4 tp -77.16 127.79 82.5 Favored Pre-proline 0 C--N 1.294 -1.831 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 175.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' HD12 ' A' ' 52' ' ' LEU . 10.0 Cg_endo -63.81 154.47 69.42 Favored 'Trans proline' 0 N--CA 1.443 -1.487 0 C-N-CA 122.03 1.82 . . . . 0.0 112.452 178.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.458 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -73.06 136.85 45.03 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.534 -0.914 . . . . 0.0 108.534 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.41 5.04 85.43 Favored Glycine 0 C--N 1.312 -0.785 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.314 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.27 145.7 37.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 117.029 0.415 . . . . 0.0 111.649 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.6 p -100.75 107.03 18.52 Favored 'General case' 0 N--CA 1.438 -1.028 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.366 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.98 141.56 18.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.6 p -116.11 116.43 52.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 171.211 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.6 p90 -111.03 167.22 10.42 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.846 -176.369 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -124.56 -3.95 7.78 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.57 -179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -153.37 154.13 33.9 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.592 -175.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.2 t -128.53 135.83 61.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.432 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 74.0 m -126.77 156.27 41.48 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.458 0.303 . . . . 0.0 110.766 179.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.46 HG12 HG12 ' A' ' 70' ' ' ILE . 66.4 mt -124.88 117.74 51.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 176.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.497 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.8 tp-100 -164.73 149.81 9.73 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.41 28.35 16.8 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.089 0.956 . . . . 0.0 110.376 178.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.25 8.04 69.16 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.537 -178.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -119.76 155.22 32.93 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 122.093 -0.651 . . . . 0.0 110.486 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.48 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 16.9 mt -104.21 134.27 45.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 174.403 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -125.78 148.72 49.02 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -171.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -106.71 137.28 38.15 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 172.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.72 125.98 8.15 Favored Glycine 0 N--CA 1.419 -2.456 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.629 -178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.511 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.1 p90 -147.76 174.17 12.08 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' A' ' 80' ' ' ASN . 16.3 m120 -120.36 134.44 55.27 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -82.24 178.59 8.18 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -53.3 -42.7 66.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -177.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -72.64 -7.67 51.47 Favored 'General case' 0 CA--C 1.551 1.012 0 CA-C-O 121.544 0.688 . . . . 0.0 110.916 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 95.91 5.25 59.85 Favored Glycine 0 CA--C 1.498 -1.017 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -178.387 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 75' ' ' ASN . 74.3 m-20 -59.0 127.83 34.17 Favored 'General case' 0 CA--C 1.498 -1.02 0 C-N-CA 123.519 0.728 . . . . 0.0 109.558 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.458 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 26.0 tpt180 -79.44 93.85 5.45 Favored 'General case' 0 C--O 1.207 -1.182 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.059 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 27.1 t -93.45 128.36 44.92 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.835 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.324 -173.298 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.516 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 58.2 m-85 -113.48 120.27 40.43 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.853 177.364 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.9 t -110.33 127.1 27.59 Favored Pre-proline 0 C--N 1.28 -2.428 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.45 131.54 17.72 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 121.454 1.436 . . . . 0.0 108.711 176.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.12 -12.58 11.35 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.573 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.6 ptm180 -178.78 174.21 1.17 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 7.0 p -98.49 167.77 10.61 Favored 'General case' 0 C--N 1.288 -2.066 0 C-N-CA 122.631 0.372 . . . . 0.0 110.414 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.2 t -149.96 118.73 6.6 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.154 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.546 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 16.1 tt0 -81.31 90.38 6.13 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 96.94 -174.56 30.31 Favored Glycine 0 N--CA 1.433 -1.515 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.134 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 25.7 m -111.81 158.76 35.73 Favored Pre-proline 0 C--N 1.302 -1.49 0 C-N-CA 122.184 0.194 . . . . 0.0 110.917 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 14.1 Cg_endo -63.4 171.5 6.57 Favored 'Trans proline' 0 CA--C 1.555 1.54 0 C-N-CA 122.728 2.286 . . . . 0.0 112.516 177.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.13 -25.01 5.99 Favored 'Cis proline' 0 C--N 1.371 1.751 0 CA-C-N 119.674 0.919 . . . . 0.0 113.4 3.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -91.99 79.34 5.23 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 122.278 1.037 . . . . 0.0 110.013 177.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.453 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 9.0 pt20 -96.17 151.29 19.62 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.205 -1.361 . . . . 0.0 107.488 177.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.546 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.1 mt -129.59 86.93 54.32 Favored Pre-proline 0 C--N 1.282 -2.349 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 88' ' ' THR . 20.3 Cg_endo -75.21 128.21 11.15 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 122.286 1.991 . . . . 0.0 112.195 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.17 -161.73 29.44 Favored Glycine 0 C--N 1.315 -0.62 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.93 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.1 p -63.81 135.16 28.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 117.099 0.449 . . . . 0.0 110.872 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.573 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -81.63 147.91 29.32 Favored 'General case' 0 N--CA 1.436 -1.152 0 CA-C-O 121.294 0.569 . . . . 0.0 111.071 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.3 m0 -96.2 13.46 27.33 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.846 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -178.89 -164.47 31.71 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -105.76 153.52 7.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.4 104.55 8.23 Favored 'General case' 0 N--CA 1.419 -2.02 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.535 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 85.4 mttt . . . . . 0 C--N 1.289 -2.059 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 176.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.242 0.677 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.2 m -94.26 119.29 66.75 Favored Pre-proline 0 N--CA 1.424 -1.764 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 177.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.33 99.26 1.0 Allowed 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.286 1.99 . . . . 0.0 114.152 -174.018 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.04 -54.43 6.02 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 85.9 m -86.89 111.94 21.28 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -163.64 141.55 5.94 Favored Pre-proline 0 C--N 1.311 -1.105 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 -177.076 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.78 91.52 1.08 Allowed 'Trans proline' 0 N--CA 1.445 -1.329 0 C-N-CA 122.038 1.825 . . . . 0.0 109.296 174.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -125.36 142.28 42.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.606 -176.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.7 t -102.31 134.57 45.38 Favored 'General case' 0 N--CA 1.418 -2.047 0 CA-C-O 121.193 0.521 . . . . 0.0 110.278 -178.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.49 179.95 23.75 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -178.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.3 m -91.59 -4.78 54.93 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.615 0.721 . . . . 0.0 110.699 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 58.2 m95 -94.82 158.46 15.49 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.182 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -125.11 138.36 54.17 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.557 ' HE2' ' HA2' ' A' ' 18' ' ' GLY . 45.2 tttm -101.87 134.51 44.95 Favored 'General case' 0 C--N 1.286 -2.181 0 CA-C-O 120.834 0.349 . . . . 0.0 110.146 -178.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.417 ' ND2' ' HB ' ' A' ' 19' ' ' THR . 36.0 p30 -94.69 -177.79 4.32 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.861 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -65.92 -16.68 64.08 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.857 0.863 . . . . 0.0 113.121 -177.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -92.42 -7.86 46.4 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.229 0.538 . . . . 0.0 110.02 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.557 ' HA2' ' HE2' ' A' ' 14' ' ' LYS . . . 83.97 22.49 55.06 Favored Glycine 0 N--CA 1.439 -1.121 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.523 -178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.417 ' HB ' ' ND2' ' A' ' 15' ' ' ASN . 90.5 m -95.3 127.41 41.32 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.205 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 73.7 m95 -86.7 123.96 32.43 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 47.6 p90 -129.0 164.22 23.68 Favored 'General case' 0 C--N 1.282 -2.359 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -177.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -152.8 142.06 14.54 Favored Pre-proline 0 C--N 1.287 -2.137 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -78.49 113.21 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 C-N-CA 122.407 2.071 . . . . 0.0 109.844 175.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -135.44 124.79 24.75 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -176.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -100.87 107.14 18.58 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -177.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.624 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -154.6 168.83 25.44 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.547 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 52.5 m -106.19 121.32 43.94 Favored 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.848 177.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.591 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 72.5 t80 -99.18 113.23 25.38 Favored 'General case' 0 N--CA 1.406 -2.642 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.3 t -100.81 116.22 43.89 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.526 0 N-CA-C 105.599 -2.001 . . . . 0.0 105.599 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -68.14 149.44 49.59 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.6 -0.44 . . . . 0.0 110.485 -177.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.28 -144.94 3.74 Favored Glycine 0 N--CA 1.433 -1.548 0 CA-C-N 116.368 -0.378 . . . . 0.0 113.174 -176.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.36 -6.06 59.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.25 0.548 . . . . 0.0 111.388 -175.392 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.4 pt20 -117.23 137.55 24.09 Favored Pre-proline 0 C--O 1.207 -1.142 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.233 -178.141 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.78 155.14 63.12 Favored 'Trans proline' 0 C--O 1.255 1.364 0 C-N-CA 122.611 2.207 . . . . 0.0 110.552 175.334 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.453 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.9 mt -126.48 134.94 65.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.646 -177.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 53.7 t -76.25 121.38 28.18 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 77.0 p -97.57 156.7 16.39 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 122.322 -0.236 . . . . 0.0 111.428 -175.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.0 mmt180 -124.0 155.12 38.81 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -178.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 82' ' ' VAL . 24.9 mt -116.55 137.83 49.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -175.264 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.56 -45.15 3.33 Favored Glycine 0 CA--C 1.502 -0.773 0 CA-C-N 114.726 -1.124 . . . . 0.0 113.299 175.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 16.1 p -138.39 155.48 73.89 Favored Pre-proline 0 C--N 1.275 -2.647 0 CA-C-N 114.483 -0.858 . . . . 0.0 111.233 -171.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 30.5 Cg_endo -95.37 58.55 0.2 Allowed 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.483 2.789 . . . . 0.0 112.043 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -121.23 155.8 33.82 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.3 mt -76.65 -23.63 53.29 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.481 0.657 . . . . 0.0 109.419 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -82.22 -13.77 56.57 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.237 177.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.53 152.68 96.01 Favored Pre-proline 0 C--O 1.249 1.072 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.365 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.3 136.72 74.09 Favored 'Trans proline' 0 C--O 1.241 0.655 0 C-N-CA 122.867 2.378 . . . . 0.0 112.728 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.01 132.84 32.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.59 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.11 -18.39 43.32 Favored Glycine 0 C--O 1.241 0.539 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 135.42 -177.31 19.5 Favored Glycine 0 N--CA 1.428 -1.871 0 N-CA-C 109.219 -1.553 . . . . 0.0 109.219 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 -97.35 131.97 43.52 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 118.043 0.922 . . . . 0.0 109.744 175.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.465 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.7 tp -78.2 126.82 82.86 Favored Pre-proline 0 C--N 1.291 -1.964 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 173.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.465 ' HD2' HD12 ' A' ' 52' ' ' LEU . 4.0 Cg_endo -62.48 151.56 82.36 Favored 'Trans proline' 0 N--CA 1.437 -1.805 0 C-N-CA 122.086 1.857 . . . . 0.0 112.507 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -68.52 137.42 54.36 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 175.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.31 22.43 77.58 Favored Glycine 0 N--CA 1.438 -1.181 0 C-N-CA 121.002 -0.618 . . . . 0.0 113.534 -178.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -89.33 152.05 21.75 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 117.8 0.8 . . . . 0.0 110.081 177.328 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.13 119.44 38.81 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-O 121.163 0.506 . . . . 0.0 109.987 -177.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.413 HG21 HD12 ' A' ' 72' ' ' ILE . 21.4 mm -117.09 130.02 72.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.77 179.069 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.7 p -101.63 116.8 45.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 169.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.624 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 53.7 p90 -112.73 160.62 17.76 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.869 -178.288 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -123.32 1.16 9.03 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 123.609 0.568 . . . . 0.0 110.75 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -155.24 152.25 29.07 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.044 -173.202 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 10.8 t -131.4 133.32 62.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 56.7 m -124.56 148.5 47.77 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 123.014 0.526 . . . . 0.0 110.747 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 70' ' ' ILE . 59.4 mt -117.95 116.6 52.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.415 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.7 tp-100 -163.19 147.4 11.03 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 123.572 0.545 . . . . 0.0 109.585 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 60.23 30.99 20.33 Favored 'General case' 0 C--O 1.242 0.71 0 C-N-CA 124.052 0.941 . . . . 0.0 111.446 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 6.62 81.24 Favored Glycine 0 CA--C 1.508 -0.351 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.682 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -120.2 154.2 35.17 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 122.608 -0.348 . . . . 0.0 110.338 -178.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 65' ' ' ILE . 19.5 mt -105.81 133.82 49.09 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 172.116 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -125.69 149.96 48.06 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.07 0.548 . . . . 0.0 109.753 -171.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 28.7 pt -106.47 137.01 39.01 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 171.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.08 121.33 6.98 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -141.72 173.97 11.01 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -107.68 141.47 39.15 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -84.29 166.69 17.26 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 79.3 t80 -62.56 -18.24 61.65 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.85 0.833 . . . . 0.0 109.924 175.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -77.4 -6.15 52.34 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.754 177.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 83.77 7.89 85.22 Favored Glycine 0 C--N 1.34 0.765 0 C-N-CA 121.066 -0.588 . . . . 0.0 111.979 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -101.23 160.66 14.22 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 122.691 -0.299 . . . . 0.0 110.403 -174.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 -83.73 126.76 33.23 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.407 HG22 HG12 ' A' ' 39' ' ' ILE . 45.2 t -123.56 135.88 61.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.323 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.499 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.1 m-85 -115.65 123.5 48.53 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.627 -1.17 . . . . 0.0 109.942 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.2 t -111.31 125.85 29.74 Favored Pre-proline 0 C--N 1.281 -2.375 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 177.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.453 ' O ' HG21 ' A' ' 35' ' ' ILE . 33.7 Cg_endo -71.88 129.9 16.03 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 121.54 1.493 . . . . 0.0 108.638 176.195 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.45 -10.39 12.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.47 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 6.5 ptm180 178.81 173.54 0.72 Allowed 'General case' 0 C--O 1.246 0.899 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.2 p -98.96 167.37 10.78 Favored 'General case' 0 C--N 1.289 -2.033 0 C-N-CA 122.238 0.215 . . . . 0.0 110.737 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.476 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 48.6 t -145.2 128.03 16.35 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 177.046 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 60.8 tt0 -90.1 96.31 10.61 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 97.64 -157.94 20.84 Favored Glycine 0 N--CA 1.418 -2.505 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.688 177.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.3 m -130.26 150.86 77.31 Favored Pre-proline 0 C--N 1.297 -1.712 0 C-N-CA 123.353 0.661 . . . . 0.0 109.619 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.443 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 42.2 Cg_endo -66.57 165.63 24.62 Favored 'Trans proline' 0 CA--C 1.555 1.534 0 C-N-CA 122.363 2.042 . . . . 0.0 111.175 -178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.42 -5.89 20.15 Favored 'Cis proline' 0 C--N 1.356 0.973 0 C-N-CA 124.301 -1.125 . . . . 0.0 113.329 4.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -101.43 77.48 1.78 Allowed 'General case' 0 N--CA 1.427 -1.597 0 C-N-CA 118.315 -1.354 . . . . 0.0 108.355 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.476 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.5 pm0 -103.08 153.03 20.7 Favored 'General case' 0 N--CA 1.427 -1.584 0 CA-C-N 114.756 -1.111 . . . . 0.0 108.034 178.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 58.1 mt -131.27 87.56 47.17 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 88' ' ' THR . 67.7 Cg_endo -73.53 135.6 22.32 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.544 2.163 . . . . 0.0 112.841 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.45 -170.85 44.52 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.4 p -69.01 138.26 22.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 116.994 0.397 . . . . 0.0 110.25 -178.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -72.01 141.36 49.34 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.163 -178.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 43.6 m0 -87.54 2.49 50.61 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.329 -179.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -159.39 -160.03 10.15 Favored Glycine 0 N--CA 1.43 -1.748 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 178.373 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -115.15 149.37 17.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -117.56 106.73 13.44 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 175.411 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 63.4 mttm . . . . . 0 C--N 1.288 -2.092 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 176.27 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.511 -0.528 0 N-CA-C 110.827 -0.064 . . . . 0.0 110.827 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 44.8 m 64.73 97.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.756 0 C-N-CA 123.716 0.806 . . . . 0.0 109.669 -173.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -65.08 91.5 0.2 Allowed 'Trans proline' 0 N--CA 1.458 -0.61 0 C-N-CA 122.407 2.071 . . . . 0.0 112.8 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.15 -31.26 30.6 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 p -78.62 81.39 4.94 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.456 174.222 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 63.5 mtp180 -79.0 137.92 57.12 Favored Pre-proline 0 N--CA 1.429 -1.494 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.745 -175.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_exo -46.51 112.9 0.53 Allowed 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 123.937 3.091 . . . . 0.0 113.102 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.94 153.57 10.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.59 ' OG1' ' HD3' ' A' ' 94' ' ' PRO . 26.4 m -80.07 116.36 20.15 Favored 'General case' 0 C--N 1.286 -2.155 0 C-N-CA 122.66 0.384 . . . . 0.0 110.833 -178.005 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -118.43 -9.8 9.15 Favored Glycine 0 N--CA 1.443 -0.85 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.369 177.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.0 p -63.13 -42.06 99.42 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 175.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 61.4 m95 -110.02 139.74 44.81 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 104.371 -2.455 . . . . 0.0 104.371 168.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 37.1 mtmm -117.01 135.74 53.47 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.863 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.472 ' HD3' ' NE1' ' A' ' 20' ' ' TRP . 38.8 ttpt -96.4 134.4 39.6 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 120.851 0.358 . . . . 0.0 110.302 -178.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -98.02 -173.86 2.71 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.471 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -63.16 -17.54 62.49 Favored 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 123.301 0.64 . . . . 0.0 112.334 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 -85.93 -10.31 55.44 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.37 0.605 . . . . 0.0 109.461 -176.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.97 18.9 68.64 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -177.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 64' ' ' CYS . 84.5 m -98.33 130.3 45.0 Favored 'General case' 0 N--CA 1.403 -2.783 0 CA-C-N 114.201 -1.0 . . . . 0.0 108.707 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.494 ' CZ3' ' HB ' ' A' ' 9' ' ' THR . 86.0 m95 -88.97 127.05 35.65 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -133.82 158.85 42.34 Favored 'General case' 0 C--N 1.292 -1.91 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.382 -178.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -149.03 150.71 32.89 Favored Pre-proline 0 N--CA 1.426 -1.672 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 170.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.37 131.79 18.22 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 121.742 1.628 . . . . 0.0 110.064 176.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.41 ' HB3' HG23 ' A' ' 63' ' ' VAL . 8.0 tp10 -151.81 123.62 8.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -108.72 106.18 16.09 Favored 'General case' 0 C--N 1.292 -1.903 0 C-N-CA 118.776 -1.17 . . . . 0.0 108.563 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -150.1 167.74 25.93 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.8 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.472 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.1 m -111.06 122.58 48.25 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-O 121.534 0.683 . . . . 0.0 111.134 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.51 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 55.2 t80 -98.62 122.4 41.78 Favored 'General case' 0 N--CA 1.415 -2.18 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG21 ' HE3' ' A' ' 106' ' ' LYS . 48.2 t -105.32 114.96 46.16 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 176.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.438 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 52.5 t30 -67.66 148.22 51.65 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 123.429 0.456 . . . . 0.0 110.003 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -90.47 -119.98 2.15 Favored Glycine 0 N--CA 1.419 -2.437 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.8 -176.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -85.94 -28.61 24.17 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 -172.42 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 10.9 pt20 -110.21 136.18 20.52 Favored Pre-proline 0 C--N 1.286 -2.188 0 O-C-N 122.046 -0.409 . . . . 0.0 111.652 -174.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -68.46 140.05 46.85 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.969 1.78 . . . . 0.0 109.809 175.166 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -112.4 131.1 64.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.913 -172.329 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.1 t -72.19 116.18 13.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 80.4 p -95.54 162.84 13.47 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.251 -178.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 47' ' ' PRO . 33.4 mmt180 -129.8 155.38 46.06 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -176.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.532 HG23 ' HB3' ' A' ' 80' ' ' ASN . 26.5 mt -116.37 137.29 50.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -175.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.55 -48.67 3.93 Favored Glycine 0 CA--C 1.494 -1.277 0 CA-C-N 114.218 -1.355 . . . . 0.0 112.623 174.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 43.7 m -139.05 146.9 51.5 Favored Pre-proline 0 C--N 1.264 -3.148 0 CA-C-N 114.353 -0.924 . . . . 0.0 110.264 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -85.9 84.88 1.14 Allowed 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.075 1.85 . . . . 0.0 112.239 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -142.25 156.91 45.32 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.3 mt -76.85 -22.44 53.52 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -90.32 8.0 35.61 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.916 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.95 156.68 42.19 Favored Pre-proline 0 C--O 1.253 1.274 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.436 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 15.6 Cg_endo -57.99 150.79 61.98 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.972 2.448 . . . . 0.0 112.007 179.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.547 HG12 ' H ' ' A' ' 50' ' ' GLY . 59.3 t -86.04 125.08 40.64 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.59 -177.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.41 -8.05 78.33 Favored Glycine 0 CA--C 1.496 -1.15 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.547 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 128.08 179.38 15.83 Favored Glycine 0 N--CA 1.411 -2.983 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -109.66 110.84 22.01 Favored 'General case' 0 C--N 1.269 -2.921 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 53' ' ' PRO . 29.6 tp -63.14 126.84 89.98 Favored Pre-proline 0 C--N 1.303 -1.415 0 CA-C-N 114.288 -1.324 . . . . 0.0 109.466 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.515 ' HD2' HD12 ' A' ' 52' ' ' LEU . 11.9 Cg_exo -60.6 146.72 96.56 Favored 'Trans proline' 0 N--CA 1.431 -2.2 0 C-N-CA 122.402 2.068 . . . . 0.0 112.551 -178.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -70.94 116.26 11.03 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.86 -0.66 45.07 Favored Glycine 0 C--N 1.306 -1.09 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.337 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -74.83 143.79 43.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.237 0.541 . . . . 0.0 111.608 -178.04 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -98.42 117.13 32.15 Favored 'General case' 0 N--CA 1.421 -1.885 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.819 -176.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.5 mm -115.23 127.41 72.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 123.707 0.803 . . . . 0.0 111.389 -179.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 79.2 t -98.95 116.76 42.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 171.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.456 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 55.0 p90 -114.53 164.59 13.78 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.441 -178.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -124.11 3.5 8.62 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.769 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -155.37 147.9 24.06 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.638 -0.825 . . . . 0.0 109.888 -175.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 24' ' ' GLU . 12.5 t -122.46 135.41 62.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.459 ' HB3' ' CG2' ' A' ' 19' ' ' THR . 82.7 m -130.4 150.91 51.41 Favored 'General case' 0 C--N 1.286 -2.17 0 O-C-N 123.306 0.379 . . . . 0.0 110.748 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -119.68 121.37 66.04 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 176.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.403 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.5 tp-100 -167.86 150.08 5.6 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 123.723 0.639 . . . . 0.0 109.51 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 59.49 31.28 20.91 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 123.93 0.892 . . . . 0.0 111.301 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.21 6.77 70.06 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.57 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 77.0 m80 -120.1 156.68 30.52 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 122.537 -0.39 . . . . 0.0 110.69 -177.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.467 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 23.2 mt -104.87 134.35 46.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.6 m95 -125.72 153.82 43.36 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -170.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.523 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.5 pt -113.44 136.61 49.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 173.373 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.28 123.59 7.48 Favored Glycine 0 N--CA 1.423 -2.178 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.947 -178.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.456 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 37.7 p90 -141.42 172.36 12.79 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 -109.62 143.61 39.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.762 -177.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -95.37 165.45 12.37 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.653 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -55.67 -35.28 65.83 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 124.987 1.315 . . . . 0.0 111.487 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -83.93 8.6 14.57 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.404 0.52 . . . . 0.0 112.404 -177.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.82 82.92 Favored Glycine 0 C--O 1.228 -0.26 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.187 176.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.532 ' HB3' HG23 ' A' ' 39' ' ' ILE . 27.4 m120 -92.25 155.99 17.59 Favored 'General case' 0 C--N 1.31 -1.14 0 O-C-N 122.821 -0.223 . . . . 0.0 111.139 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -87.83 125.9 34.72 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 177.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.46 HG22 HG12 ' A' ' 39' ' ' ILE . 39.4 t -118.14 131.79 69.87 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 C-N-CA 119.399 -0.92 . . . . 0.0 109.774 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.523 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 66.6 m-85 -114.06 128.2 56.28 Favored 'General case' 0 C--N 1.286 -2.191 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.31 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.6 t -115.96 128.43 25.98 Favored Pre-proline 0 C--N 1.285 -2.2 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -74.01 130.52 14.46 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.427 1.418 . . . . 0.0 108.74 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.8 m -114.32 -13.5 11.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -175.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.531 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.5 ptm180 -176.51 174.31 1.92 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -178.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.473 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.1 p -98.25 165.23 11.97 Favored 'General case' 0 C--N 1.286 -2.175 0 C-N-CA 122.781 0.432 . . . . 0.0 110.832 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.713 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.0 t -149.98 116.29 5.74 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 122.901 0.48 . . . . 0.0 110.202 177.582 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 46.8 tt0 -83.86 103.23 12.96 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.86 -176.04 40.65 Favored Glycine 0 N--CA 1.432 -1.626 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.437 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.415 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 16.1 m -112.69 155.12 44.4 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.116 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 36.3 Cg_endo -63.67 164.9 19.68 Favored 'Trans proline' 0 CA--C 1.552 1.4 0 C-N-CA 122.432 2.088 . . . . 0.0 110.861 -178.648 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.59 ' HD3' ' OG1' ' A' ' 9' ' ' THR . 91.9 Cg_endo -77.49 -5.05 30.82 Favored 'Cis proline' 0 C--N 1.359 1.094 0 C-N-CA 124.573 -1.011 . . . . 0.0 113.363 7.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -104.49 78.82 1.5 Allowed 'General case' 0 CA--C 1.475 -1.916 0 C-N-CA 119.548 -0.861 . . . . 0.0 109.088 171.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.713 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -98.93 151.42 20.9 Favored 'General case' 0 N--CA 1.418 -2.071 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 60.1 mt -125.86 86.06 58.24 Favored Pre-proline 0 C--N 1.291 -1.962 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.473 ' HA ' ' O ' ' A' ' 88' ' ' THR . 54.7 Cg_endo -68.92 129.03 17.72 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.355 2.036 . . . . 0.0 112.666 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.33 -166.83 41.64 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 177.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.7 p -63.34 135.91 26.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.158 0.504 . . . . 0.0 110.596 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.531 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -76.86 144.63 38.88 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.569 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 44.4 m0 -90.35 8.79 31.68 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.334 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -170.51 -156.48 11.37 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.569 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 6.7 t -111.61 154.47 13.15 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -125.97 102.84 7.44 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 176.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 93.3 mttt . . . . . 0 C--N 1.288 -2.087 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 . . . . . 0 CA--C 1.515 -0.39 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.3 m -108.65 121.0 44.58 Favored Pre-proline 0 N--CA 1.422 -1.845 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.64 -39.28 92.46 Favored 'Trans proline' 0 C--N 1.355 0.894 0 C-N-CA 122.816 2.344 . . . . 0.0 112.855 -178.515 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.47 18.37 6.29 Favored 'General case' 0 C--O 1.246 0.878 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.454 -178.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 m 73.76 -63.22 0.44 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.585 1.154 . . . . 0.0 111.546 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -92.78 124.59 58.22 Favored Pre-proline 0 N--CA 1.429 -1.497 0 CA-C-O 120.69 0.281 . . . . 0.0 110.679 -176.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.24 110.99 1.91 Allowed 'Trans proline' 0 C--O 1.247 0.939 0 C-N-CA 122.967 2.444 . . . . 0.0 111.49 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.25 126.25 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.099 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.43 ' HB ' ' O ' ' A' ' 12' ' ' TRP . 7.9 m 74.62 1.5 3.83 Favored 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 123.905 0.882 . . . . 0.0 111.21 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 77.54 -100.2 1.53 Allowed Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.829 175.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.4 m -77.05 -33.33 57.29 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 122.625 0.37 . . . . 0.0 111.738 -176.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.43 ' O ' ' HB ' ' A' ' 9' ' ' THR . 91.6 m95 -96.85 129.76 44.24 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.754 -175.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -121.99 155.61 35.19 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 176.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.541 ' HD3' ' CE2' ' A' ' 20' ' ' TRP . 35.4 ttpt -106.58 130.89 54.26 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.003 -174.492 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.444 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 41.0 t-20 -78.27 151.04 33.24 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 176.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -54.48 -19.18 5.26 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -87.13 2.8 48.71 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.046 -0.409 . . . . 0.0 112.014 178.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.0 12.81 67.57 Favored Glycine 0 C--N 1.319 -0.412 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 179.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.454 HG23 ' HB2' ' A' ' 66' ' ' GLN . 56.6 m -90.37 119.3 30.55 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.541 ' CE2' ' HD3' ' A' ' 14' ' ' LYS . 81.9 m95 -82.94 130.77 35.18 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.413 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.2 p90 -141.39 159.33 42.45 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -176.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -150.28 147.47 21.96 Favored Pre-proline 0 N--CA 1.419 -2.015 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -76.37 121.95 6.31 Favored 'Trans proline' 0 N--CA 1.449 -1.109 0 C-N-CA 122.575 2.184 . . . . 0.0 110.121 174.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.28 123.15 8.71 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.518 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 23.9 t-20 -107.26 106.46 16.93 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.613 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.5 166.09 29.23 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.794 -175.487 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 98.0 m -103.9 119.78 39.63 Favored 'General case' 0 N--CA 1.414 -2.271 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.239 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -98.99 118.89 36.79 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.25 106.1 19.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.917 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 177.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -62.87 142.68 58.17 Favored 'General case' 0 C--N 1.316 -0.854 0 O-C-N 124.024 0.827 . . . . 0.0 111.325 -176.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.75 -140.72 0.91 Allowed Glycine 0 N--CA 1.428 -1.87 0 CA-C-N 115.696 -0.683 . . . . 0.0 113.688 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.67 -13.53 56.26 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 -173.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -110.67 138.71 21.11 Favored Pre-proline 0 C--N 1.31 -1.151 0 O-C-N 121.415 -0.803 . . . . 0.0 111.389 -177.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -69.29 145.85 61.19 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 122.334 2.023 . . . . 0.0 110.422 174.133 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.37 136.26 56.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.784 -175.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.7 t -75.8 121.89 28.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.519 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.5 p -104.59 158.24 16.63 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 110.375 -0.231 . . . . 0.0 110.375 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 26.5 mmt180 -127.6 160.97 29.95 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -174.19 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.465 HG12 HG22 ' A' ' 82' ' ' VAL . 50.3 mt -122.79 138.1 54.04 Favored 'Isoleucine or valine' 0 C--O 1.243 0.75 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.62 -47.1 2.54 Favored Glycine 0 CA--C 1.497 -1.081 0 CA-C-N 114.517 -1.219 . . . . 0.0 112.561 174.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 45.2 m -139.24 151.83 68.24 Favored Pre-proline 0 C--N 1.273 -2.742 0 C-N-CA 123.794 0.838 . . . . 0.0 111.052 -174.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -90.78 80.85 0.46 Allowed 'Trans proline' 0 N--CA 1.446 -1.293 0 C-N-CA 122.712 2.275 . . . . 0.0 111.761 175.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -141.69 157.76 44.66 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -76.72 -20.72 56.23 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.717 0.77 . . . . 0.0 109.189 178.21 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -98.48 13.09 32.99 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.994 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -87.56 152.14 51.53 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -58.11 138.79 87.78 Favored 'Trans proline' 0 C--O 1.249 1.054 0 C-N-CA 122.641 2.227 . . . . 0.0 112.568 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 69.4 t -68.61 118.03 11.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -80.65 -19.52 68.12 Favored Glycine 0 C--N 1.292 -1.907 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 144.11 -177.11 22.98 Favored Glycine 0 N--CA 1.401 -3.67 0 N-CA-C 107.97 -2.052 . . . . 0.0 107.97 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -112.5 140.06 47.56 Favored 'General case' 0 C--N 1.263 -3.191 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.466 HD12 ' HD2' ' A' ' 53' ' ' PRO . 21.8 tp -85.25 126.11 68.19 Favored Pre-proline 0 C--N 1.281 -2.393 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.335 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.466 ' HD2' HD12 ' A' ' 52' ' ' LEU . 5.2 Cg_endo -62.46 154.07 66.76 Favored 'Trans proline' 0 N--CA 1.438 -1.756 0 C-N-CA 122.101 1.867 . . . . 0.0 112.511 178.189 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -71.66 135.37 46.86 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 175.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.68 12.96 79.19 Favored Glycine 0 C--N 1.312 -0.799 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.57 146.71 32.44 Favored 'General case' 0 CA--C 1.495 -1.152 0 CA-C-O 121.224 0.535 . . . . 0.0 110.773 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.9 m -108.77 110.62 22.06 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.896 -1.047 . . . . 0.0 109.001 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 27' ' ' THR . 16.8 mm -110.41 133.9 54.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 123.201 0.6 . . . . 0.0 110.841 -177.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.72 117.0 50.65 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 171.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.613 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.0 p90 -111.86 163.4 14.24 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.128 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.39 2.45 8.41 Favored 'General case' 0 C--N 1.309 -1.195 0 O-C-N 123.613 0.571 . . . . 0.0 111.309 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -157.22 152.81 26.63 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.545 -175.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.2 t -130.54 137.3 56.5 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.455 ' HG ' ' HE2' ' A' ' 83' ' ' TYR . 99.3 m -126.73 152.95 46.14 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.89 0.476 . . . . 0.0 110.998 178.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -123.34 110.35 25.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 173.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.454 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.3 tp-100 -159.52 147.34 17.25 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.534 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.42 30.21 18.82 Favored 'General case' 0 C--O 1.246 0.916 0 C-N-CA 123.952 0.901 . . . . 0.0 110.209 178.418 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.58 11.01 64.66 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.051 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.8 m80 -120.48 154.0 35.86 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 122.186 -0.597 . . . . 0.0 110.152 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.523 HG13 ' HB2' ' A' ' 89' ' ' CYS . 18.0 mt -101.5 133.16 45.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 171.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 57.8 m95 -125.31 148.13 48.84 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -172.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.6 pt -106.99 136.89 40.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 171.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.96 123.67 7.4 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.496 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 33.5 p90 -138.86 152.9 48.2 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -95.12 122.51 37.87 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.11 174.77 5.88 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.795 -175.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -64.62 -32.16 73.69 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.593 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -91.35 4.13 53.17 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-O 121.706 0.765 . . . . 0.0 110.703 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.21 8.28 75.33 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 119.788 -1.196 . . . . 0.0 113.858 177.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -75.66 144.64 41.54 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 178.538 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.41 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 23.0 tpt180 -85.53 101.25 12.51 Favored 'General case' 0 CA--C 1.494 -1.209 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.465 HG22 HG12 ' A' ' 39' ' ' ILE . 23.1 t -102.75 129.15 54.82 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.025 -176.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.513 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 64.5 m-85 -111.63 134.88 52.89 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.583 177.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -123.13 127.0 25.81 Favored Pre-proline 0 C--N 1.287 -2.117 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 178.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -72.95 128.7 13.43 Favored 'Trans proline' 0 N--CA 1.437 -1.808 0 N-CA-C 108.334 -1.449 . . . . 0.0 108.334 175.105 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -112.9 -9.35 12.14 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -176.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.4 ptm180 179.75 167.29 1.2 Allowed 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.2 p -90.45 171.19 9.61 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.043 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 46.1 t -153.62 127.81 9.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.575 0.703 . . . . 0.0 109.863 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB2' ' HB ' ' A' ' 97' ' ' ILE . 37.6 mt-30 -93.15 112.16 24.02 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.228 173.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.09 167.11 32.72 Favored Glycine 0 N--CA 1.422 -2.292 0 CA-C-N 115.081 -0.963 . . . . 0.0 113.17 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.417 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 17.3 m -97.73 156.19 36.33 Favored Pre-proline 0 C--N 1.289 -2.054 0 CA-C-N 114.749 -0.725 . . . . 0.0 109.144 176.1 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.509 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 19.3 Cg_endo -62.65 168.86 9.35 Favored 'Trans proline' 0 CA--C 1.559 1.759 0 C-N-CA 122.536 2.158 . . . . 0.0 111.672 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -68.34 -18.14 9.96 Favored 'Cis proline' 0 C--N 1.366 1.49 0 CA-C-N 119.715 0.934 . . . . 0.0 114.024 4.15 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -99.55 79.7 2.3 Favored 'General case' 0 CA--C 1.484 -1.585 0 CA-C-O 121.435 0.636 . . . . 0.0 110.086 175.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.634 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -99.59 146.26 26.64 Favored 'General case' 0 N--CA 1.421 -1.889 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 174.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB2' ' A' ' 90' ' ' GLN . 63.8 mt -122.02 88.51 47.97 Favored Pre-proline 0 C--N 1.29 -1.993 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.638 177.48 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 87' ' ' ARG . 29.1 Cg_endo -65.73 140.75 63.08 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.347 2.032 . . . . 0.0 112.095 177.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.32 -158.4 33.47 Favored Glycine 0 C--N 1.306 -1.088 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.3 p -66.73 132.68 32.02 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-N 116.996 0.398 . . . . 0.0 110.182 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.577 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.02 139.32 38.2 Favored 'General case' 0 CA--C 1.49 -1.335 0 CA-C-O 120.89 0.376 . . . . 0.0 110.28 178.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 33.6 m0 -92.58 15.29 14.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.016 -177.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.71 -177.46 46.54 Favored Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.975 178.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.7 t -92.7 153.7 3.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -127.0 103.15 7.31 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 176.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.522 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 84.9 mttt . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 177.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.223 -0.31 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.3 m 65.42 77.54 0.28 Allowed Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 124.722 1.209 . . . . 0.0 112.998 179.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -110.75 -153.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 124.229 3.286 . . . . 0.0 108.683 170.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.06 120.66 27.69 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 172.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.3 m -70.57 -45.97 64.38 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -174.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -79.48 152.27 75.49 Favored Pre-proline 0 C--N 1.315 -0.917 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.872 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.3 106.47 0.84 Allowed 'Trans proline' 0 C--O 1.247 0.945 0 C-N-CA 122.142 1.895 . . . . 0.0 108.997 173.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.03 142.63 35.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.971 -173.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.314 5.1 p 59.16 -6.98 0.05 Allowed 'General case' 0 CA--C 1.56 1.341 0 N-CA-C 117.582 2.438 . . . . 0.0 117.582 175.208 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.27 -97.64 0.86 Allowed Glycine 0 C--O 1.25 1.123 0 CA-C-O 120.929 0.183 . . . . 0.0 113.236 175.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.8 m -63.54 -57.64 9.54 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 123.129 0.571 . . . . 0.0 109.926 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' TRP . . . . . 0.412 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 88.9 m95 -83.38 146.52 28.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.207 -179.164 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.6 mtmm -146.37 153.59 40.67 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 177.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -104.51 137.48 42.3 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.699 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.0 p30 -91.74 -177.48 4.77 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -56.77 -30.49 63.68 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.287 1.035 . . . . 0.0 113.373 -178.218 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -82.6 -8.01 59.62 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.862 0.363 . . . . 0.0 111.425 -176.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.24 18.45 59.1 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m -95.84 131.95 41.62 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.412 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 170.106 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 0.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 0.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 0.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 0.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 0.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 0.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 0.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 0.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 0.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 0.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 0.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 0.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 0.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 0.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 0.0 109.389 175.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 0.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 0.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 0.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 0.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 0.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 0.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 0.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 48.3 tp60 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 0.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 0.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 0.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 -142.19 171.97 13.34 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -111.45 145.22 39.38 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.416 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -92.35 171.48 9.03 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 173.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -62.75 -20.58 65.09 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 123.331 0.652 . . . . 0.0 111.876 -177.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.671 ' HB2' ' OD1' ' A' ' 80' ' ' ASN . 61.3 m-20 -91.23 1.99 56.69 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.888 -0.507 . . . . 0.0 110.099 179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.13 8.65 68.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 119.996 -1.097 . . . . 0.0 112.094 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.671 ' OD1' ' HB2' ' A' ' 78' ' ' ASN . 6.9 m120 -71.91 139.19 48.65 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 -86.41 97.56 10.52 Favored 'General case' 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 175.389 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 0.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 0.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 0.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 0.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 0.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 0.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 0.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 0.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 0.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 0.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 19.0 108.555 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 20.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 21.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 22.0 107.943 170.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 23.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 24.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 25.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 26.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 27.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 28.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 29.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 30.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 31.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 32.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 33.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 34.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 35.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 36.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 37.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 38.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 39.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 40.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 41.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 42.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 43.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 44.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 45.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 46.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 47.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 48.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 49.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 50.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 51.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 52.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 53.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 54.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 55.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 56.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 57.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 58.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 59.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 60.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 61.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 62.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 63.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 64.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 65.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 66.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 67.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 68.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 69.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 70.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 71.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 72.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 73.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 . . . . . 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 74.0 108.98 177.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 . . . . . 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 81.0 107.254 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 82.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 83.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 84.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 85.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 86.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 87.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 88.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 89.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 90.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 91.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 92.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 93.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 94.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 95.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 96.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 97.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 98.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 99.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 100.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 101.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 102.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 103.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 104.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 105.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 106.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 62.6 m . . . . . 0 N--CA 1.41 -2.431 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.413 ' CD1' ' HB ' ' A' ' 92' ' ' VAL . 79.1 m95 -93.93 134.41 36.34 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -137.68 162.65 33.28 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.564 0.54 . . . . 0.0 110.742 -177.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 61.2 pttt -155.04 145.25 15.84 Favored Pre-proline 0 C--N 1.298 -1.639 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 170.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -76.64 132.31 13.19 Favored 'Trans proline' 0 N--CA 1.445 -1.336 0 C-N-CA 122.161 1.908 . . . . 0.0 109.956 175.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.4 ' HB3' HG23 ' A' ' 63' ' ' VAL . 34.5 tt0 -151.77 123.85 8.14 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.401 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 17.8 t-20 -105.42 110.61 23.01 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.66 166.76 32.53 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.701 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 76.9 m -103.54 119.55 39.11 Favored 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.19 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.569 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 60.0 t80 -99.09 120.08 38.89 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.543 ' HB ' HG22 ' A' ' 104' ' ' VAL . 92.5 t -107.37 109.81 29.52 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 176.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.516 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 55.5 t30 -61.02 148.47 40.09 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 123.804 0.69 . . . . 0.0 110.443 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -85.68 -130.74 2.51 Favored Glycine 0 N--CA 1.432 -1.623 0 CA-C-O 121.321 0.401 . . . . 0.0 113.638 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.24 -7.68 52.88 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -172.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -120.37 141.02 31.14 Favored Pre-proline 0 C--N 1.307 -1.276 0 C-N-CA 120.347 -0.541 . . . . 0.0 111.156 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.73 150.85 68.91 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.069 1.846 . . . . 0.0 110.955 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.528 HG21 ' SG ' ' A' ' 84' ' ' CYS . 7.5 mm -116.24 141.34 34.31 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.186 -174.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.412 ' HA ' HD22 ' A' ' 51' ' ' ASN . 61.8 t -92.79 117.2 35.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.2 p -97.4 158.79 15.29 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 116.862 -0.153 . . . . 0.0 111.382 -174.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mmt180 -130.06 156.51 44.39 Favored 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 51.0 mt -115.96 137.64 49.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.55 -36.83 2.61 Favored Glycine 0 CA--C 1.493 -1.333 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.802 174.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.421 ' HB3' ' HD2' ' A' ' 43' ' ' PHE . 6.8 m -138.08 151.12 69.31 Favored Pre-proline 0 C--N 1.28 -2.425 0 CA-C-N 114.944 -0.628 . . . . 0.0 111.46 -171.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 19.6 Cg_endo -94.01 49.69 0.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.369 2.713 . . . . 0.0 111.328 177.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.421 ' HD2' ' HB3' ' A' ' 41' ' ' SER . 99.9 m-85 -121.3 153.04 38.22 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -77.27 -8.78 58.18 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.808 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -103.7 4.63 35.57 Favored 'General case' 0 C--O 1.245 0.842 0 CA-C-O 121.618 0.723 . . . . 0.0 110.647 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.5 158.73 70.96 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.78 140.32 93.27 Favored 'Trans proline' 0 C--O 1.247 0.93 0 C-N-CA 122.491 2.127 . . . . 0.0 111.834 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.488 HG12 ' H ' ' A' ' 50' ' ' GLY . 44.0 t -74.13 126.63 35.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.75 -14.27 65.54 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.488 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 129.9 -176.57 18.61 Favored Glycine 0 N--CA 1.414 -2.814 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.412 HD22 ' HA ' ' A' ' 36' ' ' VAL . 14.6 m120 -108.56 130.26 55.3 Favored 'General case' 0 C--N 1.273 -2.729 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -80.99 124.71 81.13 Favored Pre-proline 0 C--N 1.281 -2.402 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 9.4 Cg_endo -61.97 149.98 88.15 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.288 1.992 . . . . 0.0 112.59 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.516 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -68.7 117.82 10.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.572 177.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 30' ' ' ASN . . . 101.78 4.67 51.7 Favored Glycine 0 C--N 1.304 -1.204 0 C-N-CA 121.121 -0.562 . . . . 0.0 112.96 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB2' ' HG2' ' A' ' 53' ' ' PRO . . . -68.05 146.39 53.55 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.5 0.556 . . . . 0.0 112.5 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.409 HG22 HG22 ' A' ' 29' ' ' VAL . 7.6 p -101.57 105.42 16.37 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.778 0.831 . . . . 0.0 110.791 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 27' ' ' THR . 19.9 mm -107.74 134.79 48.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 123.339 0.656 . . . . 0.0 111.296 -178.082 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.78 116.17 48.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 170.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -111.05 162.15 15.17 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.053 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -129.28 6.0 5.3 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 123.791 0.682 . . . . 0.0 111.376 -177.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -158.74 154.89 27.02 Favored 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.4 HG23 ' HB3' ' A' ' 24' ' ' GLU . 8.8 t -133.51 133.75 57.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 172.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 54.5 m -126.25 154.26 43.61 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 123.419 0.688 . . . . 0.0 110.576 178.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 70' ' ' ILE . 66.0 mt -123.21 123.12 67.04 Favored 'Isoleucine or valine' 0 C--O 1.255 1.377 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.7 tp-100 -171.9 152.72 3.06 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.76 26.42 15.6 Favored 'General case' 0 C--O 1.243 0.757 0 C-N-CA 123.682 0.793 . . . . 0.0 111.045 177.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.33 5.8 82.45 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.202 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -120.6 153.86 36.22 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 121.053 0.454 . . . . 0.0 111.34 -177.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 65' ' ' ILE . 24.0 mt -100.74 131.91 47.44 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 172.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.414 ' CZ3' ' HD3' ' A' ' 85' ' ' PRO . 55.3 m95 -123.62 140.47 52.96 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -172.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.3 pt -97.37 134.44 35.3 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 172.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.13 124.45 8.06 Favored Glycine 0 N--CA 1.425 -2.08 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.56 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.6 p90 . . . . . 0 C--N 1.299 -1.626 0 CA-C-O 120.734 0.302 . . . . 0.0 110.625 179.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 . . . . . 0 C--O 1.202 -1.412 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 26.6 t -104.91 132.91 50.51 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.948 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.05 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.4 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 61.1 m-85 -111.12 125.94 54.31 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.216 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.528 ' SG ' HG21 ' A' ' 35' ' ' ILE . 41.0 t -116.49 120.46 34.63 Favored Pre-proline 0 C--N 1.286 -2.159 0 CA-C-N 115.373 -0.831 . . . . 0.0 108.883 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.414 ' HD3' ' CZ3' ' A' ' 71' ' ' TRP . 37.9 Cg_endo -72.31 119.26 6.03 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 121.708 1.605 . . . . 0.0 109.134 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 29.0 m -105.85 -14.15 9.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.507 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.1 ptt180 -176.23 176.31 1.71 Allowed 'General case' 0 CA--C 1.503 -0.834 0 O-C-N 123.732 0.645 . . . . 0.0 109.581 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.6 p -95.6 167.15 11.48 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 123.357 0.411 . . . . 0.0 110.862 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.1 t -150.71 127.91 11.25 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 174.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.598 HE21 HD12 ' A' ' 97' ' ' ILE . 6.2 tt0 -87.24 110.52 20.24 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.5 -155.45 32.36 Favored Glycine 0 N--CA 1.423 -2.219 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.735 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.413 ' HB ' ' CD1' ' A' ' 20' ' ' TRP . 8.3 m -134.39 155.52 79.7 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.493 ' HA ' ' N ' ' A' ' 95' ' ' ASN . 19.6 Cg_endo -63.19 167.68 12.21 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.198 1.932 . . . . 0.0 111.515 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.81 -4.76 5.97 Favored 'Cis proline' 0 C--N 1.352 0.752 0 N-CA-C 115.513 1.313 . . . . 0.0 115.513 4.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . 0.493 ' N ' ' HA ' ' A' ' 93' ' ' PRO . 39.1 m-80 -108.79 80.45 1.33 Allowed 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.482 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.0 pt20 -96.57 146.08 25.15 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.598 HD12 HE21 ' A' ' 90' ' ' GLN . 83.7 mt -122.0 87.77 47.43 Favored Pre-proline 0 C--N 1.273 -2.734 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.7 128.52 11.0 Favored 'Trans proline' 0 N--CA 1.442 -1.534 0 C-N-CA 122.647 2.232 . . . . 0.0 112.987 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.53 -175.79 49.56 Favored Glycine 0 N--CA 1.433 -1.558 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.793 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.1 p -67.31 133.98 30.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 120.947 0.403 . . . . 0.0 110.009 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -67.13 143.18 56.78 Favored 'General case' 0 N--CA 1.434 -1.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.777 -179.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 39.4 m0 -92.48 17.41 10.06 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.907 176.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.85 -173.39 42.38 Favored Glycine 0 N--CA 1.427 -1.959 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.796 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.569 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.8 OUTLIER -96.6 156.49 3.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -177.605 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -129.02 102.97 6.74 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 175.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.495 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 65.4 mttm . . . . . 0 C--N 1.301 -1.524 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.384 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.6 m . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.434 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 95.4 m95 -88.41 140.06 29.86 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 175.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 39.7 p90 -146.51 154.6 41.74 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 120.568 0.223 . . . . 0.0 110.954 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -144.83 145.69 28.73 Favored Pre-proline 0 C--N 1.305 -1.332 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -80.88 119.74 3.67 Favored 'Trans proline' 0 C--O 1.249 1.056 0 C-N-CA 122.64 2.227 . . . . 0.0 110.784 178.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -145.86 123.56 11.87 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -99.12 109.33 22.05 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.564 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.81 162.85 40.41 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.59 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.475 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.4 m -100.54 119.7 38.91 Favored 'General case' 0 N--CA 1.419 -2.024 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.059 177.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.534 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 67.2 t80 -98.97 113.98 26.41 Favored 'General case' 0 N--CA 1.416 -2.163 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 57' ' ' THR . 41.4 t -101.67 109.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 N-CA-C 106.001 -1.852 . . . . 0.0 106.001 176.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.49 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 53.6 t30 -61.56 149.43 39.1 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 123.567 0.542 . . . . 0.0 110.252 -177.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -88.71 -126.46 2.69 Favored Glycine 0 N--CA 1.423 -2.215 0 N-CA-C 114.259 0.464 . . . . 0.0 114.259 -174.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -89.92 -21.93 22.23 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -172.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -105.24 137.41 19.24 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.842 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.95 147.97 50.43 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.191 1.928 . . . . 0.0 109.319 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.417 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.6 mt -120.67 136.49 57.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.059 -174.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 69.8 t -79.16 116.82 23.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.484 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 72.2 p -91.49 157.12 17.22 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.686 -0.233 . . . . 0.0 110.617 -176.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -124.31 152.13 43.46 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 82' ' ' VAL . 21.0 mt -116.2 136.38 53.34 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -176.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.62 -45.83 3.5 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.868 174.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 40.8 m -138.17 144.33 42.87 Favored Pre-proline 0 C--N 1.274 -2.709 0 CA-C-N 113.972 -1.114 . . . . 0.0 110.324 -173.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -89.34 79.84 0.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.083 0 C-N-CA 122.411 2.074 . . . . 0.0 112.43 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -143.14 154.12 43.58 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 89.9 mt -76.6 -13.5 60.06 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.079 0.942 . . . . 0.0 108.773 174.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -91.24 -8.41 48.47 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.766 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -83.32 156.04 66.26 Favored Pre-proline 0 C--O 1.256 1.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.024 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.62 143.89 93.88 Favored 'Trans proline' 0 C--N 1.359 1.103 0 C-N-CA 123.145 2.563 . . . . 0.0 112.396 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.8 t -82.36 131.57 33.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.05 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.52 -27.9 28.61 Favored Glycine 0 C--N 1.3 -1.438 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 177.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 147.36 -176.33 26.27 Favored Glycine 0 N--CA 1.426 -2.012 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.24 117.5 34.67 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.411 HD12 ' HD2' ' A' ' 53' ' ' PRO . 20.4 tp -69.36 123.86 89.26 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.411 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.4 Cg_endo -55.94 141.21 86.31 Favored 'Trans proline' 0 N--CA 1.432 -2.105 0 C-N-CA 122.487 2.125 . . . . 0.0 113.266 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -67.26 116.58 8.2 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.73 0.11 42.48 Favored Glycine 0 C--N 1.304 -1.2 0 C-N-CA 120.728 -0.749 . . . . 0.0 113.1 -177.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -71.86 149.73 44.92 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.899 0.35 . . . . 0.0 111.554 -179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.428 HG22 HG22 ' A' ' 29' ' ' VAL . 20.9 p -104.79 108.83 20.52 Favored 'General case' 0 N--CA 1.439 -1.006 0 CA-C-O 121.55 0.691 . . . . 0.0 111.76 -178.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.5 mm -105.48 132.64 51.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 C-N-CA 123.841 0.857 . . . . 0.0 110.954 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.19 116.89 48.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.564 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 52.0 p90 -112.84 164.71 13.07 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.395 -0.522 . . . . 0.0 110.241 -177.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -123.52 -3.01 8.37 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.436 0.46 . . . . 0.0 111.666 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -154.92 154.43 32.62 Favored 'General case' 0 N--CA 1.434 -1.229 0 C-N-CA 119.445 -0.902 . . . . 0.0 109.85 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 21.6 t -127.04 135.58 63.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 175.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 61.6 m -125.35 157.03 37.76 Favored 'General case' 0 C--N 1.293 -1.853 0 O-C-N 123.199 0.312 . . . . 0.0 110.98 -178.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.426 HG12 HG12 ' A' ' 70' ' ' ILE . 73.0 mt -127.51 109.91 21.27 Favored 'Isoleucine or valine' 0 C--O 1.253 1.259 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 175.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -156.36 151.61 26.55 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.26 24.99 15.03 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 123.699 0.799 . . . . 0.0 110.361 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.56 13.27 68.11 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.398 -178.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -120.18 154.72 34.4 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 122.3 -0.53 . . . . 0.0 109.781 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.448 HG13 ' HB2' ' A' ' 89' ' ' CYS . 20.4 mt -101.29 133.89 43.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 174.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 53.9 m95 -126.02 150.82 47.82 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -172.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 29.0 pt -106.39 130.71 57.7 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.707 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 170.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -100.05 119.02 6.36 Favored Glycine 0 N--CA 1.417 -2.572 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 51.9 p90 . . . . . 0 N--CA 1.414 -2.257 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 25.2 tpt180 . . . . . 0 CA--C 1.487 -1.453 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.484 ' CG1' ' HB ' ' A' ' 37' ' ' THR . 38.3 t -116.93 134.95 58.87 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.681 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.54 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.8 m-85 -117.4 123.2 45.85 Favored 'General case' 0 C--N 1.281 -2.408 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.2 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -112.39 126.01 29.11 Favored Pre-proline 0 C--N 1.279 -2.467 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 35' ' ' ILE . 36.8 Cg_endo -71.79 129.78 15.96 Favored 'Trans proline' 0 N--CA 1.439 -1.678 0 C-N-CA 121.374 1.382 . . . . 0.0 108.778 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.51 -13.11 11.48 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -174.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.456 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.6 ptm180 -178.31 167.0 1.91 Allowed 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 16.2 p -92.33 162.68 14.17 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.501 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.8 t -141.39 120.69 13.06 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.554 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 28.1 tt0 -83.63 111.32 19.01 Favored 'General case' 0 N--CA 1.424 -1.768 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 177.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.17 -166.13 51.24 Favored Glycine 0 N--CA 1.426 -1.994 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.455 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 13.9 m -121.22 160.49 45.28 Favored Pre-proline 0 C--N 1.297 -1.707 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 31.4 Cg_endo -65.67 167.41 17.33 Favored 'Trans proline' 0 CA--C 1.547 1.155 0 C-N-CA 121.987 1.792 . . . . 0.0 112.48 179.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.407 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.4 Cg_endo -65.37 -28.46 4.36 Favored 'Cis proline' 0 C--N 1.363 1.307 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.985 4.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -90.86 79.31 5.96 Favored 'General case' 0 CA--C 1.485 -1.549 0 CA-C-O 122.17 0.986 . . . . 0.0 110.169 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.501 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 0.9 OUTLIER -94.26 143.82 26.06 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 176.409 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.554 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.0 mt -122.15 92.46 48.88 Favored Pre-proline 0 C--N 1.27 -2.873 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 177.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.529 ' HA ' ' O ' ' A' ' 88' ' ' THR . 58.7 Cg_endo -79.66 135.69 11.72 Favored 'Trans proline' 0 N--CA 1.434 -2.029 0 C-N-CA 122.263 1.976 . . . . 0.0 112.226 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.71 -159.07 23.38 Favored Glycine 0 C--N 1.311 -0.816 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -63.83 139.19 21.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.456 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.75 135.1 36.42 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 42.3 m0 -83.77 9.41 11.94 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.786 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -174.02 -172.08 38.97 Favored Glycine 0 N--CA 1.428 -1.891 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 178.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.5 t -97.36 149.35 5.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 -178.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -122.2 108.67 13.56 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 175.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.475 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 82.3 mttt . . . . . 0 C--N 1.285 -2.229 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.2 m . . . . . 0 N--CA 1.412 -2.327 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 89.6 m95 -86.38 125.37 33.61 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.135 -1.432 . . . . 0.0 107.135 175.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -134.64 151.57 51.14 Favored 'General case' 0 C--N 1.281 -2.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.562 -177.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -135.59 143.53 45.34 Favored Pre-proline 0 C--N 1.292 -1.926 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 173.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -76.8 113.03 3.56 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.216 1.944 . . . . 0.0 109.542 176.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -147.82 124.13 10.91 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.434 -178.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -100.06 106.59 18.35 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -178.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -147.11 160.4 42.46 Favored 'General case' 0 C--N 1.288 -2.067 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.616 -178.429 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.6 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 55.6 m -102.81 121.57 42.75 Favored 'General case' 0 C--N 1.288 -2.1 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.835 178.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.554 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.5 t80 -99.25 112.09 24.33 Favored 'General case' 0 C--N 1.284 -2.269 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.501 ' HB ' HG22 ' A' ' 104' ' ' VAL . 99.3 t -97.17 108.28 21.28 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -63.84 143.76 57.59 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 123.502 0.501 . . . . 0.0 110.069 -178.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -83.12 -128.05 1.27 Allowed Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 116.112 -0.494 . . . . 0.0 113.319 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -90.67 -14.61 31.93 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -172.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -108.26 136.86 19.8 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.947 -0.471 . . . . 0.0 111.575 -177.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -71.44 142.24 40.32 Favored 'Trans proline' 0 C--O 1.247 0.949 0 C-N-CA 121.974 1.783 . . . . 0.0 109.711 172.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.424 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.4 mt -117.26 133.24 64.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.085 -174.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -77.56 113.08 16.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.403 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 70.7 p -89.04 156.57 18.77 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.679 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -126.95 156.28 41.79 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -177.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.436 HG12 HG22 ' A' ' 82' ' ' VAL . 50.7 mt -122.09 135.83 60.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -177.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.54 -35.17 3.04 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.301 -0.863 . . . . 0.0 113.511 173.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 56.1 m -139.43 139.48 22.75 Favored Pre-proline 0 C--N 1.261 -3.253 0 C-N-CA 123.16 0.584 . . . . 0.0 111.343 -176.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 21.1 Cg_endo -87.13 55.06 2.99 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.714 2.276 . . . . 0.0 111.179 177.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -123.81 157.76 33.34 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.044 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.87 -14.03 59.93 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.551 0.691 . . . . 0.0 110.232 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -97.58 4.28 50.29 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.414 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.11 155.08 64.0 Favored Pre-proline 0 C--N 1.314 -0.935 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.64 136.75 77.61 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 122.991 2.46 . . . . 0.0 112.33 -178.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -78.27 124.48 36.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 115.355 -0.838 . . . . 0.0 109.701 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.36 -25.97 53.0 Favored Glycine 0 C--N 1.302 -1.331 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.56 -176.73 21.26 Favored Glycine 0 N--CA 1.421 -2.345 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -95.66 130.62 42.48 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.427 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.4 tp -77.01 126.31 85.69 Favored Pre-proline 0 C--N 1.285 -2.196 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 173.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HD2' HD12 ' A' ' 52' ' ' LEU . 6.2 Cg_endo -60.78 148.41 92.06 Favored 'Trans proline' 0 N--CA 1.44 -1.673 0 C-N-CA 121.913 1.742 . . . . 0.0 112.3 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.26 132.81 47.06 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 175.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 91.23 2.66 70.64 Favored Glycine 0 C--N 1.302 -1.333 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.069 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -75.24 144.67 42.46 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.37 0.605 . . . . 0.0 110.974 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.423 HG23 HG22 ' A' ' 29' ' ' VAL . 3.1 m -104.8 107.92 19.13 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.12 -176.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.4 mm -106.95 130.09 59.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 C-N-CA 123.38 0.672 . . . . 0.0 111.323 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.0 t -100.03 117.54 45.36 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 170.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 55.1 p90 -116.09 163.57 15.74 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.906 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -121.74 -0.59 9.61 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 123.409 0.443 . . . . 0.0 111.689 -178.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -153.27 148.54 26.93 Favored 'General case' 0 N--CA 1.433 -1.322 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.11 -176.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.4 t -120.98 133.48 67.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 105.681 -1.97 . . . . 0.0 105.681 173.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 3.9 m -125.66 150.1 47.9 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -175.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.41 HG12 HG12 ' A' ' 70' ' ' ILE . 64.3 mt -123.01 118.19 54.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 173.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -160.31 145.5 14.85 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -178.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.87 29.59 17.94 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 124.191 0.996 . . . . 0.0 110.759 177.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.06 10.47 73.4 Favored Glycine 0 CA--C 1.519 0.29 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.414 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -119.58 153.13 35.92 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 122.402 -0.469 . . . . 0.0 110.114 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' A' ' 87' ' ' ARG . 23.5 mt -103.37 133.94 45.88 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 174.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -127.73 153.61 46.32 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -171.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.49 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -109.96 130.25 63.47 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.774 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 171.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.47 122.52 7.55 Favored Glycine 0 N--CA 1.42 -2.424 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.536 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.2 p90 . . . . . 0 C--N 1.292 -1.928 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.7 tpt180 . . . . . 0 CA--C 1.492 -1.267 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.436 HG22 HG12 ' A' ' 39' ' ' ILE . 35.9 t -97.39 130.48 45.99 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.494 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.6 m-85 -112.4 125.17 53.92 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.309 178.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -114.14 125.06 29.83 Favored Pre-proline 0 C--N 1.278 -2.501 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 176.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.424 ' O ' HG21 ' A' ' 35' ' ' ILE . 42.8 Cg_endo -72.59 129.07 14.17 Favored 'Trans proline' 0 N--CA 1.439 -1.731 0 C-N-CA 121.271 1.314 . . . . 0.0 108.724 177.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.7 m -112.39 -15.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptt180 -177.48 173.12 1.73 Allowed 'General case' 0 CA--C 1.503 -0.853 0 C-N-CA 123.629 0.772 . . . . 0.0 109.457 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.6 p -99.93 168.3 9.96 Favored 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.598 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 45.1 t -147.55 123.86 10.91 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.568 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.3 tt0 -82.91 96.31 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.56 174.83 44.58 Favored Glycine 0 N--CA 1.429 -1.809 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.759 178.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.63 154.91 39.73 Favored Pre-proline 0 C--N 1.295 -1.797 0 C-N-CA 122.081 0.152 . . . . 0.0 111.011 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.431 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 38.4 Cg_endo -63.47 167.01 13.9 Favored 'Trans proline' 0 CA--C 1.556 1.617 0 C-N-CA 122.677 2.252 . . . . 0.0 112.8 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.431 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.1 Cg_endo -66.13 -24.58 6.17 Favored 'Cis proline' 0 C--N 1.372 1.794 0 C-N-CA 124.156 -1.185 . . . . 0.0 113.278 5.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -89.21 79.04 7.2 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 121.727 0.775 . . . . 0.0 109.26 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.598 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 12.8 pt20 -101.84 152.06 21.34 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.568 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 68.0 mt -130.28 88.02 49.03 Favored Pre-proline 0 C--N 1.284 -2.277 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -73.46 133.81 19.65 Favored 'Trans proline' 0 N--CA 1.443 -1.453 0 C-N-CA 122.433 2.089 . . . . 0.0 112.536 -178.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -85.42 -163.38 37.32 Favored Glycine 0 N--CA 1.441 -1.002 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.748 178.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -69.54 131.85 33.65 Favored 'Isoleucine or valine' 0 C--O 1.251 1.145 0 CA-C-O 120.88 0.371 . . . . 0.0 110.695 -178.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.482 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -71.6 140.55 49.82 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.445 177.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.4 m0 -90.2 10.86 22.95 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.799 179.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -167.54 -159.95 14.08 Favored Glycine 0 N--CA 1.43 -1.712 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.22 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.7 OUTLIER -113.03 154.64 14.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.045 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -123.76 103.61 8.48 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.6 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 87.5 mttt . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 173.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 87.3 m . . . . . 0 N--CA 1.421 -1.91 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -84.91 135.9 33.86 Favored 'General case' 0 CA--C 1.485 -1.536 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 175.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -149.5 162.51 40.01 Favored 'General case' 0 C--N 1.281 -2.388 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -177.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -150.36 144.7 17.71 Favored Pre-proline 0 N--CA 1.422 -1.852 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.17 126.84 11.46 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.621 2.214 . . . . 0.0 109.73 176.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -152.76 123.7 7.45 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.7 108.88 20.85 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.21 164.77 38.35 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.642 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.542 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 65.1 m -105.72 120.85 42.74 Favored 'General case' 0 N--CA 1.416 -2.154 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.43 177.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.7 t80 -98.98 125.25 44.4 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.1 109.72 29.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.416 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 51.8 t30 -65.33 145.28 56.39 Favored 'General case' 0 C--N 1.308 -1.205 0 O-C-N 123.778 0.674 . . . . 0.0 110.699 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -84.54 -108.49 0.62 Allowed Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 114.863 0.705 . . . . 0.0 114.863 -174.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.26 -25.04 13.82 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 122.599 0.36 . . . . 0.0 111.717 -170.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -110.84 133.63 21.18 Favored Pre-proline 0 C--N 1.295 -1.769 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.802 -176.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.05 140.72 55.25 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.211 1.941 . . . . 0.0 110.568 175.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.85 136.25 52.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.746 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.402 HG22 ' ND2' ' A' ' 51' ' ' ASN . 52.6 t -77.36 121.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.8 p -94.19 157.84 15.87 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.034 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.44 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 27.0 mmt180 -130.72 155.01 47.35 Favored 'General case' 0 C--O 1.21 -0.985 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 -174.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.441 HG12 HG22 ' A' ' 82' ' ' VAL . 18.6 mt -112.46 138.95 39.67 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.45 -48.74 4.11 Favored Glycine 0 CA--C 1.502 -0.719 0 C-N-CA 124.921 1.248 . . . . 0.0 113.752 174.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 14.8 m -137.35 154.2 75.26 Favored Pre-proline 0 C--N 1.279 -2.499 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.991 -170.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -91.03 67.22 1.31 Allowed 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 123.006 2.47 . . . . 0.0 111.77 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -131.17 156.45 45.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.7 mt -76.46 -19.98 57.49 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.959 0.409 . . . . 0.0 111.024 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -100.39 18.16 19.68 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 121.556 0.694 . . . . 0.0 111.208 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -85.22 152.62 58.6 Favored Pre-proline 0 C--N 1.308 -1.239 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.4 143.24 94.61 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 50' ' ' GLY . 51.7 t -79.57 126.19 39.05 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.01 7.69 67.36 Favored Glycine 0 C--N 1.308 -0.976 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.637 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 122.28 170.51 13.71 Favored Glycine 0 N--CA 1.423 -2.21 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.402 ' ND2' HG22 ' A' ' 36' ' ' VAL . 2.3 m-20 -113.19 117.17 31.17 Favored 'General case' 0 C--N 1.28 -2.418 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.494 HD12 ' HD2' ' A' ' 53' ' ' PRO . 19.6 tp -68.78 125.7 92.08 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.212 -176.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.3 Cg_endo -63.14 156.8 52.99 Favored 'Trans proline' 0 N--CA 1.439 -1.735 0 C-N-CA 122.28 1.986 . . . . 0.0 112.768 178.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.416 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -76.99 128.19 34.06 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 176.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.76 21.36 50.95 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.828 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 146.1 24.43 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-O 120.706 0.289 . . . . 0.0 110.799 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.8 p -98.18 120.8 39.22 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.453 -179.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mm -118.69 134.91 60.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 123.894 0.877 . . . . 0.0 109.834 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.0 t -108.94 117.49 54.44 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 172.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.59 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 53.4 p90 -111.38 172.96 6.57 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 120.494 -0.483 . . . . 0.0 110.95 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -131.47 2.61 4.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.364 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -158.08 152.96 25.16 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.218 -175.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.4 t -126.37 134.63 65.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 172.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.406 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 76.1 m -127.64 155.63 43.61 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 122.509 0.323 . . . . 0.0 110.987 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 70' ' ' ILE . 60.4 mt -124.86 114.41 40.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 175.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -164.59 150.77 10.6 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.2 29.69 17.5 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 123.781 0.832 . . . . 0.0 110.021 178.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.04 8.76 65.31 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.125 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -120.67 157.34 29.8 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 122.346 -0.502 . . . . 0.0 110.795 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 65' ' ' ILE . 20.1 mt -104.96 133.45 49.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 173.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -127.13 154.17 45.09 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -170.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 32.5 pt -109.24 136.04 46.34 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 171.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -108.15 130.38 10.06 Favored Glycine 0 N--CA 1.42 -2.425 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.59 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 39.0 p90 . . . . . 0 C--N 1.293 -1.853 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.417 ' HD2' ' HA ' ' A' ' 81' ' ' ARG . 18.1 tpt180 . . . . . 0 N--CA 1.428 -1.55 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.441 HG22 HG12 ' A' ' 39' ' ' ILE . 46.6 t -126.16 135.47 63.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.277 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.7 m-85 -118.06 151.94 36.54 Favored 'General case' 0 C--N 1.281 -2.38 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.273 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 45.2 t -141.9 128.73 11.29 Favored Pre-proline 0 C--N 1.275 -2.647 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -74.12 134.94 20.14 Favored 'Trans proline' 0 N--CA 1.436 -1.858 0 C-N-CA 121.483 1.455 . . . . 0.0 109.395 177.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.8 m -116.52 -13.12 11.25 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.523 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.6 ptm180 -176.34 168.94 2.76 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.9 p -97.07 165.43 12.07 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 53.2 t -145.53 121.45 10.65 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 177.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.607 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 0.5 OUTLIER -86.56 115.18 23.88 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.898 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 -167.49 45.88 Favored Glycine 0 N--CA 1.428 -1.897 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.212 -179.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 8.3 m -132.07 155.27 81.54 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 123.869 0.868 . . . . 0.0 108.838 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.463 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 19.3 Cg_endo -59.51 163.04 13.55 Favored 'Trans proline' 0 CA--C 1.555 1.562 0 C-N-CA 122.232 1.955 . . . . 0.0 113.2 -178.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.463 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 55.3 Cg_endo -68.38 -26.32 6.77 Favored 'Cis proline' 0 C--N 1.364 1.346 0 C-N-CA 123.822 -1.324 . . . . 0.0 112.824 7.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -91.93 78.75 5.32 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.862 0.839 . . . . 0.0 109.288 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.435 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.7 pt20 -95.25 147.17 23.76 Favored 'General case' 0 N--CA 1.426 -1.634 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 175.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.607 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 85.7 mt -123.37 87.99 51.61 Favored Pre-proline 0 C--N 1.265 -3.076 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -78.6 132.43 10.99 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.285 1.99 . . . . 0.0 112.71 -177.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -83.32 -171.5 47.61 Favored Glycine 0 N--CA 1.437 -1.251 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.31 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.3 p -64.21 136.67 26.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-O 120.751 0.31 . . . . 0.0 110.417 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.523 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -73.46 145.09 45.97 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.069 0.461 . . . . 0.0 110.602 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.6 m0 -94.27 11.31 30.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.538 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.03 -174.32 40.05 Favored Glycine 0 N--CA 1.419 -2.489 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.94 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 2.9 t -96.63 151.11 4.16 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -177.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -122.53 102.98 8.4 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 176.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.542 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 57.7 mttm . . . . . 0 C--N 1.298 -1.643 0 CA-C-O 118.276 -0.869 . . . . 0.0 108.682 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.497 HG23 ' HB2' ' A' ' 66' ' ' GLN . 86.9 m . . . . . 0 N--CA 1.424 -1.727 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 74.4 m95 -90.86 134.38 34.5 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -138.85 153.51 48.33 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -137.29 145.38 49.52 Favored Pre-proline 0 C--N 1.291 -1.973 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 173.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -75.56 124.75 8.49 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.342 2.028 . . . . 0.0 109.122 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.86 123.05 4.44 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -103.73 108.52 19.85 Favored 'General case' 0 C--N 1.29 -1.983 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.78 165.99 29.78 Favored 'General case' 0 C--N 1.284 -2.252 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.952 -178.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.535 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 82.7 m -102.5 118.69 37.4 Favored 'General case' 0 N--CA 1.41 -2.433 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.845 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.523 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -99.03 111.92 24.19 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.62 110.09 25.33 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.458 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 50.1 t30 -63.03 145.71 54.82 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.637 0.586 . . . . 0.0 110.705 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.78 -118.75 0.4 Allowed Glycine 0 N--CA 1.426 -1.984 0 CA-C-N 115.889 -0.596 . . . . 0.0 114.016 -176.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -100.44 -11.38 20.24 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 112.748 0.648 . . . . 0.0 112.748 -170.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -121.96 137.44 27.35 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.435 -174.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -67.92 142.58 57.53 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 121.98 1.787 . . . . 0.0 110.364 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mt -116.22 141.83 32.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 C-N-CA 120.287 -0.565 . . . . 0.0 110.66 -174.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.9 t -84.92 117.55 30.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.431 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 82.4 p -93.77 153.8 18.11 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.513 -0.312 . . . . 0.0 111.083 -176.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.479 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 35.5 mmt180 -121.74 160.88 23.63 Favored 'General case' 0 C--O 1.208 -1.1 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -177.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 56.2 mt -126.21 135.99 62.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.415 0.626 . . . . 0.0 112.566 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.52 -48.09 3.08 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.414 173.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 25.3 m -138.15 146.15 50.6 Favored Pre-proline 0 C--N 1.271 -2.833 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.793 -174.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -87.17 81.12 1.34 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.363 2.042 . . . . 0.0 112.235 177.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -144.46 157.26 44.33 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 86.0 mt -76.29 -16.9 59.68 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.995 0.902 . . . . 0.0 108.661 175.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -91.15 3.14 55.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 114.249 -1.341 . . . . 0.0 110.695 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.45 50.42 Favored Pre-proline 0 C--O 1.256 1.437 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.835 -176.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -57.51 147.07 80.71 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 123.167 2.578 . . . . 0.0 111.616 176.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.593 HG12 ' H ' ' A' ' 50' ' ' GLY . 32.8 t -90.42 135.71 25.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.8 -175.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.15 -14.56 54.17 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 177.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.593 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 127.91 -176.77 17.92 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.9 128.89 51.38 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.959 0.88 . . . . 0.0 109.802 176.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.42 HD12 ' HD2' ' A' ' 53' ' ' PRO . 16.4 tp -77.16 127.79 82.5 Favored Pre-proline 0 C--N 1.294 -1.831 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 175.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' HD12 ' A' ' 52' ' ' LEU . 10.0 Cg_endo -63.81 154.47 69.42 Favored 'Trans proline' 0 N--CA 1.443 -1.487 0 C-N-CA 122.03 1.82 . . . . 0.0 112.452 178.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.458 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -73.06 136.85 45.03 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.534 -0.914 . . . . 0.0 108.534 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.41 5.04 85.43 Favored Glycine 0 C--N 1.312 -0.785 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.314 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.27 145.7 37.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 117.029 0.415 . . . . 0.0 111.649 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.6 p -100.75 107.03 18.52 Favored 'General case' 0 N--CA 1.438 -1.028 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.366 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.98 141.56 18.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.6 p -116.11 116.43 52.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 171.211 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.6 p90 -111.03 167.22 10.42 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.846 -176.369 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -124.56 -3.95 7.78 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.57 -179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -153.37 154.13 33.9 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.592 -175.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.2 t -128.53 135.83 61.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.432 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 74.0 m -126.77 156.27 41.48 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.458 0.303 . . . . 0.0 110.766 179.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.46 HG12 HG12 ' A' ' 70' ' ' ILE . 66.4 mt -124.88 117.74 51.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 176.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . 0.497 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.8 tp-100 -164.73 149.81 9.73 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.41 28.35 16.8 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.089 0.956 . . . . 0.0 110.376 178.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.25 8.04 69.16 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.537 -178.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -119.76 155.22 32.93 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 122.093 -0.651 . . . . 0.0 110.486 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.48 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 16.9 mt -104.21 134.27 45.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 174.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -125.78 148.72 49.02 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -171.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -106.71 137.28 38.15 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 172.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.72 125.98 8.15 Favored Glycine 0 N--CA 1.419 -2.456 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.629 -178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.511 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.1 p90 . . . . . 0 C--N 1.294 -1.824 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 176.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.458 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 26.0 tpt180 . . . . . 0 C--O 1.207 -1.182 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 27.1 t -93.45 128.36 44.92 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.835 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.324 -173.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.516 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 58.2 m-85 -113.48 120.27 40.43 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.853 177.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.9 t -110.33 127.1 27.59 Favored Pre-proline 0 C--N 1.28 -2.428 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.45 131.54 17.72 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 121.454 1.436 . . . . 0.0 108.711 176.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.12 -12.58 11.35 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.573 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.6 ptm180 -178.78 174.21 1.17 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 7.0 p -98.49 167.77 10.61 Favored 'General case' 0 C--N 1.288 -2.066 0 C-N-CA 122.631 0.372 . . . . 0.0 110.414 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.2 t -149.96 118.73 6.6 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.546 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 16.1 tt0 -81.31 90.38 6.13 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 96.94 -174.56 30.31 Favored Glycine 0 N--CA 1.433 -1.515 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.134 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 25.7 m -111.81 158.76 35.73 Favored Pre-proline 0 C--N 1.302 -1.49 0 C-N-CA 122.184 0.194 . . . . 0.0 110.917 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.516 ' HB3' HE21 ' A' ' 96' ' ' GLN . 14.1 Cg_endo -63.4 171.5 6.57 Favored 'Trans proline' 0 CA--C 1.555 1.54 0 C-N-CA 122.728 2.286 . . . . 0.0 112.516 177.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.13 -25.01 5.99 Favored 'Cis proline' 0 C--N 1.371 1.751 0 CA-C-N 119.674 0.919 . . . . 0.0 113.4 3.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -91.99 79.34 5.23 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 122.278 1.037 . . . . 0.0 110.013 177.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.516 HE21 ' HB3' ' A' ' 93' ' ' PRO . 1.7 pt20 -96.17 151.29 19.62 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.205 -1.361 . . . . 0.0 107.488 177.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.546 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.1 mt -129.59 86.93 54.32 Favored Pre-proline 0 C--N 1.282 -2.349 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 88' ' ' THR . 20.3 Cg_endo -75.21 128.21 11.15 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 122.286 1.991 . . . . 0.0 112.195 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.17 -161.73 29.44 Favored Glycine 0 C--N 1.315 -0.62 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.93 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.1 p -63.81 135.16 28.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 117.099 0.449 . . . . 0.0 110.872 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.573 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -81.63 147.91 29.32 Favored 'General case' 0 N--CA 1.436 -1.152 0 CA-C-O 121.294 0.569 . . . . 0.0 111.071 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.3 m0 -96.2 13.46 27.33 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.846 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -178.89 -164.47 31.71 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -105.76 153.52 7.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.4 104.55 8.23 Favored 'General case' 0 N--CA 1.419 -2.02 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.535 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 85.4 mttt . . . . . 0 C--N 1.289 -2.059 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 176.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.415 HG23 ' HB2' ' A' ' 66' ' ' GLN . 90.5 m . . . . . 0 N--CA 1.414 -2.226 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 73.7 m95 -86.7 123.96 32.43 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 47.6 p90 -129.0 164.22 23.68 Favored 'General case' 0 C--N 1.282 -2.359 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -177.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -152.8 142.06 14.54 Favored Pre-proline 0 C--N 1.287 -2.137 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -78.49 113.21 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 C-N-CA 122.407 2.071 . . . . 0.0 109.844 175.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -135.44 124.79 24.75 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -176.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -100.87 107.14 18.58 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -177.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.624 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -154.6 168.83 25.44 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.547 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 52.5 m -106.19 121.32 43.94 Favored 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.848 177.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.591 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 72.5 t80 -99.18 113.23 25.38 Favored 'General case' 0 N--CA 1.406 -2.642 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.3 t -100.81 116.22 43.89 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.526 0 N-CA-C 105.599 -2.001 . . . . 0.0 105.599 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -68.14 149.44 49.59 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.6 -0.44 . . . . 0.0 110.485 -177.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.28 -144.94 3.74 Favored Glycine 0 N--CA 1.433 -1.548 0 CA-C-N 116.368 -0.378 . . . . 0.0 113.174 -176.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.36 -6.06 59.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.25 0.548 . . . . 0.0 111.388 -175.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.4 pt20 -117.23 137.55 24.09 Favored Pre-proline 0 C--O 1.207 -1.142 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.233 -178.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.78 155.14 63.12 Favored 'Trans proline' 0 C--O 1.255 1.364 0 C-N-CA 122.611 2.207 . . . . 0.0 110.552 175.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.453 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.9 mt -126.48 134.94 65.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.646 -177.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 53.7 t -76.25 121.38 28.18 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 77.0 p -97.57 156.7 16.39 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 122.322 -0.236 . . . . 0.0 111.428 -175.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.0 mmt180 -124.0 155.12 38.81 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -178.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 82' ' ' VAL . 24.9 mt -116.55 137.83 49.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -175.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.56 -45.15 3.33 Favored Glycine 0 CA--C 1.502 -0.773 0 CA-C-N 114.726 -1.124 . . . . 0.0 113.299 175.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 16.1 p -138.39 155.48 73.89 Favored Pre-proline 0 C--N 1.275 -2.647 0 CA-C-N 114.483 -0.858 . . . . 0.0 111.233 -171.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 30.5 Cg_endo -95.37 58.55 0.2 Allowed 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.483 2.789 . . . . 0.0 112.043 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -121.23 155.8 33.82 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.3 mt -76.65 -23.63 53.29 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.481 0.657 . . . . 0.0 109.419 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -82.22 -13.77 56.57 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.237 177.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.53 152.68 96.01 Favored Pre-proline 0 C--O 1.249 1.072 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.365 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.3 136.72 74.09 Favored 'Trans proline' 0 C--O 1.241 0.655 0 C-N-CA 122.867 2.378 . . . . 0.0 112.728 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.01 132.84 32.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.59 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.11 -18.39 43.32 Favored Glycine 0 C--O 1.241 0.539 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 135.42 -177.31 19.5 Favored Glycine 0 N--CA 1.428 -1.871 0 N-CA-C 109.219 -1.553 . . . . 0.0 109.219 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.35 131.97 43.52 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 118.043 0.922 . . . . 0.0 109.744 175.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.465 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.7 tp -78.2 126.82 82.86 Favored Pre-proline 0 C--N 1.291 -1.964 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 173.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.465 ' HD2' HD12 ' A' ' 52' ' ' LEU . 4.0 Cg_endo -62.48 151.56 82.36 Favored 'Trans proline' 0 N--CA 1.437 -1.805 0 C-N-CA 122.086 1.857 . . . . 0.0 112.507 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -68.52 137.42 54.36 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 175.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.31 22.43 77.58 Favored Glycine 0 N--CA 1.438 -1.181 0 C-N-CA 121.002 -0.618 . . . . 0.0 113.534 -178.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -89.33 152.05 21.75 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 117.8 0.8 . . . . 0.0 110.081 177.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.13 119.44 38.81 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-O 121.163 0.506 . . . . 0.0 109.987 -177.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.413 HG21 HD12 ' A' ' 72' ' ' ILE . 21.4 mm -117.09 130.02 72.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.77 179.069 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.7 p -101.63 116.8 45.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 169.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.624 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 53.7 p90 -112.73 160.62 17.76 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.869 -178.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -123.32 1.16 9.03 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 123.609 0.568 . . . . 0.0 110.75 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -155.24 152.25 29.07 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.044 -173.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 10.8 t -131.4 133.32 62.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 56.7 m -124.56 148.5 47.77 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 123.014 0.526 . . . . 0.0 110.747 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 70' ' ' ILE . 59.4 mt -117.95 116.6 52.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . 0.415 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.7 tp-100 -163.19 147.4 11.03 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 123.572 0.545 . . . . 0.0 109.585 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 60.23 30.99 20.33 Favored 'General case' 0 C--O 1.242 0.71 0 C-N-CA 124.052 0.941 . . . . 0.0 111.446 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 6.62 81.24 Favored Glycine 0 CA--C 1.508 -0.351 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.682 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -120.2 154.2 35.17 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 122.608 -0.348 . . . . 0.0 110.338 -178.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 65' ' ' ILE . 19.5 mt -105.81 133.82 49.09 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 172.116 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -125.69 149.96 48.06 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.07 0.548 . . . . 0.0 109.753 -171.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 28.7 pt -106.47 137.01 39.01 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 171.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.08 121.33 6.98 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 41.5 p90 . . . . . 0 C--N 1.302 -1.489 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.419 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 . . . . . 0 CA--C 1.498 -1.031 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.407 HG22 HG12 ' A' ' 39' ' ' ILE . 45.2 t -123.56 135.88 61.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.499 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.1 m-85 -115.65 123.5 48.53 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.627 -1.17 . . . . 0.0 109.942 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.2 t -111.31 125.85 29.74 Favored Pre-proline 0 C--N 1.281 -2.375 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 177.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.453 ' O ' HG21 ' A' ' 35' ' ' ILE . 33.7 Cg_endo -71.88 129.9 16.03 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 121.54 1.493 . . . . 0.0 108.638 176.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.45 -10.39 12.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.47 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 6.5 ptm180 178.81 173.54 0.72 Allowed 'General case' 0 C--O 1.246 0.899 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.2 p -98.96 167.37 10.78 Favored 'General case' 0 C--N 1.289 -2.033 0 C-N-CA 122.238 0.215 . . . . 0.0 110.737 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.476 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 48.6 t -145.2 128.03 16.35 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 177.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 60.8 tt0 -90.1 96.31 10.61 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 97.64 -157.94 20.84 Favored Glycine 0 N--CA 1.418 -2.505 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.688 177.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.3 m -130.26 150.86 77.31 Favored Pre-proline 0 C--N 1.297 -1.712 0 C-N-CA 123.353 0.661 . . . . 0.0 109.619 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.443 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 42.2 Cg_endo -66.57 165.63 24.62 Favored 'Trans proline' 0 CA--C 1.555 1.534 0 C-N-CA 122.363 2.042 . . . . 0.0 111.175 -178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.42 -5.89 20.15 Favored 'Cis proline' 0 C--N 1.356 0.973 0 C-N-CA 124.301 -1.125 . . . . 0.0 113.329 4.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -101.43 77.48 1.78 Allowed 'General case' 0 N--CA 1.427 -1.597 0 C-N-CA 118.315 -1.354 . . . . 0.0 108.355 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.476 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.5 pm0 -103.08 153.03 20.7 Favored 'General case' 0 N--CA 1.427 -1.584 0 CA-C-N 114.756 -1.111 . . . . 0.0 108.034 178.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 58.1 mt -131.27 87.56 47.17 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 88' ' ' THR . 67.7 Cg_endo -73.53 135.6 22.32 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.544 2.163 . . . . 0.0 112.841 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.45 -170.85 44.52 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.4 p -69.01 138.26 22.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 116.994 0.397 . . . . 0.0 110.25 -178.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -72.01 141.36 49.34 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.163 -178.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 43.6 m0 -87.54 2.49 50.61 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.329 -179.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -159.39 -160.03 10.15 Favored Glycine 0 N--CA 1.43 -1.748 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 178.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -115.15 149.37 17.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -117.56 106.73 13.44 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 175.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 63.4 mttm . . . . . 0 C--N 1.288 -2.092 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 176.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 64' ' ' CYS . 84.5 m . . . . . 0 N--CA 1.403 -2.783 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.404 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 86.0 m95 -88.97 127.05 35.65 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -133.82 158.85 42.34 Favored 'General case' 0 C--N 1.292 -1.91 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.382 -178.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -149.03 150.71 32.89 Favored Pre-proline 0 N--CA 1.426 -1.672 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 170.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.37 131.79 18.22 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 121.742 1.628 . . . . 0.0 110.064 176.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.41 ' HB3' HG23 ' A' ' 63' ' ' VAL . 8.0 tp10 -151.81 123.62 8.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -108.72 106.18 16.09 Favored 'General case' 0 C--N 1.292 -1.903 0 C-N-CA 118.776 -1.17 . . . . 0.0 108.563 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -150.1 167.74 25.93 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.8 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.472 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.1 m -111.06 122.58 48.25 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-O 121.534 0.683 . . . . 0.0 111.134 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.51 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 55.2 t80 -98.62 122.4 41.78 Favored 'General case' 0 N--CA 1.415 -2.18 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.463 HG21 ' HE3' ' A' ' 106' ' ' LYS . 48.2 t -105.32 114.96 46.16 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 176.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.438 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 52.5 t30 -67.66 148.22 51.65 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 123.429 0.456 . . . . 0.0 110.003 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -90.47 -119.98 2.15 Favored Glycine 0 N--CA 1.419 -2.437 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.8 -176.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -85.94 -28.61 24.17 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 -172.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 10.9 pt20 -110.21 136.18 20.52 Favored Pre-proline 0 C--N 1.286 -2.188 0 O-C-N 122.046 -0.409 . . . . 0.0 111.652 -174.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -68.46 140.05 46.85 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.969 1.78 . . . . 0.0 109.809 175.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -112.4 131.1 64.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.913 -172.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.1 t -72.19 116.18 13.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 80.4 p -95.54 162.84 13.47 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.251 -178.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 47' ' ' PRO . 33.4 mmt180 -129.8 155.38 46.06 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -176.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.46 HG12 HG22 ' A' ' 82' ' ' VAL . 26.5 mt -116.37 137.29 50.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -175.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.55 -48.67 3.93 Favored Glycine 0 CA--C 1.494 -1.277 0 CA-C-N 114.218 -1.355 . . . . 0.0 112.623 174.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 43.7 m -139.05 146.9 51.5 Favored Pre-proline 0 C--N 1.264 -3.148 0 CA-C-N 114.353 -0.924 . . . . 0.0 110.264 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -85.9 84.88 1.14 Allowed 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.075 1.85 . . . . 0.0 112.239 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -142.25 156.91 45.32 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.3 mt -76.85 -22.44 53.52 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -90.32 8.0 35.61 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.916 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.95 156.68 42.19 Favored Pre-proline 0 C--O 1.253 1.274 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.436 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 15.6 Cg_endo -57.99 150.79 61.98 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.972 2.448 . . . . 0.0 112.007 179.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.547 HG12 ' H ' ' A' ' 50' ' ' GLY . 59.3 t -86.04 125.08 40.64 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.59 -177.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.41 -8.05 78.33 Favored Glycine 0 CA--C 1.496 -1.15 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.547 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 128.08 179.38 15.83 Favored Glycine 0 N--CA 1.411 -2.983 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -109.66 110.84 22.01 Favored 'General case' 0 C--N 1.269 -2.921 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 53' ' ' PRO . 29.6 tp -63.14 126.84 89.98 Favored Pre-proline 0 C--N 1.303 -1.415 0 CA-C-N 114.288 -1.324 . . . . 0.0 109.466 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.515 ' HD2' HD12 ' A' ' 52' ' ' LEU . 11.9 Cg_exo -60.6 146.72 96.56 Favored 'Trans proline' 0 N--CA 1.431 -2.2 0 C-N-CA 122.402 2.068 . . . . 0.0 112.551 -178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -70.94 116.26 11.03 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.86 -0.66 45.07 Favored Glycine 0 C--N 1.306 -1.09 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.337 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -74.83 143.79 43.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.237 0.541 . . . . 0.0 111.608 -178.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -98.42 117.13 32.15 Favored 'General case' 0 N--CA 1.421 -1.885 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.819 -176.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.5 mm -115.23 127.41 72.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 123.707 0.803 . . . . 0.0 111.389 -179.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 79.2 t -98.95 116.76 42.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 171.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.456 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 55.0 p90 -114.53 164.59 13.78 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.441 -178.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -124.11 3.5 8.62 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.769 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -155.37 147.9 24.06 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.638 -0.825 . . . . 0.0 109.888 -175.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 24' ' ' GLU . 12.5 t -122.46 135.41 62.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.459 ' HB3' ' CG2' ' A' ' 19' ' ' THR . 82.7 m -130.4 150.91 51.41 Favored 'General case' 0 C--N 1.286 -2.17 0 O-C-N 123.306 0.379 . . . . 0.0 110.748 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -119.68 121.37 66.04 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 176.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . 0.403 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.5 tp-100 -167.86 150.08 5.6 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 123.723 0.639 . . . . 0.0 109.51 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 59.49 31.28 20.91 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 123.93 0.892 . . . . 0.0 111.301 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.21 6.77 70.06 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.57 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 77.0 m80 -120.1 156.68 30.52 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 122.537 -0.39 . . . . 0.0 110.69 -177.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.467 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 23.2 mt -104.87 134.35 46.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.6 m95 -125.72 153.82 43.36 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -170.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.523 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.5 pt -113.44 136.61 49.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 173.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.28 123.59 7.48 Favored Glycine 0 N--CA 1.423 -2.178 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.947 -178.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.456 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 37.7 p90 . . . . . 0 C--N 1.296 -1.76 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 . . . . . 0 C--O 1.209 -1.056 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.46 HG22 HG12 ' A' ' 39' ' ' ILE . 39.4 t -118.14 131.79 69.87 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 C-N-CA 119.399 -0.92 . . . . 0.0 109.774 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.523 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 66.6 m-85 -114.06 128.2 56.28 Favored 'General case' 0 C--N 1.286 -2.191 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.31 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.6 t -115.96 128.43 25.98 Favored Pre-proline 0 C--N 1.285 -2.2 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -74.01 130.52 14.46 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.427 1.418 . . . . 0.0 108.74 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.8 m -114.32 -13.5 11.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -175.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.531 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.5 ptm180 -176.51 174.31 1.92 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -178.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.473 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.1 p -98.25 165.23 11.97 Favored 'General case' 0 C--N 1.286 -2.175 0 C-N-CA 122.781 0.432 . . . . 0.0 110.832 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.713 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.0 t -149.98 116.29 5.74 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 122.901 0.48 . . . . 0.0 110.202 177.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.2 tt0 -83.86 103.23 12.96 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.86 -176.04 40.65 Favored Glycine 0 N--CA 1.432 -1.626 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.437 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.415 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 16.1 m -112.69 155.12 44.4 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 36.3 Cg_endo -63.67 164.9 19.68 Favored 'Trans proline' 0 CA--C 1.552 1.4 0 C-N-CA 122.432 2.088 . . . . 0.0 110.861 -178.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -77.49 -5.05 30.82 Favored 'Cis proline' 0 C--N 1.359 1.094 0 C-N-CA 124.573 -1.011 . . . . 0.0 113.363 7.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -104.49 78.82 1.5 Allowed 'General case' 0 CA--C 1.475 -1.916 0 C-N-CA 119.548 -0.861 . . . . 0.0 109.088 171.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.713 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -98.93 151.42 20.9 Favored 'General case' 0 N--CA 1.418 -2.071 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 60.1 mt -125.86 86.06 58.24 Favored Pre-proline 0 C--N 1.291 -1.962 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.473 ' HA ' ' O ' ' A' ' 88' ' ' THR . 54.7 Cg_endo -68.92 129.03 17.72 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.355 2.036 . . . . 0.0 112.666 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.33 -166.83 41.64 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 177.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.7 p -63.34 135.91 26.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.158 0.504 . . . . 0.0 110.596 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.531 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -76.86 144.63 38.88 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.569 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 44.4 m0 -90.35 8.79 31.68 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.334 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -170.51 -156.48 11.37 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.569 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 6.7 t -111.61 154.47 13.15 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -125.97 102.84 7.44 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 176.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 93.3 mttt . . . . . 0 C--N 1.288 -2.087 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.454 HG23 ' HB2' ' A' ' 66' ' ' GLN . 56.6 m . . . . . 0 N--CA 1.434 -1.271 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.422 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 81.9 m95 -82.94 130.77 35.18 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.413 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.2 p90 -141.39 159.33 42.45 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -176.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -150.28 147.47 21.96 Favored Pre-proline 0 N--CA 1.419 -2.015 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -76.37 121.95 6.31 Favored 'Trans proline' 0 N--CA 1.449 -1.109 0 C-N-CA 122.575 2.184 . . . . 0.0 110.121 174.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.28 123.15 8.71 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.518 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 23.9 t-20 -107.26 106.46 16.93 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.613 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.5 166.09 29.23 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.794 -175.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 98.0 m -103.9 119.78 39.63 Favored 'General case' 0 N--CA 1.414 -2.271 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.239 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -98.99 118.89 36.79 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.25 106.1 19.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.917 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 177.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -62.87 142.68 58.17 Favored 'General case' 0 C--N 1.316 -0.854 0 O-C-N 124.024 0.827 . . . . 0.0 111.325 -176.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.75 -140.72 0.91 Allowed Glycine 0 N--CA 1.428 -1.87 0 CA-C-N 115.696 -0.683 . . . . 0.0 113.688 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.67 -13.53 56.26 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 -173.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -110.67 138.71 21.11 Favored Pre-proline 0 C--N 1.31 -1.151 0 O-C-N 121.415 -0.803 . . . . 0.0 111.389 -177.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -69.29 145.85 61.19 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 122.334 2.023 . . . . 0.0 110.422 174.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.37 136.26 56.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.784 -175.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.7 t -75.8 121.89 28.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.5 p -104.59 158.24 16.63 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 110.375 -0.231 . . . . 0.0 110.375 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 26.5 mmt180 -127.6 160.97 29.95 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -174.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.465 HG12 HG22 ' A' ' 82' ' ' VAL . 50.3 mt -122.79 138.1 54.04 Favored 'Isoleucine or valine' 0 C--O 1.243 0.75 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.62 -47.1 2.54 Favored Glycine 0 CA--C 1.497 -1.081 0 CA-C-N 114.517 -1.219 . . . . 0.0 112.561 174.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 45.2 m -139.24 151.83 68.24 Favored Pre-proline 0 C--N 1.273 -2.742 0 C-N-CA 123.794 0.838 . . . . 0.0 111.052 -174.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -90.78 80.85 0.46 Allowed 'Trans proline' 0 N--CA 1.446 -1.293 0 C-N-CA 122.712 2.275 . . . . 0.0 111.761 175.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -141.69 157.76 44.66 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -76.72 -20.72 56.23 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.717 0.77 . . . . 0.0 109.189 178.21 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -98.48 13.09 32.99 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.994 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -87.56 152.14 51.53 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -58.11 138.79 87.78 Favored 'Trans proline' 0 C--O 1.249 1.054 0 C-N-CA 122.641 2.227 . . . . 0.0 112.568 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 69.4 t -68.61 118.03 11.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -80.65 -19.52 68.12 Favored Glycine 0 C--N 1.292 -1.907 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 144.11 -177.11 22.98 Favored Glycine 0 N--CA 1.401 -3.67 0 N-CA-C 107.97 -2.052 . . . . 0.0 107.97 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -112.5 140.06 47.56 Favored 'General case' 0 C--N 1.263 -3.191 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.466 HD12 ' HD2' ' A' ' 53' ' ' PRO . 21.8 tp -85.25 126.11 68.19 Favored Pre-proline 0 C--N 1.281 -2.393 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.335 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.466 ' HD2' HD12 ' A' ' 52' ' ' LEU . 5.2 Cg_endo -62.46 154.07 66.76 Favored 'Trans proline' 0 N--CA 1.438 -1.756 0 C-N-CA 122.101 1.867 . . . . 0.0 112.511 178.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -71.66 135.37 46.86 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 175.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.68 12.96 79.19 Favored Glycine 0 C--N 1.312 -0.799 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.57 146.71 32.44 Favored 'General case' 0 CA--C 1.495 -1.152 0 CA-C-O 121.224 0.535 . . . . 0.0 110.773 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.9 m -108.77 110.62 22.06 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.896 -1.047 . . . . 0.0 109.001 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 27' ' ' THR . 16.8 mm -110.41 133.9 54.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 123.201 0.6 . . . . 0.0 110.841 -177.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.72 117.0 50.65 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 171.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.613 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.0 p90 -111.86 163.4 14.24 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.128 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.39 2.45 8.41 Favored 'General case' 0 C--N 1.309 -1.195 0 O-C-N 123.613 0.571 . . . . 0.0 111.309 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -157.22 152.81 26.63 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.545 -175.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.2 t -130.54 137.3 56.5 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.455 ' HG ' ' HE2' ' A' ' 83' ' ' TYR . 99.3 m -126.73 152.95 46.14 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.89 0.476 . . . . 0.0 110.998 178.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -123.34 110.35 25.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 173.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . 0.454 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.3 tp-100 -159.52 147.34 17.25 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.42 30.21 18.82 Favored 'General case' 0 C--O 1.246 0.916 0 C-N-CA 123.952 0.901 . . . . 0.0 110.209 178.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.58 11.01 64.66 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.051 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.8 m80 -120.48 154.0 35.86 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 122.186 -0.597 . . . . 0.0 110.152 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.523 HG13 ' HB2' ' A' ' 89' ' ' CYS . 18.0 mt -101.5 133.16 45.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 171.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 57.8 m95 -125.31 148.13 48.84 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -172.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.6 pt -106.99 136.89 40.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 171.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.96 123.67 7.4 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.496 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 33.5 p90 . . . . . 0 C--N 1.297 -1.701 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.41 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 23.0 tpt180 . . . . . 0 CA--C 1.494 -1.209 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.465 HG22 HG12 ' A' ' 39' ' ' ILE . 23.1 t -102.75 129.15 54.82 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.025 -176.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.513 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 64.5 m-85 -111.63 134.88 52.89 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.583 177.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -123.13 127.0 25.81 Favored Pre-proline 0 C--N 1.287 -2.117 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 178.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -72.95 128.7 13.43 Favored 'Trans proline' 0 N--CA 1.437 -1.808 0 N-CA-C 108.334 -1.449 . . . . 0.0 108.334 175.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -112.9 -9.35 12.14 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -176.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.4 ptm180 179.75 167.29 1.2 Allowed 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.2 p -90.45 171.19 9.61 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 46.1 t -153.62 127.81 9.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.575 0.703 . . . . 0.0 109.863 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB2' ' HB ' ' A' ' 97' ' ' ILE . 11.6 mt-30 -93.15 112.16 24.02 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.228 173.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.09 167.11 32.72 Favored Glycine 0 N--CA 1.422 -2.292 0 CA-C-N 115.081 -0.963 . . . . 0.0 113.17 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.417 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 17.3 m -97.73 156.19 36.33 Favored Pre-proline 0 C--N 1.289 -2.054 0 CA-C-N 114.749 -0.725 . . . . 0.0 109.144 176.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.509 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 19.3 Cg_endo -62.65 168.86 9.35 Favored 'Trans proline' 0 CA--C 1.559 1.759 0 C-N-CA 122.536 2.158 . . . . 0.0 111.672 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -68.34 -18.14 9.96 Favored 'Cis proline' 0 C--N 1.366 1.49 0 CA-C-N 119.715 0.934 . . . . 0.0 114.024 4.15 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -99.55 79.7 2.3 Favored 'General case' 0 CA--C 1.484 -1.585 0 CA-C-O 121.435 0.636 . . . . 0.0 110.086 175.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.634 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -99.59 146.26 26.64 Favored 'General case' 0 N--CA 1.421 -1.889 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 174.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB2' ' A' ' 90' ' ' GLN . 63.8 mt -122.02 88.51 47.97 Favored Pre-proline 0 C--N 1.29 -1.993 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.638 177.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 87' ' ' ARG . 29.1 Cg_endo -65.73 140.75 63.08 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.347 2.032 . . . . 0.0 112.095 177.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.32 -158.4 33.47 Favored Glycine 0 C--N 1.306 -1.088 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.3 p -66.73 132.68 32.02 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-N 116.996 0.398 . . . . 0.0 110.182 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.577 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.02 139.32 38.2 Favored 'General case' 0 CA--C 1.49 -1.335 0 CA-C-O 120.89 0.376 . . . . 0.0 110.28 178.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 33.6 m0 -92.58 15.29 14.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.016 -177.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.71 -177.46 46.54 Favored Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.975 178.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.7 t -92.7 153.7 3.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -127.0 103.15 7.31 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 176.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.522 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 84.9 mttt . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 177.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m . . . . . 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 170.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 0.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 0.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 0.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 0.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 0.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 0.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 0.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 0.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 0.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 0.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 0.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 0.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 0.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 0.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 0.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 0.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 0.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 0.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 0.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 0.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 0.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 0.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 0.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 0.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 0.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 . . . . . 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 . . . . . 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 0.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 0.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 0.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 0.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 0.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 0.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 0.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 0.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 0.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 0.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.223 -0.31 0 N-CA-C 109.006 -0.738 . . . . 1.0 109.006 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.3 m 65.42 77.54 0.28 Allowed Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 124.722 1.209 . . . . 2.0 112.998 179.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -110.75 -153.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 124.229 3.286 . . . . 3.0 108.683 170.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.06 120.66 27.69 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.344 -1.354 . . . . 4.0 107.344 172.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.3 m -70.57 -45.97 64.38 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 112.04 0.385 . . . . 5.0 112.04 -174.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -79.48 152.27 75.49 Favored Pre-proline 0 C--N 1.315 -0.917 0 CA-C-N 116.535 -0.302 . . . . 6.0 110.872 -178.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.3 106.47 0.84 Allowed 'Trans proline' 0 C--O 1.247 0.945 0 C-N-CA 122.142 1.895 . . . . 7.0 108.997 173.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.03 142.63 35.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 116.07 -0.514 . . . . 8.0 109.971 -173.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.314 5.1 p 59.16 -6.98 0.05 Allowed 'General case' 0 CA--C 1.56 1.341 0 N-CA-C 117.582 2.438 . . . . 9.0 117.582 175.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.27 -97.64 0.86 Allowed Glycine 0 C--O 1.25 1.123 0 CA-C-O 120.929 0.183 . . . . 10.0 113.236 175.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.8 m -63.54 -57.64 9.54 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 123.129 0.571 . . . . 11.0 109.926 -179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.412 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 88.9 m95 -83.38 146.52 28.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.6 -0.727 . . . . 12.0 109.207 -179.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.6 mtmm -146.37 153.59 40.67 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.948 -1.501 . . . . 13.0 106.948 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -104.51 137.48 42.3 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.005 -0.678 . . . . 14.0 110.699 -177.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.0 p30 -91.74 -177.48 4.77 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 116.16 -0.473 . . . . 15.0 111.044 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -56.77 -30.49 63.68 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.287 1.035 . . . . 16.0 113.373 -178.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -82.6 -8.01 59.62 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.862 0.363 . . . . 17.0 111.425 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.24 18.45 59.1 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.734 -0.946 . . . . 18.0 110.734 -176.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m -95.84 131.95 41.62 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 19.0 108.555 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 20.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 21.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.412 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 22.0 107.943 170.106 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 23.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 24.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 25.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 26.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 27.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 28.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 29.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 30.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 31.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 32.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 33.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 34.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 35.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 36.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 37.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 38.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 39.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 40.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 41.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 42.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 43.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 44.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 45.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 46.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 47.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 48.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 49.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 50.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 51.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 52.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 53.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 54.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 55.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 56.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 57.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 58.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 59.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 60.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 61.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 62.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 63.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 64.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 65.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 66.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 67.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 68.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 69.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 70.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 71.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 72.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 73.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 -142.19 171.97 13.34 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 74.0 108.98 177.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -111.45 145.22 39.38 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.785 -0.366 . . . . 75.0 110.416 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -92.35 171.48 9.03 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.981 -1.118 . . . . 76.0 107.981 173.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -62.75 -20.58 65.09 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 123.331 0.652 . . . . 77.0 111.876 -177.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.671 ' HB2' ' OD1' ' A' ' 80' ' ' ASN . 61.3 m-20 -91.23 1.99 56.69 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.888 -0.507 . . . . 78.0 110.099 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.13 8.65 68.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 119.996 -1.097 . . . . 79.0 112.094 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.671 ' OD1' ' HB2' ' A' ' 78' ' ' ASN . 6.9 m120 -71.91 139.19 48.65 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 109.462 -0.57 . . . . 80.0 109.462 -178.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 -86.41 97.56 10.52 Favored 'General case' 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 81.0 107.254 175.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 82.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 83.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 84.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 85.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 86.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 87.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 88.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 89.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 90.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 91.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 92.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 93.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 94.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 95.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 96.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 97.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 98.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 99.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 100.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 101.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 102.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 103.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 104.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 105.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 106.0 109.449 179.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 . . . . . 0 N--CA 1.452 -0.35 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.6 m -79.78 114.98 50.51 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.112 0.965 . . . . 0.0 108.924 177.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_exo -69.05 -31.44 23.66 Favored 'Trans proline' 0 C--O 1.233 0.268 0 C-N-CA 122.647 2.231 . . . . 0.0 111.26 179.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -65.03 140.43 58.85 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.362 177.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.2 p -67.87 114.79 6.74 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.858 177.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 78.0 mtt180 -67.53 140.8 94.98 Favored Pre-proline 0 C--O 1.244 0.802 0 C-N-CA 121.065 -0.254 . . . . 0.0 110.718 -179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -80.02 87.38 1.53 Allowed 'Trans proline' 0 N--CA 1.433 -2.076 0 C-N-CA 121.948 1.765 . . . . 0.0 110.797 179.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.1 p -79.04 -43.34 24.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.323 -178.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 29.9 p -126.85 109.11 11.63 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -120.14 -87.33 1.02 Allowed Glycine 0 CA--C 1.498 -1.012 0 N-CA-C 111.176 -0.77 . . . . 0.0 111.176 -178.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 28.2 m -65.15 -48.65 72.79 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -85.19 122.88 30.01 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.41 -178.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 31.0 mtmm -125.75 144.48 50.61 Favored 'General case' 0 C--N 1.293 -1.851 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.549 179.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.449 ' HE2' ' HA2' ' A' ' 18' ' ' GLY . 51.7 tttm -95.21 132.53 40.08 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.212 0.53 . . . . 0.0 110.123 -175.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.433 HD21 ' HB ' ' A' ' 19' ' ' THR . 37.6 p30 -93.24 -177.33 4.42 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.936 -178.553 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.7 pt20 -60.18 -25.71 65.77 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.531 0.732 . . . . 0.0 112.638 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -87.48 -6.47 58.37 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.485 0.659 . . . . 0.0 110.135 -176.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.449 ' HA2' ' HE2' ' A' ' 14' ' ' LYS . . . 83.99 16.2 68.08 Favored Glycine 0 CA--C 1.498 -1.009 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.416 -178.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.433 ' HB ' HD21 ' A' ' 15' ' ' ASN . 62.6 m -92.21 138.8 31.23 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 177.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.413 ' CD1' ' HB ' ' A' ' 92' ' ' VAL . 79.1 m95 -93.93 134.41 36.34 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -137.68 162.65 33.28 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.564 0.54 . . . . 0.0 110.742 -177.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 61.2 pttt -155.04 145.25 15.84 Favored Pre-proline 0 C--N 1.298 -1.639 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 170.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -76.64 132.31 13.19 Favored 'Trans proline' 0 N--CA 1.445 -1.336 0 C-N-CA 122.161 1.908 . . . . 0.0 109.956 175.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.4 ' HB3' HG23 ' A' ' 63' ' ' VAL . 34.5 tt0 -151.77 123.85 8.14 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 179.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.401 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 17.8 t-20 -105.42 110.61 23.01 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.66 166.76 32.53 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.701 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 76.9 m -103.54 119.55 39.11 Favored 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.19 178.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.569 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 60.0 t80 -99.09 120.08 38.89 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.543 ' HB ' HG22 ' A' ' 104' ' ' VAL . 92.5 t -107.37 109.81 29.52 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 176.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.516 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 55.5 t30 -61.02 148.47 40.09 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 123.804 0.69 . . . . 0.0 110.443 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -85.68 -130.74 2.51 Favored Glycine 0 N--CA 1.432 -1.623 0 CA-C-O 121.321 0.401 . . . . 0.0 113.638 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.24 -7.68 52.88 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -172.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 21.8 pt20 -120.37 141.02 31.14 Favored Pre-proline 0 C--N 1.307 -1.276 0 C-N-CA 120.347 -0.541 . . . . 0.0 111.156 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.73 150.85 68.91 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.069 1.846 . . . . 0.0 110.955 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.528 HG21 ' SG ' ' A' ' 84' ' ' CYS . 7.5 mm -116.24 141.34 34.31 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.186 -174.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.412 ' HA ' HD22 ' A' ' 51' ' ' ASN . 61.8 t -92.79 117.2 35.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.798 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.2 p -97.4 158.79 15.29 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 116.862 -0.153 . . . . 0.0 111.382 -174.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.3 mmt180 -130.06 156.51 44.39 Favored 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -176.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 51.0 mt -115.96 137.64 49.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -176.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.55 -36.83 2.61 Favored Glycine 0 CA--C 1.493 -1.333 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.802 174.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.421 ' HB3' ' HD2' ' A' ' 43' ' ' PHE . 6.8 m -138.08 151.12 69.31 Favored Pre-proline 0 C--N 1.28 -2.425 0 CA-C-N 114.944 -0.628 . . . . 0.0 111.46 -171.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 19.6 Cg_endo -94.01 49.69 0.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 123.369 2.713 . . . . 0.0 111.328 177.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.421 ' HD2' ' HB3' ' A' ' 41' ' ' SER . 99.9 m-85 -121.3 153.04 38.22 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -77.27 -8.78 58.18 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.808 -178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -103.7 4.63 35.57 Favored 'General case' 0 C--O 1.245 0.842 0 CA-C-O 121.618 0.723 . . . . 0.0 110.647 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -80.5 158.73 70.96 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -57.78 140.32 93.27 Favored 'Trans proline' 0 C--O 1.247 0.93 0 C-N-CA 122.491 2.127 . . . . 0.0 111.834 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.488 HG12 ' H ' ' A' ' 50' ' ' GLY . 44.0 t -74.13 126.63 35.16 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.75 -14.27 65.54 Favored Glycine 0 CA--C 1.493 -1.341 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.488 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 129.9 -176.57 18.61 Favored Glycine 0 N--CA 1.414 -2.814 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.412 HD22 ' HA ' ' A' ' 36' ' ' VAL . 14.6 m120 -108.56 130.26 55.3 Favored 'General case' 0 C--N 1.273 -2.729 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -80.99 124.71 81.13 Favored Pre-proline 0 C--N 1.281 -2.402 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 9.4 Cg_endo -61.97 149.98 88.15 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.288 1.992 . . . . 0.0 112.59 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.516 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -68.7 117.82 10.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.572 177.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 30' ' ' ASN . . . 101.78 4.67 51.7 Favored Glycine 0 C--N 1.304 -1.204 0 C-N-CA 121.121 -0.562 . . . . 0.0 112.96 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.404 ' HB2' ' HG2' ' A' ' 53' ' ' PRO . . . -68.05 146.39 53.55 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.5 0.556 . . . . 0.0 112.5 -178.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.409 HG22 HG22 ' A' ' 29' ' ' VAL . 7.6 p -101.57 105.42 16.37 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 123.778 0.831 . . . . 0.0 110.791 -179.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 27' ' ' THR . 19.9 mm -107.74 134.79 48.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 C-N-CA 123.339 0.656 . . . . 0.0 111.296 -178.082 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.78 116.17 48.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 170.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -111.05 162.15 15.17 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.361 -0.536 . . . . 0.0 110.053 -178.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -129.28 6.0 5.3 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 123.791 0.682 . . . . 0.0 111.376 -177.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -158.74 154.89 27.02 Favored 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.4 HG23 ' HB3' ' A' ' 24' ' ' GLU . 8.8 t -133.51 133.75 57.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 172.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.402 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 54.5 m -126.25 154.26 43.61 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 123.419 0.688 . . . . 0.0 110.576 178.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 70' ' ' ILE . 66.0 mt -123.21 123.12 67.04 Favored 'Isoleucine or valine' 0 C--O 1.255 1.377 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.7 tp-100 -171.9 152.72 3.06 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.76 26.42 15.6 Favored 'General case' 0 C--O 1.243 0.757 0 C-N-CA 123.682 0.793 . . . . 0.0 111.045 177.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.33 5.8 82.45 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.202 178.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -120.6 153.86 36.22 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 121.053 0.454 . . . . 0.0 111.34 -177.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.404 HG12 HG12 ' A' ' 65' ' ' ILE . 24.0 mt -100.74 131.91 47.44 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 172.348 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.414 ' CZ3' ' HD3' ' A' ' 85' ' ' PRO . 55.3 m95 -123.62 140.47 52.96 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -172.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.3 pt -97.37 134.44 35.3 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 172.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.13 124.45 8.06 Favored Glycine 0 N--CA 1.425 -2.08 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.56 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.6 p90 -141.62 165.89 26.26 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 120.734 0.302 . . . . 0.0 110.625 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 18.9 m120 -105.7 122.97 47.15 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -74.9 175.96 7.58 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 70.3 t80 -56.35 -35.49 67.7 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.403 0.62 . . . . 0.0 110.444 178.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -77.81 0.31 24.3 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.557 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.39 -20.65 29.31 Favored Glycine 0 C--O 1.24 0.473 0 O-C-N 121.985 -0.447 . . . . 0.0 112.294 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -53.78 135.58 41.31 Favored 'General case' 0 C--O 1.247 0.942 0 C-N-CA 124.636 1.174 . . . . 0.0 111.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.0 tpt180 -76.9 107.73 9.44 Favored 'General case' 0 C--O 1.202 -1.412 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 178.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 26.6 t -104.91 132.91 50.51 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.948 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.05 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.4 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 61.1 m-85 -111.12 125.94 54.31 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.216 177.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.528 ' SG ' HG21 ' A' ' 35' ' ' ILE . 41.0 t -116.49 120.46 34.63 Favored Pre-proline 0 C--N 1.286 -2.159 0 CA-C-N 115.373 -0.831 . . . . 0.0 108.883 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.414 ' HD3' ' CZ3' ' A' ' 71' ' ' TRP . 37.9 Cg_endo -72.31 119.26 6.03 Favored 'Trans proline' 0 N--CA 1.446 -1.268 0 C-N-CA 121.708 1.605 . . . . 0.0 109.134 177.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 29.0 m -105.85 -14.15 9.16 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -174.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.507 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.1 ptt180 -176.23 176.31 1.71 Allowed 'General case' 0 CA--C 1.503 -0.834 0 O-C-N 123.732 0.645 . . . . 0.0 109.581 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 15.6 p -95.6 167.15 11.48 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 123.357 0.411 . . . . 0.0 110.862 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.585 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.1 t -150.71 127.91 11.25 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 174.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.598 HE21 HD12 ' A' ' 97' ' ' ILE . 6.2 tt0 -87.24 110.52 20.24 Favored 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 83.5 -155.45 32.36 Favored Glycine 0 N--CA 1.423 -2.219 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.735 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.413 ' HB ' ' CD1' ' A' ' 20' ' ' TRP . 8.3 m -134.39 155.52 79.7 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.493 ' HA ' ' N ' ' A' ' 95' ' ' ASN . 19.6 Cg_endo -63.19 167.68 12.21 Favored 'Trans proline' 0 CA--C 1.549 1.254 0 C-N-CA 122.198 1.932 . . . . 0.0 111.515 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.81 -4.76 5.97 Favored 'Cis proline' 0 C--N 1.352 0.752 0 N-CA-C 115.513 1.313 . . . . 0.0 115.513 4.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . 0.493 ' N ' ' HA ' ' A' ' 93' ' ' PRO . 39.1 m-80 -108.79 80.45 1.33 Allowed 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.482 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.0 pt20 -96.57 146.08 25.15 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 178.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.598 HD12 HE21 ' A' ' 90' ' ' GLN . 83.7 mt -122.0 87.77 47.43 Favored Pre-proline 0 C--N 1.273 -2.734 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.7 128.52 11.0 Favored 'Trans proline' 0 N--CA 1.442 -1.534 0 C-N-CA 122.647 2.232 . . . . 0.0 112.987 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.53 -175.79 49.56 Favored Glycine 0 N--CA 1.433 -1.558 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.793 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.1 p -67.31 133.98 30.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 120.947 0.403 . . . . 0.0 110.009 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -67.13 143.18 56.78 Favored 'General case' 0 N--CA 1.434 -1.235 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.777 -179.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 39.4 m0 -92.48 17.41 10.06 Favored 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.907 176.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -176.85 -173.39 42.38 Favored Glycine 0 N--CA 1.427 -1.959 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.796 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.569 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.8 OUTLIER -96.6 156.49 3.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -177.605 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -129.02 102.97 6.74 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 107.98 -1.118 . . . . 0.0 107.98 175.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.495 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 65.4 mttm . . . . . 0 C--N 1.301 -1.524 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.384 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 10.9 mm-40 . . . . . 0 C--O 1.243 0.753 0 CA-C-O 120.364 0.126 . . . . 0.0 110.803 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.4 ' HA ' ' HD3' ' A' ' 3' ' ' PRO . 2.9 m -58.86 114.3 8.7 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.429 1.092 . . . . 0.0 112.092 -176.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 2' ' ' THR . 21.2 Cg_exo -65.9 141.26 64.14 Favored 'Trans proline' 0 C--O 1.25 1.077 0 C-N-CA 122.617 2.212 . . . . 0.0 111.19 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.98 84.41 7.46 Favored 'General case' 0 N--CA 1.437 -1.106 0 CA-C-O 121.005 0.431 . . . . 0.0 110.034 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.7 p -103.14 -17.43 15.38 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.714 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.403 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -83.69 136.08 42.5 Favored Pre-proline 0 C--N 1.323 -0.553 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.766 -179.821 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.421 ' HB3' ' O ' ' A' ' 10' ' ' GLY . 47.5 Cg_exo -59.25 123.29 13.1 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 123.081 2.521 . . . . 0.0 111.948 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 47.0 t -91.28 -64.67 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 28.0 p -114.48 35.77 4.07 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 122.137 0.97 . . . . 0.0 108.897 178.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.421 ' O ' ' HB3' ' A' ' 7' ' ' PRO . . . 104.01 -119.47 6.32 Favored Glycine 0 N--CA 1.424 -2.136 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 15.7 m -73.47 -25.57 60.53 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.7 0.762 . . . . 0.0 110.038 178.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 77.3 m95 -84.71 130.43 34.7 Favored 'General case' 0 N--CA 1.423 -1.783 0 CA-C-N 114.855 -1.066 . . . . 0.0 111.115 -175.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 mtmm -129.63 151.97 49.65 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.488 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 26.4 ttpp -114.05 146.09 40.69 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 120.191 -0.604 . . . . 0.0 110.423 -176.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.2 p30 -98.33 -177.92 3.86 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.655 175.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -58.61 -23.46 58.9 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 124.637 1.175 . . . . 0.0 113.485 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -90.31 -6.07 55.53 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.024 0.44 . . . . 0.0 111.0 -176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.488 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 88.0 15.66 60.7 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.921 -0.657 . . . . 0.0 111.981 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 71.6 m -89.19 125.84 35.23 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.434 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 95.4 m95 -88.41 140.06 29.86 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 175.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.407 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 39.7 p90 -146.51 154.6 41.74 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-O 120.568 0.223 . . . . 0.0 110.954 -178.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -144.83 145.69 28.73 Favored Pre-proline 0 C--N 1.305 -1.332 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -80.88 119.74 3.67 Favored 'Trans proline' 0 C--O 1.249 1.056 0 C-N-CA 122.64 2.227 . . . . 0.0 110.784 178.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -145.86 123.56 11.87 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -99.12 109.33 22.05 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.564 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.81 162.85 40.41 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 120.591 -0.444 . . . . 0.0 111.59 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.475 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.4 m -100.54 119.7 38.91 Favored 'General case' 0 N--CA 1.419 -2.024 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.059 177.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.534 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 67.2 t80 -98.97 113.98 26.41 Favored 'General case' 0 N--CA 1.416 -2.163 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 178.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 57' ' ' THR . 41.4 t -101.67 109.14 25.17 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 N-CA-C 106.001 -1.852 . . . . 0.0 106.001 176.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.49 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 53.6 t30 -61.56 149.43 39.1 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 123.567 0.542 . . . . 0.0 110.252 -177.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -88.71 -126.46 2.69 Favored Glycine 0 N--CA 1.423 -2.215 0 N-CA-C 114.259 0.464 . . . . 0.0 114.259 -174.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -89.92 -21.93 22.23 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -172.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -105.24 137.41 19.24 Favored Pre-proline 0 C--N 1.307 -1.25 0 C-N-CA 120.378 -0.529 . . . . 0.0 110.842 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.95 147.97 50.43 Favored 'Trans proline' 0 N--CA 1.456 -0.68 0 C-N-CA 122.191 1.928 . . . . 0.0 109.319 174.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.417 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.6 mt -120.67 136.49 57.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.059 -174.359 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 69.8 t -79.16 116.82 23.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.484 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 72.2 p -91.49 157.12 17.22 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.686 -0.233 . . . . 0.0 110.617 -176.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.3 mmt180 -124.31 152.13 43.46 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -178.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 82' ' ' VAL . 21.0 mt -116.2 136.38 53.34 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -176.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.62 -45.83 3.5 Favored Glycine 0 CA--C 1.497 -1.04 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.868 174.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 40.8 m -138.17 144.33 42.87 Favored Pre-proline 0 C--N 1.274 -2.709 0 CA-C-N 113.972 -1.114 . . . . 0.0 110.324 -173.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -89.34 79.84 0.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.083 0 C-N-CA 122.411 2.074 . . . . 0.0 112.43 178.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -143.14 154.12 43.58 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 179.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 89.9 mt -76.6 -13.5 60.06 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.079 0.942 . . . . 0.0 108.773 174.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -91.24 -8.41 48.47 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.766 177.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -83.32 156.04 66.26 Favored Pre-proline 0 C--O 1.256 1.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.024 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.62 143.89 93.88 Favored 'Trans proline' 0 C--N 1.359 1.103 0 C-N-CA 123.145 2.563 . . . . 0.0 112.396 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 91.8 t -82.36 131.57 33.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.05 -177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.52 -27.9 28.61 Favored Glycine 0 C--N 1.3 -1.438 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 177.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 147.36 -176.33 26.27 Favored Glycine 0 N--CA 1.426 -2.012 0 N-CA-C 108.906 -1.677 . . . . 0.0 108.906 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.24 117.5 34.67 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.411 HD12 ' HD2' ' A' ' 53' ' ' PRO . 20.4 tp -69.36 123.86 89.26 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.411 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.4 Cg_endo -55.94 141.21 86.31 Favored 'Trans proline' 0 N--CA 1.432 -2.105 0 C-N-CA 122.487 2.125 . . . . 0.0 113.266 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.49 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -67.26 116.58 8.2 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.73 0.11 42.48 Favored Glycine 0 C--N 1.304 -1.2 0 C-N-CA 120.728 -0.749 . . . . 0.0 113.1 -177.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -71.86 149.73 44.92 Favored 'General case' 0 C--O 1.237 0.439 0 CA-C-N 116.899 0.35 . . . . 0.0 111.554 -179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.428 HG22 HG22 ' A' ' 29' ' ' VAL . 20.9 p -104.79 108.83 20.52 Favored 'General case' 0 N--CA 1.439 -1.006 0 CA-C-O 121.55 0.691 . . . . 0.0 111.76 -178.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.5 mm -105.48 132.64 51.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 C-N-CA 123.841 0.857 . . . . 0.0 110.954 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.19 116.89 48.83 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 169.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.564 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 52.0 p90 -112.84 164.71 13.07 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.395 -0.522 . . . . 0.0 110.241 -177.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -123.52 -3.01 8.37 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.436 0.46 . . . . 0.0 111.666 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.5 tt0 -154.92 154.43 32.62 Favored 'General case' 0 N--CA 1.434 -1.229 0 C-N-CA 119.445 -0.902 . . . . 0.0 109.85 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 21.6 t -127.04 135.58 63.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.374 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 175.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 61.6 m -125.35 157.03 37.76 Favored 'General case' 0 C--N 1.293 -1.853 0 O-C-N 123.199 0.312 . . . . 0.0 110.98 -178.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.426 HG12 HG12 ' A' ' 70' ' ' ILE . 73.0 mt -127.51 109.91 21.27 Favored 'Isoleucine or valine' 0 C--O 1.253 1.259 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 175.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -156.36 151.61 26.55 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.26 24.99 15.03 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 123.699 0.799 . . . . 0.0 110.361 179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.56 13.27 68.11 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.398 -178.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -120.18 154.72 34.4 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 122.3 -0.53 . . . . 0.0 109.781 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.448 HG13 ' HB2' ' A' ' 89' ' ' CYS . 20.4 mt -101.29 133.89 43.22 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 174.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 53.9 m95 -126.02 150.82 47.82 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -172.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 29.0 pt -106.39 130.71 57.7 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.707 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 170.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -100.05 119.02 6.36 Favored Glycine 0 N--CA 1.417 -2.572 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 51.9 p90 -142.34 168.15 20.41 Favored 'General case' 0 N--CA 1.414 -2.257 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -104.41 127.67 52.13 Favored 'General case' 0 C--N 1.276 -2.63 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 174.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.483 ' HB2' HG21 ' A' ' 82' ' ' VAL . . . -78.54 172.06 14.22 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.708 -177.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 74.9 t80 -64.64 -21.6 66.76 Favored 'General case' 0 C--O 1.22 -0.495 0 CA-C-O 121.994 0.902 . . . . 0.0 108.754 175.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -79.08 -7.49 58.19 Favored 'General case' 0 CA--C 1.555 1.146 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.922 177.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.64 7.51 87.33 Favored Glycine 0 C--O 1.227 -0.327 0 O-C-N 121.537 -0.727 . . . . 0.0 113.338 177.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 -99.05 157.61 16.23 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 122.348 -0.501 . . . . 0.0 111.826 179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 25.2 tpt180 -79.43 114.34 18.28 Favored 'General case' 0 CA--C 1.487 -1.453 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.484 ' CG1' ' HB ' ' A' ' 37' ' ' THR . 38.3 t -116.93 134.95 58.87 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.681 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.54 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.8 m-85 -117.4 123.2 45.85 Favored 'General case' 0 C--N 1.281 -2.408 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.2 178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -112.39 126.01 29.11 Favored Pre-proline 0 C--N 1.279 -2.467 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 35' ' ' ILE . 36.8 Cg_endo -71.79 129.78 15.96 Favored 'Trans proline' 0 N--CA 1.439 -1.678 0 C-N-CA 121.374 1.382 . . . . 0.0 108.778 176.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.3 m -112.51 -13.11 11.48 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -174.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.456 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.6 ptm180 -178.31 167.0 1.91 Allowed 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 16.2 p -92.33 162.68 14.17 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.501 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.8 t -141.39 120.69 13.06 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.554 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 28.1 tt0 -83.63 111.32 19.01 Favored 'General case' 0 N--CA 1.424 -1.768 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 177.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.17 -166.13 51.24 Favored Glycine 0 N--CA 1.426 -1.994 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 -178.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.455 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 13.9 m -121.22 160.49 45.28 Favored Pre-proline 0 C--N 1.297 -1.707 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.455 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 31.4 Cg_endo -65.67 167.41 17.33 Favored 'Trans proline' 0 CA--C 1.547 1.155 0 C-N-CA 121.987 1.792 . . . . 0.0 112.48 179.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.407 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.4 Cg_endo -65.37 -28.46 4.36 Favored 'Cis proline' 0 C--N 1.363 1.307 0 C-N-CA 124.62 -0.992 . . . . 0.0 113.985 4.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 52.4 m-80 -90.86 79.31 5.96 Favored 'General case' 0 CA--C 1.485 -1.549 0 CA-C-O 122.17 0.986 . . . . 0.0 110.169 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.501 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 0.9 OUTLIER -94.26 143.82 26.06 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 176.409 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.554 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.0 mt -122.15 92.46 48.88 Favored Pre-proline 0 C--N 1.27 -2.873 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 177.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.529 ' HA ' ' O ' ' A' ' 88' ' ' THR . 58.7 Cg_endo -79.66 135.69 11.72 Favored 'Trans proline' 0 N--CA 1.434 -2.029 0 C-N-CA 122.263 1.976 . . . . 0.0 112.226 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.71 -159.07 23.38 Favored Glycine 0 C--N 1.311 -0.816 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 177.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -63.83 139.19 21.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.456 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.75 135.1 36.42 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 42.3 m0 -83.77 9.41 11.94 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.786 -177.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -174.02 -172.08 38.97 Favored Glycine 0 N--CA 1.428 -1.891 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 178.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.5 t -97.36 149.35 5.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 -178.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -122.2 108.67 13.56 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 175.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.475 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 82.3 mttt . . . . . 0 C--N 1.285 -2.229 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 177.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 121.192 0.52 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.5 m -95.73 130.35 31.97 Favored Pre-proline 0 N--CA 1.428 -1.572 0 N-CA-C 107.389 -1.338 . . . . 0.0 107.389 177.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -72.22 34.94 0.3 Allowed 'Trans proline' 0 N--CA 1.496 1.642 0 C-N-CA 123.419 2.746 . . . . 0.0 112.874 178.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.7 158.58 43.94 Favored 'General case' 0 N--CA 1.429 -1.513 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 -178.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 7.3 p -72.97 159.95 32.87 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-O 121.109 0.48 . . . . 0.0 111.262 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 81.2 mtt180 -74.3 134.66 76.7 Favored Pre-proline 0 C--N 1.308 -1.212 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.799 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_exo -58.54 112.88 1.33 Allowed 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.616 2.21 . . . . 0.0 111.515 -178.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.8 t -67.39 -41.32 86.14 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 175.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.648 ' HB ' ' O ' ' A' ' 12' ' ' TRP . 0.2 OUTLIER -146.03 108.26 4.41 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.156 -1.383 . . . . 0.0 110.625 179.519 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.69 -26.01 7.0 Favored Glycine 0 C--N 1.31 -0.876 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 175.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 p -73.38 -54.79 7.47 Favored 'General case' 0 N--CA 1.433 -1.277 0 C-N-CA 124.322 1.049 . . . . 0.0 110.077 178.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.648 ' O ' ' HB ' ' A' ' 9' ' ' THR . 72.7 m95 -103.87 143.5 32.75 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 177.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 53.7 mtmt -125.65 140.23 52.89 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.418 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 25.9 ttpp -103.98 139.44 39.1 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 120.051 -0.66 . . . . 0.0 109.784 -179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.8 p30 -95.27 -177.8 4.23 Favored 'General case' 0 C--N 1.303 -1.418 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.105 176.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -63.18 -23.91 67.64 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -75.58 -17.52 60.02 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.533 0.682 . . . . 0.0 109.597 -178.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.418 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 93.79 8.7 60.45 Favored Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -178.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 32.2 m -86.08 125.4 33.43 Favored 'General case' 0 N--CA 1.412 -2.327 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.436 ' O ' ' HA ' ' A' ' 64' ' ' CYS . 89.6 m95 -86.38 125.37 33.61 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.135 -1.432 . . . . 0.0 107.135 175.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.2 p90 -134.64 151.57 51.14 Favored 'General case' 0 C--N 1.281 -2.404 0 CA-C-O 121.094 0.473 . . . . 0.0 110.562 -177.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -135.59 143.53 45.34 Favored Pre-proline 0 C--N 1.292 -1.926 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 173.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -76.8 113.03 3.56 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.216 1.944 . . . . 0.0 109.542 176.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 25.1 tt0 -147.82 124.13 10.91 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.434 -178.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -100.06 106.59 18.35 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -178.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.542 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -147.11 160.4 42.46 Favored 'General case' 0 C--N 1.288 -2.067 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.616 -178.429 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.6 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 55.6 m -102.81 121.57 42.75 Favored 'General case' 0 C--N 1.288 -2.1 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.835 178.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.554 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.5 t80 -99.25 112.09 24.33 Favored 'General case' 0 C--N 1.284 -2.269 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.501 ' HB ' HG22 ' A' ' 104' ' ' VAL . 99.3 t -97.17 108.28 21.28 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -63.84 143.76 57.59 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 123.502 0.501 . . . . 0.0 110.069 -178.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -83.12 -128.05 1.27 Allowed Glycine 0 N--CA 1.425 -2.057 0 CA-C-N 116.112 -0.494 . . . . 0.0 113.319 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -90.67 -14.61 31.93 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -172.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.2 pt20 -108.26 136.86 19.8 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.947 -0.471 . . . . 0.0 111.575 -177.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -71.44 142.24 40.32 Favored 'Trans proline' 0 C--O 1.247 0.949 0 C-N-CA 121.974 1.783 . . . . 0.0 109.711 172.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.424 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.4 mt -117.26 133.24 64.64 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.085 -174.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -77.56 113.08 16.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.403 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 70.7 p -89.04 156.57 18.77 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.679 -175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.3 mmt180 -126.95 156.28 41.79 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -177.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.436 HG12 HG22 ' A' ' 82' ' ' VAL . 50.7 mt -122.09 135.83 60.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -177.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.54 -35.17 3.04 Favored Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.301 -0.863 . . . . 0.0 113.511 173.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.437 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 56.1 m -139.43 139.48 22.75 Favored Pre-proline 0 C--N 1.261 -3.253 0 C-N-CA 123.16 0.584 . . . . 0.0 111.343 -176.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 21.1 Cg_endo -87.13 55.06 2.99 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.714 2.276 . . . . 0.0 111.179 177.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -123.81 157.76 33.34 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.044 -178.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.7 mt -76.87 -14.03 59.93 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.551 0.691 . . . . 0.0 110.232 179.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -97.58 4.28 50.29 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.414 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -84.11 155.08 64.0 Favored Pre-proline 0 C--N 1.314 -0.935 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -57.64 136.75 77.61 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 122.991 2.46 . . . . 0.0 112.33 -178.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -78.27 124.48 36.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 115.355 -0.838 . . . . 0.0 109.701 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -81.36 -25.97 53.0 Favored Glycine 0 C--N 1.302 -1.331 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 177.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.56 -176.73 21.26 Favored Glycine 0 N--CA 1.421 -2.345 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -95.66 130.62 42.48 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 173.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.427 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.4 tp -77.01 126.31 85.69 Favored Pre-proline 0 C--N 1.285 -2.196 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 173.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HD2' HD12 ' A' ' 52' ' ' LEU . 6.2 Cg_endo -60.78 148.41 92.06 Favored 'Trans proline' 0 N--CA 1.44 -1.673 0 C-N-CA 121.913 1.742 . . . . 0.0 112.3 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.26 132.81 47.06 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 175.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 91.23 2.66 70.64 Favored Glycine 0 C--N 1.302 -1.333 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.069 -177.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -75.24 144.67 42.46 Favored 'General case' 0 CA--C 1.505 -0.771 0 CA-C-O 121.37 0.605 . . . . 0.0 110.974 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.423 HG23 HG22 ' A' ' 29' ' ' VAL . 3.1 m -104.8 107.92 19.13 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.12 -176.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.4 mm -106.95 130.09 59.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.727 0 C-N-CA 123.38 0.672 . . . . 0.0 111.323 -176.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 85.0 t -100.03 117.54 45.36 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 170.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.542 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 55.1 p90 -116.09 163.57 15.74 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.906 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -121.74 -0.59 9.61 Favored 'General case' 0 C--N 1.306 -1.289 0 O-C-N 123.409 0.443 . . . . 0.0 111.689 -178.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -153.27 148.54 26.93 Favored 'General case' 0 N--CA 1.433 -1.322 0 C-N-CA 119.82 -0.752 . . . . 0.0 110.11 -176.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 14.4 t -120.98 133.48 67.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 105.681 -1.97 . . . . 0.0 105.681 173.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 20' ' ' TRP . 3.9 m -125.66 150.1 47.9 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -175.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.41 HG12 HG12 ' A' ' 70' ' ' ILE . 64.3 mt -123.01 118.19 54.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 173.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -160.31 145.5 14.85 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -178.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.87 29.59 17.94 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 124.191 0.996 . . . . 0.0 110.759 177.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.06 10.47 73.4 Favored Glycine 0 CA--C 1.519 0.29 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.414 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -119.58 153.13 35.92 Favored 'General case' 0 C--N 1.295 -1.798 0 O-C-N 122.402 -0.469 . . . . 0.0 110.114 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.422 HD12 ' HG3' ' A' ' 87' ' ' ARG . 23.5 mt -103.37 133.94 45.88 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 174.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 54.5 m95 -127.73 153.61 46.32 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -171.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.49 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -109.96 130.25 63.47 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.774 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 171.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.47 122.52 7.55 Favored Glycine 0 N--CA 1.42 -2.424 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 -178.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.536 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.2 p90 -142.38 149.56 39.54 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 178.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -86.98 122.74 31.25 Favored 'General case' 0 C--N 1.291 -1.951 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -67.89 175.58 2.99 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 123.656 0.597 . . . . 0.0 109.617 178.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -57.36 -34.51 68.89 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 123.122 0.569 . . . . 0.0 111.175 -178.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -83.51 -10.05 58.57 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-O 121.482 0.658 . . . . 0.0 110.97 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.83 -9.81 55.43 Favored Glycine 0 C--N 1.312 -0.794 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.035 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -58.43 139.92 54.68 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 122.918 0.487 . . . . 0.0 110.875 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 18.7 tpt180 -82.74 99.04 9.41 Favored 'General case' 0 CA--C 1.492 -1.267 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.436 HG22 HG12 ' A' ' 39' ' ' ILE . 35.9 t -97.39 130.48 45.99 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.527 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.494 -177.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 97.6 m-85 -112.4 125.17 53.92 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.622 -1.172 . . . . 0.0 108.309 178.04 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -114.14 125.06 29.83 Favored Pre-proline 0 C--N 1.278 -2.501 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 176.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.424 ' O ' HG21 ' A' ' 35' ' ' ILE . 42.8 Cg_endo -72.59 129.07 14.17 Favored 'Trans proline' 0 N--CA 1.439 -1.731 0 C-N-CA 121.271 1.314 . . . . 0.0 108.724 177.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.7 m -112.39 -15.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.482 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptt180 -177.48 173.12 1.73 Allowed 'General case' 0 CA--C 1.503 -0.853 0 C-N-CA 123.629 0.772 . . . . 0.0 109.457 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.6 p -99.93 168.3 9.96 Favored 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.598 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 45.1 t -147.55 123.86 10.91 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.568 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.3 tt0 -82.91 96.31 8.24 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.56 174.83 44.58 Favored Glycine 0 N--CA 1.429 -1.809 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.759 178.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 16.0 m -106.63 154.91 39.73 Favored Pre-proline 0 C--N 1.295 -1.797 0 C-N-CA 122.081 0.152 . . . . 0.0 111.011 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.431 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 38.4 Cg_endo -63.47 167.01 13.9 Favored 'Trans proline' 0 CA--C 1.556 1.617 0 C-N-CA 122.677 2.252 . . . . 0.0 112.8 -178.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.431 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 44.1 Cg_endo -66.13 -24.58 6.17 Favored 'Cis proline' 0 C--N 1.372 1.794 0 C-N-CA 124.156 -1.185 . . . . 0.0 113.278 5.577 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -89.21 79.04 7.2 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-O 121.727 0.775 . . . . 0.0 109.26 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.598 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 12.8 pt20 -101.84 152.06 21.34 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 177.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.568 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 68.0 mt -130.28 88.02 49.03 Favored Pre-proline 0 C--N 1.284 -2.277 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -73.46 133.81 19.65 Favored 'Trans proline' 0 N--CA 1.443 -1.453 0 C-N-CA 122.433 2.089 . . . . 0.0 112.536 -178.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -85.42 -163.38 37.32 Favored Glycine 0 N--CA 1.441 -1.002 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.748 178.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.9 p -69.54 131.85 33.65 Favored 'Isoleucine or valine' 0 C--O 1.251 1.145 0 CA-C-O 120.88 0.371 . . . . 0.0 110.695 -178.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.482 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -71.6 140.55 49.82 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.445 177.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.4 m0 -90.2 10.86 22.95 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.799 179.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -167.54 -159.95 14.08 Favored Glycine 0 N--CA 1.43 -1.712 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.22 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 0.7 OUTLIER -113.03 154.64 14.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 -179.045 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -123.76 103.61 8.48 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.6 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 87.5 mttt . . . . . 0 C--N 1.301 -1.537 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 173.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 . . . . . 0 C--O 1.234 0.264 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 78.1 m -103.26 121.37 48.97 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 179.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.58 93.5 0.37 Allowed 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.006 1.804 . . . . 0.0 110.474 175.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -113.8 9.69 17.68 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.469 0.652 . . . . 0.0 110.108 -179.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.1 m -94.67 26.95 3.24 Favored 'General case' 0 CA--C 1.558 1.268 0 CA-C-O 122.3 1.048 . . . . 0.0 108.974 -176.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 58.3 ttt180 -63.41 134.12 95.73 Favored Pre-proline 0 C--O 1.246 0.91 0 CA-C-N 114.253 -1.34 . . . . 0.0 111.966 -177.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.31 140.16 57.44 Favored 'Trans proline' 0 C--O 1.239 0.57 0 C-N-CA 123.182 2.588 . . . . 0.0 110.705 177.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 27.2 m -86.47 -33.5 7.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 113.417 0.895 . . . . 0.0 113.417 -175.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 36.2 p -96.83 -28.92 14.03 Favored 'General case' 0 C--N 1.318 -0.803 0 C-N-CA 119.876 -0.73 . . . . 0.0 110.964 178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 135.63 -68.78 0.53 Allowed Glycine 0 N--CA 1.43 -1.714 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.207 179.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.7 t -92.97 -20.23 20.81 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 120.635 0.255 . . . . 0.0 110.603 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -115.92 151.73 34.8 Favored 'General case' 0 C--O 1.254 1.317 0 CA-C-O 121.659 0.743 . . . . 0.0 111.68 -177.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -126.75 149.82 49.42 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.5 ttpp -117.94 134.02 55.35 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.985 -0.686 . . . . 0.0 109.391 176.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.1 p30 -92.72 -175.37 3.92 Favored 'General case' 0 C--N 1.293 -1.874 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.86 -177.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -64.04 -19.01 64.9 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 114.112 1.153 . . . . 0.0 114.112 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -92.99 -3.24 54.79 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.947 0.403 . . . . 0.0 110.766 178.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 83.53 17.04 67.12 Favored Glycine 0 CA--C 1.507 -0.43 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 -178.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 87.3 m -89.68 127.6 35.95 Favored 'General case' 0 N--CA 1.421 -1.91 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 177.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -84.91 135.9 33.86 Favored 'General case' 0 CA--C 1.485 -1.536 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 175.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -149.5 162.51 40.01 Favored 'General case' 0 C--N 1.281 -2.388 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -177.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 62.8 pttt -150.36 144.7 17.71 Favored Pre-proline 0 N--CA 1.422 -1.852 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -73.17 126.84 11.46 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 122.621 2.214 . . . . 0.0 109.73 176.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -152.76 123.7 7.45 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -178.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -100.7 108.88 20.85 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -155.21 164.77 38.35 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.642 -178.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.542 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 65.1 m -105.72 120.85 42.74 Favored 'General case' 0 N--CA 1.416 -2.154 0 CA-C-N 114.823 -1.081 . . . . 0.0 109.43 177.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 65.7 t80 -98.98 125.25 44.4 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -113.1 109.72 29.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.165 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.416 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 51.8 t30 -65.33 145.28 56.39 Favored 'General case' 0 C--N 1.308 -1.205 0 O-C-N 123.778 0.674 . . . . 0.0 110.699 -177.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -84.54 -108.49 0.62 Allowed Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 114.863 0.705 . . . . 0.0 114.863 -174.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.26 -25.04 13.82 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 122.599 0.36 . . . . 0.0 111.717 -170.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 23.3 pt20 -110.84 133.63 21.18 Favored Pre-proline 0 C--N 1.295 -1.769 0 C-N-CA 120.215 -0.594 . . . . 0.0 111.802 -176.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.05 140.72 55.25 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.211 1.941 . . . . 0.0 110.568 175.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.85 136.25 52.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.746 -173.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.402 HG22 ' ND2' ' A' ' 51' ' ' ASN . 52.6 t -77.36 121.03 28.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 68.8 p -94.19 157.84 15.87 Favored 'General case' 0 C--N 1.319 -0.758 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.034 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.44 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 27.0 mmt180 -130.72 155.01 47.35 Favored 'General case' 0 C--O 1.21 -0.985 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 -174.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.441 HG12 HG22 ' A' ' 82' ' ' VAL . 18.6 mt -112.46 138.95 39.67 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 N-CA-C 113.7 1.0 . . . . 0.0 113.7 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.45 -48.74 4.11 Favored Glycine 0 CA--C 1.502 -0.719 0 C-N-CA 124.921 1.248 . . . . 0.0 113.752 174.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 14.8 m -137.35 154.2 75.26 Favored Pre-proline 0 C--N 1.279 -2.499 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.991 -170.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -91.03 67.22 1.31 Allowed 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 123.006 2.47 . . . . 0.0 111.77 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -131.17 156.45 45.29 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.7 mt -76.46 -19.98 57.49 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.959 0.409 . . . . 0.0 111.024 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -100.39 18.16 19.68 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 121.556 0.694 . . . . 0.0 111.208 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.44 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -85.22 152.62 58.6 Favored Pre-proline 0 C--N 1.308 -1.239 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 175.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.4 143.24 94.61 Favored 'Trans proline' 0 C--N 1.35 0.608 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 -179.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.637 HG12 ' H ' ' A' ' 50' ' ' GLY . 51.7 t -79.57 126.19 39.05 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -96.01 7.69 67.36 Favored Glycine 0 C--N 1.308 -0.976 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 -178.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.637 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 122.28 170.51 13.71 Favored Glycine 0 N--CA 1.423 -2.21 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 -178.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.402 ' ND2' HG22 ' A' ' 36' ' ' VAL . 2.3 m-20 -113.19 117.17 31.17 Favored 'General case' 0 C--N 1.28 -2.418 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.494 HD12 ' HD2' ' A' ' 53' ' ' PRO . 19.6 tp -68.78 125.7 92.08 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.212 -176.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HD2' HD12 ' A' ' 52' ' ' LEU . 1.3 Cg_endo -63.14 156.8 52.99 Favored 'Trans proline' 0 N--CA 1.439 -1.735 0 C-N-CA 122.28 1.986 . . . . 0.0 112.768 178.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.416 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -76.99 128.19 34.06 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 176.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.76 21.36 50.95 Favored Glycine 0 C--N 1.305 -1.191 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.828 -176.436 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -94.82 146.1 24.43 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-O 120.706 0.289 . . . . 0.0 110.799 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 9.8 p -98.18 120.8 39.22 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.453 -179.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mm -118.69 134.91 60.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 123.894 0.877 . . . . 0.0 109.834 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.0 t -108.94 117.49 54.44 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 172.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.59 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 53.4 p90 -111.38 172.96 6.57 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 120.494 -0.483 . . . . 0.0 110.95 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -131.47 2.61 4.18 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.364 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -158.08 152.96 25.16 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.218 -175.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 18.4 t -126.37 134.63 65.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 172.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.406 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 76.1 m -127.64 155.63 43.61 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 122.509 0.323 . . . . 0.0 110.987 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 70' ' ' ILE . 60.4 mt -124.86 114.41 40.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 175.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -164.59 150.77 10.6 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.2 29.69 17.5 Favored 'General case' 0 C--O 1.238 0.482 0 C-N-CA 123.781 0.832 . . . . 0.0 110.021 178.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.04 8.76 65.31 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.125 179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.2 m80 -120.67 157.34 29.8 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 122.346 -0.502 . . . . 0.0 110.795 -178.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.427 HG12 HG12 ' A' ' 65' ' ' ILE . 20.1 mt -104.96 133.45 49.14 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 173.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -127.13 154.17 45.09 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -170.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.491 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 32.5 pt -109.24 136.04 46.34 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 171.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -108.15 130.38 10.06 Favored Glycine 0 N--CA 1.42 -2.425 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.59 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 39.0 p90 -146.85 172.31 13.86 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -107.92 142.94 37.25 Favored 'General case' 0 C--N 1.29 -2.012 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.323 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -81.58 178.22 8.47 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 175.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -61.99 -28.12 69.34 Favored 'General case' 0 C--N 1.313 -1.004 0 C-N-CA 122.459 0.304 . . . . 0.0 110.802 179.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 -70.74 -19.35 62.74 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-O 121.469 0.652 . . . . 0.0 110.884 174.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.9 0.96 68.06 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 -173.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 -70.13 154.04 42.41 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 -179.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.417 ' HD2' ' HA ' ' A' ' 81' ' ' ARG . 18.1 tpt180 -83.67 128.23 34.37 Favored 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.441 HG22 HG12 ' A' ' 39' ' ' ILE . 46.6 t -126.16 135.47 63.73 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.277 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.7 m-85 -118.06 151.94 36.54 Favored 'General case' 0 C--N 1.281 -2.38 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.273 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 45.2 t -141.9 128.73 11.29 Favored Pre-proline 0 C--N 1.275 -2.647 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -74.12 134.94 20.14 Favored 'Trans proline' 0 N--CA 1.436 -1.858 0 C-N-CA 121.483 1.455 . . . . 0.0 109.395 177.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.8 m -116.52 -13.12 11.25 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.523 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.6 ptm180 -176.34 168.94 2.76 Favored 'General case' 0 C--O 1.243 0.715 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.9 p -97.07 165.43 12.07 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 53.2 t -145.53 121.45 10.65 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 177.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.607 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 0.5 OUTLIER -86.56 115.18 23.88 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.898 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 82.97 -167.49 45.88 Favored Glycine 0 N--CA 1.428 -1.897 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.212 -179.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 8.3 m -132.07 155.27 81.54 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 123.869 0.868 . . . . 0.0 108.838 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.463 ' HA ' ' C ' ' A' ' 94' ' ' PRO . 19.3 Cg_endo -59.51 163.04 13.55 Favored 'Trans proline' 0 CA--C 1.555 1.562 0 C-N-CA 122.232 1.955 . . . . 0.0 113.2 -178.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.463 ' C ' ' HA ' ' A' ' 93' ' ' PRO . 55.3 Cg_endo -68.38 -26.32 6.77 Favored 'Cis proline' 0 C--N 1.364 1.346 0 C-N-CA 123.822 -1.324 . . . . 0.0 112.824 7.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -91.93 78.75 5.32 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.862 0.839 . . . . 0.0 109.288 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.435 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 10.7 pt20 -95.25 147.17 23.76 Favored 'General case' 0 N--CA 1.426 -1.634 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 175.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.607 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 85.7 mt -123.37 87.99 51.61 Favored Pre-proline 0 C--N 1.265 -3.076 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -78.6 132.43 10.99 Favored 'Trans proline' 0 N--CA 1.443 -1.475 0 C-N-CA 122.285 1.99 . . . . 0.0 112.71 -177.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -83.32 -171.5 47.61 Favored Glycine 0 N--CA 1.437 -1.251 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.31 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.3 p -64.21 136.67 26.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-O 120.751 0.31 . . . . 0.0 110.417 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.523 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -73.46 145.09 45.97 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-O 121.069 0.461 . . . . 0.0 110.602 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 31.6 m0 -94.27 11.31 30.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.538 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.03 -174.32 40.05 Favored Glycine 0 N--CA 1.419 -2.489 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.94 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 2.9 t -96.63 151.11 4.16 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -177.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -122.53 102.98 8.4 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 176.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.542 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 57.7 mttm . . . . . 0 C--N 1.298 -1.643 0 CA-C-O 118.276 -0.869 . . . . 0.0 108.682 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 . . . . . 0 N--CA 1.469 0.483 0 N-CA-C 110.77 -0.085 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 19.3 m -75.46 113.63 28.0 Favored Pre-proline 0 N--CA 1.438 -1.03 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -77.06 129.68 10.71 Favored 'Trans proline' 0 N--CA 1.448 -1.164 0 C-N-CA 122.122 1.881 . . . . 0.0 112.001 -177.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.96 45.78 1.3 Allowed 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.809 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -68.75 101.75 1.39 Allowed 'General case' 0 N--CA 1.425 -1.703 0 CA-C-O 121.93 0.871 . . . . 0.0 111.306 -178.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 46.8 mtm-85 -95.14 156.02 38.28 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.561 -176.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -68.51 102.6 0.86 Allowed 'Trans proline' 0 N--CA 1.452 -0.94 0 C-N-CA 122.327 2.018 . . . . 0.0 110.962 176.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 48.7 t -100.07 138.11 25.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.272 6.4 p 57.34 -82.66 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.583 1.553 . . . . 0.0 114.77 178.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 115.16 -57.36 0.48 Allowed Glycine 0 CA--C 1.493 -1.293 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.728 178.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 6.2 p -74.22 -65.41 0.85 Allowed 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 176.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.431 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 85.5 m95 -79.4 143.13 35.35 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-N 114.748 -1.115 . . . . 0.0 108.682 175.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -133.94 153.63 51.63 Favored 'General case' 0 C--N 1.283 -2.302 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 174.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.437 ' HD2' ' HA2' ' A' ' 18' ' ' GLY . 27.1 ttpp -102.82 135.08 45.15 Favored 'General case' 0 C--N 1.292 -1.928 0 C-N-CA 120.029 -0.669 . . . . 0.0 110.065 -179.076 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 34.3 p30 -95.26 -178.89 4.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.577 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -62.34 -16.04 51.94 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 124.119 0.967 . . . . 0.0 113.505 -177.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -87.54 -2.04 58.35 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.437 ' HA2' ' HD2' ' A' ' 14' ' ' LYS . . . 70.38 29.94 69.64 Favored Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 -174.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.497 HG23 ' HB2' ' A' ' 66' ' ' GLN . 86.9 m -105.26 134.89 47.62 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 74.4 m95 -90.86 134.38 34.5 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -138.85 153.51 48.33 Favored 'General case' 0 C--N 1.292 -1.916 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.431 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 59.6 pttt -137.29 145.38 49.52 Favored Pre-proline 0 C--N 1.291 -1.973 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 173.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -75.56 124.75 8.49 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.342 2.028 . . . . 0.0 109.122 173.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -157.86 123.05 4.44 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -103.73 108.52 19.85 Favored 'General case' 0 C--N 1.29 -1.983 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.78 165.99 29.78 Favored 'General case' 0 C--N 1.284 -2.252 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.952 -178.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.535 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 82.7 m -102.5 118.69 37.4 Favored 'General case' 0 N--CA 1.41 -2.433 0 CA-C-N 115.353 -0.84 . . . . 0.0 109.845 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.523 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -99.03 111.92 24.19 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 178.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.62 110.09 25.33 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.2 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 176.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.458 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 50.1 t30 -63.03 145.71 54.82 Favored 'General case' 0 C--N 1.309 -1.156 0 O-C-N 123.637 0.586 . . . . 0.0 110.705 -177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.78 -118.75 0.4 Allowed Glycine 0 N--CA 1.426 -1.984 0 CA-C-N 115.889 -0.596 . . . . 0.0 114.016 -176.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -100.44 -11.38 20.24 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 112.748 0.648 . . . . 0.0 112.748 -170.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 -121.96 137.44 27.35 Favored Pre-proline 0 C--N 1.29 -2.012 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.435 -174.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -67.92 142.58 57.53 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 121.98 1.787 . . . . 0.0 110.364 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 mt -116.22 141.83 32.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 C-N-CA 120.287 -0.565 . . . . 0.0 110.66 -174.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.9 t -84.92 117.55 30.39 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.431 ' HB ' ' CG1' ' A' ' 82' ' ' VAL . 82.4 p -93.77 153.8 18.11 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.513 -0.312 . . . . 0.0 111.083 -176.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.479 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 35.5 mmt180 -121.74 160.88 23.63 Favored 'General case' 0 C--O 1.208 -1.1 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -177.599 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 56.2 mt -126.21 135.99 62.16 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-O 121.415 0.626 . . . . 0.0 112.566 -178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.52 -48.09 3.08 Favored Glycine 0 N--CA 1.441 -1.026 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.414 173.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 25.3 m -138.15 146.15 50.6 Favored Pre-proline 0 C--N 1.271 -2.833 0 CA-C-N 114.912 -0.644 . . . . 0.0 110.793 -174.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -87.17 81.12 1.34 Allowed 'Trans proline' 0 N--CA 1.451 -0.978 0 C-N-CA 122.363 2.042 . . . . 0.0 112.235 177.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -144.46 157.26 44.33 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 86.0 mt -76.29 -16.9 59.68 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.995 0.902 . . . . 0.0 108.661 175.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -91.15 3.14 55.55 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 114.249 -1.341 . . . . 0.0 110.695 179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -88.31 157.45 50.42 Favored Pre-proline 0 C--O 1.256 1.437 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.835 -176.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -57.51 147.07 80.71 Favored 'Trans proline' 0 C--N 1.36 1.138 0 C-N-CA 123.167 2.578 . . . . 0.0 111.616 176.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.593 HG12 ' H ' ' A' ' 50' ' ' GLY . 32.8 t -90.42 135.71 25.79 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.8 -175.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.15 -14.56 54.17 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 177.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.593 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 127.91 -176.77 17.92 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 109.022 -1.631 . . . . 0.0 109.022 -179.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -103.9 128.89 51.38 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.959 0.88 . . . . 0.0 109.802 176.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.42 HD12 ' HD2' ' A' ' 53' ' ' PRO . 16.4 tp -77.16 127.79 82.5 Favored Pre-proline 0 C--N 1.294 -1.831 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 175.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' HD12 ' A' ' 52' ' ' LEU . 10.0 Cg_endo -63.81 154.47 69.42 Favored 'Trans proline' 0 N--CA 1.443 -1.487 0 C-N-CA 122.03 1.82 . . . . 0.0 112.452 178.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.458 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -73.06 136.85 45.03 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.534 -0.914 . . . . 0.0 108.534 177.105 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.41 5.04 85.43 Favored Glycine 0 C--N 1.312 -0.785 0 C-N-CA 120.93 -0.652 . . . . 0.0 113.314 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.27 145.7 37.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 117.029 0.415 . . . . 0.0 111.649 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 20.6 p -100.75 107.03 18.52 Favored 'General case' 0 N--CA 1.438 -1.028 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.366 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 mm -101.98 141.56 18.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.6 p -116.11 116.43 52.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.912 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 171.211 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.6 p90 -111.03 167.22 10.42 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 120.802 -0.359 . . . . 0.0 110.846 -176.369 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.4 p30 -124.56 -3.95 7.78 Favored 'General case' 0 C--N 1.309 -1.155 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.57 -179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -153.37 154.13 33.9 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.592 -175.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.2 t -128.53 135.83 61.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 N-CA-C 106.388 -1.708 . . . . 0.0 106.388 173.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.432 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 74.0 m -126.77 156.27 41.48 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.458 0.303 . . . . 0.0 110.766 179.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.46 HG12 HG12 ' A' ' 70' ' ' ILE . 66.4 mt -124.88 117.74 51.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 N-CA-C 108.504 -0.924 . . . . 0.0 108.504 176.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.497 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.8 tp-100 -164.73 149.81 9.73 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.41 28.35 16.8 Favored 'General case' 0 C--O 1.234 0.274 0 C-N-CA 124.089 0.956 . . . . 0.0 110.376 178.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.25 8.04 69.16 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.537 -178.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -119.76 155.22 32.93 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 122.093 -0.651 . . . . 0.0 110.486 -178.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.48 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 16.9 mt -104.21 134.27 45.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 174.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 61.1 m95 -125.78 148.72 49.02 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -171.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 31.1 pt -106.71 137.28 38.15 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.495 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 172.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -107.72 125.98 8.15 Favored Glycine 0 N--CA 1.419 -2.456 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.629 -178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.511 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 49.1 p90 -147.76 174.17 12.08 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . 0.484 ' HA ' ' O ' ' A' ' 80' ' ' ASN . 16.3 m120 -120.36 134.44 55.27 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -82.24 178.59 8.18 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 177.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -53.3 -42.7 66.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -177.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -72.64 -7.67 51.47 Favored 'General case' 0 CA--C 1.551 1.012 0 CA-C-O 121.544 0.688 . . . . 0.0 110.916 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 95.91 5.25 59.85 Favored Glycine 0 CA--C 1.498 -1.017 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -178.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 75' ' ' ASN . 74.3 m-20 -59.0 127.83 34.17 Favored 'General case' 0 CA--C 1.498 -1.02 0 C-N-CA 123.519 0.728 . . . . 0.0 109.558 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.458 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 26.0 tpt180 -79.44 93.85 5.45 Favored 'General case' 0 C--O 1.207 -1.182 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 178.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 27.1 t -93.45 128.36 44.92 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.835 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.324 -173.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.516 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 58.2 m-85 -113.48 120.27 40.43 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.853 177.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.9 t -110.33 127.1 27.59 Favored Pre-proline 0 C--N 1.28 -2.428 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 177.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.45 131.54 17.72 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 121.454 1.436 . . . . 0.0 108.711 176.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 24.6 m -117.12 -12.58 11.35 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.853 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.573 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.6 ptm180 -178.78 174.21 1.17 Allowed 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 7.0 p -98.49 167.77 10.61 Favored 'General case' 0 C--N 1.288 -2.066 0 C-N-CA 122.631 0.372 . . . . 0.0 110.414 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 97' ' ' ILE . 42.2 t -149.96 118.73 6.6 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.546 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 16.1 tt0 -81.31 90.38 6.13 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 96.94 -174.56 30.31 Favored Glycine 0 N--CA 1.433 -1.515 0 C-N-CA 120.445 -0.883 . . . . 0.0 112.134 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 25.7 m -111.81 158.76 35.73 Favored Pre-proline 0 C--N 1.302 -1.49 0 C-N-CA 122.184 0.194 . . . . 0.0 110.917 -179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.516 ' HB3' HE21 ' A' ' 96' ' ' GLN . 14.1 Cg_endo -63.4 171.5 6.57 Favored 'Trans proline' 0 CA--C 1.555 1.54 0 C-N-CA 122.728 2.286 . . . . 0.0 112.516 177.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -66.13 -25.01 5.99 Favored 'Cis proline' 0 C--N 1.371 1.751 0 CA-C-N 119.674 0.919 . . . . 0.0 113.4 3.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -91.99 79.34 5.23 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 122.278 1.037 . . . . 0.0 110.013 177.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.516 HE21 ' HB3' ' A' ' 93' ' ' PRO . 1.7 pt20 -96.17 151.29 19.62 Favored 'General case' 0 N--CA 1.437 -1.125 0 CA-C-N 114.205 -1.361 . . . . 0.0 107.488 177.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.546 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 71.1 mt -129.59 86.93 54.32 Favored Pre-proline 0 C--N 1.282 -2.349 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 88' ' ' THR . 20.3 Cg_endo -75.21 128.21 11.15 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 122.286 1.991 . . . . 0.0 112.195 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.17 -161.73 29.44 Favored Glycine 0 C--N 1.315 -0.62 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.93 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.1 p -63.81 135.16 28.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 117.099 0.449 . . . . 0.0 110.872 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.573 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -81.63 147.91 29.32 Favored 'General case' 0 N--CA 1.436 -1.152 0 CA-C-O 121.294 0.569 . . . . 0.0 111.071 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.3 m0 -96.2 13.46 27.33 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.846 -178.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -178.89 -164.47 31.71 Favored Glycine 0 N--CA 1.427 -1.929 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -105.76 153.52 7.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 108.318 -0.994 . . . . 0.0 108.318 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.4 104.55 8.23 Favored 'General case' 0 N--CA 1.419 -2.02 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 177.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.535 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 85.4 mttt . . . . . 0 C--N 1.289 -2.059 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 176.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.242 0.677 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 18.2 m -94.26 119.29 66.75 Favored Pre-proline 0 N--CA 1.424 -1.764 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 177.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -72.33 99.26 1.0 Allowed 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.286 1.99 . . . . 0.0 114.152 -174.018 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -79.04 -54.43 6.02 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 85.9 m -86.89 111.94 21.28 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 27.7 tpt180 -163.64 141.55 5.94 Favored Pre-proline 0 C--N 1.311 -1.105 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 -177.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.78 91.52 1.08 Allowed 'Trans proline' 0 N--CA 1.445 -1.329 0 C-N-CA 122.038 1.825 . . . . 0.0 109.296 174.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -125.36 142.28 42.68 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.606 -176.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.7 t -102.31 134.57 45.38 Favored 'General case' 0 N--CA 1.418 -2.047 0 CA-C-O 121.193 0.521 . . . . 0.0 110.278 -178.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.49 179.95 23.75 Favored Glycine 0 N--CA 1.44 -1.076 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -178.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 68.3 m -91.59 -4.78 54.93 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.615 0.721 . . . . 0.0 110.699 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 58.2 m95 -94.82 158.46 15.49 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.182 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 28.5 mtpp -125.11 138.36 54.17 Favored 'General case' 0 C--N 1.29 -1.997 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.557 ' HE2' ' HA2' ' A' ' 18' ' ' GLY . 45.2 tttm -101.87 134.51 44.95 Favored 'General case' 0 C--N 1.286 -2.181 0 CA-C-O 120.834 0.349 . . . . 0.0 110.146 -178.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.417 ' ND2' ' HB ' ' A' ' 19' ' ' THR . 36.0 p30 -94.69 -177.79 4.32 Favored 'General case' 0 C--N 1.291 -1.948 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.861 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 20.9 pt20 -65.92 -16.68 64.08 Favored 'General case' 0 CA--C 1.546 0.789 0 C-N-CA 123.857 0.863 . . . . 0.0 113.121 -177.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -92.42 -7.86 46.4 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.229 0.538 . . . . 0.0 110.02 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.557 ' HA2' ' HE2' ' A' ' 14' ' ' LYS . . . 83.97 22.49 55.06 Favored Glycine 0 N--CA 1.439 -1.121 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.523 -178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.417 ' HB ' ' ND2' ' A' ' 15' ' ' ASN . 90.5 m -95.3 127.41 41.32 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 73.7 m95 -86.7 123.96 32.43 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 175.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 47.6 p90 -129.0 164.22 23.68 Favored 'General case' 0 C--N 1.282 -2.359 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -177.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -152.8 142.06 14.54 Favored Pre-proline 0 C--N 1.287 -2.137 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -78.49 113.21 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.339 0 C-N-CA 122.407 2.071 . . . . 0.0 109.844 175.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -135.44 124.79 24.75 Favored 'General case' 0 C--N 1.292 -1.923 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -176.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -100.87 107.14 18.58 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -177.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.624 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -154.6 168.83 25.44 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.547 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 52.5 m -106.19 121.32 43.94 Favored 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.848 177.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.591 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 72.5 t80 -99.18 113.23 25.38 Favored 'General case' 0 N--CA 1.406 -2.642 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.3 t -100.81 116.22 43.89 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.526 0 N-CA-C 105.599 -2.001 . . . . 0.0 105.599 175.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -68.14 149.44 49.59 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.6 -0.44 . . . . 0.0 110.485 -177.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -80.28 -144.94 3.74 Favored Glycine 0 N--CA 1.433 -1.548 0 CA-C-N 116.368 -0.378 . . . . 0.0 113.174 -176.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.36 -6.06 59.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.25 0.548 . . . . 0.0 111.388 -175.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 22.4 pt20 -117.23 137.55 24.09 Favored Pre-proline 0 C--O 1.207 -1.142 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.233 -178.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -70.78 155.14 63.12 Favored 'Trans proline' 0 C--O 1.255 1.364 0 C-N-CA 122.611 2.207 . . . . 0.0 110.552 175.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.453 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.9 mt -126.48 134.94 65.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.646 -177.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 53.7 t -76.25 121.38 28.18 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 77.0 p -97.57 156.7 16.39 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 122.322 -0.236 . . . . 0.0 111.428 -175.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 29.0 mmt180 -124.0 155.12 38.81 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 -178.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.407 HG12 HG22 ' A' ' 82' ' ' VAL . 24.9 mt -116.55 137.83 49.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -175.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.56 -45.15 3.33 Favored Glycine 0 CA--C 1.502 -0.773 0 CA-C-N 114.726 -1.124 . . . . 0.0 113.299 175.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 42' ' ' PRO . 16.1 p -138.39 155.48 73.89 Favored Pre-proline 0 C--N 1.275 -2.647 0 CA-C-N 114.483 -0.858 . . . . 0.0 111.233 -171.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 41' ' ' SER . 30.5 Cg_endo -95.37 58.55 0.2 Allowed 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 123.483 2.789 . . . . 0.0 112.043 -179.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -121.23 155.8 33.82 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.3 mt -76.65 -23.63 53.29 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.481 0.657 . . . . 0.0 109.419 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -82.22 -13.77 56.57 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.237 177.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.53 152.68 96.01 Favored Pre-proline 0 C--O 1.249 1.072 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.365 -177.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.3 136.72 74.09 Favored 'Trans proline' 0 C--O 1.241 0.655 0 C-N-CA 122.867 2.378 . . . . 0.0 112.728 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.9 t -74.01 132.84 32.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.59 178.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -92.11 -18.39 43.32 Favored Glycine 0 C--O 1.241 0.539 0 N-CA-C 111.403 -0.679 . . . . 0.0 111.403 177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 135.42 -177.31 19.5 Favored Glycine 0 N--CA 1.428 -1.871 0 N-CA-C 109.219 -1.553 . . . . 0.0 109.219 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -97.35 131.97 43.52 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 118.043 0.922 . . . . 0.0 109.744 175.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.465 HD12 ' HD2' ' A' ' 53' ' ' PRO . 17.7 tp -78.2 126.82 82.86 Favored Pre-proline 0 C--N 1.291 -1.964 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 173.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.465 ' HD2' HD12 ' A' ' 52' ' ' LEU . 4.0 Cg_endo -62.48 151.56 82.36 Favored 'Trans proline' 0 N--CA 1.437 -1.805 0 C-N-CA 122.086 1.857 . . . . 0.0 112.507 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -68.52 137.42 54.36 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 175.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.31 22.43 77.58 Favored Glycine 0 N--CA 1.438 -1.181 0 C-N-CA 121.002 -0.618 . . . . 0.0 113.534 -178.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -89.33 152.05 21.75 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 117.8 0.8 . . . . 0.0 110.081 177.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.13 119.44 38.81 Favored 'General case' 0 N--CA 1.423 -1.799 0 CA-C-O 121.163 0.506 . . . . 0.0 109.987 -177.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.413 HG21 HD12 ' A' ' 72' ' ' ILE . 21.4 mm -117.09 130.02 72.69 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.77 179.069 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 6.7 p -101.63 116.8 45.91 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 169.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.624 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 53.7 p90 -112.73 160.62 17.76 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 120.122 -0.631 . . . . 0.0 109.869 -178.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -123.32 1.16 9.03 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 123.609 0.568 . . . . 0.0 110.75 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -155.24 152.25 29.07 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 120.489 -0.485 . . . . 0.0 110.044 -173.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 10.8 t -131.4 133.32 62.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 173.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . . . . . . . . . 56.7 m -124.56 148.5 47.77 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 123.014 0.526 . . . . 0.0 110.747 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 70' ' ' ILE . 59.4 mt -117.95 116.6 52.14 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.415 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.7 tp-100 -163.19 147.4 11.03 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 123.572 0.545 . . . . 0.0 109.585 -178.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 60.23 30.99 20.33 Favored 'General case' 0 C--O 1.242 0.71 0 C-N-CA 124.052 0.941 . . . . 0.0 111.446 177.097 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 6.62 81.24 Favored Glycine 0 CA--C 1.508 -0.351 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.682 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -120.2 154.2 35.17 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 122.608 -0.348 . . . . 0.0 110.338 -178.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.438 HG12 HG12 ' A' ' 65' ' ' ILE . 19.5 mt -105.81 133.82 49.09 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 106.492 -1.67 . . . . 0.0 106.492 172.116 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -125.69 149.96 48.06 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.07 0.548 . . . . 0.0 109.753 -171.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 28.7 pt -106.47 137.01 39.01 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.433 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 171.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -104.08 121.33 6.98 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -141.72 173.97 11.01 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -107.68 141.47 39.15 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -84.29 166.69 17.26 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 79.3 t80 -62.56 -18.24 61.65 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.85 0.833 . . . . 0.0 109.924 175.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -77.4 -6.15 52.34 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.754 177.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 83.77 7.89 85.22 Favored Glycine 0 C--N 1.34 0.765 0 C-N-CA 121.066 -0.588 . . . . 0.0 111.979 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -101.23 160.66 14.22 Favored 'General case' 0 C--N 1.311 -1.091 0 O-C-N 122.691 -0.299 . . . . 0.0 110.403 -174.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 19.5 tpt180 -83.73 126.76 33.23 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.407 HG22 HG12 ' A' ' 39' ' ' ILE . 45.2 t -123.56 135.88 61.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.499 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 72.1 m-85 -115.65 123.5 48.53 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.627 -1.17 . . . . 0.0 109.942 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.2 t -111.31 125.85 29.74 Favored Pre-proline 0 C--N 1.281 -2.375 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 177.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.453 ' O ' HG21 ' A' ' 35' ' ' ILE . 33.7 Cg_endo -71.88 129.9 16.03 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 121.54 1.493 . . . . 0.0 108.638 176.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 25.4 m -114.45 -10.39 12.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.144 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.47 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 6.5 ptm180 178.81 173.54 0.72 Allowed 'General case' 0 C--O 1.246 0.899 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -178.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.472 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.2 p -98.96 167.37 10.78 Favored 'General case' 0 C--N 1.289 -2.033 0 C-N-CA 122.238 0.215 . . . . 0.0 110.737 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.476 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 48.6 t -145.2 128.03 16.35 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 109.163 -0.681 . . . . 0.0 109.163 177.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 60.8 tt0 -90.1 96.31 10.61 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 97.64 -157.94 20.84 Favored Glycine 0 N--CA 1.418 -2.505 0 C-N-CA 120.472 -0.87 . . . . 0.0 112.688 177.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.3 m -130.26 150.86 77.31 Favored Pre-proline 0 C--N 1.297 -1.712 0 C-N-CA 123.353 0.661 . . . . 0.0 109.619 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.443 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 42.2 Cg_endo -66.57 165.63 24.62 Favored 'Trans proline' 0 CA--C 1.555 1.534 0 C-N-CA 122.363 2.042 . . . . 0.0 111.175 -178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.42 -5.89 20.15 Favored 'Cis proline' 0 C--N 1.356 0.973 0 C-N-CA 124.301 -1.125 . . . . 0.0 113.329 4.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -101.43 77.48 1.78 Allowed 'General case' 0 N--CA 1.427 -1.597 0 C-N-CA 118.315 -1.354 . . . . 0.0 108.355 174.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.476 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.5 pm0 -103.08 153.03 20.7 Favored 'General case' 0 N--CA 1.427 -1.584 0 CA-C-N 114.756 -1.111 . . . . 0.0 108.034 178.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 58.1 mt -131.27 87.56 47.17 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 176.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 88' ' ' THR . 67.7 Cg_endo -73.53 135.6 22.32 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.544 2.163 . . . . 0.0 112.841 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -81.45 -170.85 44.52 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.4 p -69.01 138.26 22.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 116.994 0.397 . . . . 0.0 110.25 -178.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.47 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -72.01 141.36 49.34 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.163 -178.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 43.6 m0 -87.54 2.49 50.61 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.329 -179.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -159.39 -160.03 10.15 Favored Glycine 0 N--CA 1.43 -1.748 0 N-CA-C 109.882 -1.287 . . . . 0.0 109.882 178.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.2 t -115.15 149.37 17.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.2 m-85 -117.56 106.73 13.44 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 175.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 63.4 mttm . . . . . 0 C--N 1.288 -2.092 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 176.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.511 -0.528 0 N-CA-C 110.827 -0.064 . . . . 0.0 110.827 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 44.8 m 64.73 97.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.756 0 C-N-CA 123.716 0.806 . . . . 0.0 109.669 -173.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -65.08 91.5 0.2 Allowed 'Trans proline' 0 N--CA 1.458 -0.61 0 C-N-CA 122.407 2.071 . . . . 0.0 112.8 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -82.15 -31.26 30.6 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 p -78.62 81.39 4.94 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-N 114.961 -1.018 . . . . 0.0 108.456 174.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 63.5 mtp180 -79.0 137.92 57.12 Favored Pre-proline 0 N--CA 1.429 -1.494 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.745 -175.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_exo -46.51 112.9 0.53 Allowed 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 123.937 3.091 . . . . 0.0 113.102 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 12.4 p -148.94 153.57 10.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 108.099 -1.075 . . . . 0.0 108.099 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.59 ' OG1' ' HD3' ' A' ' 94' ' ' PRO . 26.4 m -80.07 116.36 20.15 Favored 'General case' 0 C--N 1.286 -2.155 0 C-N-CA 122.66 0.384 . . . . 0.0 110.833 -178.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -118.43 -9.8 9.15 Favored Glycine 0 N--CA 1.443 -0.85 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.369 177.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.0 p -63.13 -42.06 99.42 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 175.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . . . . . . . . . 61.4 m95 -110.02 139.74 44.81 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 104.371 -2.455 . . . . 0.0 104.371 168.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 37.1 mtmm -117.01 135.74 53.47 Favored 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.863 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.472 ' HD3' ' NE1' ' A' ' 20' ' ' TRP . 38.8 ttpt -96.4 134.4 39.6 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 120.851 0.358 . . . . 0.0 110.302 -178.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -98.02 -173.86 2.71 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.471 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.2 pt20 -63.16 -17.54 62.49 Favored 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 123.301 0.64 . . . . 0.0 112.334 -177.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 53.3 m-85 -85.93 -10.31 55.44 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.37 0.605 . . . . 0.0 109.461 -176.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.97 18.9 68.64 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -177.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 64' ' ' CYS . 84.5 m -98.33 130.3 45.0 Favored 'General case' 0 N--CA 1.403 -2.783 0 CA-C-N 114.201 -1.0 . . . . 0.0 108.707 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.494 ' CZ3' ' HB ' ' A' ' 9' ' ' THR . 86.0 m95 -88.97 127.05 35.65 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -133.82 158.85 42.34 Favored 'General case' 0 C--N 1.292 -1.91 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.382 -178.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 16.4 pttp -149.03 150.71 32.89 Favored Pre-proline 0 N--CA 1.426 -1.672 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 170.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.37 131.79 18.22 Favored 'Trans proline' 0 N--CA 1.447 -1.207 0 C-N-CA 121.742 1.628 . . . . 0.0 110.064 176.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.41 ' HB3' HG23 ' A' ' 63' ' ' VAL . 8.0 tp10 -151.81 123.62 8.0 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.601 -0.888 . . . . 0.0 108.601 179.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -108.72 106.18 16.09 Favored 'General case' 0 C--N 1.292 -1.903 0 C-N-CA 118.776 -1.17 . . . . 0.0 108.563 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -150.1 167.74 25.93 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 115.103 -0.953 . . . . 0.0 108.8 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.472 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 53.1 m -111.06 122.58 48.25 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-O 121.534 0.683 . . . . 0.0 111.134 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.51 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 55.2 t80 -98.62 122.4 41.78 Favored 'General case' 0 N--CA 1.415 -2.18 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG21 ' HE3' ' A' ' 106' ' ' LYS . 48.2 t -105.32 114.96 46.16 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 176.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.438 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 52.5 t30 -67.66 148.22 51.65 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 123.429 0.456 . . . . 0.0 110.003 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -90.47 -119.98 2.15 Favored Glycine 0 N--CA 1.419 -2.437 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.8 -176.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -85.94 -28.61 24.17 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 -172.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 10.9 pt20 -110.21 136.18 20.52 Favored Pre-proline 0 C--N 1.286 -2.188 0 O-C-N 122.046 -0.409 . . . . 0.0 111.652 -174.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -68.46 140.05 46.85 Favored 'Trans proline' 0 N--CA 1.447 -1.214 0 C-N-CA 121.969 1.78 . . . . 0.0 109.809 175.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -112.4 131.1 64.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.913 -172.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.1 t -72.19 116.18 13.74 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 177.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 80.4 p -95.54 162.84 13.47 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.251 -178.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 47' ' ' PRO . 33.4 mmt180 -129.8 155.38 46.06 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -176.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.532 HG23 ' HB3' ' A' ' 80' ' ' ASN . 26.5 mt -116.37 137.29 50.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.118 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -175.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.55 -48.67 3.93 Favored Glycine 0 CA--C 1.494 -1.277 0 CA-C-N 114.218 -1.355 . . . . 0.0 112.623 174.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 43.7 m -139.05 146.9 51.5 Favored Pre-proline 0 C--N 1.264 -3.148 0 CA-C-N 114.353 -0.924 . . . . 0.0 110.264 -176.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -85.9 84.88 1.14 Allowed 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.075 1.85 . . . . 0.0 112.239 178.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -142.25 156.91 45.32 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.3 mt -76.85 -22.44 53.52 Favored 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -90.32 8.0 35.61 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.916 178.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.95 156.68 42.19 Favored Pre-proline 0 C--O 1.253 1.274 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.436 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 15.6 Cg_endo -57.99 150.79 61.98 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 122.972 2.448 . . . . 0.0 112.007 179.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.547 HG12 ' H ' ' A' ' 50' ' ' GLY . 59.3 t -86.04 125.08 40.64 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.59 -177.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -86.41 -8.05 78.33 Favored Glycine 0 CA--C 1.496 -1.15 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.547 ' H ' HG12 ' A' ' 48' ' ' VAL . . . 128.08 179.38 15.83 Favored Glycine 0 N--CA 1.411 -2.983 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -109.66 110.84 22.01 Favored 'General case' 0 C--N 1.269 -2.921 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.515 HD12 ' HD2' ' A' ' 53' ' ' PRO . 29.6 tp -63.14 126.84 89.98 Favored Pre-proline 0 C--N 1.303 -1.415 0 CA-C-N 114.288 -1.324 . . . . 0.0 109.466 -179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.515 ' HD2' HD12 ' A' ' 52' ' ' LEU . 11.9 Cg_exo -60.6 146.72 96.56 Favored 'Trans proline' 0 N--CA 1.431 -2.2 0 C-N-CA 122.402 2.068 . . . . 0.0 112.551 -178.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.438 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -70.94 116.26 11.03 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.86 -0.66 45.07 Favored Glycine 0 C--N 1.306 -1.09 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.337 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -74.83 143.79 43.75 Favored 'General case' 0 C--O 1.243 0.733 0 CA-C-O 121.237 0.541 . . . . 0.0 111.608 -178.04 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.8 m -98.42 117.13 32.15 Favored 'General case' 0 N--CA 1.421 -1.885 0 CA-C-N 114.761 -1.109 . . . . 0.0 109.819 -176.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.5 mm -115.23 127.41 72.81 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 123.707 0.803 . . . . 0.0 111.389 -179.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 79.2 t -98.95 116.76 42.8 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 171.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.456 ' HA ' ' HB3' ' A' ' 74' ' ' TYR . 55.0 p90 -114.53 164.59 13.78 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.441 -178.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -124.11 3.5 8.62 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.736 -0.386 . . . . 0.0 111.769 -179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -155.37 147.9 24.06 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.638 -0.825 . . . . 0.0 109.888 -175.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 24' ' ' GLU . 12.5 t -122.46 135.41 62.63 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 N-CA-C 105.708 -1.96 . . . . 0.0 105.708 173.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.459 ' HB3' ' CG2' ' A' ' 19' ' ' THR . 82.7 m -130.4 150.91 51.41 Favored 'General case' 0 C--N 1.286 -2.17 0 O-C-N 123.306 0.379 . . . . 0.0 110.748 -178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -119.68 121.37 66.04 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 176.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.403 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.5 tp-100 -167.86 150.08 5.6 Favored 'General case' 0 C--N 1.324 -0.507 0 O-C-N 123.723 0.639 . . . . 0.0 109.51 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 59.49 31.28 20.91 Favored 'General case' 0 C--O 1.241 0.642 0 C-N-CA 123.93 0.892 . . . . 0.0 111.301 175.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.21 6.77 70.06 Favored Glycine 0 C--O 1.227 -0.341 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.57 179.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 77.0 m80 -120.1 156.68 30.52 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 122.537 -0.39 . . . . 0.0 110.69 -177.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.467 ' CG1' ' HB2' ' A' ' 89' ' ' CYS . 23.2 mt -104.87 134.35 46.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 106.142 -1.799 . . . . 0.0 106.142 171.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 56.6 m95 -125.72 153.82 43.36 Favored 'General case' 0 C--N 1.293 -1.891 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -170.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.523 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.5 pt -113.44 136.61 49.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 173.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.28 123.59 7.48 Favored Glycine 0 N--CA 1.423 -2.178 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.947 -178.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.456 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 37.7 p90 -141.42 172.36 12.79 Favored 'General case' 0 C--N 1.296 -1.76 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 -109.62 143.61 39.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.762 -177.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -95.37 165.45 12.37 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.653 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -55.67 -35.28 65.83 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 124.987 1.315 . . . . 0.0 111.487 179.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -83.93 8.6 14.57 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 112.404 0.52 . . . . 0.0 112.404 -177.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.82 82.92 Favored Glycine 0 C--O 1.228 -0.26 0 C-N-CA 120.437 -0.887 . . . . 0.0 113.187 176.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.532 ' HB3' HG23 ' A' ' 39' ' ' ILE . 57.3 m-80 -92.25 155.99 17.59 Favored 'General case' 0 C--N 1.31 -1.14 0 O-C-N 122.821 -0.223 . . . . 0.0 111.139 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 25.7 tpt180 -87.83 125.9 34.72 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 177.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.46 HG22 HG12 ' A' ' 39' ' ' ILE . 39.4 t -118.14 131.79 69.87 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 C-N-CA 119.399 -0.92 . . . . 0.0 109.774 179.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.523 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 66.6 m-85 -114.06 128.2 56.28 Favored 'General case' 0 C--N 1.286 -2.191 0 CA-C-N 114.792 -1.095 . . . . 0.0 110.31 178.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.6 t -115.96 128.43 25.98 Favored Pre-proline 0 C--N 1.285 -2.2 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -74.01 130.52 14.46 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.427 1.418 . . . . 0.0 108.74 175.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 21.8 m -114.32 -13.5 11.33 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 -175.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.531 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 9.5 ptm180 -176.51 174.31 1.92 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -178.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.473 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 2.1 p -98.25 165.23 11.97 Favored 'General case' 0 C--N 1.286 -2.175 0 C-N-CA 122.781 0.432 . . . . 0.0 110.832 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.713 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 42.0 t -149.98 116.29 5.74 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 122.901 0.48 . . . . 0.0 110.202 177.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.499 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 8.2 tt0 -83.86 103.23 12.96 Favored 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.86 -176.04 40.65 Favored Glycine 0 N--CA 1.432 -1.626 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.437 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.415 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 16.1 m -112.69 155.12 44.4 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 179.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 92' ' ' VAL . 36.3 Cg_endo -63.67 164.9 19.68 Favored 'Trans proline' 0 CA--C 1.552 1.4 0 C-N-CA 122.432 2.088 . . . . 0.0 110.861 -178.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.59 ' HD3' ' OG1' ' A' ' 9' ' ' THR . 91.9 Cg_endo -77.49 -5.05 30.82 Favored 'Cis proline' 0 C--N 1.359 1.094 0 C-N-CA 124.573 -1.011 . . . . 0.0 113.363 7.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 36.2 m-80 -104.49 78.82 1.5 Allowed 'General case' 0 CA--C 1.475 -1.916 0 C-N-CA 119.548 -0.861 . . . . 0.0 109.088 171.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.713 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -98.93 151.42 20.9 Favored 'General case' 0 N--CA 1.418 -2.071 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 175.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.499 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 60.1 mt -125.86 86.06 58.24 Favored Pre-proline 0 C--N 1.291 -1.962 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.473 ' HA ' ' O ' ' A' ' 88' ' ' THR . 54.7 Cg_endo -68.92 129.03 17.72 Favored 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.355 2.036 . . . . 0.0 112.666 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.33 -166.83 41.64 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 177.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.7 p -63.34 135.91 26.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.158 0.504 . . . . 0.0 110.596 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.531 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -76.86 144.63 38.88 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.569 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 44.4 m0 -90.35 8.79 31.68 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.334 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -170.51 -156.48 11.37 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.569 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 6.7 t -111.61 154.47 13.15 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -125.97 102.84 7.44 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 176.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.472 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 93.3 mttt . . . . . 0 C--N 1.288 -2.087 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 . . . . . 0 CA--C 1.515 -0.39 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 21.3 m -108.65 121.0 44.58 Favored Pre-proline 0 N--CA 1.422 -1.845 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.64 -39.28 92.46 Favored 'Trans proline' 0 C--N 1.355 0.894 0 C-N-CA 122.816 2.344 . . . . 0.0 112.855 -178.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -90.47 18.37 6.29 Favored 'General case' 0 C--O 1.246 0.878 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.454 -178.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 m 73.76 -63.22 0.44 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 124.585 1.154 . . . . 0.0 111.546 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -92.78 124.59 58.22 Favored Pre-proline 0 N--CA 1.429 -1.497 0 CA-C-O 120.69 0.281 . . . . 0.0 110.679 -176.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.24 110.99 1.91 Allowed 'Trans proline' 0 C--O 1.247 0.939 0 C-N-CA 122.967 2.444 . . . . 0.0 111.49 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.25 126.25 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 178.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.43 ' HB ' ' O ' ' A' ' 12' ' ' TRP . 7.9 m 74.62 1.5 3.83 Favored 'General case' 0 CA--C 1.568 1.658 0 C-N-CA 123.905 0.882 . . . . 0.0 111.21 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 77.54 -100.2 1.53 Allowed Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.829 175.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.4 m -77.05 -33.33 57.29 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 122.625 0.37 . . . . 0.0 111.738 -176.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.43 ' O ' ' HB ' ' A' ' 9' ' ' THR . 91.6 m95 -96.85 129.76 44.24 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.754 -175.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -121.99 155.61 35.19 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 176.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.541 ' HD3' ' CE2' ' A' ' 20' ' ' TRP . 35.4 ttpt -106.58 130.89 54.26 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.003 -174.492 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.444 ' HB3' ' HB ' ' A' ' 19' ' ' THR . 41.0 t-20 -78.27 151.04 33.24 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 176.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -54.48 -19.18 5.26 Favored 'General case' 0 CA--C 1.548 0.895 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -87.13 2.8 48.71 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.046 -0.409 . . . . 0.0 112.014 178.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 87.0 12.81 67.57 Favored Glycine 0 C--N 1.319 -0.412 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 179.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.454 HG23 ' HB2' ' A' ' 66' ' ' GLN . 56.6 m -90.37 119.3 30.55 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.541 ' CE2' ' HD3' ' A' ' 14' ' ' LYS . 81.9 m95 -82.94 130.77 35.18 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.413 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 14.2 p90 -141.39 159.33 42.45 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -176.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 52.8 pttt -150.28 147.47 21.96 Favored Pre-proline 0 N--CA 1.419 -2.015 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -76.37 121.95 6.31 Favored 'Trans proline' 0 N--CA 1.449 -1.109 0 C-N-CA 122.575 2.184 . . . . 0.0 110.121 174.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -150.28 123.15 8.71 Favored 'General case' 0 C--N 1.297 -1.677 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 179.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.518 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 23.9 t-20 -107.26 106.46 16.93 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.613 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -148.5 166.09 29.23 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.794 -175.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 98.0 m -103.9 119.78 39.63 Favored 'General case' 0 N--CA 1.414 -2.271 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.239 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 58.5 t80 -98.99 118.89 36.79 Favored 'General case' 0 C--N 1.288 -2.085 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.25 106.1 19.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.917 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 177.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -62.87 142.68 58.17 Favored 'General case' 0 C--N 1.316 -0.854 0 O-C-N 124.024 0.827 . . . . 0.0 111.325 -176.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -75.75 -140.72 0.91 Allowed Glycine 0 N--CA 1.428 -1.87 0 CA-C-N 115.696 -0.683 . . . . 0.0 113.688 -178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -82.67 -13.53 56.26 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.984 0.735 . . . . 0.0 112.984 -173.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -110.67 138.71 21.11 Favored Pre-proline 0 C--N 1.31 -1.151 0 O-C-N 121.415 -0.803 . . . . 0.0 111.389 -177.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -69.29 145.85 61.19 Favored 'Trans proline' 0 C--O 1.242 0.689 0 C-N-CA 122.334 2.023 . . . . 0.0 110.422 174.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 mt -118.37 136.26 56.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.784 -175.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.7 t -75.8 121.89 28.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 81.5 p -104.59 158.24 16.63 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 110.375 -0.231 . . . . 0.0 110.375 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 46' ' ' ALA . 26.5 mmt180 -127.6 160.97 29.95 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -174.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.465 HG12 HG22 ' A' ' 82' ' ' VAL . 50.3 mt -122.79 138.1 54.04 Favored 'Isoleucine or valine' 0 C--O 1.243 0.75 0 N-CA-C 113.634 0.976 . . . . 0.0 113.634 -177.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.62 -47.1 2.54 Favored Glycine 0 CA--C 1.497 -1.081 0 CA-C-N 114.517 -1.219 . . . . 0.0 112.561 174.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 45.2 m -139.24 151.83 68.24 Favored Pre-proline 0 C--N 1.273 -2.742 0 C-N-CA 123.794 0.838 . . . . 0.0 111.052 -174.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -90.78 80.85 0.46 Allowed 'Trans proline' 0 N--CA 1.446 -1.293 0 C-N-CA 122.712 2.275 . . . . 0.0 111.761 175.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -141.69 157.76 44.66 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 179.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 87.4 mt -76.72 -20.72 56.23 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.717 0.77 . . . . 0.0 109.189 178.21 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -98.48 13.09 32.99 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.994 179.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 38' ' ' ARG . . . -87.56 152.14 51.53 Favored Pre-proline 0 C--N 1.307 -1.274 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 175.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -58.11 138.79 87.78 Favored 'Trans proline' 0 C--O 1.249 1.054 0 C-N-CA 122.641 2.227 . . . . 0.0 112.568 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 69.4 t -68.61 118.03 11.97 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -80.65 -19.52 68.12 Favored Glycine 0 C--N 1.292 -1.907 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 144.11 -177.11 22.98 Favored Glycine 0 N--CA 1.401 -3.67 0 N-CA-C 107.97 -2.052 . . . . 0.0 107.97 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -112.5 140.06 47.56 Favored 'General case' 0 C--N 1.263 -3.191 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 176.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.466 HD12 ' HD2' ' A' ' 53' ' ' PRO . 21.8 tp -85.25 126.11 68.19 Favored Pre-proline 0 C--N 1.281 -2.393 0 CA-C-N 114.768 -1.105 . . . . 0.0 108.335 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.466 ' HD2' HD12 ' A' ' 52' ' ' LEU . 5.2 Cg_endo -62.46 154.07 66.76 Favored 'Trans proline' 0 N--CA 1.438 -1.756 0 C-N-CA 122.101 1.867 . . . . 0.0 112.511 178.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -71.66 135.37 46.86 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 175.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.68 12.96 79.19 Favored Glycine 0 C--N 1.312 -0.799 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.57 146.71 32.44 Favored 'General case' 0 CA--C 1.495 -1.152 0 CA-C-O 121.224 0.535 . . . . 0.0 110.773 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 3.9 m -108.77 110.62 22.06 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.896 -1.047 . . . . 0.0 109.001 -177.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.43 ' O ' ' HA ' ' A' ' 27' ' ' THR . 16.8 mm -110.41 133.9 54.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 C-N-CA 123.201 0.6 . . . . 0.0 110.841 -177.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 60.7 t -105.72 117.0 50.65 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 171.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.613 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 49.0 p90 -111.86 163.4 14.24 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 120.732 -0.387 . . . . 0.0 110.128 -178.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -124.39 2.45 8.41 Favored 'General case' 0 C--N 1.309 -1.195 0 O-C-N 123.613 0.571 . . . . 0.0 111.309 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -157.22 152.81 26.63 Favored 'General case' 0 N--CA 1.433 -1.317 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.545 -175.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.2 t -130.54 137.3 56.5 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 174.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.455 ' HG ' ' HE2' ' A' ' 83' ' ' TYR . 99.3 m -126.73 152.95 46.14 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 122.89 0.476 . . . . 0.0 110.998 178.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 63.9 mt -123.34 110.35 25.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 173.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.454 ' HB2' HG23 ' A' ' 19' ' ' THR . 6.3 tp-100 -159.52 147.34 17.25 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -177.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 61.42 30.21 18.82 Favored 'General case' 0 C--O 1.246 0.916 0 C-N-CA 123.952 0.901 . . . . 0.0 110.209 178.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 69.58 11.01 64.66 Favored Glycine 0 CA--C 1.521 0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.051 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 71.8 m80 -120.48 154.0 35.86 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 122.186 -0.597 . . . . 0.0 110.152 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.523 HG13 ' HB2' ' A' ' 89' ' ' CYS . 18.0 mt -101.5 133.16 45.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 171.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 57.8 m95 -125.31 148.13 48.84 Favored 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -172.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 30.6 pt -106.99 136.89 40.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 171.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -106.96 123.67 7.4 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.496 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 33.5 p90 -138.86 152.9 48.2 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 10.1 t30 -95.12 122.51 37.87 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.11 174.77 5.88 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.795 -175.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -64.62 -32.16 73.69 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.593 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -91.35 4.13 53.17 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-O 121.706 0.765 . . . . 0.0 110.703 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.21 8.28 75.33 Favored Glycine 0 CA--C 1.517 0.179 0 C-N-CA 119.788 -1.196 . . . . 0.0 113.858 177.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -75.66 144.64 41.54 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 178.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.41 ' O ' ' HA ' ' A' ' 39' ' ' ILE . 23.0 tpt180 -85.53 101.25 12.51 Favored 'General case' 0 CA--C 1.494 -1.209 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.465 HG22 HG12 ' A' ' 39' ' ' ILE . 23.1 t -102.75 129.15 54.82 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.485 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.025 -176.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.513 ' HA ' ' O ' ' A' ' 72' ' ' ILE . 64.5 m-85 -111.63 134.88 52.89 Favored 'General case' 0 C--N 1.283 -2.307 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.583 177.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 53.1 t -123.13 127.0 25.81 Favored Pre-proline 0 C--N 1.287 -2.117 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 178.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -72.95 128.7 13.43 Favored 'Trans proline' 0 N--CA 1.437 -1.808 0 N-CA-C 108.334 -1.449 . . . . 0.0 108.334 175.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -112.9 -9.35 12.14 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.074 0 N-CA-C 112.519 0.562 . . . . 0.0 112.519 -176.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 8.4 ptm180 179.75 167.29 1.2 Allowed 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.2 p -90.45 171.19 9.61 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.634 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 46.1 t -153.62 127.81 9.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-O 121.575 0.703 . . . . 0.0 109.863 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.62 ' HB2' ' HB ' ' A' ' 97' ' ' ILE . 11.6 mt-30 -93.15 112.16 24.02 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.228 173.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 79.09 167.11 32.72 Favored Glycine 0 N--CA 1.422 -2.292 0 CA-C-N 115.081 -0.963 . . . . 0.0 113.17 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.417 ' HB ' ' HD2' ' A' ' 93' ' ' PRO . 17.3 m -97.73 156.19 36.33 Favored Pre-proline 0 C--N 1.289 -2.054 0 CA-C-N 114.749 -0.725 . . . . 0.0 109.144 176.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.509 ' HB3' ' NE2' ' A' ' 96' ' ' GLN . 19.3 Cg_endo -62.65 168.86 9.35 Favored 'Trans proline' 0 CA--C 1.559 1.759 0 C-N-CA 122.536 2.158 . . . . 0.0 111.672 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -68.34 -18.14 9.96 Favored 'Cis proline' 0 C--N 1.366 1.49 0 CA-C-N 119.715 0.934 . . . . 0.0 114.024 4.15 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 38.0 m-80 -99.55 79.7 2.3 Favored 'General case' 0 CA--C 1.484 -1.585 0 CA-C-O 121.435 0.636 . . . . 0.0 110.086 175.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.634 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 1.6 pm0 -99.59 146.26 26.64 Favored 'General case' 0 N--CA 1.421 -1.889 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 174.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.62 ' HB ' ' HB2' ' A' ' 90' ' ' GLN . 63.8 mt -122.02 88.51 47.97 Favored Pre-proline 0 C--N 1.29 -1.993 0 C-N-CA 120.064 -0.654 . . . . 0.0 109.638 177.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 87' ' ' ARG . 29.1 Cg_endo -65.73 140.75 63.08 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.347 2.032 . . . . 0.0 112.095 177.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.32 -158.4 33.47 Favored Glycine 0 C--N 1.306 -1.088 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 177.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.3 p -66.73 132.68 32.02 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 CA-C-N 116.996 0.398 . . . . 0.0 110.182 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.577 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.02 139.32 38.2 Favored 'General case' 0 CA--C 1.49 -1.335 0 CA-C-O 120.89 0.376 . . . . 0.0 110.28 178.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 33.6 m0 -92.58 15.29 14.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.016 -177.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -177.71 -177.46 46.54 Favored Glycine 0 N--CA 1.425 -2.076 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.975 178.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.7 t -92.7 153.7 3.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -127.0 103.15 7.31 Favored 'General case' 0 N--CA 1.42 -1.925 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 176.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.522 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 84.9 mttt . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 177.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.223 -0.31 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 10.3 m 65.42 77.54 0.28 Allowed Pre-proline 0 CA--C 1.559 1.305 0 C-N-CA 124.722 1.209 . . . . 0.0 112.998 179.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -110.75 -153.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 124.229 3.286 . . . . 0.0 108.683 170.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -86.06 120.66 27.69 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 172.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 17.3 m -70.57 -45.97 64.38 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -174.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -79.48 152.27 75.49 Favored Pre-proline 0 C--N 1.315 -0.917 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.872 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -65.3 106.47 0.84 Allowed 'Trans proline' 0 C--O 1.247 0.945 0 C-N-CA 122.142 1.895 . . . . 0.0 108.997 173.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.6 p -138.03 142.63 35.29 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.971 -173.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . 0.314 5.1 p 59.16 -6.98 0.05 Allowed 'General case' 0 CA--C 1.56 1.341 0 N-CA-C 117.582 2.438 . . . . 0.0 117.582 175.208 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.27 -97.64 0.86 Allowed Glycine 0 C--O 1.25 1.123 0 CA-C-O 120.929 0.183 . . . . 0.0 113.236 175.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.8 m -63.54 -57.64 9.54 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 123.129 0.571 . . . . 0.0 109.926 -179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' TRP . . . . . 0.412 ' CZ2' ' HE2' ' A' ' 22' ' ' LYS . 88.9 m95 -83.38 146.52 28.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.207 -179.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 32.6 mtmm -146.37 153.59 40.67 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 177.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -104.51 137.48 42.3 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.699 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 37.0 p30 -91.74 -177.48 4.77 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 -56.77 -30.49 63.68 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.287 1.035 . . . . 0.0 113.373 -178.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . . . . . . . . . 81.0 m-85 -82.6 -8.01 59.62 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.862 0.363 . . . . 0.0 111.425 -176.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.24 18.45 59.1 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 63.5 m -95.84 131.95 41.62 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 177.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . . . . . . . . . 78.9 m95 -86.73 135.23 33.45 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.41 ' HA ' ' O ' ' A' ' 63' ' ' VAL . 43.6 p90 -142.85 167.25 22.52 Favored 'General case' 0 C--N 1.285 -2.197 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.412 ' HE2' ' CZ2' ' A' ' 12' ' ' TRP . 57.6 pttt -152.76 139.4 12.44 Favored Pre-proline 0 C--N 1.287 -2.122 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 170.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -76.41 112.94 3.57 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.623 2.215 . . . . 0.0 109.651 175.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -146.1 123.77 11.84 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 -178.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . 0.515 ' HA ' ' O ' ' A' ' 60' ' ' TYR . 2.9 t-20 -101.92 106.53 17.48 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 -177.131 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 60' ' ' TYR . . . -144.84 167.9 21.51 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.524 -177.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' A' ' 106' ' ' LYS . 66.5 m -106.66 120.01 40.82 Favored 'General case' 0 N--CA 1.411 -2.395 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.086 178.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.525 ' HA ' ' O ' ' A' ' 104' ' ' VAL . 49.4 t80 -98.66 115.64 29.13 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 178.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.445 HG22 HG22 ' A' ' 57' ' ' THR . 22.0 t -97.87 110.36 25.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 N-CA-C 106.169 -1.789 . . . . 0.0 106.169 177.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.445 ' ND2' ' HA ' ' A' ' 54' ' ' ALA . 49.9 t30 -66.49 139.4 57.95 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 123.665 0.603 . . . . 0.0 110.052 -179.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -74.87 -124.22 0.13 Allowed Glycine 0 N--CA 1.428 -1.88 0 O-C-N 123.74 0.65 . . . . 0.0 114.204 -175.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 25.6 m120 -107.0 14.76 26.05 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.37 0.605 . . . . 0.0 112.536 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -135.75 134.52 20.79 Favored Pre-proline 0 C--N 1.279 -2.481 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.389 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -71.73 139.73 34.3 Favored 'Trans proline' 0 C--O 1.251 1.163 0 C-N-CA 122.168 1.912 . . . . 0.0 110.494 175.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 ' O ' ' A' ' 85' ' ' PRO . 1.3 mt -115.21 140.57 35.87 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.656 -174.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.2 t -78.87 114.26 19.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 O-C-N 122.245 -0.284 . . . . 0.0 110.494 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 74.0 p -94.5 151.25 19.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.717 -0.219 . . . . 0.0 111.517 -176.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 82' ' ' VAL . 32.8 mmt180 -122.07 165.16 16.49 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -175.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.442 ' HA ' ' O ' ' A' ' 81' ' ' ARG . 51.9 mt -126.8 135.13 64.57 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.239 0 CA-C-O 121.059 0.457 . . . . 0.0 111.713 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.63 -45.8 3.27 Favored Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.964 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 31.4 m -137.3 143.3 40.93 Favored Pre-proline 0 C--N 1.27 -2.869 0 CA-C-N 114.629 -0.785 . . . . 0.0 111.005 -172.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -89.12 76.64 1.3 Allowed 'Trans proline' 0 N--CA 1.446 -1.299 0 C-N-CA 122.536 2.157 . . . . 0.0 112.051 177.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -141.73 157.85 44.53 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 83.7 mt -76.56 -20.1 57.21 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-O 122.37 1.081 . . . . 0.0 108.324 175.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -95.63 8.63 42.86 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 114.266 -1.334 . . . . 0.0 110.611 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -87.32 156.27 54.13 Favored Pre-proline 0 C--N 1.314 -0.947 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.02 135.77 70.76 Favored 'Trans proline' 0 C--O 1.243 0.74 0 C-N-CA 122.218 1.945 . . . . 0.0 110.757 177.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -85.51 134.22 27.67 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.834 0 CA-C-O 121.183 0.516 . . . . 0.0 110.4 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -91.87 -20.5 36.55 Favored Glycine 0 N--CA 1.441 -1.028 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.332 179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 140.45 -176.11 21.6 Favored Glycine 0 N--CA 1.426 -2.03 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.74 139.83 37.81 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 117.8 0.8 . . . . 0.0 109.389 175.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 17.8 tp -84.86 125.35 71.07 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 176.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -61.45 149.6 88.89 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 C-N-CA 122.12 1.88 . . . . 0.0 112.437 178.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.445 ' HA ' ' ND2' ' A' ' 30' ' ' ASN . . . -69.2 131.9 45.67 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 176.137 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 92.91 1.17 67.81 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.458 -0.877 . . . . 0.0 113.769 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -78.66 136.68 37.53 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 117.323 0.561 . . . . 0.0 110.494 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.445 HG22 HG22 ' A' ' 29' ' ' VAL . 9.4 p -96.58 115.18 27.0 Favored 'General case' 0 N--CA 1.421 -1.876 0 CA-C-O 121.444 0.64 . . . . 0.0 110.475 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 27' ' ' THR . 20.1 mm -104.0 130.46 54.58 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.089 -178.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.65 115.78 41.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.892 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 172.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.52 ' CZ ' ' HB3' ' A' ' 26' ' ' ALA . 54.8 p90 -115.48 162.2 17.5 Favored 'General case' 0 C--N 1.299 -1.587 0 C-N-CA 120.304 -0.559 . . . . 0.0 110.211 -177.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -120.93 0.94 10.38 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 123.26 0.35 . . . . 0.0 111.364 -178.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -155.52 151.22 27.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.338 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 21' ' ' TYR . 11.8 t -124.77 133.07 70.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 N-CA-C 105.928 -1.879 . . . . 0.0 105.928 173.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' CYS . . . . . 0.43 ' HG ' ' HE1' ' A' ' 83' ' ' TYR . 75.4 m -125.88 159.37 32.71 Favored 'General case' 0 C--N 1.293 -1.849 0 O-C-N 123.09 0.244 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.441 HG12 HG12 ' A' ' 70' ' ' ILE . 66.3 mt -128.38 122.46 57.79 Favored 'Isoleucine or valine' 0 C--O 1.255 1.376 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 175.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -170.77 150.72 3.3 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . 62.68 30.93 16.9 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.74 0.816 . . . . 0.0 110.827 176.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 70.57 8.05 62.31 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.441 -0.8 . . . . 0.0 112.809 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -120.62 157.09 30.29 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 122.26 -0.553 . . . . 0.0 111.282 -178.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.495 ' HB ' ' HG2' ' A' ' 87' ' ' ARG . 21.2 mt -104.73 136.06 39.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 60.3 m95 -126.78 155.92 42.05 Favored 'General case' 0 C--N 1.292 -1.912 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -171.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.495 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 34.0 pt -113.31 134.23 56.67 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.464 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 172.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -102.82 120.46 6.81 Favored Glycine 0 N--CA 1.418 -2.557 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 60' ' ' TYR . 34.1 p90 -142.19 171.97 13.34 Favored 'General case' 0 C--N 1.29 -2.015 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -111.45 145.22 39.38 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.416 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -92.35 171.48 9.03 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 173.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -62.75 -20.58 65.09 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 123.331 0.652 . . . . 0.0 111.876 -177.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.671 ' HB2' ' OD1' ' A' ' 80' ' ' ASN . 61.3 m-20 -91.23 1.99 56.69 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.888 -0.507 . . . . 0.0 110.099 179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.13 8.65 68.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 119.996 -1.097 . . . . 0.0 112.094 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.671 ' OD1' ' HB2' ' A' ' 78' ' ' ASN . 6.9 m120 -71.91 139.19 48.65 Favored 'General case' 0 CA--C 1.503 -0.857 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.522 ' HG3' ' CE2' ' A' ' 83' ' ' TYR . 25.4 tpt180 -86.41 97.56 10.52 Favored 'General case' 0 C--O 1.206 -1.213 0 N-CA-C 107.254 -1.388 . . . . 0.0 107.254 175.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 38' ' ' ARG . 25.3 t -96.26 130.17 45.31 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.863 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.255 -174.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.522 ' CE2' ' HG3' ' A' ' 81' ' ' ARG . 61.1 m-85 -115.18 123.35 48.67 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.596 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.7 t -113.01 128.81 25.17 Favored Pre-proline 0 C--N 1.286 -2.176 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.407 ' O ' HG21 ' A' ' 35' ' ' ILE . 34.7 Cg_endo -73.94 128.79 12.67 Favored 'Trans proline' 0 N--CA 1.438 -1.75 0 C-N-CA 121.62 1.547 . . . . 0.0 108.615 175.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.5 m -113.78 -12.36 11.76 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.03 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 -174.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . 0.542 ' HB3' ' HA ' ' A' ' 101' ' ' ALA . 10.5 ptm180 -178.56 175.65 1.09 Allowed 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -179.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' A' ' 98' ' ' PRO . 17.1 p -97.99 164.21 12.45 Favored 'General case' 0 C--N 1.29 -1.989 0 O-C-N 123.142 0.276 . . . . 0.0 110.358 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 96' ' ' GLN . 51.7 t -147.55 115.45 6.46 Favored 'General case' 0 N--CA 1.433 -1.288 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 176.29 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . 0.495 ' HB3' ' HB ' ' A' ' 97' ' ' ILE . 13.3 tt0 -82.67 104.86 13.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 177.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 90.47 -170.01 34.98 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 121.22 -0.514 . . . . 0.0 112.085 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 11.9 m -121.6 152.16 58.06 Favored Pre-proline 0 C--N 1.302 -1.492 0 C-N-CA 122.909 0.484 . . . . 0.0 109.96 -179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -63.65 166.98 14.31 Favored 'Trans proline' 0 CA--C 1.554 1.495 0 C-N-CA 122.663 2.242 . . . . 0.0 112.379 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -68.69 -22.59 8.7 Favored 'Cis proline' 0 C--N 1.359 1.093 0 C-N-CA 124.371 -1.096 . . . . 0.0 113.282 6.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 72.7 m-20 -91.51 79.03 5.56 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.619 ' HB2' ' SG ' ' A' ' 89' ' ' CYS . 14.6 pt20 -101.24 153.62 19.47 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 106.31 -1.737 . . . . 0.0 106.31 176.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 90' ' ' GLN . 65.0 mt -127.08 89.32 52.22 Favored Pre-proline 0 C--N 1.273 -2.744 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 88' ' ' THR . 39.0 Cg_endo -76.47 127.5 9.73 Favored 'Trans proline' 0 N--CA 1.445 -1.358 0 C-N-CA 122.38 2.054 . . . . 0.0 112.371 -178.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.25 -165.29 29.62 Favored Glycine 0 C--O 1.251 1.157 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 178.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 14.0 p -66.61 139.88 20.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.542 ' HA ' ' HB3' ' A' ' 87' ' ' ARG . . . -79.61 143.58 34.59 Favored 'General case' 0 N--CA 1.43 -1.425 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.81 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TRP . . . . . . . . . . . . . 49.5 m0 -89.64 15.92 8.73 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.572 0.701 . . . . 0.0 110.403 -179.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -179.45 -162.34 28.42 Favored Glycine 0 N--CA 1.422 -2.291 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.158 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 3.3 t -108.06 154.6 9.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -178.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -124.86 103.32 8.0 Favored 'General case' 0 N--CA 1.418 -2.064 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 177.095 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . 0.523 ' HB2' ' HB ' ' A' ' 27' ' ' THR . 88.3 mttt . . . . . 0 C--N 1.291 -1.948 0 CA-C-O 118.711 -0.661 . . . . 0.0 109.449 179.139 . . . . . . . . 1 1 . 1 stop_ save_